<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="c">
		<monograph id="1" status="active">
			<mono_name>calcitonin (salmon) (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x191">Fortical</tradename>
					<tradename id="tnidelem4x190">Miacalcin</tradename>
				</tradenames>
				<class type="func"> Parathyroid agents (calcium regulator)</class>
				<class type="chem"> Polypeptide hormone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x29">
				<para>
					<confusion>
						<tradename id="tnidelem4x290">Calcitonin</tradename>
						<drug type="generic" refid="idelem4x290">calcitriol/calcifediol/calcium</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x33">
				<sec_title>Action:</sec_title>
				<para>Decreases bone resorption, blood calcium levels; increases deposits of calcium in bones; opposes parathyroid hormone</para>
			</section>
			<section type="uses" id="sidelem4x38">
				<sec_title>Uses:</sec_title>
				<para>Paget’s disease, postmenopausal osteoporosis, hypercalcemia</para>
				<section type="none" id="sidelem4x43">
					<section type="none" id="sidelem4x44">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bone/neuropathic pain, diabetic neuropathy, osteolytic metastases, osteoporosis prophylaxis, phantom limb pain</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x49">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, fish</para>
				<section type="none" id="sidelem4x54">
					<section type="none" id="sidelem4x55">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hypotension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x60">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x63">
					<section type="none" id="sidelem4x64">
						<sec_title>Postmenopausal osteoporosis</sec_title>
						<section type="none" id="sidelem4x72">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x72">
									<item>
										<label>•</label>
										<para> 100 international units every other day;  200 international units (1 spray) daily, alternating nostrils daily, activate pump before 1st dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x79">
						<sec_title>Paget’s disease</sec_title>
						<section type="none" id="sidelem4x87">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x87">
									<item>
										<label>•</label>
										<para> 100 international units/day, maintenance 50 international units daily, every other day, or 3 × per wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x91">
						<sec_title>Hypercalcemia</sec_title>
						<section type="none" id="sidelem4x99">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x99">
									<item>
										<label>•</label>
										<para> 4 international units/kg q12hr, increase to 8 international units/kg q12hr if response is unsatisfactory, no more than 4-7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x103">
						<sec_title>Neuropathic pain/phantom limb pain/diabetic neuropathy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x111">
							<label>•</label>
							<sec_title>Adult<route> IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x111">
									<item>
										<label>•</label>
										<para> 100-200 international units/day for phantom limb pain;  200 international units over 20 min and 2nd infusion given</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x118">
						<sec_title>Bone pain due to osteoporosis, osteolytic metastases (unlabeled)</sec_title>
						<section type="none" id="sidelem4x126">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x126">
									<item>
										<label>•</label>
										<para> 50-100 international units/day or  200 international units in 1 nostril/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x133">
						<sec_title>Available forms:</sec_title>
						<para> Inj 200 units/ml; nasal spray 200 units/actuation</para>
					</section>
					<section type="none" id="sidelem4x138">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x142">
								<item>
									<label>•</label>
									<para>Store at &lt;77° F (25° C); protect from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x148">
							<sec_title>SUBCUT route</sec_title>
							<section type="none" id="sidelem4x156">
								<label>•</label>
								<sec_title>
									<route>give</route>
								</sec_title>
								<para>
									<list id="lidelem4x156">
										<item>
											<label>•</label>
											<para>Rotate inj sites; use within 6 hr of reconstitution;  at bedtime to minimize nausea, vomiting</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x161">
							<sec_title>IM route</sec_title>
							<section type="none" id="sidelem4x169">
								<label>•</label>
								<sec_title>
									<route>give</route>
								</sec_title>
								<para>
									<list id="lidelem4x169">
										<item>
											<label>•</label>
											<para>After test dose of 10 international units/ml, 0.1 ml intradermally; watch for 15 min;  only with EPINEPHrine, emergency meds available</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x174">
									<item>
										<label>•</label>
										<para>IM inj slowly into deep muscle mass; rotate sites; preferred route if volume is &gt;2 ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x179">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x182">
					<section type="none" id="sidelem4x183">
						<sec_title>CNS:</sec_title>
						<para> Headache, tetany, chills, weakness, dizziness, fever, tremors</para>
					</section>
					<section type="none" id="sidelem4x188">
						<sec_title>CV:</sec_title>
						<para> Chest pressure, hypertension</para>
					</section>
					<section type="none" id="sidelem4x193">
						<sec_title>EENT:</sec_title>
						<para> Nasal congestion, eye pain</para>
					</section>
					<section type="none" id="sidelem4x198">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, vomiting, anorexia, abdominal pain, salty taste, epigastric pain</para>
					</section>
					<section type="none" id="sidelem4x203">
						<sec_title>GU:</sec_title>
						<para> Diuresis, nocturia, urine sediment, frequency, cystitis</para>
					</section>
					<section type="none" id="sidelem4x208">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, pruritus of earlobes, edema of feet, reaction at inj site</para>
					</section>
					<section type="none" id="sidelem4x213">
						<sec_title>MS:</sec_title>
						<para> Swelling, tingling of hands, backache, myalgia</para>
					</section>
					<section type="none" id="sidelem4x218">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, flulike symptoms, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x225">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x233">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x236">
					<section type="none" id="sidelem4x237">
						<sec_title>IM/SUBCUT:</sec_title>
						<para> Onset 15 min, peak 4 hr, duration 8-24 hr, metabolized by kidneys, excreted as inactive metabolites via kidneys</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x242">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lithium effect</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of nasal spray—bisphosphonates (Paget’s disease)</para>
			</section>
			<section type="considerations" id="sidelem4x254">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x257">
					<section type="none" id="sidelem4x258">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x264">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis, hypersensitivity reaction (rash, fever, inability to breathe); emergency equipment should be nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x269">
								<item>
									<label>•</label>
									<para>GI symptoms, polyuria, flushing, head swelling, tingling, headache; may indicate hypercalcemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x274">
								<item>
									<label>•</label>
									<para>Nutritional status; diet for sources of vit D (milk, some seafood), calcium (dairy products, dark green vegetables), phosphates</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x279">
								<item>
									<label>•</label>
									<para>Vit D 50-135 international units/dl), alk phos baseline, q3-6mo; monitor urine hydroproline with Paget’s disease, biochemical markers of bone formation/absorption, radiologic evidence of fracture; bone density (osteoporosis)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x287">
							<label>•</label>
							<sec_title>
								<route>Toxicity (can occur rapidly), increased drug level; have parenteral calcium on hand if calcium level drops too low; check for tetany (irritability, paresthesia, nervousness, muscle twitching, seizures, tetanic spasms)</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x290">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x294">
								<item>
									<label>•</label>
									<para>Therapeutic response: calcium levels 9-10 mg/dl, decreasing symptoms of Paget’s disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x300">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x304">
								<item>
									<label>•</label>
									<para>About the method of inj if patient will be responsible for self-medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To report difficulty swallowing, any changes in side effects to prescriber immediately</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x315">
					<sec_title>
						<emphasis style="italic">Nasal</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x320">
							<item>
								<label>•</label>
								<para>To use alternating nostrils for nasal spray; use after allowing to warm to room temperature; prime to get full spray</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>calcitriol vitamin D3 (Rx)</mono_name>
			<info>
				<pronunciation>(kal-sih-try′ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3342">Calcijex</tradename>
					<tradename id="tnidelem4x3341">Rocaltrol</tradename>
					<tradename id="tnidelem4x3340">Vectical</tradename>
				</tradenames>
				<class type="func"> Parathyroid agent (calcium regulator)</class>
				<class type="chem"> Vit D hormone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x345">
				<para>
					<confusion>
						<tradename id="tnidelem4x3450">calcitriol</tradename>
						<drug type="generic" refid="idelem4x3450">Calciferol/calcitonin/calcium</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x349">
				<sec_title>Action:</sec_title>
				<para>Increases intestinal absorption of calcium; provides calcium for bones; increases renal tubular reabsorption of phosphate</para>
			</section>
			<section type="uses" id="sidelem4x354">
				<sec_title>Uses:</sec_title>
				<para>Hypocalcemia with chronic renal disease, hyperparathyroidism pseudohypoparathyroidism, psoriasis, renal osteodystrophy</para>
				<section type="none" id="sidelem4x359">
					<section type="none" id="sidelem4x360">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Osteopetrosis, osteoporosis, osteoporosis prophylaxis, rickets, familial hypophosphatemia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x365">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hyperphosphatemia, hypercalcemia, vit D toxicity</para>
				<section type="none" id="sidelem4x370">
					<section type="none" id="sidelem4x371">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, renal calculi, CV disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x376">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x379">
					<section type="none" id="sidelem4x380">
						<sec_title>Hypocalcemia (stage 5 chronic kidney disease, on dialysis)</sec_title>
						<section type="none" id="sidelem4x388">
							<label>•</label>
							<sec_title>Adult and child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x388">
									<item>
										<label>•</label>
										<para> 0.25 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x395">
							<label>•</label>
							<sec_title>
								<route>Adults</route>
							</sec_title>
							<para>
								<list id="lidelem4x395">
									<item>
										<label>•</label>
										<para>:  1 mcg (0.02 mcg/kg) to 2 mcg 3×/wk, initial doses of 0.5-4 mcg 3×/wk have been used, may increase by 0.5-1 mcg at 2-4 wk intervals if needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x405">
							<label>•</label>
							<sec_title>Child 1-5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x405">
									<item>
										<label>•</label>
										<para> 0.25-2 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x409">
						<sec_title>Renal osteodystrophy</sec_title>
						<section type="none" id="sidelem4x417">
							<label>•</label>
							<sec_title>Adult and child ≥3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x417">
									<item>
										<label>•</label>
										<para> 0.25 mcg/day, may increase to 0.5 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x424">
							<label>•</label>
							<sec_title>Child &lt;3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x424">
									<item>
										<label>•</label>
										<para> 0.01-0.015 mcg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x428">
						<sec_title>Hypoparathyroidism</sec_title>
						<section type="none" id="sidelem4x436">
							<label>•</label>
							<sec_title>Adult and child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x436">
									<item>
										<label>•</label>
										<para> 0.25 mcg/day, may increase q2-4wk, maintenance 0.5-2 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x443">
							<label>•</label>
							<sec_title>Child 1-5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x443">
									<item>
										<label>•</label>
										<para> 0.25-0.75 mcg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x450">
							<label>•</label>
							<sec_title>Child &lt;1 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x450">
									<item>
										<label>•</label>
										<para> 0.04-0.08 mcg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x454">
						<sec_title>Rickets (unlabeled)</sec_title>
						<section type="none" id="sidelem4x462">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x462">
									<item>
										<label>•</label>
										<para> 1 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x466">
						<sec_title>Familial hypophosphatemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x474">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x474">
									<item>
										<label>•</label>
										<para> 2 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x481">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x481">
									<item>
										<label>•</label>
										<para> 0.015-0.02 mcg/kg/day, maintenance 0.03-0.06 mcg/kg/day; max 2 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x485">
						<sec_title>Postmenopausal osteoporosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x493">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x493">
									<item>
										<label>•</label>
										<para> 0.25 mcg bid, adjust to serum calcium levels</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x497">
						<sec_title>Osteopetrosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x505">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x505">
									<item>
										<label>•</label>
										<para> high-dose calcitriol 1-2 mcg/kg/day given in 4-6 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x509">
						<sec_title>Osteoporosis prophylaxis in corticosteroid therapy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x517">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x517">
									<item>
										<label>•</label>
										<para> 0.5-1 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x521">
						<sec_title>Available forms:</sec_title>
						<para> Caps 0.25, 0.5 mcg; inj 1 mcg/ml; oral sol 1 mcg/ml; top 3 mcg/g</para>
					</section>
					<section type="none" id="sidelem4x526">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x529">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x533">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew caps</para>
									</item>
									<item>
										<label>•</label>
										<para>Give without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Store protected from light, heat, moisture</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x549">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x553">
									<item>
										<label>•</label>
										<para>Give by direct IV over 1 min through catheter at hemodialysis conclusion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x559">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x562">
					<section type="none" id="sidelem4x563">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, headache, vertigo, fever, lethargy, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x568">
						<sec_title>CV:</sec_title>
						<para> Palpitations, hypertension</para>
					</section>
					<section type="none" id="sidelem4x573">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, photophobia</para>
					</section>
					<section type="none" id="sidelem4x578">
						<sec_title>ENDO:</sec_title>
						<para>Hypercalcemia</para>
					</section>
					<section type="none" id="sidelem4x583">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, vomiting, jaundice, anorexia, dry mouth, constipation, cramps, metallic taste</para>
					</section>
					<section type="none" id="sidelem4x588">
						<sec_title>GU:</sec_title>
						<para> Polyuria, hypercalciuria, hyperphosphatemia, hematuria, thirst</para>
					</section>
					<section type="none" id="sidelem4x593">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia, decreased bone development, weakness</para>
					</section>
					<section type="none" id="sidelem4x598">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x605">
						<sec_title>INTEG:</sec_title>
						<para> Pain at injection site, rash, pruritus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x610">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x613">
					<section type="none" id="sidelem4x614">
						<sec_title>IV:</sec_title>
						<para> Duration up to 2 hr</para>
					</section>
					<section type="none" id="sidelem4x619">
						<sec_title>PO:</sec_title>
						<para> Absorbed readily from GI tract, peak 10-12 hr, duration 3-5 days, half-life 3-6 hr, undergoes hepatic recycling, excreted in bile</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x624">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x632">
					<label>•</label>
					<sec_title>Hypercalcemia</sec_title>
					<para>
						<list id="lidelem4x632">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Hypercalcemia:</emphasis> thiazide diuretics, calcium supplements</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<list id="lidelem4x636">
						<item>
							<label>•</label>
							<para>Cardiac dysrhythmias: cardiac glycosides, verapamil</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x644">
					<label>•</label>
					<sec_title>Hypermagnesemia</sec_title>
					<para>
						<list id="lidelem4x644">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Hypermagnesemia:</emphasis> magnesium antacids/supplements</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x651">
					<label>•</label>
					<sec_title>Toxicity</sec_title>
					<para>
						<list id="lidelem4x651">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Toxicity:</emphasis> other vit D products</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> metabolism of vit D—phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of calcitriol—cholestyramine, mineral oil, fat-soluble vitamins</para>
				<section type="none" id="sidelem4x663">
					<section type="none" id="sidelem4x664">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x668">
								<item>
									<label>•</label>
									<para>Large amounts of high-calcium foods may cause hypercalcemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x674">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> Cholesterol</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> Alk phos, electrolytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x689">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x692">
					<section type="none" id="sidelem4x693">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x698">
								<item>
									<label>•</label>
									<para>BUN, urinary calcium, PTH, creatinine, chloride, magnesium, electrolytes, phosphate; may increase calcium; should be kept at 9-10 mg/dl, vit D 50-135 international units/dl, phosphate 70 mg/dl; toxic reactions may occur rapidly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x706">
							<label>•</label>
							<sec_title>Hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x706">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercalcemia:</emphasis> dry mouth, metallic taste, polyuria, bone pain, muscle weakness, headache, fatigue, change in level of consciousness, dysrhythmias, increased respirations, anorexia, nausea, vomiting, cramps, diarrhea, constipation; paresthesia, twitching, dysrhythmias, Chvostek’s sign, Trousseau’s sign </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x712">
								<item>
									<label>•</label>
									<para>Renal status: decreased urinary output (oliguria, anuria), edema in extremities, weight gain 5-7 lb, periorbital edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x717">
								<item>
									<label>•</label>
									<para>Nutritional status, diet for sources of vit D (milk, some seafood); calcium (dairy products, dark green vegetables), phosphates (dairy products) must be avoided</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x722">
								<item>
									<label>•</label>
									<para>Restrict sodium, potassium if required; restriction of fluids if required for chronic renal failure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x727">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x731">
								<item>
									<label>•</label>
									<para>Therapeutic response: calcium 9-10 mg/dl; decreasing symptoms of hypocalcemia, hypoparathyroidism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x738">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x746">
							<label>•</label>
							<sec_title>About symptoms of hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x746">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">About symptoms of hypercalcemia:</emphasis> renal stones, nausea, vomiting, anorexia, lethargy, thirst, bone, or flank pain, confusion</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x750">
								<item>
									<label>•</label>
									<para>To avoid products with sodium: cured meats, dairy products, cold cuts, olives, beets, pickles, soups, meat tenderizers with chronic renal failure; products with potassium: oranges, bananas, dried fruit, peas, dark green leafy vegetables, milk, melons, beans</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x755">
								<item>
									<label>•</label>
									<para>To avoid OTC products that contain calcium, potassium, sodium with chronic renal failure</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x760">
								<item>
									<label>•</label>
									<para>To monitor weight weekly; to maintain fluid intake</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>calcium carbonate (<emphasis style="smallcaps">po-otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x77116">Alka-Mints</tradename>
					<tradename id="tnidelem4x77115">Amitone</tradename>
					<tradename id="tnidelem4x77114">
						<country code="CAN">Apo-Cal </country>
					</tradename>
					<tradename id="tnidelem4x77113">BioCal</tradename>
					<tradename id="tnidelem4x77112">Calcarb</tradename>
					<tradename id="tnidelem4x77111">Calci-Chew</tradename>
					<tradename id="tnidelem4x77110">Calci-Mix</tradename>
					<tradename id="tnidelem4x7719">Calciday</tradename>
					<tradename id="tnidelem4x7718">
						<country code="CAN">Calcite </country>
					</tradename>
					<tradename id="tnidelem4x7717">
						<country code="CAN">Calsan </country>
					</tradename>
					<tradename id="tnidelem4x7716">
						<country code="CAN">Caltrate </country>
					</tradename>
					<tradename id="tnidelem4x7715">Chooz</tradename>
					<tradename id="tnidelem4x7714">Maalox Antacid</tradename>
					<tradename id="tnidelem4x7713">Os-Cal</tradename>
					<tradename id="tnidelem4x7712">Rolaids Extra Strength Softchew</tradename>
					<tradename id="tnidelem4x7711">Tums</tradename>
					<tradename id="tnidelem4x7710">Tums E-X</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="4" status="active">
			<mono_name>calcium acetate (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(kal′see-um ass′e-tate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7932">Eliphos</tradename>
					<tradename id="tnidelem4x7931">PhosLo</tradename>
					<tradename id="tnidelem4x7930">Phoslyra</tradename>
				</tradenames>
				<class type="func"> Antacid, calcium supplement</class>
				<class type="chem"> Calcium product</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x803">
				<para>
					<confusion>
						<tradename id="tnidelem4x8030">Os-Cal</tradename>
						<drug type="generic" refid="idelem4x8030">Asacol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x810">
				<sec_title>Action:</sec_title>
				<para>Neutralizes gastric acidity</para>
			</section>
			<section type="uses" id="sidelem4x815">
				<sec_title>Uses:</sec_title>
				<para>Antacid, calcium supplement; not suitable for chronic therapy, hyperphosphatemia, hypertension during pregnancy, osteoporosis, prevention, treatment of hypocalcemia, hypoparathyroidism</para>
				<section type="none" id="sidelem4x820">
					<section type="none" id="sidelem4x821">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Duodenal ulcer, PMS, stress gastritis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x826">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypercalcemia</para>
				<section type="none" id="sidelem4x831">
					<section type="none" id="sidelem4x832">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, fluid restriction, decreased GI motility, GI obstruction, dehydration, renal disease, hyperparathyroidism, bone tumors</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x837">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x840">
					<section type="none" id="sidelem4x841">
						<sec_title>Nutritional supplement including osteoporosis prophylaxis</sec_title>
						<section type="none" id="sidelem4x849">
							<label>•</label>
							<sec_title>Adult ≥51 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x849">
									<item>
										<label>•</label>
										<para> 1000-1500 mg/day elemental calcium (2500-3750 mg/day calcium carbonate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x856">
							<label>•</label>
							<sec_title>Adult 19-50 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x856">
									<item>
										<label>•</label>
										<para> 1000 mg/day elemental calcium (2500 mg/day calcium carbonate)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x860">
						<sec_title>Chronic hypocalcemia</sec_title>
						<section type="none" id="sidelem4x868">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x868">
									<item>
										<label>•</label>
										<para> 2-4 g/day elemental calcium (5-10 g/day calcium carbonate) in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x875">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x875">
									<item>
										<label>•</label>
										<para> 45-65 mg/kg/day elemental calcium (112.5-162.5 mg/kg/day calcium carbonate) in 4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x882">
							<label>•</label>
							<sec_title>Neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x882">
									<item>
										<label>•</label>
										<para> 50-150 mg/kg/day elemental calcium (125-375 mg/kg/day in 4-6 divided doses, max 1 g/day)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x886">
						<sec_title>Supplementation</sec_title>
						<section type="none" id="sidelem4x894">
							<label>•</label>
							<sec_title>Adolescent and child 9-18 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x894">
									<item>
										<label>•</label>
										<para> 1300 mg elemental calcium (3250 mg calcium carbonate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x901">
							<label>•</label>
							<sec_title>Child 4-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x901">
									<item>
										<label>•</label>
										<para> 800 mg/day elemental calcium (2000 mg/day calcium carbonate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x908">
							<label>•</label>
							<sec_title>Child 1-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x908">
									<item>
										<label>•</label>
										<para> 500 mg/day elemental calcium (1250 mg/day calcium carbonate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x915">
							<label>•</label>
							<sec_title>Infant 6-12 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x915">
									<item>
										<label>•</label>
										<para> 270 mg/day elemental calcium based on total intake</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x922">
							<label>•</label>
							<sec_title>Neonates and infants &lt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x922">
									<item>
										<label>•</label>
										<para> 210 mg/day elemental calcium based on total intake</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x926">
						<sec_title>Hyperphosphatemia</sec_title>
						<section type="none" id="sidelem4x934">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x934">
									<item>
										<label>•</label>
										<para> Individualized on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x938">
						<sec_title>Heartburn, dyspepsia, hyperacidity (OTC)</sec_title>
						<section type="none" id="sidelem4x946">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x946">
									<item>
										<label>•</label>
										<para> 1-2 tabs q2hr, max 9 tabs/24 hr (Alka-mints); chew 2-4 tab q1hr prn, max 16 tabs (Tums regular strength); chew 2-4 tab q1hr prn, max 10 tabs (Tums E-X); chew 2-3 tabs q1hr prn, max 10 tabs/24 hr (Tums Ultra); chew 2 tabs q2-3hr, max 19 tabs/24 hr (Titralac Extra Strength)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x952">
						<sec_title>Duodenal ulcer/stress gastritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x960">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x960">
									<item>
										<label>•</label>
										<para> 80-140 mEq q3-6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x964">
						<sec_title>PMS (unlabeled)</sec_title>
						<section type="none" id="sidelem4x972">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x972">
									<item>
										<label>•</label>
										<para> (Tums E-X, Tums Calcium for Life PMS) Chew 2 tabs bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x976">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Calcium carbonate: chewable tabs</emphasis> 350, 420, 450, 500, 750, 1000, 1250 mg; tabs 500, 600, 650, 667, 1000, 1250, 1500 mg; <emphasis style="bold">gum</emphasis> 300, 450, 500 mg; <emphasis style="bold">susp</emphasis> 1250 mg/5 ml; <emphasis style="bold">caps</emphasis> 1250 mg; <emphasis style="bold">powder</emphasis> 6.5 g/packet; <emphasis style="bold">calcium acetate: tabs</emphasis> 667 mg (169 mg elemental Ca), <emphasis style="bold">gelcaps:</emphasis> 667 mg (169 mg elemental calcium); caps 500 mg (125 mg elemental Ca)</para>
					</section>
					<section type="none" id="sidelem4x1002">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1005">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1009">
									<item>
										<label>•</label>
										<para>1 g calcium carbonate = 400 mg elemental calcium = 10 mmol calcium = 20 mEq calcium</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give enteric-coated within 1 hr of calcium carbonate</para>
									</item>
									<item>
										<label>•</label>
										<para>For ulcer treatment (adjunct): give 1 and 3 hr after meals and at bedtime</para>
									</item>
									<item>
										<label>•</label>
										<para>For a phosphate binder: give 1 hr after each meal or snack and at bedtime</para>
									</item>
									<item>
										<label>•</label>
										<para>For supplement: give 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr after meals; avoid oxalic acid foods (spinach, rhubarb), phytic acid (brans, cereals) or phosphorus (milk, dairy), may decrease calcium absorption</para>
									</item>
									<item>
										<label>•</label>
										<para>Suspension: shake well; use calibrated measuring device</para>
									</item>
									<item>
										<label>•</label>
										<para>Laxatives or stool softeners if constipation occurs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1051">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1054">
					<section type="none" id="sidelem4x1055">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation,</emphasis> anorexia, nausea, vomiting, flatulence, diarrhea, rebound hyperacidity, eructation</para>
					</section>
					<section type="none" id="sidelem4x1063">
						<sec_title>GU:</sec_title>
						<para> Calculi, hypercalciuria</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1068">
				<sec_title>Pharmacokinetics</sec_title>
				<para>
					<emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> of dose absorbed by small intestine, excreted in feces and urine, crosses placenta, must have adequate vit D for absorption</para>
			</section>
			<section type="interactions" id="sidelem4x1078">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin toxicity—hypercalcemia</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma levels of quiNIDine, amphetamines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypercalcemia—thiazide diuretics, calcium supplements</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of salicylates, calcium channel blockers, ketoconazole, iron salts, tetracyclines, fluoroquinolones, phenytoin, etidronate, risedronate, atenolol PO</para>
				<section type="none" id="sidelem4x1097">
					<section type="none" id="sidelem4x1098">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> phosphates</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> chloride</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> benzodiazepines</para>
						<para>
							<emphasis style="bold">False decrease:</emphasis> magnesium, oxylate, lipase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1117">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1120">
					<section type="none" id="sidelem4x1121">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1126">
								<item>
									<label>•</label>
									<para>Calcium (serum, urine), calcium should be 8.5-10.5 mg/dl, urine calcium should be 150 mg/day, monitor weekly; serum phosphate</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1132">
								<item>
									<para>
										<emphasis alert="nurse">Milk-alkali syndrome: nausea, vomiting, disorientation, headache</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1137">
								<item>
									<label>•</label>
									<para>Constipation; increase bulk in the diet if needed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1145">
							<label>•</label>
							<sec_title>Hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x1145">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercalcemia:</emphasis> headache, nausea, vomiting, confusion; hypocalcemia: paresthesia, twitching colic, dysrhythmias, Chvostek’s sign, Trousseau’s sign</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1149">
								<item>
									<label>•</label>
									<para>Those taking digoxin for toxicity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1154">
								<item>
									<label>•</label>
									<para>Antacid—for abdominal pain, heartburn, indigestion before, after administration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1159">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1163">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain, decreased acidity; decreased hyperphosphatemia with renal failure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1169">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1173">
								<item>
									<label>•</label>
									<para>To increase fluids to 2 L unless contraindicated; to add bulk to diet for constipation; to notify prescriber of constipation</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to switch antacids unless directed by prescriber; not to use as antacid for &gt;2 wk without approval by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That therapeutic dose recommendations are figured as elemental calcium</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid excessive use of alcohol, caffeine, tobacco</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid spinach, cereals, dairy products in large amounts</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>CALCIUM SALTS</mono_name>
			<info>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1225">
				<sec_title>Action:</sec_title>
				<para>Calcium needed for maintenance of nervous, muscular, skeletal function; enzyme reactions; normal cardiac contractility; coagulation of blood; affects secretory activity of endocrine, exocrine glands</para>
			</section>
			<section type="uses" id="sidelem4x1230">
				<sec_title>Uses:</sec_title>
				<para>Prevention and treatment of hypocalcemia, hypermagnesemia, hypoparathyroidism, neonatal tetany, cardiac toxicity caused by hyperkalemia, lead colic, hyperphosphatemia, vit D deficiency, osteoporosis prophylaxis, calcium antagonist toxicity (calcium channel blocker toxicity)</para>
				<section type="none" id="sidelem4x1235">
					<section type="none" id="sidelem4x1236">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Electrolyte abnormalities in cardiac arrest, CPR</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1241">
				<sec_title>Contraindications:</sec_title>
				<para>Hypercalcemia, digoxin toxicity, ventricular fibrillation, renal calculi</para>
				<section type="none" id="sidelem4x1246">
					<section type="none" id="sidelem4x1247">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, respiratory/renal disease, cor pulmonale, digitalized patient, respiratory failure, diarrhea, dehydration</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1252">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1255">
					<sec_title>Acute hypocalcemia</sec_title>
					<section type="none" id="sidelem4x1258">
						<sec_title>Calcium Chloride 10%</sec_title>
						<section type="none" id="sidelem4x1266">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1266">
									<item>
										<label>•</label>
										<para> 0.5-1 g; , give over 5-10 min. Repeat q4-6hr, as needed by calcium concentrations <emphasis style="italic">or</emphasis> 15 mg/kg elemental calcium (37.5 mg/kg calcium chloride) over 4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1281">
							<label>•</label>
							<sec_title>Child/Infant<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1281">
									<item>
										<label>•</label>
										<para> Range from 2.7-5 mg/kg/dose (0.027-0.05 ml/kg/dose of 10%.  Slow IV 10 mg/kg/dose over 5-10 minutes, may repeat initial dosage in 4-6 hr. The initial dose can be followed by a  max 200 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1291">
						<sec_title>Calcium Gluconate</sec_title>
						<section type="none" id="sidelem4x1299">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1299">
									<item>
										<label>•</label>
										<para> 2-3 g slowly, max 5 ml/min (47.5 mg/min calcium ion);  Give over 5-10 min, repeat q6hr, as needed, as determined by serum calcium concentrations, max 15 g/day or  15 mg/kg elemental calcium (167 mg/kg) over 4-6 hr may be administered if symptoms recur after initial IV calcium replacement</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1312">
							<label>•</label>
							<sec_title>Child/Infant<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1312">
									<item>
										<label>•</label>
										<para> 200-500 mg/kg/day  or given in 4 divided doses, at max rate 5 ml/min (47.5 mg/min calcium ion);  IV 100-200 mg/kg over 5-10 min, may repeat after 6 hr or followed by 500 mg/kg/day IV as a  or in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1328">
							<label>•</label>
							<sec_title>Neonate<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1328">
									<item>
										<label>•</label>
										<para> 200-800 mg/kg/day as a  or given in 3-4 divided doses;  100-200 mg/kg IV is recommended, followed by 500 mg/kg/day  or given in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1341">
						<sec_title>Calcium Lactate</sec_title>
						<section type="none" id="sidelem4x1349">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x1349">
									<item>
										<label>•</label>
										<para> 10 ml 1-2×/wk for 4-5 wk, may repeat if needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1356">
							<label>•</label>
							<sec_title>PO (calcium citrate)</sec_title>
						</section>
						<section type="none" id="sidelem4x1362">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1362">
									<item>
										<label>•</label>
										<para> 9.5-19 g/day PO in divided doses 2-4 times a day after meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1369">
							<label>•</label>
							<sec_title>PO (calcium gluconate)</sec_title>
						</section>
						<section type="none" id="sidelem4x1375">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1375">
									<item>
										<label>•</label>
										<para> 22.5-45 g/day in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1382">
							<label>•</label>
							<sec_title>Child/Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1382">
									<item>
										<label>•</label>
										<para> 500-725 mg/kg/day in 4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1389">
							<label>•</label>
							<sec_title>Neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1389">
									<item>
										<label>•</label>
										<para> 500-1500 mg/kg/day in 4-6 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1396">
							<label>•</label>
							<sec_title>PO (calcium lactate)</sec_title>
						</section>
						<section type="none" id="sidelem4x1402">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1402">
									<item>
										<label>•</label>
										<para> 15.4-30.8 g/day divided q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1409">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1409">
									<item>
										<label>•</label>
										<para> 345-500 mg/kg/day in divided doses q6-8hr, max 9 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1417">
							<label>•</label>
							<sec_title>Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1417">
									<item>
										<label>•</label>
										<para> 400-500 mg/kg/day in divided doses q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1424">
							<label>•</label>
							<sec_title>
								<route>CPR/cardiac arrest associated with hyperkalemia, hypermagnesemia, or ionized hypocalcemia (unlabeled)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1430">
							<label>•</label>
							<sec_title>IV (calcium chloride 10%)</sec_title>
						</section>
						<section type="none" id="sidelem4x1436">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1436">
									<item>
										<label>•</label>
										<para> 5-10 ml of a 10% solution (500-1000 mg) or 8-16 mg/kg given by slow IV inj; may repeat</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1443">
							<label>•</label>
							<sec_title>IV (calcium gluconate)</sec_title>
						</section>
						<section type="none" id="sidelem4x1449">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1449">
									<item>
										<label>•</label>
										<para> 500-800 mg of 10% solution (5-8 ml), max 3 g</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1456">
							<label>•</label>
							<sec_title>Infant/Child</sec_title>
							<para>
								<list id="lidelem4x1456">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infant/Child:</emphasis> IV 60-100 mg/kg or intraosseous (0.6-1 ml/kg), max 3 g</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1463">
							<label>•</label>
							<sec_title>For nutritional supplementation</sec_title>
						</section>
						<section type="none" id="sidelem4x1469">
							<label>•</label>
							<sec_title>PO (any oral calcium salt; dosage expressed as elemental calcium)</sec_title>
						</section>
						<section type="none" id="sidelem4x1475">
							<label>•</label>
							<sec_title>Adults ≥51 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1475">
									<item>
										<label>•</label>
										<para> 1200 mg/day (range 1000-1500 mg/day)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1482">
							<label>•</label>
							<sec_title>Adults 19-50 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1482">
									<item>
										<label>•</label>
										<para> 1000 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1489">
							<label>•</label>
							<sec_title>Children and Adolescents 9-18 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1489">
									<item>
										<label>•</label>
										<para> 1300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1496">
							<label>•</label>
							<sec_title>Children 4-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1496">
									<item>
										<label>•</label>
										<para> 800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1503">
							<label>•</label>
							<sec_title>Children 1-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1503">
									<item>
										<label>•</label>
										<para> 500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1510">
							<label>•</label>
							<sec_title>Infants 6-12 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1510">
									<item>
										<label>•</label>
										<para> 270 mg/day based on total intake (consumption from breast milk/infant formula and solid food)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1517">
							<label>•</label>
							<sec_title>Neonate/Infant &lt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1517">
									<item>
										<label>•</label>
										<para> 210 mg/day based on total intake (content in human milk/infant formula). Source of calcium intake should come from food/breast milk only to prevent high levels of intake</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1521">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1524">
							<sec_title>PO route (only acetate, carbonate, citrate, glubionate, lactate, phosphate)</sec_title>
							<section type="none" id="sidelem4x1532">
								<label>•</label>
								<sec_title>chew tab</sec_title>
								<para>
									<list id="lidelem4x1532">
										<item>
											<label>•</label>
											<para>Give in 3-4 divided doses with or 1 hr after meals, follow with full glass of water; if using as phosphate binder in renal dialysis, do not follow with water, do not give oral medications within 1 hr of oral calcium; <emphasis style="bold">chew tab:</emphasis> chew thoroughly; <emphasis style="bold">effervescent tab:</emphasis> dissolve in full glass of water; <emphasis style="bold">oral powder:</emphasis> mix and give with food; <emphasis style="bold">oral solution:</emphasis> give before meals; <emphasis style="bold">oral suspension:</emphasis> shake well</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x1549">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1554">
							<sec_title>IM route</sec_title>
							<section type="none" id="sidelem4x1562">
								<label>•</label>
								<sec_title>
									<route>Glycerophosphate,</route>
								</sec_title>
								<para>
									<list id="lidelem4x1562">
										<item>
											<label>•</label>
											<para> lactate may be given IM</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x1569">
								<label>•</label>
								<sec_title>
									<route>Do not give chloride, gluconate IM;</route>
								</sec_title>
								<para>
									<list id="lidelem4x1569">
										<item>
											<label>•</label>
											<para> use only if IV is not feasible. Inject into gluteal region (adult), lateral thigh (child)</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x1573">
									<item>
										<label>•</label>
										<para>Aspirate before inj</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1578">
									<item>
										<label>•</label>
										<para>Do not give chloride subcut</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1583">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x1587">
									<item>
										<label>•</label>
										<para>Undiluted or diluted with equal amounts of NS to a 5% sol for inj, give 0.5-1 ml/min</para>
									</item>
									<item>
										<label>•</label>
										<para>Through small-bore needle into large vein; if extravasation occurs, necrosis will result (IV)</para>
									</item>
									<item>
										<label>•</label>
										<para>Remain recumbent <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr after IV dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1609">
						<sec_title>Calcium chloride</sec_title>
						<para>
							<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, arsenic trioxide, ascorbic acid injection, asparaginase, atenolol, atracurium atropine, azithromycin, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, carmustine, caspofungin acetate, cefotaxime, cefoTEtan, cefOXitin, ceftaroline, ceftizoxime, chloramphenicol, chlorothiazide, chlorpheniramine, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cloxacillin, colistimethate, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, doxapram, DOXOrubicin, doxycycline, edetate calcium disodium, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ergonovine, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, furosemide, gallamine, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin sodium, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, inamrinone, insulin, regular, irinotecan, isoproterenol, isoproterenol, kanamycin, labetalol, lactated ringer’s, lepirudin, leucovorin, lidocaine, lincomycin, linezolid, LORazepam, mannitol, meperidine, mephentermine, mesna, methohexital, methotrexate, methyldopate, metoclopramide, metoprolol, metronidazole, micafungin, midazolam, milrinone, minocycline, mitoMYcin mitoXANtrone, mivacurium, morphine, moxifloxacin, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, nalorphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxytocin, PAClitaxel (solvent/surfactant) pancuronium, papaverine, penicillin G potassium/sodium, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium potassium chloride, procainamide, prochlorperazine, promazine, promethazine, propranolol, protamine, pyridoxine, quinupristin-dalfopristin, ranitidine, ringer’s injection, rocuronium, streptomycin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin -clavulanate, tigecycline, tirofiban, tna (3-in-1), tobramycin, tolazoline, topotecan, trimetaphan, tubocurarine, urokinase, vancomycin, vasopressin vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole</para>
						<para>
							<emphasis alert="lifethreat">Calcium gluconate</emphasis>
						</para>
						<para>Acyclovir, aldesleukin, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, arsenic trioxide, ascorbic acid injection, asparaginase, atenolol, atracurium, atropine, azaTHIOprine, azithromycin, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride, carboplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, ceftaroline, cefTAZidime, ceftizoxime, cefuroxime, chloramphenicol sodium succinate, chlorothiazide, chlorpheniramine, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, cloxacillin, codeine, colistimethate, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposome, daunorubicin, dexmedetomidine, dexrazoxane, digoxin, diltiazem, dimenhyDRINATE, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, doxapram, doxorubicin, DOXOrubicin liposomal, doxycycline, edetate calcium disodium, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ergonovine, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fludarabine, fluorouracil, folic acid (as sodium salt), furosemide, gallamine, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin sodium, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, insulin (regular), irinotecan, isoproterenol, kanamycin, ketamine, labetalol, lactated ringer’s injection, lepirudin, leucovorin, levofloxacin, lidocaine, lincomycin, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, mephentermine, mesna, methohexital, methotrexate, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, multiple vitamins injection, nafcillin, nalbuphine, nalorphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oritavancin, oxaliplatin, oxytocin, PACLitaxel (solvent/surfactant), palonosetron, pancuronium, papaverine, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, piperacillin, polymyxin B, potassium acetate/, chloride, procainamide, prochlorperazine, promazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, ringer’s, riTUXimab, rocuronium, sargramostim, sodium acetate, streptomycin, succinylcholine, SUFentanil, tacrolimus, telavancin, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin -clavulanate, tigecycline, tirofiban, tna (3-in-1), tobramycin, tolazoline, tpn (2-in-1), trastuzumab, trimetaphan, tubocurarine, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, vitamin B complex with C, voriconazole</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1625">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1628">
					<section type="none" id="sidelem4x1629">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Shortened QT, heart block,</emphasis> hypotension, bradycardia, <emphasis style="bold">dysrhythmias; cardiac arrest (IV)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1639">
						<sec_title>GI:</sec_title>
						<para> Vomiting, nausea, constipation</para>
					</section>
					<section type="none" id="sidelem4x1644">
						<sec_title>HYPERCALCEMIA:</sec_title>
						<para> Drowsiness, lethargy, muscle weakness, headache, constipation, <emphasis style="bold">coma,</emphasis> anorexia, nausea, vomiting, polyuria, thirst</para>
					</section>
					<section type="none" id="sidelem4x1652">
						<sec_title>INTEG:</sec_title>
						<para> Pain, burning at IV site, <emphasis style="bold">severe venous thrombosis, necrosis, extravasation</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1659">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Crosses placenta, enters breast milk, excreted via urine and feces, half-life unknown, protein binding 40%-50%</para>
				<section type="none" id="sidelem4x1664">
					<section type="none" id="sidelem4x1665">
						<sec_title>PO:</sec_title>
						<para> Onset, peak, duration unknown, absorption from GI tract</para>
					</section>
					<section type="none" id="sidelem4x1670">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, duration <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-2 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1681">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> milk-alkali syndrome—antacids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—digoxin glycosides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—verapamil, diltiazem</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypercalcemia—thiazide diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of fluoroquinolones, tetracyclines, iron salts, phenytoin, thyroid hormones when calcium is taken PO</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of atenolol, verapamil</para>
				<section type="none" id="sidelem4x1708">
					<section type="none" id="sidelem4x1709">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> action/side effects—lily of the valley, pheasant’s eye, shark cartilage, squill</para>
					</section>
					<section type="none" id="sidelem4x1716">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> calcium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1723">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1726">
					<section type="none" id="sidelem4x1727">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1735">
							<label>•</label>
							<sec_title>ECG for decreased QT and T wave inversion<route> hypercalcemia, product should be reduced or discontinued, consider cardiac monitoring</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1738">
								<item>
									<label>•</label>
									<para>Calcium levels during treatment (8.5-11.5 g/dl is normal level); urine calcium if hypercaluria occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1743">
								<item>
									<label>•</label>
									<para>Cardiac status: rate, rhythm, CVP (PWP, PAWP if being monitored directly)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1751">
							<label>•</label>
							<sec_title>Hypocalcemia</sec_title>
							<para>
								<list id="lidelem4x1751">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypocalcemia:</emphasis> muscle twitching, paresthesia, dysrhythmias, laryngospasm</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1755">
								<item>
									<label>•</label>
									<para>Digitalized patients frequently; an increase in calcium increases digoxin toxicity risk</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1763">
							<label>•</label>
							<sec_title>Seizure precautions<route> padded side rails, decreased stimuli (noise, light); place airway suction equipment, padded mouth gag if calcium levels are low</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1766">
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1771">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1775">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased twitching, paresthesias, muscle spasms; absence of tremors, seizures, dysrhythmias, dyspnea, laryngospasm; negative Chvostek’s sign, negative Trousseau’s sign</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1781">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1785">
								<item>
									<label>•</label>
									<para>To add foods high in vit D</para>
								</item>
								<item>
									<label>•</label>
									<para>To add calcium-rich foods to diet: dairy products, shellfish, dark green leafy vegetables; to decrease oxalate- and zinc-rich foods: nuts, legumes, chocolate, spinach, soy</para>
								</item>
								<item>
									<label>•</label>
									<para>To prevent injuries; to avoid immobilization</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="1" status="active" ha="yes">
			<mono_name>canagliflozin</mono_name>
			<info>
				<pronunciation>(kan′a-gli-floe′zin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18110">Invokana</tradename>
				</tradenames>
				<class type="func"> Oral antidiabetic</class>
				<class type="chem"> SGLT 2 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1821">
				<sec_title>Action:</sec_title>
				<para>Blocks glucose reabsorption by the kidney, increases glucose excretion, lowers blood glucose concentrations</para>
			</section>
			<section type="uses" id="sidelem4x1826">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus, with diet and exercise</para>
			</section>
			<section type="contra" id="sidelem4x1831">
				<sec_title>Contraindications:</sec_title>
				<para>Dialysis, renal failure, hypersensitivity, breastfeeding, diabetic ketoacidosis</para>
				<section type="none" id="sidelem4x1836">
					<section type="none" id="sidelem4x1837">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, renal/hepatic disease, hypothyroidism, hyperglycemia, hypotension, pituitary insufficiency, type 1 diabetes mellitus, malnutrition, fever, dehydration, adrenal insufficiency, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1842">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1850">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1850">
							<item>
								<label>•</label>
								<para> 100 mg/day, may increase to 300 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1854">
					<section type="none" id="sidelem4x1855">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x1863">
							<label>•</label>
							<sec_title>
								<route>Adult PO eGFR 45-59 ml/min/1.73 m</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1875">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x1880">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1883">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1887">
									<item>
										<label>•</label>
										<para>Once daily with first meal of the day</para>
									</item>
									<item>
										<label>•</label>
										<para>Correct volume depletion before use</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1898">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1901">
					<section type="none" id="sidelem4x1902">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x1907">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, <emphasis style="bold">pancreatitis,</emphasis> constipation, nausea</para>
					</section>
					<section type="none" id="sidelem4x1915">
						<sec_title>GU:</sec_title>
						<para> Cystisis, candidiasis, urinary frequency, polyclipsia, polyuria</para>
					</section>
					<section type="none" id="sidelem4x1920">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity, rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x1925">
						<sec_title>META:</sec_title>
						<para> Hypercholesterolemia, lipidemia, hypoglycemia, <emphasis style="bold">hyperkalemia,</emphasis> hypermagnesemia, hyperphosphatemia</para>
					</section>
					<section type="none" id="sidelem4x1933">
						<sec_title>MISC:</sec_title>
						<para> Bone fractures</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1938">
				<sec_title>Pharmacokinetics</sec_title>
				<para>99% protein binding, metabolized by UGT1A9, UGT2B4, excreted 33% in urine, peak 1-2 hr, half-life 10.6-13 hr depending on dose</para>
			</section>
			<section type="interactions" id="sidelem4x1943">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1951">
					<label>•</label>
					<sec_title>
						<route>Do not use gatifloxacin</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia-sulfonylureas, insulin, MAOIs, salycilates, fibric acid derivatives, bile acid sequestrants, ACE inhibitors, angiotensin II receptor antagonists, beta blockers, SSRIs</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> glycemic control-androgens, lithium, bortezomib, quinolones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect hyperglycemia—digestive enzymes, intestinal absorbents, thiazide diuretics, loop diuretics, corticosteroids, estrogen, progestins, oral contraceptives, sympathomimetics, isoniazid, phenothiazines; protease inhibitors, atypical antipsychotics, carbonic anhydrase inhibitors, cycloSPORINE, tacrolimus, baclofen</para>
				<section type="none" id="sidelem4x1966">
					<section type="none" id="sidelem4x1967">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> urine, glucose, potassium, lipids, cholesterol</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1978">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1981">
					<section type="none" id="sidelem4x1982">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1986">
								<item>
									<label>•</label>
									<para>Hypoglycemia (weakness, hunger, dizziness, tremors, anxiety, tachycardia, sweating), hyperglycemia; even though product does not cause hypoglycemia, if patient is on sulfonylureas or insulin, hypoglycemia may be additive; if hypoglycemia occurs, treat with dextrose, or, if severe, with IV glucagon</para>
								</item>
								<item>
									<label>•</label>
									<para>For stress, surgery, or other trauma that may require a change in dose</para>
								</item>
								<item>
									<label>•</label>
									<para>A1c q3mo, monitor serum glucose; 1 hr PP throughout treatment; serum cholesterol, serum creatinine/BUN, serum electrolytes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2002">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2006">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved signs/symptoms of diabetes mellitus (decreased polyuria, polydipsia, polyphagia); clear sensorium, absence of dizziness, stable gait</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2014">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2018">
								<item>
									<label>•</label>
									<para>The symptoms of hypo/hyperglycemia, what to do about each</para>
								</item>
								<item>
									<label>•</label>
									<para>That medication must be taken as prescribed; explain consequences of discontinuing medication abruptly; that insulin may need to be used for stress, including trauma, fever, surgery</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications and herbal supplements unless approved by health care provider</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that the diet and exercise regimen must be followed; that this product is not a cure</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID and glucose source; to avoid sugar, because sugar is blocked by acarbose</para>
								</item>
								<item>
									<label>•</label>
									<para>That blood glucose monitoring is required to assess product effect</para>
								</item>
								<item>
									<label>•</label>
									<para>That GI side effects may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>candesartan (Rx)</mono_name>
			<info>
				<pronunciation>(can-deh-sar′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x20590">Atacand</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor (type AT) antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2072">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x2080">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination; CHF NYHA Class II-IV and ejection fraction ≤40%</para>
			</section>
			<section type="contra" id="sidelem4x2085">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimesters</bbw>
				</para>
				<section type="none" id="sidelem4x2100">
					<section type="none" id="sidelem4x2101">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st trimester, breastfeeding, children, geriatric patients, hypersensitivity to ACE inhibitors, volume depletion, renal/hepatic impairment, renal artery stenosis, hypotension, electrolyte abnormalities</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2106">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2109">
					<section type="none" id="sidelem4x2110">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x2118">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2118">
									<item>
										<label>•</label>
										<para> single agent 16 mg/day initially in patients who are not volume depleted, range 8-32 mg/day, with diuretic or volume depletion 8-32 mg/day as single dose or divided bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2125">
							<label>•</label>
							<sec_title>Adolescent and child ≥6 yr and weight &gt;50 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2125">
									<item>
										<label>•</label>
										<para> 8-16 mg/day or divided bid, adjust to B/P; usual range 4-32 mg/day, max 32 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2132">
							<label>•</label>
							<sec_title>Child ≥6 yr, weight &lt;50 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2132">
									<item>
										<label>•</label>
										<para> 2-16 mg/day divided 1-2 doses, max 16mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2139">
							<label>•</label>
							<sec_title>Child ≥1 yr and &lt;6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2139">
									<item>
										<label>•</label>
										<para> 0.2 mg/kg/day in 1 dose or in 2 divided doses, adjust to B/P, max 0.4 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2143">
						<sec_title>Heart failure</sec_title>
						<section type="none" id="sidelem4x2151">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2151">
									<item>
										<label>•</label>
										<para> 4 mg/day, may be doubled ≥2 wk, target dose 32 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2155">
						<sec_title>Renal/hepatic disease</sec_title>
						<section type="none" id="sidelem4x2163">
							<label>•</label>
							<sec_title>Adult<route> PO ≤8 mg/day for severe renal disease/moderate hepatic disease, adjust dose as needed</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2166">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 4, 8, 16, 32 mg</para>
					</section>
					<section type="none" id="sidelem4x2171">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2175">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Oral liquid (compounded): shake well, do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2186">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2189">
					<section type="none" id="sidelem4x2190">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> fatigue, headache, syncope</para>
					</section>
					<section type="none" id="sidelem4x2198">
						<sec_title>CV:</sec_title>
						<para> Chest pain, peripheral edema, hypotension, palpitations</para>
					</section>
					<section type="none" id="sidelem4x2203">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis, rhinitis, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x2208">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> nausea, abdominal pain, vomiting</para>
					</section>
					<section type="none" id="sidelem4x2216">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2223">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, pain</para>
					</section>
					<section type="none" id="sidelem4x2229">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, upper respiratory infection</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2236">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2243">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-4 hr, protein binding 99%, half-life 9-12 hr, duration 24 hr, extensively metabolized, excreted in urine (33%) and feces (67%)</para>
			</section>
			<section type="interactions" id="sidelem4x2248">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> lithium level—lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium, potassium-sparing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—ACE inhibitors, β-blockers, calcium channel blockers, α-blockers, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—salicylates, NSAIDs</para>
				<section type="none" id="sidelem4x2267">
					<section type="none" id="sidelem4x2268">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x2279">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> albumin, ALT/AST, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2286">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2289">
					<section type="none" id="sidelem4x2290">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="nurse">Serious hypersensitivity reaction: angioedema, anaphylaxis: facial swelling, difficulty breathing (rare)</emphasis>
						</para>
						<para>
							<bbw>For pregnancy; this product can cause fetal death when given during pregnancy (D), 2nd/3rd trimester</bbw>
						</para>
						<para>
							<list id="lidelem4x2309">
								<item>
									<label>•</label>
									<para>Response and adverse reactions, especially with renal disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2314">
								<item>
									<label>•</label>
									<para>B/P, pulse q4hr; note rate, rhythm, quality; electrolytes: potassium, sodium, calcium; baselines of renal/hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2322">
							<label>•</label>
							<sec_title>Heart failure<route> jugular venous distention, weight, edema, dyspnea, crackles</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2325">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2329">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2335">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2340">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2348">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, fever, swelling of hands or feet, irregular heartbeat, chest pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2351">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur
<bbw>To notify prescriber immediately if pregnant (D) 2nd/3rd trimester, (C) 1st trimester; to use if breastfeeding</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2365">
								<item>
									<label>•</label>
									<para>To avoid all OTC medications unless approved by prescriber; to inform all health care providers of medication use, full effect 4 wk, onset 2 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2370">
								<item>
									<label>•</label>
									<para>To use proper technique for obtaining B/P; to understand acceptable parameters; to rise slowly to sitting or standing position to minimize orthostatic hypotension; that product may cause dizziness, fainting, light-headedness</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name>capecitabine (Rx)</mono_name>
			<info>
				<pronunciation>(cap-eh-sit′ah-bean)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x23820">Xeloda</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antimetabolite</class>
				<class type="chem"> Fluoropyrimidine carbamate</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2392">
				<para>
					<confusion>
						<tradename id="tnidelem4x23920">Xeloda</tradename>
						<drug type="generic" refid="idelem4x23920">Xenical</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2396">
				<sec_title>Action:</sec_title>
				<para>Competes with physiologic substrate of DNA synthesis, thereby interfering with cell replication in the S phase of cell cycle (before mitosis); also interferes with RNA and protein synthesis; product is converted to 5-FU</para>
			</section>
			<section type="uses" id="sidelem4x2401">
				<sec_title>Uses:</sec_title>
				<para>PACLitaxel and anthracycline-resistant metastatic breast, colorectal cancer when 5-FU monotherapy is preferred; treatment of colorectal cancer patients who have undergone complete resection of their primary tumors</para>
				<section type="none" id="sidelem4x2406">
					<section type="none" id="sidelem4x2407">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Gastric/biliary tract, ovarian cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2413">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to 5-FU, infants, severe renal impairment (CCr &lt;30 ml/min)</para>
				<section type="none" id="sidelem4x2418">
					<section type="none" id="sidelem4x2419">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, infections, radiation therapy, anticoagulation, geriatric patients, renal/hepatic/cardiac disease, DPD deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2424">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2427">
					<section type="none" id="sidelem4x2428">
						<sec_title>Metastatic breast cancer resistant to both PACLitaxel and anthracycline or resistant to PACLitaxel and when further anthracycline therapy is not indicated</sec_title>
						<section type="none" id="sidelem4x2436">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2436">
									<item>
										<label>•</label>
										<para> 2500 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr after a meal × 2 wk, repeat q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2443">
						<sec_title>Breast cancer (locally advanced/metastatic) with DOCEtaxel, previously treated with anthracycline</sec_title>
						<section type="none" id="sidelem4x2451">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2451">
									<item>
										<label>•</label>
										<para> 2500 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr after a meal on days 1-14, with DOCEtaxel 75 mg/m<emphasis style="sup">2</emphasis> IV on day 1</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2461">
						<sec_title>Advanced/metastatic breast cancer (HER2 positive) previously treated with anthracycline, taxane, and trastuzumab</sec_title>
						<section type="none" id="sidelem4x2469">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2469">
									<item>
										<label>•</label>
										<para> 2000 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr after a meal on days 1-14 with lapatinib 1250 mg/day on days 1-21, repeat q21days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2476">
						<sec_title>Metastatic/locally advanced breast cancer resistant to anthracycline, previously treated with a taxane or taxane resistant, and when further anthracycline is contraindicated</sec_title>
						<section type="none" id="sidelem4x2484">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2484">
									<item>
										<label>•</label>
										<para> 2000 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr on days 1-14 with ixabepilone 40 mg/m<emphasis style="sup">2</emphasis> IV over 3 hr, repeat q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2494">
						<sec_title>As an adjuvant for Dukes C colorectal cancer with a complete resection when fluoropyrimidine alone is preferred</sec_title>
						<section type="none" id="sidelem4x2502">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2502">
									<item>
										<label>•</label>
										<para> 2500 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr within 30 min of a meal × 2 wk, repeat q3wk for 8 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2510">
						<sec_title>First-line treatment of metastatic colorectal cancer when fluoropyrimidine alone is preferred</sec_title>
						<section type="none" id="sidelem4x2518">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2518">
									<item>
										<label>•</label>
										<para> 2500 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr after a meal × 2 wk, repeat q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2525">
						<sec_title>First-line treatment of metastatic colorectal cancer with oxaliplatin with or without bevacizumab (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2533">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2533">
									<item>
										<label>•</label>
										<para> 2000 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr after a meal on days 1-14 with oxaliplatin on day 1, repeat q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2540">
						<sec_title>First-/second-line treatment of advanced colorectal cancer with oxaliplatin (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2548">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2548">
									<item>
										<label>•</label>
										<para> 2000 mg/m<emphasis style="sup">2</emphasis>/day divided q12hr on days 1-14 and oxaliplatin 130 mg/m<emphasis style="sup">2</emphasis> IV on day 1, repeat q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2558">
						<sec_title>Unresectable advanced/metastatic biliary tract cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2566">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2566">
									<item>
										<label>•</label>
										<para> 2500 mg/m<emphasis style="sup">2</emphasis> divided q12hr on days 1-14, then 7-day rest period; given with CISplatin 60 mg/m<emphasis style="sup">2</emphasis> IV over 1 hr on day 1, repeat q21days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2576">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2584">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-50 ml/min, decrease initial dose to 75% of usual dose; CCr &lt;30 ml/min, contraindicated</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2587">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x2592">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2600">
							<label>•</label>
							<sec_title>Dosage adjustments of capecitabine monotherapy based on most severe toxicity OR when used in combination with ixabepilone based on nonhematologic toxicity<route> Grade 1 toxicity</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2603">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2606">
					<section type="none" id="sidelem4x2607">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, <emphasis style="italic">headache, paresthesia, fatigue,</emphasis> insomnia</para>
					</section>
					<section type="none" id="sidelem4x2615">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Venous thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2622">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea, stomatitis, abdominal pain, constipation, dyspepsia,</emphasis><emphasis style="bold">intestinal obstruction, necrotizing enterocolitis,</emphasis> hyperbilirubinemia, <emphasis style="bold">hepatic failure, GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2634">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, lymphopenia, thrombocytopenia,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x2642">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Hand and foot syndrome, dermatitis,</emphasis> nail disorders, alopecia, rash</para>
					</section>
					<section type="none" id="sidelem4x2650">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="italic">Eye irritation, edema, myalgia,</emphasis> limb pain, <emphasis style="italic">pyrexia,</emphasis> dehydration, renal impairment</para>
					</section>
					<section type="none" id="sidelem4x2661">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, dyspnea,</emphasis><emphasis style="bold">pulmonary embolism</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2670">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Readily absorbed, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, food decreases absorption, extensively metabolized in the liver, elimination half-life 45 min</para>
			</section>
			<section type="interactions" id="sidelem4x2681">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—leucovorin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> capecitabine levels—antacids (aluminum, magnesium)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> phenytoin level—phenytoin</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> bleeding risk—anticoagulants, NSAIDs, salicylates, platelet inhibitors, thrombolytics</bbw>
				</para>
				<section type="none" id="sidelem4x2707">
					<section type="none" id="sidelem4x2708">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption; give within 30 min of a meal</para>
					</section>
					<section type="none" id="sidelem4x2715">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/HcT/RBC, neutrophils, platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2726">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2729">
					<section type="none" id="sidelem4x2730">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2738">
							<label>•</label>
							<sec_title>
								<route>Bone marrow suppression, CBC (RBC, Hct, Hgb), differential, platelet count weekly; withhold product if WBC is &lt;1000/mm</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2751">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2756">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr; fever may indicate beginning infection; no rectal temperatures</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2764">
							<para>
								<list id="lidelem4x2764">
									<item>
										<label>•</label>
										<para>Hepatic studies before, during therapy: bilirubin, ALT, AST, alk phos as needed or monthly
<bbw>
												<emphasis alert="lifethreat">Bleeding:</emphasis> hematuria, heme-positive stools, bruising or petechiae of mucosa or orifices q8hr, monitor INR and PT in those taking anticoagulants</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2777">
								<item>
									<label>•</label>
									<para>Dyspnea, crackles, unproductive cough, chest pain, tachypnea, fatigue, increased pulse, pallor, lethargy; personality changes with high doses</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2785">
							<label>•</label>
							<sec_title>Hand and foot syndrome<route> paresthesia, tingling, painful/painless swelling, blistering, erythema with severe pain of hands or feet</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2791">
							<label>•</label>
							<sec_title>Toxicity<route> severe diarrhea (multiple times/day or at night), nausea, vomiting, stomatitis, fever</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2794">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2802">
							<label>•</label>
							<sec_title>GI symptoms</sec_title>
							<para>
								<list id="lidelem4x2802">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI symptoms:</emphasis> frequency of stools, cramping; if severe diarrhea occurs, fluid, electrolytes may need to be given</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2806">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2811">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2815">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2821">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2826">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture if stomatitis is present; take with water within 30 min of end of meal</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2835">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D); to avoid pregnancy while taking this product; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2838">
								<item>
									<label>•</label>
									<para>Not to double dose if dose is missed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2844">
								<item>
									<para>
										<emphasis alert="nurse">To immediately report severe diarrhea, vomiting, stomatitis, fever of more than 100° F (37.8° C), hand and foot syndrome, anorexia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2852">
							<label>•</label>
							<sec_title>To report signs of infection<route> increased temperature, sore throat, flulike symptoms; signs of anemia</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2855">
								<item>
									<label>•</label>
									<para>OTC antidiarrheals for mild diarrhea (4-6 stools/day or diarrhea at night)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>captopril (Rx)</mono_name>
			<info>
				<pronunciation>(kap′toe-pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28650">
						<country code="CAN">Apo-Capto </country>
					</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme (ACE) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2877">
				<para>
					<confusion>
						<tradename id="tnidelem4x28770">captopril</tradename>
						<drug type="generic" refid="idelem4x28770">Capitrol/carvedilol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2881">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE; prevents conversion of angiotensin I to angiotensin II</para>
			</section>
			<section type="uses" id="sidelem4x2886">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, CHF, left ventricular dysfunction after MI, diabetic nephropathy, proteinuria</para>
				<section type="none" id="sidelem4x2891">
					<section type="none" id="sidelem4x2892">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute MI, hypertensive emergency/urgency, scleroderma renal crisis (SRC)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2897">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity, heart block, potassium-sparing diuretics, bilateral renal artery stenosis, angioedema</para>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimester</bbw>
				</para>
				<section type="none" id="sidelem4x2912">
					<section type="none" id="sidelem4x2913">
						<sec_title>Precautions:</sec_title>
						<para> Dialysis patients, hypovolemia, leukemia, scleroderma, SLE, blood dyscrasias, CHF, diabetes mellitus, thyroid/renal/hepatic disease, African descent, pregnancy (C) 1st trimester, collagen vascular disease, hyperkalemia, hyponatremia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2918">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2921">
					<section type="none" id="sidelem4x2922">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x2930">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2930">
									<item>
										<label>•</label>
										<para> initial dose: 12.5-25 mg bid-tid; may increase to 50 mg bid-tid at 1-2 wk intervals; usual range: 25-150 mg bid-tid; max 450 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2937">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2937">
									<item>
										<label>•</label>
										<para> 0.3-0.5 mg/kg/dose, may titrate up to 6 mg/kg/day in 2-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2944">
							<label>•</label>
							<sec_title>Infant (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2944">
									<item>
										<label>•</label>
										<para> 0.15-0.3 mg/kg/dose initially, max 6 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2951">
							<label>•</label>
							<sec_title>Neonate (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2951">
									<item>
										<label>•</label>
										<para> 0.01-0.1 mg/kg/dose, may increase as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2955">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x2963">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2963">
									<item>
										<label>•</label>
										<para> 25 mg bid; may increase to 50 mg tid; after 14 days, may increase to 150 mg tid if needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2970">
							<label>•</label>
							<sec_title>Adolescent (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2970">
									<item>
										<label>•</label>
										<para> 6.25-12.5 mg q8-12hr titrated up to max 50-75 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2977">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2977">
									<item>
										<label>•</label>
										<para> 0.1-2 mg/kg/dose q6-12hr, max 6 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2984">
							<label>•</label>
							<sec_title>Infant (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2984">
									<item>
										<label>•</label>
										<para> 0.15-0.3 mg/kg/dose, max 6 mg/kg/day in 1-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2991">
							<label>•</label>
							<sec_title>Neonates (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2991">
									<item>
										<label>•</label>
										<para> 0.05-0.1 mg/kg q8-24hr titrate to 0.5 mg/kg q6-24hr, max 2 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2995">
						<sec_title>Diabetic nephropathy</sec_title>
						<section type="none" id="sidelem4x3003">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3003">
									<item>
										<label>•</label>
										<para> 25 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3007">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3015">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &gt;50 ml/min, no change; CCr 10-50 ml/min, decrease dose by 25%; CCr &lt;10 ml/min, decrease dose by 50%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3018">
						<sec_title>Acute MI (unlabeled) or post-MI</sec_title>
						<section type="none" id="sidelem4x3026">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3026">
									<item>
										<label>•</label>
										<para> 6.25-12.5 mg tid, increase to 25 mg tid gradually</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3030">
						<sec_title>Hypertensive emergency/urgency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3038">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3038">
									<item>
										<label>•</label>
										<para> 25 mg, may repeat q30min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3042">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 12.5, 25, 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x3048">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3053">
								<item>
									<label>•</label>
									<para>Store in tight container at 86° F (30° C) or less</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3058">
								<item>
									<label>•</label>
									<para>1 hr before or 2 hr after meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3066">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x3066">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> may crush 25 mg tab, dissolve in 50-100 ml water; give within <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr; make sure tab completely dissolved</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3076">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3079">
					<section type="none" id="sidelem4x3080">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills</para>
					</section>
					<section type="none" id="sidelem4x3085">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> postural hypotension, <emphasis style="italic">tachycardia,</emphasis> angina</para>
					</section>
					<section type="none" id="sidelem4x3096">
						<sec_title>GI:</sec_title>
						<para> Loss of taste, increased LFTs</para>
					</section>
					<section type="none" id="sidelem4x3101">
						<sec_title>GU:</sec_title>
						<para> Impotence, dysuria, nocturia, proteinuria, <emphasis style="bold">nephrotic syndrome, acute reversible renal failure,</emphasis> polyuria, oliguria, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x3109">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, agranulocytosis, pancytopenia, thrombocytopenia,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x3117">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x3122">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema,</emphasis> hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x3130">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis><emphasis style="italic">dyspnea, cough</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3139">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1 hr; duration 2-6 hr; half-life &lt;2 hr, increased in renal disease; metabolized by liver (metabolites); excreted in urine; crosses placenta; excreted in breast milk, small amounts; protein binding 25%-30%</para>
			</section>
			<section type="interactions" id="sidelem4x3144">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x3152">
					<label>•</label>
					<sec_title>
						<route>Do not use with potassium-sparing diuretics, sympathomimetics, potassium supplements</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> possible toxicity—lithium, digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—insulin, oral antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, phenothiazines, nitrates, acute alcohol ingestion, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> captopril effect—antacids, NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x3171">
					<section type="none" id="sidelem4x3172">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x3183">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption of captopril</para>
					</section>
					<section type="none" id="sidelem4x3190">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, bilirubin, uric acid, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC, RBC, Hgb/HcT</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine acetone, ANA titer</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3205">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3208">
					<section type="none" id="sidelem4x3209">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3217">
							<label>•</label>
							<sec_title>Blood dyscrasias<route> blood studies</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3228">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x3228">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse rates at baseline, frequently</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3232">
								<item>
									<label>•</label>
									<para>Renal studies: protein, BUN, creatinine; watch for raised levels, may indicate nephrotic syndrome; increased LFTs, uric acid; glucose, potassium</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3240">
							<label>•</label>
							<sec_title>Allergic reaction<route> rash, fever, pruritus, urticaria; discontinue product if antihistamines fail to help</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3246">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x3246">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema, dyspnea, wet crackles, increased B/P, weight gain</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3250">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3254">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P with hypertension; decreased edema, moist crackles (CHF)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3260">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3265">
								<item>
									<label>•</label>
									<para>To take 1 hr before or 2 hr after meals; not to discontinue product abruptly; if dose is missed, take as soon as remembered but not if almost time for next dose; not to double doses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3270">
								<item>
									<label>•</label>
									<para>Not to use OTC products (cough, cold, or allergy) unless directed by prescriber; avoid salt substitutes, high-potassium or high-sodium foods</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3275">
								<item>
									<label>•</label>
									<para>To adhere to dosage schedule, even if feeling better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3280">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3288">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, signs of angioedema, rash, hoarseness, difficulty breathing</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3291">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3298">
								<item>
									<label>•</label>
									<para>That dizziness, fainting, light-headedness may occur during first few days of therapy; to avoid activities that require concentration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3303">
								<item>
									<label>•</label>
									<para>How to take B/P and when to notify prescriber
<bbw>To report if pregnancy is suspected or planned, pregnancy (D)</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>carbachol ophthalmic</mono_name>
			<section type="none" id="sidelem4x3325">
				<para>See <see refid="trapii:B978-0-323-44826-0.00036-7">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>carBAMazepine (Rx)</mono_name>
			<info>
				<pronunciation>(kar-ba-maz′e-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x33345">Carbatrol</tradename>
					<tradename id="tnidelem4x33344">Equetro</tradename>
					<tradename id="tnidelem4x33343">Mazepine   </tradename>
					<tradename id="tnidelem4x33342">
						<country code="CAN">Novo-Carbamaz </country>
					</tradename>
					<tradename id="tnidelem4x33341">TEGretol</tradename>
					<tradename id="tnidelem4x33340">TEGretol-XR</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> Iminostilbene derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3350">
				<para>
					<confusion>
						<tradename id="tnidelem4x33500">TEGretol</tradename>
						<drug type="generic" refid="idelem4x33500">Toradol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3354">
				<sec_title>Action:</sec_title>
				<para>Exact mechanism unknown; appears to decrease polysynaptic responses and block posttetanic potentiation</para>
			</section>
			<section type="uses" id="sidelem4x3359">
				<sec_title>Uses:</sec_title>
				<para>Tonic-clonic, complex-partial, mixed seizures; trigeminal neuralgia; bipolar disorder</para>
				<section type="none" id="sidelem4x3364">
					<section type="none" id="sidelem4x3365">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neurogenic pain, diabetic neuropathy, hiccups</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3370">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to carBAMazepine or tricyclics</para>
				<para>
					<bbw>Bone marrow suppression</bbw>
				</para>
				<section type="none" id="sidelem4x3385">
					<section type="none" id="sidelem4x3386">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children &lt;6 yr, glaucoma, AV or bundle branch block, cardiac/renal/hepatic disease, psychosis, alcoholism, hepatic porphyria</para>
						<para>
							<bbw>Hematologic disease, Asian patients, agranulocytosis, leukopenia, neutropenia, thrombocytopenia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3401">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3404">
					<section type="none" id="sidelem4x3405">
						<sec_title>Seizures</sec_title>
						<section type="none" id="sidelem4x3413">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3413">
									<item>
										<label>•</label>
										<para> 200 mg bid, may be increased by 200 mg/day in weekly intervals, give in divided doses q6-8hr; maintenance 800-1200 mg/day, max 1600 mg/day (adult); max child 12-15 yr 1000 mg/day; max child &gt;15 yr 1200 mg/day; adjust to minimum dose to control seizures;  give bid; rectal administration of  200 mg/10 ml or 6 mg/kg as a single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3426">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3426">
									<item>
										<label>•</label>
										<para> tabs 100 mg bid or susp 50 mg qid; may increase by &lt;100 mg weekly; max 1000 mg/day, usual dose 15-30 mg/kg/day;  tabs daily-bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3436">
							<label>•</label>
							<sec_title>Child &lt;6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3436">
									<item>
										<label>•</label>
										<para> 10-20 mg/kg/day in 2-3 divided doses or 4 divided dose (susp), may increase every wk, do not use ext rel</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3440">
						<sec_title>Trigeminal neuralgia</sec_title>
						<section type="none" id="sidelem4x3448">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3448">
									<item>
										<label>•</label>
										<para> 100 mg bid with meals; may increase 100 mg q12hr until pain subsides, max 1200 mg/day; maintenance 200-400 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3452">
						<sec_title>Diabetic neuropathy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3460">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3460">
									<item>
										<label>•</label>
										<para> 100 mg bid or 50 mg qid, titrate to 600-800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3464">
						<sec_title>Bipolar disorder</sec_title>
						<section type="none" id="sidelem4x3472">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3472">
									<item>
										<label>•</label>
										<para> (Equetro only [regular release]) 200 mg bid, may adjust dose q3-4days to achieve carBAMazepine level to 8-12 mcg/ml micro response, max 1600 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3477">
						<sec_title>Hiccups (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3485">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3485">
									<item>
										<label>•</label>
										<para> 200 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3489">
						<sec_title>Available forms:</sec_title>
						<para> Chewable tabs 100 mg; tabs 200 mg; ext rel tabs (XR) 100, 200, 400 mg; oral susp 100 mg/5 ml; ext rel caps 100, 200, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x3494">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3497">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3502">
									<item>
										<label>•</label>
										<para>Do not crush, chew ext rel tab; ext rel cap may be opened and beads sprinkled over food; patient should chew chewable tab, not swallow it whole</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3507">
									<item>
										<label>•</label>
										<para>With food, milk to decrease GI symptoms; shake oral susp before use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3515">
								<label>•</label>
								<sec_title>(Susp)</sec_title>
								<para>
									<list id="lidelem4x3515">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">(Susp):</emphasis> Turn off NG/enteral feeding 15 min before and hold for 15 min after</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x3519">
									<item>
										<label>•</label>
										<para>Mix an equal amount of water, D<emphasis style="inf">5</emphasis>W, 0.9% NaCl when giving by NG tube; flush tube with 15-30 ml of above sol, do not give at same time as other liquid products or diluents</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3527">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3532">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3535">
					<section type="none" id="sidelem4x3536">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness,</emphasis> dizziness, unsteadiness, confusion, fatigue, <emphasis style="bold">paralysis,</emphasis> headache, hallucinations, <emphasis style="bold">worsening of seizures,</emphasis> speech disturbance, <emphasis style="bold">suicidal thoughts/behaviors, neuroleptic malignant syndrome (when used with psychotropics),</emphasis> tremor</para>
					</section>
					<section type="none" id="sidelem4x3553">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Hypertension, CHF, dysrhythmias, AV block,</emphasis> hypotension, aggravation of cardiac artery disease</para>
					</section>
					<section type="none" id="sidelem4x3561">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, dry mouth, blurred vision, diplopia, nystagmus, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x3566">
						<sec_title>ENDO:</sec_title>
						<para> SIADH (geriatric patients)</para>
					</section>
					<section type="none" id="sidelem4x3571">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, constipation, diarrhea,</emphasis> anorexia, vomiting, abdominal pain, stomatitis, glossitis, increased hepatic enzymes, <emphasis style="bold">hepatitis, hepatic porphyria, hypercholesterolemia, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3581">
						<sec_title>GU:</sec_title>
						<para> Frequency, retention, albuminuria, glycosuria, impotence, increased BUN, <emphasis style="bold">renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3588">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, agranulocytosis, leukocytosis, aplastic anemia, eosinophilia,</emphasis> increased PT, lymphadenopathy</para>
					</section>
					<section type="none" id="sidelem4x3596">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">Stevens-Johnson syndrome,</emphasis> urticaria, photosensitivity, <emphasis style="bold">toxic epidermal necrolysis, DRESS, alopecia,</emphasis> pruritus</para>
					</section>
					<section type="none" id="sidelem4x3609">
						<sec_title>MS:</sec_title>
						<para> Osteoporosis</para>
					</section>
					<section type="none" id="sidelem4x3614">
						<sec_title>RESP:</sec_title>
						<para> Pulmonary hypersensitivity (fever, dyspnea, pneumonitis)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3619">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset slow; peak 4-5 hr (PO), 1.5 hr (susp) metabolized by liver; excreted in urine, feces; crosses placenta, blood-brain barrier; excreted in breast milk; half-life 18-65 hr, then 8-29 hr after 1st month; protein binding 76%; metabolized by CYP3A4</para>
			</section>
			<section type="interactions" id="sidelem4x3624">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x3629">
						<item>
							<label>•</label>
							<para>CNS toxicity: lithium</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x3635">
						<item>
							<para>
								<emphasis alert="nurse">Fatal reaction: MAOIs</emphasis>
							</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x3643">
					<label>•</label>
					<sec_title>Do not use with<route> NNRTIs (non-nucleoside reverse transcriptase inhibitors nefazodone)</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> carBAMazepine levels—CYP3A inhibitors (cimetidine, clarithromycin, danazol, diltiazem, erythromycin, FLUoxetine, fluvoxamine, isoniazid, valproic acid, verapamil, voriconazole)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of desmopressin, lithium, lypressin, vasopressin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> carBAMazepine effect—CYP1A2, CYP2C9 substrates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of CYP3A inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of benzodiazepines, doxycycline, felbamate, haloperidol, oral contraceptives, PHENobarbital, phenytoin, primidone, theophylline, thyroid hormones, warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> carBAMazepine levels—CYP3A4 inducers (CISplatin, darunavir, delavirdine, DOXOrubicin, felbamate, nefazodone, OXcarbazepine, PHENobarbital, phenytoin, primidone, rifampin, theophylline)</para>
				<section type="none" id="sidelem4x3670">
					<section type="none" id="sidelem4x3671">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> carBAMazepine metabolism, increased levels—echinacea</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> anticonvulsant effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x3682">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> peak concentration of carBAMazepine—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x3690">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum calcium, sodium</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3701">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3704">
					<section type="none" id="sidelem4x3705">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Asian patients for serious skin reaction; genetic test for HLA-B1502 allele before administration</bbw>
						</para>
						<section type="none" id="sidelem4x3722">
							<label>•</label>
							<sec_title>Seizures<route> character, location, duration, intensity, frequency, presence of aura, in mixed seizure disorder, worsening of symptoms may occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3728">
							<label>•</label>
							<sec_title>Trigeminal neuralgia</sec_title>
							<para>
								<list id="lidelem4x3728">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Trigeminal neuralgia:</emphasis> facial pain including location, duration, intensity, character, activity that stimulates pain</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3732">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine q3mo</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3740">
							<label>•</label>
							<sec_title>Serious skin, multiorgan hypersensitivity (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS)<route> may be increased in HLA-A 3101 gene and may be fatal</route></sec_title>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> blood studies: CBC reticulocyte counts every wk for 4 wk, then q3-6mo if on long-term therapy; if myelosuppression occurs, product should be discontinued; blood dyscrasias: fever, sore throat, bruising, rash, jaundice, agranulocytosis and aplastic anemia may occur</bbw>
						</para>
						<para>
							<list id="lidelem4x3756">
								<item>
									<label>•</label>
									<para>Blood studies: ALT, AST, bilirubin; serum calcium, may be decreased and lead to osteoporosis; cholesterol periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3764">
							<label>•</label>
							<sec_title>
								<route>Product levels during initial treatment or when changing dose; should remain at 4-12 mcg/ml; anorexia may indicate increased blood levels</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3768">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3773">
								<item>
									<label>•</label>
									<para>Eye problems: need for ophthalmic examinations before, during, after treatment (slit lamp, funduscopy, tonometry)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3778">
								<item>
									<label>•</label>
									<para>Allergic reaction: purpura, red, raised rash; if these occur, product should be discontinued; increased risk if past hypersensitivity to hydantoins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3784">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: bone marrow depression, nausea, vomiting, ataxia, diplopia, CV collapse</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3789">
								<item>
									<label>•</label>
									<para>Hard candy, gum, frequent rinsing for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3794">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3798">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; document on patient’s chart</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3804">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3809">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name, and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3814">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness usually for the first 3 days of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3819">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use, seizures may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3827">
							<label>•</label>
							<sec_title>
								<route>To immediately report chills, rash, light-colored stools, dark urine, yellowing of skin and eyes, abdominal pain, sore throat, mouth ulcers, bruising, blurred vision, dizziness, skin rash, fever</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3830">
								<item>
									<label>•</label>
									<para>That urine may turn pink to brown</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3838">
							<label>•</label>
							<sec_title>
								<route>To notify if pregnancy is planned or suspected, pregnancy (D), avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active" ha="yes">
			<mono_name>CARBOplatin (Rx)</mono_name>
			<info>
				<pronunciation>(kar-boe-pla′-tin)</pronunciation>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Platinum coordination compound</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3861">
				<para>
					<confusion>
						<tradename id="tnidelem4x38610">CARBOplatin</tradename>
						<drug type="generic" refid="idelem4x38610">CISplatin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3865">
				<sec_title>Action:</sec_title>
				<para>Produces interstrand DNA cross-links and, to a lesser extent, DNA-protein cross-links; activity is not cell-cycle–phase specific</para>
			</section>
			<section type="uses" id="sidelem4x3871">
				<sec_title>Uses:</sec_title>
				<para>Initial treatment of advanced ovarian cancer in combination with other agents; palliative treatment of ovarian carcinoma recurrent after treatment with other antineoplastic agents</para>
				<section type="none" id="sidelem4x3876">
					<section type="none" id="sidelem4x3877">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), bladder/breast/head/neck/lung/testicular cancer, bone marrow ablation, malignant glioma, neuroblastoma, non-Hodgkin’s lymphoma, osteogenic sarcoma, soft-tissue sarcoma, stem-cell transplant preparation, Wilms’ tumor, stage I seminoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3882">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, significant bleeding, aluminum products used to prepare or administer CARBOplatin</para>
				<para>
					<bbw>Severe bone marrow depression, platinum compound hypersensitivity (anaphylaxis)</bbw>
				</para>
				<section type="none" id="sidelem4x3897">
					<section type="none" id="sidelem4x3898">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, radiation therapy within 1 mo, other cancer chemotherapy within 1 mo, renal/hepatic disease, hearing impairment</para>
						<para>
							<bbw>Anemia, infection</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3913">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3916">
					<section type="none" id="sidelem4x3917">
						<sec_title>Dosing with the Calvert equation</sec_title>
						<section type="none" id="sidelem4x3926">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x3926">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> The total CARBOplatin dose in mg for adults may be calculated using the Calvert equation:<mml:math xmlns:mml="http://www.w3.org/Math/DTD/mathml2/mathml2.dtd">
												<mml:mtext>Total dose (mg) = target AUC × (GFR + 25)</mml:mtext>
											</mml:math></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3938">
							<label>•</label>
							<sec_title>Children</sec_title>
							<para>
								<list id="lidelem4x3938">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Children:</emphasis> Calculate CARBOplatin dosage (mg/m<emphasis style="sup">2</emphasis>) in children:<mml:math xmlns:mml="http://www.w3.org/Math/DTD/mathml2/mathml2.dtd">
												<mml:mtext>Total dose (mg/m<mml:sup>2</mml:sup>) = target AUC × [(0.93 × GFR) + 15]</mml:mtext>
											</mml:math></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3953">
						<sec_title>Advanced ovarian cancer</sec_title>
						<section type="none" id="sidelem4x3961">
							<label>•</label>
							<sec_title>Adult (single agent)<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x3961">
									<item>
										<label>•</label>
										<para> initially 300 mg/m<emphasis style="sup">2</emphasis> on day 1 with cyclophosphamide, 600 mg/m<emphasis style="sup">2</emphasis> on day 1, repeat q4wk × 6 cycles; refractory tumors 360 mg/m<emphasis style="sup">2</emphasis> single dose, may repeat q4wk as needed, do not repeat until neutrophils &gt;2000/mm<emphasis style="sup">3</emphasis> and platelets &gt;100,000/mm<emphasis style="sup">3</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3981">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3989">
							<label>•</label>
							<sec_title>Adult (single agent)<route> IV INFUSION CCr 41-59 ml/min, 250 mg/m</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4002">
						<sec_title>ALL (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4010">
							<label>•</label>
							<sec_title>Adult &lt;21 yr/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4010">
									<item>
										<label>•</label>
										<para> 635 mg/m<emphasis style="sup">2</emphasis> on day 3 with ifosfamide, mesna, etoposide</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4017">
						<sec_title>Relapsed Wilms’ tumor (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4025">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4025">
									<item>
										<label>•</label>
										<para> 400 mg/m<emphasis style="sup">2</emphasis> × 2 days with etoposide, ifosfamide</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4032">
						<sec_title>Osteogenic sarcoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4040">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4040">
									<item>
										<label>•</label>
										<para> 560 mg/m<emphasis style="sup">2</emphasis> on day 1 with ifosfamide 2.65 g/m<emphasis style="sup">2</emphasis>/day  on days 1-3</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4053">
						<sec_title>Neuroblastoma/soft-tissue sarcoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4061">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4061">
									<item>
										<label>•</label>
										<para> 300-600 mg/m<emphasis style="sup">2</emphasis> q4wk or 400 mg/m<emphasis style="sup">2</emphasis>/day for 2 days q4wk or 160 mg/m<emphasis style="sup">2</emphasis>/day × 5 days q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4074">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder for inj 50-, 150-, 450-mg vials; aqueous sol for inj 50 mg/5-ml vial, 150 mg/15-ml vial, 450 mg/45-ml vial, 600 mg/60-ml vial</para>
					</section>
					<section type="none" id="sidelem4x4079">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4083">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product and prn for vomiting</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4089">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x4097">
								<label>•</label>
								<sec_title>
									<route>Do not use needles or IV administration sets that contain aluminum; may cause precipitate or loss of potency</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x4103">
								<label>•</label>
								<sec_title>
									<route>Use cytotoxic handling procedures</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x4106">
									<item>
										<label>•</label>
										<para>Store protected from light at room temperature; reconstituted vials stable for 24 hr at room temperature, solutions further diluted in D<emphasis style="inf">5</emphasis>W or NS are stable for 8 hr at room temperature. Paraplatin multidose (10 mg/ml) vials stable for up to 14 days after entry into vial</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4117">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x4117">
										<item>
											<label>•</label>
											<para> CARBOplatin 50, 150, or 450 mg with 5, 15, or 45 ml, respectively, of sterile water for inj, D<emphasis style="inf">5</emphasis>W, or NaCl (10 mg/ml); then further  with the same sol to 0.5-4 mg/ml;  over 15 min-1 hr (intermittent INFUSION)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4133">
								<label>•</label>
								<sec_title>
									<route>Continuous IV INFUSION</route>
								</sec_title>
								<para>
									<list id="lidelem4x4133">
										<item>
											<label>•</label>
											<para> give over 24 hr; max dose based on (GFR=125 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>/0.2% NaCl, D<emphasis style="inf">5</emphasis>/0.45% NaCl, D<emphasis style="inf">5</emphasis>/0.9% NaCl, 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, sterile water for inj</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, levorphanol, lidocaine, linezolid injection, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, pentamidine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, potassium chloride, potassium phosphates, prochlorperazine, promethazine, propofol, propranolol, ranitidine, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate, sodium bicarbonate, sodium phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, topotecan, TPN, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4159">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4162">
					<section type="none" id="sidelem4x4163">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures, central neurotoxicity,</emphasis><emphasis style="italic">peripheral neuropathy,</emphasis> dizziness, confusion</para>
					</section>
					<section type="none" id="sidelem4x4173">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac abnormalities (fatal CV events), stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4180">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, <emphasis style="italic">vestibular toxicity,</emphasis> visual changes</para>
					</section>
					<section type="none" id="sidelem4x4188">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Severe nausea, vomiting,</emphasis> diarrhea, weight loss, mucositis, anorexia, constipation, taste change</para>
					</section>
					<section type="none" id="sidelem4x4196">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, pancytopenia, neutropenia, anemia,</emphasis> bleeding</para>
					</section>
					<section type="none" id="sidelem4x4204">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> dermatitis, rash, erythema, pruritus, urticaria</para>
					</section>
					<section type="none" id="sidelem4x4212">
						<sec_title>META:</sec_title>
						<para> Hypomagnesemia, hypocalcemia, hypokalemia, hyponatremia, hyperuremia</para>
					</section>
					<section type="none" id="sidelem4x4217">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4224">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Initial half-life 1-2 hr, postdistribution half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-6 hr, not bound to plasma proteins, excreted by the kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x4235">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: nephrotoxicity or ototoxicity—aminoglycosides, amphotericin B</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—aspirin, NSAIDs, thrombolytics, anticoagulants, platelet inhibitors</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—radiation, bone marrow suppressants</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—myelosuppressives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> phenytoin levels, monitor levels</para>
				<section type="none" id="sidelem4x4257">
					<section type="none" id="sidelem4x4258">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, BUN, alk phos, bilirubin, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, neutrophils, WBC, RBC, Hgb/HCT, calcium, potassium, magnesium, phosphate</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4269">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4272">
					<section type="none" id="sidelem4x4273">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>To only be used by person experienced in the use of chemotherapeutic products, in a specialized care setting</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> CBC, differential, platelet count weekly; withhold product if neutrophil count is &lt;2000/mm3 or platelet count is &lt;100,000/mm3; notify prescriber of results; calcium, magnesium, phosphate, potassium, sodium, uric acid, CCR, bilirubin; CCr &lt;60 ml/min may be responsible for increased bone marrow suppression; assess frequently for infection and treat active infection before use</bbw>
						</para>
						<para>
							<list id="lidelem4x4305">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine, serum uric acid; urine CCr before, during therapy; I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4310">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr (may indicate beginning infection)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4318">
							<label>•</label>
							<sec_title>
								<route>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed or monthly; jaundice of skin, sclera; dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</route>
							</sec_title>
						</section>
						<para>
							<bbw>Anaphylaxis: hypotension, rash, pruritus, wheezing, tachycardia may occur within a few mins of use; notify prescriber after discontinuing product; resuscitation equipment, corticosteroids, epinephrine should be available</bbw>
						</para>
						<para>
							<list id="lidelem4x4333">
								<item>
									<label>•</label>
									<para>Delay dental work until blood counts have returned to normal; regular toothbrushes, dental floss, and toothpicks should not be used; use soft bristle toothbrush</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4341">
							<label>•</label>
							<sec_title>Peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x4341">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Peripheral neuropathy:</emphasis> may be increased in geriatric patients</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4348">
							<label>•</label>
							<sec_title>
								<route>Bleeding; hematuria, stool guaiac, bruising, petechiae, mucosa or orifices; avoid all IM injections if platelets &lt;50,000/mm</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4354">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4359">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4363">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing size of tumor, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4369">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4374">
								<item>
									<label>•</label>
									<para>To report ringing/roaring in the ears; numbness, tingling in face, extremities; weight gain</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4382">
							<label>•</label>
							<sec_title>
								<route>That impotence or amenorrhea can occur; that this is reversible after treatment is discontinued; to notify prescriber if pregnancy is suspected or planned; pregnancy (D), that contraception should be used if patient is fertile</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x4388">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed during treatment</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4391">
								<item>
									<label>•</label>
									<para>To avoid OTC products with aspirin, NSAIDs, alcohol; not to receive vaccinations during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4397">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately of fever, fatigue, sore throat, bleeding, bruising, chills, back pain, blood in stools, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4402">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make the patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4407">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infections; to avoid the use of razors, stiff-bristle toothbrushes</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>carboprost (Rx)</mono_name>
			<info>
				<pronunciation>(kar′boe-prost)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x44180">Hemabate</tradename>
				</tradenames>
				<class type="func"> Oxytocic, abortifacient</class>
				<class type="chem"> Prostaglandin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4428">
				<sec_title>Action:</sec_title>
				<para>Stimulates uterine contractions, causes complete abortion in approximately 16 hr</para>
			</section>
			<section type="uses" id="sidelem4x4433">
				<sec_title>Uses:</sec_title>
				<para>Abortion at 13-20 wk gestation, postpartum hemorrhage caused by uterine atony not controlled by other methods</para>
				<section type="none" id="sidelem4x4438">
					<section type="none" id="sidelem4x4439">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hemorrhagic cystitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4444">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or benzyl alcohol, severe CV/respiratory/renal/hepatic disease, PID</para>
				<section type="none" id="sidelem4x4449">
					<section type="none" id="sidelem4x4450">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), asthma, anemia, jaundice, diabetes mellitus, hypo/hypertension, seizure disorders, past uterine surgery</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4455">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4458">
					<section type="none" id="sidelem4x4459">
						<sec_title>Pregnancy termination between 13-20 wk gestation</sec_title>
						<section type="none" id="sidelem4x4467">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4467">
									<item>
										<label>•</label>
										<para> 100 mcg (0.4 ml) test dose, then 250 mcg, then 250 mcg q1½-3½hr; may increase to 500 mcg if no response, max 12 mg total dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4471">
						<sec_title>Postpartum hemorrhage</sec_title>
						<section type="none" id="sidelem4x4479">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4479">
									<item>
										<label>•</label>
										<para> 250 mcg, repeat at 15- to 90-min intervals; max total dosage 2 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4483">
						<sec_title>Hemorrhagic cystitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4491">
							<label>•</label>
							<sec_title>Adult<route> INTRAVESICULAR</route></sec_title>
							<para>
								<list id="lidelem4x4491">
									<item>
										<label>•</label>
										<para> 0.8 mg/dl in 50 ml of saline instilled into the bladder for 60 min, q6hr × 4 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4495">
						<sec_title>Available forms:</sec_title>
						<para> Inj 250 mcg/ml ​</para>
					</section>
					<section type="none" id="sidelem4x4500">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4504">
								<item>
									<label>•</label>
									<para>Only by trained personnel in a hospital that can provide emergency services</para>
								</item>
								<item>
									<label>•</label>
									<para>Incomplete abortion may occur in 20% of patients</para>
								</item>
								<item>
									<label>•</label>
									<para>Give antiemetics to prevent nausea/vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in refrigerator</para>
								</item>
								<item>
									<label>•</label>
									<para>In deep muscle mass; aspirate before inj, rotate inj sites if additional doses given</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4530">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4533">
					<section type="none" id="sidelem4x4534">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever, chills,</emphasis> headache, anxiety, weakness</para>
					</section>
					<section type="none" id="sidelem4x4542">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4549">
						<sec_title>CV:</sec_title>
						<para> Hypertension</para>
					</section>
					<section type="none" id="sidelem4x4554">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Uterine rupture,</emphasis> vaginal pain, breast tenderness</para>
					</section>
					<section type="none" id="sidelem4x4562">
						<sec_title>MS:</sec_title>
						<para> Back pain, leg cramps</para>
					</section>
					<section type="none" id="sidelem4x4567">
						<sec_title>RESP:</sec_title>
						<para> Wheezing</para>
					</section>
					<section type="none" id="sidelem4x4572">
						<sec_title>INTEG:</sec_title>
						<para> Sweating, rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4577">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 15-60 min, duration 24 hr, excreted in urine (major metabolites)</para>
			</section>
			<section type="interactions" id="sidelem4x4582">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action—other oxytocics</para>
			</section>
			<section type="considerations" id="sidelem4x4589">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4592">
					<section type="none" id="sidelem4x4593">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4598">
								<item>
									<label>•</label>
									<para>B/P, pulse; watch for change that may indicate hemorrhage</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4606">
							<label>•</label>
							<sec_title>
								<route>For length, duration of contractions; notify prescriber of contractions that last more than 1 min or absence of contractions; watch for signs of uterine rupture</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x4612">
							<label>•</label>
							<sec_title>
								<route>For incomplete abortion, pregnancy must be terminated by another method; product is teratogenic</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4615">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4619">
								<item>
									<label>•</label>
									<para>Therapeutic response: expulsion of fetus, control of bleeding</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4626">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4634">
							<label>•</label>
							<sec_title>
								<route>To report increased blood loss, abdominal cramps, increased temperature, foul-smelling lochia</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>carfilzomib</mono_name>
			<info>
				<pronunciation>(car-fil′zoe-mib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x46420">Kyprolis</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic response modifiers</class>
				<class type="chem"> Signal transduction inhibitors (STIs)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x4652">
				<sec_title>Action:</sec_title>
				<para>Antiproliferative and proapoptotic activity</para>
			</section>
			<section type="uses" id="sidelem4x4657">
				<sec_title>Uses:</sec_title>
				<para>Multiple myeloma in those who have received ≥2 therapies (including bortezomib and immunomodulatory agents)</para>
			</section>
			<section type="contra" id="sidelem4x4662">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x4667">
					<section type="none" id="sidelem4x4668">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, cardiac disease, cardiac arrest, dysrhythmias, MI, infusion-related reactions, pulmonary/hepatic disease, edema, thrombocytopenia, neutropenia, tumor lysis syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4673">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4681">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x4681">
							<item>
								<label>•</label>
								<para> 20 mg/m<emphasis style="sup">2</emphasis> over 2-10 min on days 1, 2, 8, 9, 15, 16, then 12 day rest (days 17-28), then may increase to 27 mg/m<emphasis style="sup">2</emphasis> on days 1, 2, 8, 9, 15, 16 repeated every 28 days</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<list id="lidelem4x4692">
						<item>
							<para>
								<emphasis alert="nurse">Refer to package insert for dosage adjustments for treatment-related toxicity</emphasis>
							</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x4697">
					<section type="none" id="sidelem4x4698">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 60 mg</para>
					</section>
					<section type="none" id="sidelem4x4703">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4707">
								<item>
									<label>•</label>
									<para>Premedicate with dexamethasone 4 mg PO/IV before all carfilzomib 20-mg/m<emphasis style="sup">2</emphasis> doses during cycle 1 and before all carfilzomib 27-mg/m<emphasis style="sup">2</emphasis> doses in cycle 2; dexamethasone may be given in subsequent cycles if infusion-related reactions occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Hydration with 250-500 ml of NS or other IV fluids before each dose in cycle 1; additional hydration with 250-500 ml may be given after the carfilzomib infusion in cycle 1, continue hydration as needed</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not mix with other products</para>
								</item>
								<item>
									<label>•</label>
									<para>Flush IV line with NS or D<emphasis style="inf">5</emphasis>W for injection, before and after use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4737">
							<sec_title>Reconstitution:</sec_title>
							<para>
								<list id="lidelem4x4741">
									<item>
										<label>•</label>
										<para>Add 29 ml of sterile water for injection to the inside wall of the vial to minimize foaming (2 mg/mL); to mix, gently swirl and/or invert the vial slowly for about 1 min or until the cake or powder completely dissolves; do not shake; if foaming occurs, allow the solution to rest for 2 to 5 min or until foaming subsides; visually inspect for particulate and discoloration before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4747">
							<sec_title>IV injection route</sec_title>
							<para>
								<list id="lidelem4x4751">
									<item>
										<label>•</label>
										<para>Give over 2-10 min; do not give as an IV bolus; the reconstituted sol may be stored in the vial/syringe at room temperature × 4 hr or ≤24 hr refrigerated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4757">
							<sec_title>IV infusion route</sec_title>
							<para>
								<list id="lidelem4x4761">
									<item>
										<label>•</label>
										<para>May further dilute in D<emphasis style="inf">5</emphasis>W; measure and inject the correct dose from the reconstituted vial into 50 ml D<emphasis style="inf">5</emphasis>W</para>
									</item>
									<item>
										<label>•</label>
										<para>Administer IV over 2-10 min</para>
									</item>
									<item>
										<label>•</label>
										<para>The diluted solution may be stored at room temperature × 4 hr or ≤24 hr refrigerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4783">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4786">
					<section type="none" id="sidelem4x4787">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x4792">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure</emphasis>, hypertension</para>
					</section>
					<section type="none" id="sidelem4x4800">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, dyspepsia, anorexia, diarrhea, <emphasis style="bold">hepatic failure</emphasis>, constipation</para>
					</section>
					<section type="none" id="sidelem4x4808">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4815">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, hypercalcemia, hypomagnesemia, hyponatremia, hypophosphatemia</para>
					</section>
					<section type="none" id="sidelem4x4820">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, infusion-related reactions</para>
					</section>
					<section type="none" id="sidelem4x4825">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4830">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 97%</para>
			</section>
			<section type="considerations" id="sidelem4x4836">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4839">
					<section type="none" id="sidelem4x4840">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="nurse">Tumor lysis syndrome (TLS): hydrate well; assess for hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, uremia</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Hematologic toxicity grade 3 and 4 neutropenia and thrombocytopenia; platelet nadirs occur day 8 of each 28-day cycle; counts return to baseline before the start of the next cycle; monitor blood and platelet counts frequently; hold dose for grade 3 or 4 neutropenia or grade 4 thrombocytopenia, may require dosage reduction</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Serious liver toxicity: AST/ALT and bilirubin elevations and rare cases of fatal hepatic failure have occurred; monitor hepatic enzymes frequently; withhold doses until resolution or return to baseline in grade 3 or 4-AST/ALT or bilirubin elevations</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Serious cardiac toxicity: fatal cardiac arrest, CHF with decreased left ventricular function/ejection fraction, myocardial ischemia, and pulmonary edema; those with NYHA class III/IV CHF, MI within 6 mo, cardiac arrhythmias (conduction abnormalities) may be at increased risk; monitor for cardiac complications; withhold doses until resolution or return to baseline for grade 3 or 4 cardiac toxicity</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Infusion-related reactions: may occur ≤24 hr after dose; premedication with dexamethasone is recommended; assess for fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, angina</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4868">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4872">
								<item>
									<label>•</label>
									<para>Decreased spread of multiple myeloma</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4878">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4882">
								<item>
									<label>•</label>
									<para>To promptly report infusion-related symptoms (fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, angina), report renal/liver symptoms, avoid infections</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>carglumic acid</mono_name>
			<info>
				<pronunciation>(kar-gloo′mik)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x48930">Carbaglu</tradename>
				</tradenames>
				<class type="func"> Antihyperammonemic agent</class>
			</info>
			<section type="actions" id="sidelem4x4899">
				<sec_title>Action:</sec_title>
				<para>The enzyme <emphasis style="italic">N</emphasis>-acetylglutamate synthase (NAGS) produces <emphasis style="italic">N</emphasis>-acetylglutamate (NAG), which is an essential activator of carbamoyl phosphate synthetase 1 (CPS 1); CPS 1 is the first enzyme of the urea cycle, and the enzyme converts ammonia to urea; patients with NAGS deficiency do not produce enough NAG, resulting in hyperammonemia; carglumic acid is a synthetic structural analog of NAG that works to activate CPS 1 and thus convert ammonia to urea</para>
			</section>
			<section type="uses" id="sidelem4x4910">
				<sec_title>Uses:</sec_title>
				<para>Acute or chronic hyperammonemia in persons with <emphasis style="italic">N</emphasis>-acetylglutamate synthetase deficiency</para>
				<section type="none" id="sidelem4x4918">
					<section type="none" id="sidelem4x4919">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, pregnancy (C), geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4924">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4932">
					<label>•</label>
					<sec_title>Adult/child</sec_title>
					<para>
						<list id="lidelem4x4932">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult/child:</emphasis> PO 100-250 mg/kg/day (rounded to the nearest 100 mg) initially, divided; bid-qid, given immediately before meals, titrate to ammonia level; usual maintenance dose &lt;100 mg/kg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4936">
					<section type="none" id="sidelem4x4937">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200 mg</para>
					</section>
					<section type="none" id="sidelem4x4942">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4946">
								<item>
									<label>•</label>
									<para>Do not give whole or crushed tablets, disperse each tab in ≥2.5 ml of water immediately before use; the tabs do not dissolve completely in water, and undissolved tab particles can remain; rinse the mixing container with water and give to the patient, do not mix with foods or other fluids</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4952">
						<sec_title>Nasogastric tube</sec_title>
						<para>
							<list id="lidelem4x4956">
								<item>
									<label>•</label>
									<para>Mix each tab in ≥2.5 ml of water (80 mg/ml), shake gently, give the correct volume immediately through the NG tube, flush with additional water, discard any unused portion</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4963">
						<sec_title>Oral syringe</sec_title>
						<para>
							<list id="lidelem4x4967">
								<item>
									<label>•</label>
									<para>Mix each tab in ≥2.5 ml of water (80 mg/ml), shake gently, draw up the appropriate volume in an oral syringe and give immediately, refill syringe with ≥1-2 ml and give immediately, discard any unused portion</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4973">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4976">
					<section type="none" id="sidelem4x4977">
						<sec_title>CNS:</sec_title>
						<para> Headache, fever, asthenia</para>
					</section>
					<section type="none" id="sidelem4x4982">
						<sec_title>EENT:</sec_title>
						<para> Tonsillitis, ear infections</para>
					</section>
					<section type="none" id="sidelem4x4987">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, vomiting, taste change, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x4992">
						<sec_title>OTHER:</sec_title>
						<para> Infection, anemia, weight loss, rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4997">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3 hr, half-life 5.6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5002">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5005">
					<section type="none" id="sidelem4x5006">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb level</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5013">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5016">
					<section type="none" id="sidelem4x5017">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis style="bold">Neurologic symptoms and ammonia levels:</emphasis> Headache, fever, change in level of consciousness</para>
						<para>
							<emphasis style="bold">Infection:</emphasis> Assess for upper respiratory infections, influenza, pneumonia</para>
					</section>
					<section type="none" id="sidelem4x5028">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5032">
								<item>
									<label>•</label>
									<para>Decreasing ammonia levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5038">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5042">
								<item>
									<label>•</label>
									<para>Not to swallow whole or crush, but disperse in water</para>
								</item>
								<item>
									<label>•</label>
									<para>That blood for lab tests will be drawn regularly</para>
								</item>
								<item>
									<label>•</label>
									<para>To advise prescriber if pregnancy is planned or suspected, not to breastfeed</para>
								</item>
								<item>
									<label>•</label>
									<para>That a high-calorie, low-protein diet is necessary when ammonia levels are elevated</para>
								</item>
								<item>
									<label>•</label>
									<para>To report adverse reactions of vomiting, infection, ear pain, headache</para>
								</item>
								<item>
									<label>•</label>
									<para>To store unopened containers in refrigerator; opened bottle may be stored at room temperature for up to 1 mo; product stored at controlled room temperature should not be returned to a refrigerator; protect from moisture; discard opened bottle after 30 days</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>carisoprodol (Rx)</mono_name>
			<info>
				<pronunciation>(kar-eye-soe-proe′dole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50780">Soma</tradename>
				</tradenames>
				<class type="func"> Skeletal muscle relaxant, central acting</class>
				<class type="chem"> Meprobamate congener</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x5091">
				<para>
					<confusion>
						<tradename id="tnidelem4x50910">Soma</tradename>
						<drug type="generic" refid="idelem4x50910">Soma Compound</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5095">
				<sec_title>Action:</sec_title>
				<para>Depresses CNS by blocking interneuronal activity in descending reticular formation, spinal cord, thereby producing sedation</para>
			</section>
			<section type="uses" id="sidelem4x5100">
				<sec_title>Uses:</sec_title>
				<para>Relieving pain, stiffness with musculoskeletal disorders</para>
			</section>
			<section type="contra" id="sidelem4x5105">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to these products or carbamates, intermittent porphyria</para>
				<section type="none" id="sidelem4x5110">
					<section type="none" id="sidelem4x5111">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, Asian patients, renal/hepatic disease, substance abuse, seizure disorder, CNS depression, abrupt discontinuation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5116">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5124">
					<label>•</label>
					<sec_title>Adult/adolescent ≥16 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5124">
							<item>
								<label>•</label>
								<para> 250-350 mg tid and at bedtime, max 3 wk of use</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5128">
					<section type="none" id="sidelem4x5129">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 350 mg</para>
					</section>
					<section type="none" id="sidelem4x5134">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5138">
								<item>
									<label>•</label>
									<para>With meals for GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>For short term (2-3 wk), potential for habituation</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5154">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5157">
					<section type="none" id="sidelem4x5158">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, weakness, drowsiness,</emphasis> headache, tremor, depression, insomnia, ataxia, irritability, <emphasis style="bold">seizures</emphasis>, confusion, flushing</para>
					</section>
					<section type="none" id="sidelem4x5169">
						<sec_title>CV:</sec_title>
						<para> Postural hypotension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x5174">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, temporary loss of vision</para>
					</section>
					<section type="none" id="sidelem4x5180">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, hiccups, epigastric discomfort</para>
					</section>
					<section type="none" id="sidelem4x5188">
						<sec_title>HEMA:</sec_title>
						<para> Eosinophilia, pancytopenia</para>
					</section>
					<section type="none" id="sidelem4x5193">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, fever, facial flushing, <emphasis style="bold">erythema multiforme</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5200">
						<sec_title>RESP:</sec_title>
						<para> Asthmatic attacks</para>
					</section>
					<section type="none" id="sidelem4x5205">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5212">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5215">
					<section type="none" id="sidelem4x5216">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr; peak 4 hr; duration 4-6 hr; extensively metabolized by liver, substrate of CYP2C19; excreted in urine; crosses placenta; excreted in breast milk (large amounts); half-life 8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5227">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5235">
					<label>•</label>
					<sec_title>
						<route>Do not use together with meprobamate</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, tricyclics, opioids, barbiturates, sedatives, hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> carisoprodol effect—CYP2C19 inhibitors (FLUoxetine, fluvoxaMINE, isoniazid, modafinil)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> carisoprodol effect—CYP219 inducers (rifampin)</para>
				<section type="none" id="sidelem4x5250">
					<section type="none" id="sidelem4x5251">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> metabolism of carisoprodol—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x5262">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> eosinophils</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> RBC, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5273">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5276">
					<section type="none" id="sidelem4x5277">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5285">
							<label>•</label>
							<sec_title>
								<route>Pain,</route>
							</sec_title>
							<para>
								<list id="lidelem4x5285">
									<item>
										<label>•</label>
										<para> stiffness, mobility, activities of daily living at baseline and throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5292">
							<label>•</label>
							<sec_title>ECG in seizure patients<route> poor seizure control has occurred among patients taking this product</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5295">
								<item>
									<label>•</label>
									<para>BUN, creatinine at baseline and periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5303">
							<label>•</label>
							<sec_title>Idiosyncratic reaction<route> (weakness, dizziness, blurred vision, confusion, euphoria), anaphylaxis within a few minutes or hours of 1st to 4th dose, withhold and notify prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5309">
							<label>•</label>
							<sec_title>Allergic reactions<route> rash, fever, respiratory distress, anaphylaxis, angioedema</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5315">
							<label>•</label>
							<sec_title>CNS depression</sec_title>
							<para>
								<list id="lidelem4x5315">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS depression:</emphasis> dizziness, drowsiness, psychiatric symptoms, abuse potential</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5322">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> withdrawal reactions do occur but may be mild, dependence may occur</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5325">
								<item>
									<label>•</label>
									<para>Assistance with ambulation if dizziness, drowsiness occurs, especially for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5330">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5334">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, spasticity; increased ROM</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5340">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5345">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness, dizziness occur; not to drive while taking product; to avoid rapid position changes, postural hypotension occurs, not to use for &gt;2-3 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5350">
								<item>
									<label>•</label>
									<para>To avoid using OTC medications (cough preparations, antihistamines) unless directed by prescriber; not to take with alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5358">
							<label>•</label>
							<sec_title>Idiosyncratic reaction<route> To report weakness, dizziness, blurred vision, confusion, euphoria, if these occur, to withhold product and call prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5364">
							<label>•</label>
							<sec_title>To report allergic reaction immediately<route> rash, swelling of tongue/lips, hives, dyspnea</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5367">
								<item>
									<label>•</label>
									<para>To take with food or milk for GI symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name>carmustine (Rx)</mono_name>
			<info>
				<pronunciation>(kar-mus′teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x53841">BiCNU</tradename>
					<tradename id="tnidelem4x53840">Gliadel</tradename>
				</tradenames>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Nitrosourea</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x5394">
				<sec_title>Action:</sec_title>
				<para>Alkylates DNA, RNA; able to inhibit enzymes that allow for the synthesis of amino acids in proteins; activity is not cell-cycle–phase specific</para>
			</section>
			<section type="uses" id="sidelem4x5400">
				<sec_title>Uses:</sec_title>
				<para>Brain tumors such as glioblastoma, medulloblastoma, brain stem glioma, astrocytoma, ependymoma, metastatic brain tumors; multiple myeloma (with predniSONE), non-Hodgkin’s disease, Hodgkin’s disease, other lymphomas; GI, breast, bronchogenic, renal carcinomas; wafer, as adjunct to surgery/radiation for patients newly diagnosed with high-grade malignant glioma</para>
				<section type="none" id="sidelem4x5405">
					<section type="none" id="sidelem4x5406">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Ablation, mycosis fungoides, stem cell transplant preparation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5411">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, leukopenia, thrombocytopenia</para>
				<section type="none" id="sidelem4x5416">
					<section type="none" id="sidelem4x5417">
						<sec_title>Precautions:</sec_title>
						<para> Dental disease, extravasation, females, infection, secondary malignancy, thrombocytopenia, renal disease</para>
						<para>
							<bbw>Bone marrow suppression, pulmonary fibrosis, bleeding, infection</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5432">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5435">
					<section type="none" id="sidelem4x5436">
						<sec_title>Brain tumors, Hodgkin’s disease, malignant lymphoma, multiple myeloma</sec_title>
						<section type="none" id="sidelem4x5444">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5444">
									<item>
										<label>•</label>
										<para> 75-100 mg/m<emphasis style="sup">2</emphasis> over 1-2 hr × 2 days or 150-200 mg/m<emphasis style="sup">2</emphasis> × 1 dose q6-8wk or 30-75 mg/m<emphasis style="sup">2</emphasis>/day 40-75 mg/m<emphasis style="sup">2</emphasis>/day × 5 days q6wk  up to 8 wafers inserted into resection cavity</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5466">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5466">
									<item>
										<label>•</label>
										<para> 200-250 mg/m<emphasis style="sup">2</emphasis> as a single dose q4-6wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5473">
						<sec_title>Stem cell transplant/bone marrow ablation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5481">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5481">
									<item>
										<label>•</label>
										<para> 450-600 mg/m<emphasis style="sup">2</emphasis> as a single dose or 2 divided doses q12hr at a rate of no more than 3 mg/m<emphasis style="sup">2</emphasis>/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5491">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 100 mg; wafer 7.7 mg (intracavitary)</para>
					</section>
					<section type="none" id="sidelem4x5496">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5500">
								<item>
									<label>•</label>
									<para>Store reconstituted sol in refrigerator for 24 hr or at room temperature for 8 hr; protect from light</para>
								</item>
								<item>
									<label>•</label>
									<para>Blood transfusions, RBC colony-stimulating factors to counter anemia</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic, serotonin antagonists, dexamethasone</para>
								</item>
								<item>
									<label>•</label>
									<para>All medications PO, if possible; avoid IM inj if platelets are &lt;100,000/mm<emphasis style="sup">3</emphasis>
<bbw>Carmustine should not be given until platelets &gt;100,000/mm3 and WBC &gt;4000/mm2</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5537">
							<sec_title>Wafer route</sec_title>
							<section type="none" id="sidelem4x5545">
								<label>•</label>
								<sec_title>
									<route>Use cytotoxic handling procedures</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x5548">
									<item>
										<label>•</label>
										<para>If wafers are broken into several pieces, they should not be used</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5553">
									<item>
										<label>•</label>
										<para>Foil pouches may be kept at room temperature for 6 hr if unopened</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5558">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x5566">
								<label>•</label>
								<sec_title>
									<route>Use cytotoxic handling procedures; do not use if an oil film appears on vial (decomposition)</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x5572">
								<label>•</label>
								<sec_title>
									<route>Do not use with PVC IV tubing, do not admix</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x5578">
								<label>•</label>
								<sec_title>
									<route>diluting</route>
								</sec_title>
								<para>
									<list id="lidelem4x5578">
										<item>
											<label>•</label>
											<para>After  100 mg product/3 ml ethyl alcohol (provided),  with 100-500 ml 0.9% NaCl or D<emphasis style="inf">5</emphasis>W,  over 1 hr or more, reduce rate if discomfort is felt; use only glass containers, protect from light</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5595">
								<label>•</label>
								<sec_title>
									<route>Flush</route>
								</sec_title>
								<para>
									<list id="lidelem4x5595">
										<item>
											<label>•</label>
											<para> IV line after carmustine with 10 ml 0.9% NaCl to prevent irritation at site</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, aztreonam, bivalirudin, bleomycin, caspofungin, cefepime, codeine, DAPTOmycin, dexmedetomidine, DOCEtaxel, ertapenem, etoposide, fenoldopam, filgrastim, fludarabine, gemcitabine, granisetron, levofloxacin, melphalan, meperidine, mitoXANtrone, nesiritide, octreotide, ondansetron, PACLitaxel, palonosetron, pamidronate, pantoprazole, PEMEtrexed, piperacillin-tazobactam, riTUXimab, sargramostim, sodium acetate, tacrolimus, teniposide, thiotepa, tigecycline, tirofiban, trastuzumab, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5604">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5607">
					<section type="none" id="sidelem4x5608">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, stomatitis,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5617">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Azotemia,</emphasis><emphasis style="bold">renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5626">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5633">
						<sec_title>INTEG:</sec_title>
						<para> Pain, burning, hyperpigmentation at inj site, alopecia</para>
					</section>
					<section type="none" id="sidelem4x5638">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis, pulmonary infiltrate</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5645">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignant neoplastic disease</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5652">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Degraded within 15 min; crosses blood-brain barrier; 70% excreted in urine within 96 hr; 10% excreted as CO<emphasis style="inf">2</emphasis>, fate of 20% is unknown</para>
			</section>
			<section type="interactions" id="sidelem4x5660">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—aspirin, anticoagulants, platelets inhibitors</para>
				<para>
					<emphasis alert="lifethreat">Increase: myelosuppression—myelosuppressive agents, cimetidine</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity: other antineoplastics, radiation, cimetidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions, decreased antibody reaction—live vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of digoxin, phenytoins</para>
				<section type="none" id="sidelem4x5681">
					<section type="none" id="sidelem4x5682">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bilirubin, prolactin, uric acid, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC, neutrophils, HCT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5693">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5696">
					<section type="none" id="sidelem4x5697">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow suppression:</emphasis> CBC, differential, platelet count weekly; withhold product if WBC is &lt;4000 or platelet count is &lt;100,000; notify prescriber of results</bbw>
						</para>
						<para>
							<list id="lidelem4x5712">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, monitor regularly, hepatotoxicity occurs rarely</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Pulmonary fibrosis/infiltrate:</emphasis> pulmonary function tests, chest x-ray films before, during therapy; chest film should be obtained q2wk during treatment; monitor for dyspnea, cough, pulmonary fibrosis; infiltrate occurs after high doses or several low-dose courses (&gt;1400 mg/m2 cumulative dose), may occur months or years after treatment</bbw>
						</para>
						<para>
							<bbw>Only to be used by an experienced clinician in cases of cancer, immune suppression</bbw>
						</para>
						<para>
							<list id="lidelem4x5744">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr before, during therapy; I&amp;O ratio; report fall in urine output of 30 ml/hr, may use allopurinol for hyperuricemia with increased fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5749">
								<item>
									<label>•</label>
									<para>Monitor for cold, cough, fever (may indicate beginning infection)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5757">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x5757">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising, petechiae, mucosa, orifices q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5761">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water or club soda; use of sponge brush for stomatitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5766">
								<item>
									<label>•</label>
									<para>Warm compresses at inj site for inflammation; reduce flow rate if patient complains of burning at infusion site</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5771">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5775">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing size of tumor, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5781">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To report any changes in breathing or coughing; to avoid smoking</bbw>
						</para>
						<para>
							<list id="lidelem4x5796">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture if stomatitis is present; to report any bleeding, white spots, ulceration in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5801">
								<item>
									<label>•</label>
									<para>To avoid aspirin, ibuprofen, razors, commercial mouthwash</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5810">
							<label>•</label>
							<sec_title>
								<route>To report signs of anemia (fatigue, irritability, shortness of breath, faintness); to report signs of infection (sore throat, fever); pulmonary toxicity can occur up to 15 yr after treatment</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5816">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment; to avoid breastfeeding, pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5819">
								<item>
									<label>•</label>
									<para>Not to receive live vaccines during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5824">
								<item>
									<label>•</label>
									<para>Infusion can be painful to veins and product contains ethanol, report chest pain</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>carteolol (ophthalmic)</mono_name>
			<info>
				<pronunciation>(kar′tee-oh-lol)</pronunciation>
				<class type="func"> Antiglaucoma</class>
				<class type="chem"> β-Blocker</class>
			</info>
			<section type="actions" id="sidelem4x5842">
				<sec_title>Action:</sec_title>
				<para>May decrease aqueous humor and increase outflows</para>
			</section>
			<section type="uses" id="sidelem4x5847">
				<sec_title>Uses:</sec_title>
				<para>Treatment of chronic open-angle glaucoma and ocular hypertension</para>
			</section>
			<section type="contra" id="sidelem4x5852">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, AV block, heart failure, bradycardia, sick sinus syndrome</para>
				<section type="none" id="sidelem4x5857">
					<section type="none" id="sidelem4x5858">
						<sec_title>Precautions:</sec_title>
						<para> Abrupt discontinuation, children, pregnancy, breastfeeding, COPD, depression, diabetes mellitus, myasthenia gravis, hyperthyroidism, pulmonary disease, angle-closure glaucoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5863">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5871">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x5871">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> Instill 1 drop in the affected eye(s) bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5875">
					<section type="none" id="sidelem4x5876">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 1%</para>
					</section>
					<section type="none" id="sidelem4x5881">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5885">
								<item>
									<label>•</label>
									<para>For ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>Wash hands before and after use; tilt head back slightly and pull the lower eyelid down with the index finger; squeeze the prescribed number of drops into the pouch; close eyes to spread; to avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 1-2 min after use</para>
								</item>
								<item>
									<label>•</label>
									<para>If more than one topical ophthalmic drug product is being used, the drugs should be administered at least 5 min apart</para>
								</item>
								<item>
									<label>•</label>
									<para>Decreased intraocular pressure can take several weeks; monitor IOP after 1 mo</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5911">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5914">
					<section type="none" id="sidelem4x5915">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x5920">
						<sec_title>CV:</sec_title>
						<para> Palpitations</para>
					</section>
					<section type="none" id="sidelem4x5925">
						<sec_title>EENT:</sec_title>
						<para> Eye stinging/burning, tearing, photophobia, sinusitis</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5930">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> β-blocking effect—oral β-blockers</para>
				<para>
					<emphasis style="bold">Increased:</emphasis> intraocular pressure reduction—topical miotics, dipivefrin, EPINEPHrine, carbonic anhydrase inhibitors, this may be beneficial</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P, severe—when abruptly stopping cloNIDine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> depression of AV nodal conduction, bradycardia, or hypotension—adenosine, cardiac glycosides, disopyramide, other antiarrhythmics, class 1C antiarrhythmic drugs (flecainide, propafenone, moricizine, encainide, quiNIDine or drugs that significantly depress AV nodal conduction)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> AV block nodal conduction, induce AV block—high doses of procainamide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—other antihypertensives</para>
			</section>
			<section type="considerations" id="sidelem4x5957">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5960">
					<section type="none" id="sidelem4x5961">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5969">
							<label>•</label>
							<sec_title>Systemic absorption<route> when used in the eye, systemic absorption is common with the same adverse reactions and interactions</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5972">
								<item>
									<label>•</label>
									<para>Glaucoma: monitor intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5977">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5981">
								<item>
									<label>•</label>
									<para>Decreasing intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5987">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5991">
								<item>
									<label>•</label>
									<para>For ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>To wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops; to avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 1-2 min following use</para>
								</item>
								<item>
									<label>•</label>
									<para>If more than one topical ophthalmic drug product is being used, the drugs should be administered at least 5 min apart</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>carvedilol (Rx)</mono_name>
			<info>
				<pronunciation>(kar-ved′i-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x60191">Coreg</tradename>
					<tradename id="tnidelem4x60190">Coreg CR</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, α-/β-adrenergic blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6025">
				<para>
					<confusion>
						<tradename id="tnidelem4x60250">carvedilol</tradename>
						<drug type="generic" refid="idelem4x60250">captopril/carteolol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6029">
				<sec_title>Action:</sec_title>
				<para>A mixture of nonselective α-/β-adrenergic blocking activity; decreases cardiac output, exercise-induced tachycardia, reflex orthostatic tachycardia; causes vasodilation, reduction in peripheral vascular resistance</para>
			</section>
			<section type="uses" id="sidelem4x6034">
				<sec_title>Uses:</sec_title>
				<para>Essential hypertension alone or in combination with other antihypertensives, CHF, LV dysfunction after MI, cardiomyopathy</para>
				<section type="none" id="sidelem4x6039">
					<section type="none" id="sidelem4x6040">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Angina, pediatric patients, atrial fibrillation/flutter</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6045">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, asthma, class IV decompensated cardiac failure, 2nd- or 3rd-degree heart block, cardiogenic shock, severe bradycardia, pulmonary edema, severe hepatic disease, sick sinus symptoms</para>
				<section type="none" id="sidelem4x6050">
					<section type="none" id="sidelem4x6051">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, cardiac failure, hepatic injury, peripheral vascular disease, anesthesia, major surgery, diabetes mellitus, thyrotoxicosis, emphysema, chronic bronchitis, renal disease</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6066">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6069">
					<section type="none" id="sidelem4x6070">
						<sec_title>Essential hypertension</sec_title>
						<section type="none" id="sidelem4x6078">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6078">
									<item>
										<label>•</label>
										<para> 6.25 mg bid × 7-14 days; if tolerated well, then increase to 12.5 mg bid × 7-14 days; if tolerated well, may be increased (if needed) to 25 mg bid; not to exceed 50 mg/day;  cap 20 mg/day, may increase after 7-14 days to 40 mg/day, max 80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6085">
						<sec_title>Congestive heart failure</sec_title>
						<section type="none" id="sidelem4x6093">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6093">
									<item>
										<label>•</label>
										<para> 3.125 mg bid × 2 wk; if tolerated well, give 6.25 mg bid × 2 wk, then double q2wk to max dose of 25 mg bid &lt;85 kg or 50 mg bid &gt;85 kg;  caps (Coreg CR) 10 mg/day × 2 wk, increase to 20, 40, 80 mg/day over successive intervals of 2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6100">
						<sec_title>Postmyocardial infarction</sec_title>
						<section type="none" id="sidelem4x6108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6108">
									<item>
										<label>•</label>
										<para> 6.25 mg bid with food × 3-10 days, lower starting dose may be used if indicated; titrate upward as tolerated; may increase to 12.5 mg bid, then titrate to 25 mg bid;  20 mg daily with food, lower starting dose of 10 mg/day may be used, titrate upward after 3-10 days, increase to 40 mg daily as required</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6115">
						<sec_title>Angina (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6123">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6123">
									<item>
										<label>•</label>
										<para> 25-50 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6127">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 3.125, 6.25, 12.5, 25 mg; ext rel cap 10, 20, 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x6132">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6136">
								<item>
									<label>•</label>
									<para>With food to minimize orthostatic hypotension; tabs may be crushed or swallowed whole; give ext rel every <emphasis style="smallcaps">am</emphasis> with food; do not break, crush, chew ext rel cap; separate alcohol (including OTC products that contain ethanol) by ≥2 hr; caps may be opened and sprinkled over applesauce
<bbw>Do not discontinue before surgery</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6154">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6157">
					<section type="none" id="sidelem4x6158">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, fatigue,</emphasis> weakness, somnolence, insomnia, ataxia, hyperesthesia, paresthesia, vertigo, depression, headache</para>
					</section>
					<section type="none" id="sidelem4x6167">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Bradycardia,</emphasis><emphasis style="italic">postural hypotension,</emphasis> dependent edema, <emphasis style="italic">peripheral edema,</emphasis><emphasis style="bold">AV block,</emphasis> extrasystoles, hypo/hypertension, palpitations, peripheral ischemia, <emphasis style="bold">CHF, pulmonary edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6184">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> abdominal pain, increased alk phos, ALT, AST, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x6192">
						<sec_title>GU:</sec_title>
						<para> Decreased libido, <emphasis style="italic">impotence,</emphasis> UTI</para>
					</section>
					<section type="none" id="sidelem4x6200">
						<sec_title>INTEG:</sec_title>
						<para> Rash, Stevens-Johnson syndrome</para>
					</section>
					<section type="none" id="sidelem4x6205">
						<sec_title>MISC:</sec_title>
						<para> Injury, back pain, viral infection, hypertriglyceridemia, <emphasis style="bold">thrombocytopenia,</emphasis><emphasis style="italic">hyperglycemia,</emphasis> abnormal weight gain, aplastic anemia</para>
					</section>
					<section type="none" id="sidelem4x6215">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, pharyngitis, dyspnea, <emphasis style="bold">bronchospasm,</emphasis> cough, <emphasis style="bold">lung edema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6225">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr; duration 7-9 hr; ext rel onset 30 min, peak 5 hr, readily and extensively absorbed PO; &gt;98% protein binding; extensively metabolized by liver; excreted through bile into feces; terminal half-life 7-10 hr with increases in geriatric patients, hepatic disease</para>
			</section>
			<section type="interactions" id="sidelem4x6230">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> conduction disturbances—calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia, hypotension—levodopa, MAOIs, reserpine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—antidiabetic agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> concentrations of digoxin, cycloSPORINE, CYP2D6 inhibitors (FLUoxetine, quiNIDine)</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity of carvedilol—cimetidine, other antihypertensives, nitrates, acute alcohol ingestion</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> heart rate, B/P—cloNIDine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> carvedilol levels—rifampin, NSAIDs, thyroid medications</para>
				<section type="none" id="sidelem4x6260">
					<section type="none" id="sidelem4x6261">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra (ma huang)</para>
					</section>
					<section type="none" id="sidelem4x6272">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> blood glucose, BUN, potassium, triglycerides, uric acid, bilirubin, cholesterol, creatinine, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium, HDL</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6283">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6286">
					<section type="none" id="sidelem4x6287">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6295">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x6295">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P when beginning treatment, periodically thereafter; pulse: note rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of significant changes</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6302">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x6302">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema in feet, legs daily; fluid overload: dyspnea, weight gain, jugular venous distention, fatigue, crackles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6306">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6310">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P with hypertension; decrease anginal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6316">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6321">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule even if feeling better; that improvement may take several weeks</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6326">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6334">
							<label>•</label>
							<sec_title>
								<route>To report bradycardia, dizziness, confusion, depression, fever, weight gain, SOB, cold extremities, rash, sore throat, bleeding, bruising</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6337">
								<item>
									<label>•</label>
									<para>To weigh, take pulse, B/P at home; to advise if weight gain of &gt;2 lb/day or 5 lb/wk and when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Not to discontinue product abruptly; to taper over 1-2 wk; life-threatening dysrhythmias may occur</bbw>
						</para>
						<para>
							<list id="lidelem4x6352">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication; dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid all OTC medications unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID with product name, prescriber information at all times</para>
								</item>
								<item>
									<label>•</label>
									<para>To inform all health care providers of products, supplements taken</para>
								</item>
								<item>
									<label>•</label>
									<para>To report if pregnancy is planned or suspected, pregnancy (C), avoid breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may mask hypoglycemia</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>caspofungin (Rx)</mono_name>
			<info>
				<pronunciation>(cas-po-fun′gin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x63890">Cancidas</tradename>
				</tradenames>
				<class type="func"> Antifungal, systemic</class>
				<class type="chem"> Echinocandin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6399">
				<sec_title>Action:</sec_title>
				<para>Inhibits an essential component in fungal cell walls; causes direct damage to fungal cell wall</para>
			</section>
			<section type="uses" id="sidelem4x6404">
				<sec_title>Uses:</sec_title>
				<para>Treatment of invasive aspergillosis and candidemia that has not responded to other treatment, including peritonitis, intraabdominal abscesses; susceptible species: <emphasis style="italic">Aspergillus flavus, A. fumigatus, A. terreus, Candida albicans, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis,</emphasis> esophageal candidiasis; empirical therapy for presumed fungal infection in febrile, neutropenic patients</para>
				<section type="none" id="sidelem4x6412">
					<section type="none" id="sidelem4x6413">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Aspergillus niger,</emphasis> fungal infections in premature neonates, neonates, infants, children &lt;2 yr</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6421">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x6426">
					<section type="none" id="sidelem4x6427">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, severe hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6432">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6440">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x6440">
							<item>
								<label>•</label>
								<para> loading dose 70 mg on day 1, then 50 mg/day maintenance dose, depending on condition; max 70 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6447">
					<label>•</label>
					<sec_title>Adolescent/child/infant ≥3 mo<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x6447">
							<item>
								<label>•</label>
								<para> 70 mg/m<emphasis style="sup">2</emphasis> loading dose, then 50 mg/m<emphasis style="sup">2</emphasis>/day; max 70 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6460">
					<label>•</label>
					<sec_title>Neonate and infant &lt;3 mo (unlabeled)<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x6460">
							<item>
								<label>•</label>
								<para> 25 mg/m<emphasis style="sup">2</emphasis>/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6467">
					<section type="none" id="sidelem4x6468">
						<sec_title>Esophageal candidiasis</sec_title>
						<section type="none" id="sidelem4x6476">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6476">
									<item>
										<label>•</label>
										<para> 50 mg × 7-14 days over 1 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6483">
							<label>•</label>
							<sec_title>Child</sec_title>
							<para>
								<list id="lidelem4x6483">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child:</emphasis> 3 mo-17 yr:  70 mg/m<emphasis style="sup">2</emphasis> loading dose, then 50 mg/m<emphasis style="sup">2</emphasis> daily; max 70 mg/m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6498">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 50, 70 mg</para>
					</section>
					<section type="none" id="sidelem4x6503">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6511">
							<label>•</label>
							<sec_title>
								<route>Do not mix or confuse with other medications, do not use dextrose-containing products to dilute, do not give as bolus</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6514">
								<item>
									<label>•</label>
									<para>Store at room temperature for up to 24 hr or refrigerated for 48 hr; store reconstituted sol at room temperature for 1 hr before preparation of sol for administration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6519">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6524">
									<item>
										<label>•</label>
										<para>Allow to warm to room temperature</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x6529">
									<item>
										<label>•</label>
										<para>May administer loading dose on day 1</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6537">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x6537">
										<item>
											<label>•</label>
											<para> 50-mg vial or 70-mg vial with 10.8 ml 0.9% NaCl, sterile water for inj or bacteriostatic water for inj (5 mg/ml or 7 mg/ml), respectively;  to dissolve, withdraw 10 ml reconstituted sol, and  with 250 ml 0.9% NaCl, 0.45% NaCl, 0.225% NaCl, RL;  over 1 hr or more</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6550">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6553">
					<section type="none" id="sidelem4x6554">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, <emphasis style="italic">headache,</emphasis> fever, chills</para>
					</section>
					<section type="none" id="sidelem4x6562">
						<sec_title>CV:</sec_title>
						<para> Sinus tachycardia, hypertension</para>
					</section>
					<section type="none" id="sidelem4x6567">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, <emphasis style="italic">nausea, anorexia, vomiting, diarrhea, increased AST/ALT, alk phos</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6574">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6581">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombophlebitis,</emphasis> vasculitis, <emphasis style="bold">anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6591">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus, inj site pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6598">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x6603">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x6608">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Acute respiratory distress syndrome (ARDS), pleural effusions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6615">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, histamine-related reactions, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6622">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver to inactive metabolites; excretion in feces, urine; phase II terminal half-life 9-11 hr; phase III terminal half-life 40-50 hr; protein binding 97%</para>
			</section>
			<section type="interactions" id="sidelem4x6627">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> caspofungin levels—cycloSPORINE; may need dosage reduction</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of tacrolimus, sirolimus</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> caspofungin levels—carBAMazepine, dexamethasone, efavirenz, nelfinavir, nevirapine, phenytoin, rifampin</para>
				<section type="none" id="sidelem4x6643">
					<section type="none" id="sidelem4x6644">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, RBC, eosinophils, glucose, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> HCT/Hgb, WBC, potassium, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6655">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6658">
					<section type="none" id="sidelem4x6659">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6667">
							<label>•</label>
							<sec_title>
								<route>Infection;</route>
							</sec_title>
							<para>
								<list id="lidelem4x6667">
									<item>
										<label>•</label>
										<para> clearing of cultures during treatment; obtain culture at baseline, throughout treatment; product may be started as soon as culture is taken (esophageal candidiasis); monitor cultures during HSCT for prevention of <emphasis style="italic">Candida</emphasis> infections</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6674">
								<item>
									<label>•</label>
									<para>Blood studies before, during treatment: bilirubin, AST, ALT, alk phos, as needed; obtain baseline renal studies; CBC with differential, serum potassium</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6682">
							<label>•</label>
							<sec_title>Hypersensitivity<route> rash, pruritus, facial swelling; also for phlebitis; anaphylaxis (rare)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x6685">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping; if severe diarrhea occurs, electrolytes may need to be given</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6690">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6694">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of <emphasis style="italic">Candida, Aspergillus</emphasis> infections</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6703">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6708">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected or planned</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6713">
								<item>
									<label>•</label>
									<para>To inform prescriber of renal/hepatic disease</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6721">
							<label>•</label>
							<sec_title>
								<route>To report bleeding, facial swelling, wheezing, difficulty breathing, itching, rash, hives, increasing warmth, flushing; anaphylaxis can occur</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>cefaclor</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67270">See cephalosporins—2nd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="17" status="active">
			<mono_name>cefadroxil</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67340"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="18" status="active">
			<mono_name>ceFAZolin</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67380">See cephalosporins—1st generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="19" status="active">
			<mono_name>cefdinir</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67450"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="20" status="active">
			<mono_name>cefditoren pivoxil</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67490"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="21" status="active">
			<mono_name>cefepime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67530"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="22" status="active">
			<mono_name>cefixime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67570"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="23" status="active">
			<mono_name>cefotaxime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67610">See cephalosporins—3rd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="24" status="active">
			<mono_name>cefoTEtan</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67680"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="25" status="active">
			<mono_name>cefOXitin</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67720">See cephalosporins—2nd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="26" status="active">
			<mono_name>cefpodoxime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67790">See cephalosporins—3rd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="27" status="active">
			<mono_name>cefprozil</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67860">See cephalosporins—2nd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="28" status="active">
			<mono_name>cefTAZidime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67930"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="29" status="active">
			<mono_name>ceftibuten</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67970"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="30" status="active">
			<mono_name>ceftizoxime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68010"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="31" status="active">
			<mono_name>cefTRIAXone</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68050">See cephalosporins—3rd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="32" status="active">
			<mono_name>cefuroxime</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68120">See cephalosporins—2nd generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="33" status="active">
			<mono_name>ceftaroline (Rx)</mono_name>
			<info>
				<pronunciation>(sef-tar′oh-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x68210">Teflaro</tradename>
				</tradenames>
				<class type="func"> Cephalosporin action: Inhibits cell wall synthesis through binding to essential penicillin-binding protein (PBP)</class>
			</info>
			<section type="uses" id="sidelem4x6827">
				<sec_title>Uses:</sec_title>
				<para>Acute bacterial skin/skin structure infections (ABSSI), bacterial community-acquired pneumonia</para>
			</section>
			<section type="contra" id="sidelem4x6833">
				<sec_title>Contraindications:</sec_title>
				<para>Cephalosporin hypersensitivity</para>
				<section type="none" id="sidelem4x6838">
					<section type="none" id="sidelem4x6839">
						<sec_title>Precautions:</sec_title>
						<para> Child/infant/neonate, breastfeeding, elderly patients, antimicrobial resistance, carbapenem/penicillin hypersensitivity, coagulopathy, colitis, dialysis, diarrhea, GI disease, hypoprothrombinemia, IBS, pregnancy (B), pseudomembranous colitis, renal disease, ulcerative colitis, viral infection, vit K deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6844">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6852">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x6852">
							<item>
								<label>•</label>
								<para> 600 mg q12hr × 5-14 days (skin/skin-structure infections) or × 5-7 days (bacterial community-acquired pneumonia)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6856">
					<section type="none" id="sidelem4x6857">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6865">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6865">
									<item>
										<label>•</label>
										<para> CCr &gt;30-≤50 ml/min, 400 mg q12hr; CCr ≥15-≤30 ml/min, 300 mg q12hr, CCr &lt;15 ml/min, 200 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6869">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 400 mg, 600 mg</para>
					</section>
					<section type="none" id="sidelem4x6874">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6878">
								<item>
									<label>•</label>
									<para>Obtain culture specimen before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Identify allergies before use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6889">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6894">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter, discoloration</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6902">
								<label>•</label>
								<sec_title>Reconstitute</sec_title>
								<para>
									<list id="lidelem4x6902">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reconstitute:</emphasis> add 20 mg of sterile water to 400- or 600-mg vial (20 mg/ml for 400 mg; 30 mg/ml for 600 mg), mix gently until dissolved;  in 250 ml of 0.9% NaCl, 0.45% NaCl, LR, D<emphasis style="inf">5</emphasis>W, dextrose 2.5%,  over 1 hr, do not admix, use within 6 hr at room temperature or 24 hr refrigerated</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6915">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6918">
					<section type="none" id="sidelem4x6919">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6926">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Phlebitis,</emphasis> palpitations, <emphasis style="bold">bradycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6936">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x6941">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, constipation, abdominal pain, <emphasis style="bold">pseudomembranous colitis (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6948">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, neutropenia,</emphasis> anemia, eosinophilia</para>
					</section>
					<section type="none" id="sidelem4x6956">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6963">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6970">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, <emphasis style="bold">hyperkalemia,</emphasis> hyperglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6978">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 20%; excreted in urine 88%, feces 6%; half-life 1.6 hr; not hepatically metabolized</para>
			</section>
			<section type="interactions" id="sidelem4x6983">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> prothrombin time risk—anticoagulants</para>
				<section type="none" id="sidelem4x6990">
					<section type="none" id="sidelem4x6991">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, glucose, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, eosinophils, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7002">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7005">
					<section type="none" id="sidelem4x7006">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7014">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x7014">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> vital signs, sputum, WBC before, during therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7021">
							<label>•</label>
							<sec_title>Hypersensitivity<route> before use, obtain a history of hypersensitivity reactions to cephalosporins, carbapenems, penicillins; cross-sensitivity may occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7027">
							<label>•</label>
							<sec_title>Anaphylaxis (rare)<route> rash, pruritus, laryngeal edema, dyspnea, wheezing; discontinue product, notify health care provider immediately, keep emergency equipment nearby</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7033">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> diarrhea, abdominal pain, fever, bloody stools; report immediately if these occur; may occur several weeks after terminating therapy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7036">
								<item>
									<label>•</label>
									<para>Monitor BUN, creatinine baseline, periodically; elderly and those with renal disease are at greater risk of renal dysfunction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7041">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7045">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S, resolution of symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7051">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7056">
								<item>
									<label>•</label>
									<para>About the reason for treatment and expected result</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7065">
							<label>•</label>
							<sec_title>
								<route>To immediately report rash, itching, difficulty breathing, bloody diarrhea, fever, abdominal pain</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active" ha="yes">
			<mono_name>celecoxib (Rx)</mono_name>
			<info>
				<pronunciation>(sel-eh-cox′ib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x70750">CeleBREX</tradename>
				</tradenames>
				<class type="func"> Nonsteroidal antiinflammatory, antirheumatic</class>
				<class type="chem"> COX-2 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7085">
				<para>
					<confusion>
						<tradename id="tnidelem4x70850">CeleBREX</tradename>
						<drug type="generic" refid="idelem4x70850">CeleXA/Cerebra/Cerebyx</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7089">
				<sec_title>Action:</sec_title>
				<para>Inhibits prostaglandin synthesis by selectively inhibiting cyclooxygenase-2 (COX-2), an enzyme needed for biosynthesis</para>
			</section>
			<section type="uses" id="sidelem4x7094">
				<sec_title>Uses:</sec_title>
				<para>Acute, chronic rheumatoid arthritis, osteoarthritis, acute pain, primary dysmenorrhea, ankylosing spondylitis, juvenile rheumatoid arthritis (JRA)</para>
				<section type="none" id="sidelem4x7099">
					<section type="none" id="sidelem4x7100">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Colorectal adenoma prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7105">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 3rd trimester; hypersensitivity to salicylates, iodides, other NSAIDs, sulfonamides, severe hepatic impairment</para>
				<para>
					<bbw>For perioperative pain in CABG</bbw>
				</para>
				<section type="none" id="sidelem4x7120">
					<section type="none" id="sidelem4x7121">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st/2nd trimesters, breastfeeding, children &lt;18 yr, geriatric patients, bleeding, GI/renal/hepatic/cardiac disorders, PVD, hypertension, severe dehydration, asthma</para>
						<para>
							<bbw>GI bleeding/perforation, peptic ulcer disease, MI, stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7136">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis alert="lifethreat">Do not exceed recommended dose; deaths have occurred</emphasis>
				</para>
				<section type="none" id="sidelem4x7142">
					<section type="none" id="sidelem4x7143">
						<sec_title>Acute pain/primary dysmenorrhea</sec_title>
						<section type="none" id="sidelem4x7151">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7151">
									<item>
										<label>•</label>
										<para> 400 mg initially, then 200 mg if needed on 1st day, then 200 mg bid prn on subsequent days; start with <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose for poor CYP2C9 metabolizers</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7161">
						<sec_title>Osteoarthritis</sec_title>
						<section type="none" id="sidelem4x7169">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7169">
									<item>
										<label>•</label>
										<para> 200 mg/day as a single dose or 100 mg bid; start with <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose for poor CYP2C9 metabolizers</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7182">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7182">
									<item>
										<label>•</label>
										<para> use lowest possible dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7186">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x7194">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7194">
									<item>
										<label>•</label>
										<para> 100-200 mg bid; start with <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose for poor CYP2C9 metabolizers</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7204">
						<sec_title>Ankylosing spondylitis</sec_title>
						<section type="none" id="sidelem4x7212">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7212">
									<item>
										<label>•</label>
										<para> 200 mg/day or in divided doses (bid); start with <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose for poor CYP2C9 metabolizers</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7222">
						<sec_title>Juvenile rheumatoid arthritis (JRA)</sec_title>
						<section type="none" id="sidelem4x7230">
							<label>•</label>
							<sec_title>Adolescent and child ≥2 yr (&gt;25 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7230">
									<item>
										<label>•</label>
										<para> 100 mg bid; start with <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose for poor CYP2C9 metabolizers</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7243">
							<label>•</label>
							<sec_title>Child ≥2 yr (10-25 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7243">
									<item>
										<label>•</label>
										<para> 50 mg bid; start with <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose for poor CYP2C9 metabolizers</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7253">
						<sec_title>Hepatic disease</sec_title>
						<section type="none" id="sidelem4x7261">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh B) reduce dose by 50%; (Child-Pugh C) do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7264">
						<sec_title>Colorectal adenoma prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7272">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7272">
									<item>
										<label>•</label>
										<para> 200-400 mg bid for up to 3 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7276">
						<sec_title>Available forms:</sec_title>
						<para> Caps 50, 100, 200, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x7281">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7285">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew, or dissolve caps; give with a full glass of water to enhance absorption; caps may be opened into applesauce or soft food, ingest immediately with water</para>
								</item>
								<item>
									<label>•</label>
									<para>With food, milk to decrease gastric symptoms (with higher doses [400 mg bid]); do not increase dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7296">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7299">
					<section type="none" id="sidelem4x7300">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fatigue, anxiety, depression, nervousness, paresthesia,</emphasis> dizziness, insomnia, headache</para>
					</section>
					<section type="none" id="sidelem4x7308">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Stroke, MI, tachycardia, CHF,</emphasis> angina, palpitations, dysrhythmias, hypertension, fluid retention</para>
					</section>
					<section type="none" id="sidelem4x7316">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision, glaucoma, cataract, conjunctivitis, eye pain</para>
					</section>
					<section type="none" id="sidelem4x7322">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, vomiting, constipation, dry mouth, diverticulitis, gastritis, gastroenteritis, hemorrhoids, hiatal hernia, stomatitis, <emphasis style="bold">GI bleeding/ulceration</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7329">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity:</emphasis><emphasis style="italic">dysuria,</emphasis><emphasis style="bold">hematuria, azotemia,</emphasis> cystitis, UTI, <emphasis style="bold">renal papillary necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7343">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias,</emphasis> epistaxis, anemia</para>
					</section>
					<section type="none" id="sidelem4x7351">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Serious (sometimes fatal) Stevens-Johnson syndrome, toxic epidermal necrolysis,</emphasis> purpura, rash, pruritus, sweating, erythema, petechiae, photosensitivity, alopecia, bruising, hot flashes</para>
					</section>
					<section type="none" id="sidelem4x7359">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, SOB, pneumonia, coughing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7364">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, crosses placenta, bound to plasma proteins, metabolized by CYP2C9 in liver, very little excreted by kidneys/in feces, peak 3 hr, half-life 11 hr, protein binding ∼97%</para>
			</section>
			<section type="interactions" id="sidelem4x7369">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: bleeding risk—anticoagulants, SSRIs, antiplatelets, thrombolytics, salicylates, alcohol</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—glucocorticoids, NSAIDs, aspirin</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—lithium, antineoplastics, bisphosphonates, cidofovir</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> celecoxib blood level—fluconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of aspirin, ACE inhibitors, thiazide diuretics, furosemide</para>
				<section type="none" id="sidelem4x7390">
					<section type="none" id="sidelem4x7391">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect of feverfew</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—garlic, ginger, ginkgo</para>
					</section>
					<section type="none" id="sidelem4x7402">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, BUN, cholesterol, glucose, potassium, sodium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose, sodium, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7413">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7416">
					<section type="none" id="sidelem4x7417">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7425">
							<label>•</label>
							<sec_title>
								<route>Pain</route>
							</sec_title>
							<para>
								<list id="lidelem4x7425">
									<item>
										<label>•</label>
										<para> of rheumatoid arthritis, osteoarthritis; check ROM, inflammation of joints, characteristics of pain
<bbw>For cardiac disease that may be worse after taking product; MI, stroke; do not use with coronary artery bypass graft (CABG)</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7438">
								<item>
									<label>•</label>
									<para>CBC during therapy; watch for decreasing platelets; if low, therapy may need to be discontinued, restarted after hematologic recovery; LFTs, serum creatinine/BUN, stool guaiac
<bbw>For blood dyscrasias (thrombocytopenia): bruising, fatigue, bleeding, poor healing</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7455">
							<label>•</label>
							<sec_title>GI toxicity<route> black, tarry stools; abdominal pain</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7459">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis; may be fatal</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7464">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7468">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, inflammation in arthritic conditions; decreased number of polyps</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7474">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Not to exceed recommended dose; to notify prescriber immediately of chest pain, skin eruptions; to stop product if these occur</bbw>
						</para>
						<para>
							<list id="lidelem4x7487">
								<item>
									<label>•</label>
									<para>To check with prescriber to determine when product should be discontinued before surgery</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective; to avoid other NSAIDs, aspirin, sulfonamides</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To notify prescriber of GI symptoms: black, tarry stools; cramping or rash; edema of extremities; weight gain</bbw>
						</para>
						<para>
							<bbw>To report bleeding, bruising, fatigue, malaise because blood abnormalities do occur</bbw>
						</para>
						<section type="none" id="sidelem4x7523">
							<label>•</label>
							<sec_title>To report possible respiratory infection<route> fever, SOB, coughing, painful swallowing</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7529">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected, pregnancy (C) before 30 wk, (D) after 30 wk</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active">
			<mono_name>cephalexin</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x75350">See cephalosporins—1st generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="4" status="active">
			<mono_name>CEPHALOSPORINS—1ST GENERATION</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x75680">Do not confuse: cephalexin/cefaclor</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7568">
				<para>
					<confusion>
						<tradename id="tnidelem4x75680">cephalexin</tradename>
						<drug type="generic" refid="idelem4x75680">cefaclor</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7575">
				<sec_title>Action:</sec_title>
				<para>Inhibits bacterial cell wall synthesis; renders cell wall osmotically unstable, leads to cell death; lysis mediated by cell wall autolytic enzymes</para>
			</section>
			<section type="uses" id="sidelem4x7580">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">cefadroxil:</emphasis> Gram-negative bacilli: <emphasis style="italic">Escherichia coli, Proteus mirabilis, Klebsiella</emphasis> (UTI only); gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> upper, lower respiratory tract, urinary tract, skin infections; otitis media; tonsillitis; UTIs</para>
				<para>
					<emphasis style="bold">ceFAZolin:</emphasis> Gram-negative bacilli: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Klebsiella, pneumonial;</emphasis> gram-positive organisms: <emphasis style="italic">Staphylococcus aureus/epidermidis;</emphasis> upper, lower respiratory tract, urinary tract, skin infections; bone, joint, biliary, genital infections; endocarditis, surgical prophylaxis, septicemia; <emphasis style="italic">Streptococcus Sp.</emphasis></para>
				<para>
					<emphasis style="bold">cephalexin:</emphasis> Gram-negative bacilli: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactial, Staphylococcus aureus;</emphasis> upper, lower respiratory tract, urinary tract, skin, bone infections; otitis media</para>
			</section>
			<section type="contra" id="sidelem4x7615">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to cephalosporins, infants &lt;1 mo</para>
				<section type="none" id="sidelem4x7620">
					<section type="none" id="sidelem4x7621">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, hypersensitivity to penicillins, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7626">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7629">
					<sec_title>
						<emphasis style="italic">cefadroxil</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7638">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x7638">
								<item>
									<label>•</label>
									<para> 1-2 g/day or divided q12hr; loading dose of 1 g initially</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7645">
						<label>•</label>
						<sec_title>Child<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x7645">
								<item>
									<label>•</label>
									<para> 30 mg/kg/day in divided doses bid, max 2 g/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7649">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7657">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 25-50 ml/min, 1 g, then 500 mg q12hr; CCr 10-24 ml/min, 1 g, then 500 mg q24hr; CCr &lt;10 ml/min, 1 g, then 500 mg q36hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7660">
						<sec_title>Available forms:</sec_title>
						<para> Caps 500 mg; tabs 1 g; oral susp 250, 500 mg/5 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7665">
					<sec_title>
						<emphasis style="italic">ceFAZolin</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7669">
						<sec_title>Surgical prophylaxis</sec_title>
						<section type="none" id="sidelem4x7677">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7677">
									<item>
										<label>•</label>
										<para> 1 g 30-60 min before surgery, then 0.5-1 g q6-8hr × 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7681">
						<sec_title>Life-threatening infections</sec_title>
						<section type="none" id="sidelem4x7689">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7689">
									<item>
										<label>•</label>
										<para> 1-2 g q6-8hr; max 12 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7696">
							<label>•</label>
							<sec_title>Child &gt;1 mo<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7696">
									<item>
										<label>•</label>
										<para> 75-100 mg/kg/day in 3-4 divided doses; max 6 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7700">
						<sec_title>Mild/moderate infections</sec_title>
						<section type="none" id="sidelem4x7708">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7708">
									<item>
										<label>•</label>
										<para> 250 mg-1 g q8hr, max 12 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7715">
							<label>•</label>
							<sec_title>Child &gt;1 mo<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7715">
									<item>
										<label>•</label>
										<para> 50 mg/kg in 3-4 equal doses, max 6 g/day, or 2 g as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7720">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7728">
							<label>•</label>
							<sec_title>Adult<route> IM/IV after loading dose, CCr 35-54 ml/min, dose q8hr; CCr 10-34 ml/min, 50% of dose q12hr; CCr &lt;10 ml/min, 50% of dose q18-24hr</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7734">
							<label>•</label>
							<sec_title>Child<route> IM/IV CCr &gt;70 ml/min, no dosage adjustment; CCr 40-70 ml/min after loading dose, reduce dose to 7.5-30 mg/kg q12hr; CCr 20-39 ml/min, give 3.125-12.5 mg/kg after loading dose q12hr; CCr 5-19 ml/min, 2.5-10 mg/kg after loading dose q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7737">
						<sec_title>Available forms:</sec_title>
						<para> Inj 500 mg, 1, 10, 20 g; infusion 500 mg, 1 g/50-ml, 500 mg/50 ml vial</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7742">
					<sec_title>
						<emphasis style="italic">cephalexin</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7746">
						<sec_title>Moderate infections</sec_title>
						<section type="none" id="sidelem4x7754">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7754">
									<item>
										<label>•</label>
										<para> 250-500 mg q6hr, max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7761">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7761">
									<item>
										<label>•</label>
										<para> 25-100 mg/kg/day in 4 equal doses, max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7765">
						<sec_title>Moderate skin infections</sec_title>
						<section type="none" id="sidelem4x7773">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7773">
									<item>
										<label>•</label>
										<para> 500 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7777">
						<sec_title>Endocarditis prophylaxis</sec_title>
						<para>
							<list id="lidelem4x7781">
								<item>
									<label>•</label>
									<para>2 g 1 hr before procedure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7787">
						<sec_title>Severe infections</sec_title>
						<section type="none" id="sidelem4x7795">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7795">
									<item>
										<label>•</label>
										<para> 500 mg-1 g q6hr, max 4 g</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7802">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7802">
									<item>
										<label>•</label>
										<para> 50-100 mg/kg/day in 4 equal doses, max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7806">
						<sec_title>Community-acquired pneumonia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7814">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x7814">
									<item>
										<label>•</label>
										<para>Child: &gt;3 mo  75-100 mg/kg/day divided in 3 or 4 doses × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7819">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7827">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-40 ml/min, 250-500 mg then 250-500 mg q8-12hr; CCr &lt;10 ml/min, 250-500 mg, then 250 mg q12-24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7830">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250, 500, 750 mg; tabs 250, 500 mg; oral susp 125 mg, 250 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x7835">
						<sec_title>Administer:</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x7839">
					<sec_title>
						<emphasis style="italic">cefadroxil</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x7844">
							<item>
								<label>•</label>
								<para>For prescribed time to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>With food if needed for GI symptoms</para>
							</item>
							<item>
								<label>•</label>
								<para>Shake susp, refrigerate, discard after 2 wk</para>
							</item>
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S specimen is obtained</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7870">
					<sec_title>
						<emphasis style="italic">ceFAZolin</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x7875">
							<item>
								<label>•</label>
								<para>Obtain C&amp;S specimen before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x7886">
						<section type="none" id="sidelem4x7887">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x7891">
									<item>
										<label>•</label>
										<para>Check for irritation, extravasation often; dilute in 2 ml/500 mg or 2.5 ml/1 g sterile water for inj, inject over 3-5 min; may be further diluted with 50-100 ml of NS, D<emphasis style="inf">5</emphasis>W sol, run over 10 min-1 hr by <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock</para>
									</item>
									<item>
										<label>•</label>
										<para>After C&amp;S completed</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, alprostadil, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B liposome, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, cefamandole, cefmetazole, cefonicid, cefoTEtan, cefOXitin, cefpirome, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, DOCEtaxel, doxacurium, doxapram, DOXOrubicin liposomal, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, esmolol, etoposide, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid (as sodium salt), foscarnet, furosemide, gallium, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, lidocaine, linezolid, LORazepam, LR’s injection, mannitol, mechlorethamine, melphalan, meperidine, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, morphine, moxalactam, multiple vitamins injection, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, penicillin G potassium/sodium, peritoneal dialysis solution, perphenazine, PHENobarbital, phenylephrine, phytonadione, piperacillin, Plasma-Lyte M in dextrose 5%, polymyxin B, potassium chloride, procainamide, propofol, propranolol, ranitidine, remifentanil, Ringer’s injection, ritodrine, riTUXimab, sargramostim, sodium acetate, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, tenoxicam, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tolazoline, trastuzumab, trimetaphan, urokinase, vasopressin, vecuronium, verapamil, vinCRIStine, vitamin B complex with C, voriconazole, warfarin, zoledronic acid</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x7914">
					<sec_title>
						<emphasis style="italic">cephalexin</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x7919">
							<item>
								<label>•</label>
								<para>Shake susp, refrigerate, discard after 2 wk; use calibrated oral syringe, spoon, or measuring cup</para>
							</item>
							<item>
								<label>•</label>
								<para>With food if needed for GI symptoms</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S specimen is obtained</para>
							</item>
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
						</list>
					</para>
				</section>
			</section>
			<section type="effects" id="sidelem4x7940">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7943">
					<section type="none" id="sidelem4x7944">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, weakness, paresthesia, fever, chills, <emphasis style="bold">seizures</emphasis> (with high doses)</para>
					</section>
					<section type="none" id="sidelem4x7952">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, <emphasis style="italic">diarrhea, anorexia,</emphasis> pain, glossitis, bleeding; increased AST, ALT, bilirubin, LDH, alk phos; abdominal pain, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7962">
						<sec_title>GU:</sec_title>
						<para> Proteinuria, vaginitis, pruritus, candidiasis, increased BUN, <emphasis style="bold">nephrotoxicity, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7969">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, agranulocytosis,</emphasis> anemia, <emphasis style="bold">neutropenia, lymphocytosis, eosinophilia, pancytopenia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7979">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x7984">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, arthritis</para>
					</section>
					<section type="none" id="sidelem4x7989">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
					<section type="none" id="sidelem4x7994">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, serum sickness,</emphasis> superinfection, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8004">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8007">
					<section type="none" id="sidelem4x8008">
						<sec_title>cefadroxil:</sec_title>
						<para> Peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 12-24 hr, half-life 1-2 hr, 20% bound by plasma proteins, crosses placenta, excreted in breast milk</para>
					</section>
					<section type="none" id="sidelem4x8019">
						<sec_title>ceFAZolin</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x8023">
						<sec_title>IV:</sec_title>
						<para> Peak 10 min, duration 6-12 hr, eliminated unchanged in urine, 75%-85% protein bound</para>
					</section>
					<section type="none" id="sidelem4x8028">
						<sec_title>IM:</sec_title>
						<para> Peak 1-2 hr, duration 6-12 hr, half-life 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr</para>
					</section>
					<section type="none" id="sidelem4x8039">
						<sec_title>cephalexin:</sec_title>
						<para> Peak 1 hr, duration 6-12 hr, half-life 30-72 min, 5%-15% bound by plasma proteins, 80%-100% eliminated unchanged in urine, crosses placenta, excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8044">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> prothrombin time—anticoagulants; use cautiously</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—aminoglycosides, loop diuretics, probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> oral contraceptives possible, use another form of contraception</para>
				<section type="none" id="sidelem4x8059">
					<section type="none" id="sidelem4x8060">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, LDH, BUN, creatinine, bilirubin</para>
					</section>
					<section type="none" id="sidelem4x8067">
						<sec_title>False positive:</sec_title>
						<para> urinary protein, direct Coombs’ test, urine glucose</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> cross-matching</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8076">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8079">
					<section type="none" id="sidelem4x8080">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8085">
								<item>
									<label>•</label>
									<para>Sensitivity to penicillin and other cephalosporins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8091">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity: increased BUN, creatinine; urine output: if decreasing, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8096">
								<item>
									<label>•</label>
									<para>I&amp;O daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8101">
								<item>
									<label>•</label>
									<para>Blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alk phos, Coombs’ test monthly if patient is on long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8106">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chlorine monthly if patient is on long-term therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8115">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> bowel pattern daily; if severe diarrhea occurs, product should be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8119">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, urticaria, pruritus, chills, fever, joint pain; angioedema; may occur a few days after therapy begins; discontinue product, notify prescriber immediately, keep emergency equipment nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8124">
								<item>
									<label>•</label>
									<para>Bleeding: ecchymosis, bleeding gums, hematuria, stool guaiac daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8130">
								<item>
									<para>
										<emphasis alert="nurse">Overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8135">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8139">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection, negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8145">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8150">
								<item>
									<label>•</label>
									<para>To use yogurt or buttermilk to maintain intestinal flora, decrease diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8155">
								<item>
									<label>•</label>
									<para>To take all medication prescribed for length of time ordered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8161">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, bruising, bleeding, joint pain (may indicate blood dyscrasias [rare]); diarrhea with mucus, blood (may indicate pseudomembranous colitis)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>CEPHALOSPORINS—2ND GENERATION</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x82200">Do not confuse: cefaclor/cephalexin Cefotan/Ceftin cefprozil/ceFAZolin/cefuroxime Cefzil/Ceftin</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8220">
				<para>
					<confusion>
						<tradename id="tnidelem4x82200">cefaclor</tradename>
						<drug type="generic" refid="idelem4x82200">cephalexin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8235">
				<sec_title>Action:</sec_title>
				<para>Inhibits bacterial cell wall synthesis, renders cell wall osmotically unstable, leads to cell death by binding to cell wall membrane</para>
			</section>
			<section type="uses" id="sidelem4x8240">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">cefaclor:</emphasis> Gram-negative bacilli: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Klebsiella;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> respiratory tract, urinary tract, skin, infections; otitis media</para>
				<para>
					<emphasis style="bold">cefoTEtan:</emphasis> Gram-negative organisms: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Klebsiella, Citrobacter, Salmonella, Shigella, Acinetobacter, Bacteroides fragilis, Neisseria, Serratia;</emphasis>gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> lower, serious respiratory tract, urinary tract, skin, bone, joint, gynecologic, gonococcal, intraabdominal infections</para>
				<para>
					<emphasis style="bold">cefOXitin:</emphasis> Gram-negative bacilli: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Proteus, Klebsiella, Bacteroides fragilis, Neisseria gonorrhoeae;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> anaerobes including <emphasis style="italic">Clostridium;</emphasis> lower respiratory tract, urinary tract, skin, bone, gynecologic, gonococcal infections; septicemia, peritonitis</para>
				<para>
					<emphasis style="bold">cefprozil:</emphasis> Pharyngitis/tonsillitis; otitis media; secondary bacterial infection of acute bronchitis; acute bacterial exacerbation of chronic bronchitis; uncomplicated skin and skin-structure infections; acute sinusitis</para>
				<para>
					<emphasis style="bold">cefuroxime:</emphasis> Gram-negative bacilli: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Neisseria, Proteus mirabilis, Klebsiella;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> serious lower respiratory tract, urinary tract, skin, bone, joint, gonococcal infections; septicemia, meningitis, surgery prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x8291">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to cephalosporins or related antibiotics; seizures</para>
				<section type="none" id="sidelem4x8296">
					<section type="none" id="sidelem4x8297">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, GI/renal disease, diabetes mellitus, coagulopathy, pseudomembranous colitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8302">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8305">
					<sec_title>
						<emphasis style="italic">cefaclor</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8314">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8314">
								<item>
									<label>•</label>
									<para> 250-500 mg q8hr, ext rel 500 mg q12hr; max 1.5 g/day (cap, oral susp); 1 g/day (ext rel)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8321">
						<label>•</label>
						<sec_title>Child &gt;1 mo<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8321">
								<item>
									<label>•</label>
									<para> 20-40 mg/kg/day in divided doses q8hr or total daily dose may be divided and given q12hr, max 1 g/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8325">
						<sec_title>Available forms:</sec_title>
						<para> Caps 250, 500 mg; oral susp 125, 250, 375 mg/5 ml; ext rel tab 500 mg</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8330">
					<sec_title>
						<emphasis style="italic">cefoTEtan</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8339">
						<label>•</label>
						<sec_title>Adult<route> IM/IV</route></sec_title>
						<para>
							<list id="lidelem4x8339">
								<item>
									<label>•</label>
									<para> 1-3 g q12hr × 5-10 days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8346">
						<label>•</label>
						<sec_title>Adult<route> CCr</route></sec_title>
						<para>
							<list id="lidelem4x8346">
								<item>
									<label>•</label>
									<para> 30-50 ml/min, 1-2 g, then 1-2 g q8-12hr;  CCr 10-29 ml/min 1-2 g, then 1-2 g q12-24hr;  5-9 ml/min 1-2 g, then 0.5-1 g q12-24hr; &lt;5 ml/min 1-2 g, then 0.5-1 g q24-48hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8359">
						<sec_title>Perioperative prophylaxis</sec_title>
						<section type="none" id="sidelem4x8367">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8367">
									<item>
										<label>•</label>
										<para> 1-2 g <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-1 hr before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8377">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1, 2, 10 g</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8382">
					<sec_title>
						<emphasis style="italic">cefOXitin</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8391">
						<label>•</label>
						<sec_title>Adult<route> IM/IV</route></sec_title>
						<para>
							<list id="lidelem4x8391">
								<item>
									<label>•</label>
									<para> 1-2 g q6-8hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8395">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x8404">
							<label>•</label>
							<sec_title>Adult<route> IM/IV after loading dose, CCr 30-50 ml/min, 1-2 g q8-12hr; CCr 10-29 ml/min, 1-2 g q12-24hr; CCr &lt;10 ml/min, 0.5-1 g q12-24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8407">
						<sec_title>Uncomplicated gonorrhea (outpatient)</sec_title>
						<section type="none" id="sidelem4x8415">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥45 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x8415">
									<item>
										<label>•</label>
										<para> 2 g as single dose with 1 g  probenecid at same time</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8422">
						<sec_title>Severe infections</sec_title>
						<section type="none" id="sidelem4x8430">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x8430">
									<item>
										<label>•</label>
										<para> 2 g q4hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8437">
							<label>•</label>
							<sec_title>Child ≥3 mo<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x8437">
									<item>
										<label>•</label>
										<para> 80-160 mg/kg/day divided q4-6hr; max 12 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8441">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 1, 2, 10 g</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8446">
					<sec_title>
						<emphasis style="italic">cefprozil</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8450">
						<sec_title>Upper respiratory infections</sec_title>
						<section type="none" id="sidelem4x8458">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8458">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8462">
						<sec_title>Otitis media</sec_title>
						<section type="none" id="sidelem4x8470">
							<label>•</label>
							<sec_title>Child 6 mo-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8470">
									<item>
										<label>•</label>
										<para> 15 mg/kg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8474">
						<sec_title>Lower respiratory infections</sec_title>
						<section type="none" id="sidelem4x8482">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8482">
									<item>
										<label>•</label>
										<para> 500 mg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8486">
						<sec_title>Skin/skin-structure infections</sec_title>
						<section type="none" id="sidelem4x8494">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8494">
									<item>
										<label>•</label>
										<para> 250-500 mg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8498">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x8506">
							<label>•</label>
							<sec_title>
								<route>CCr &lt;30 ml/min, 50% of dose</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8509">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500 mg; susp 125, 250 mg/5 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8514">
					<sec_title>
						<emphasis style="italic">cefuroxime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8523">
						<label>•</label>
						<sec_title>Adult and child<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x8523">
								<item>
									<label>•</label>
									<para> 250 mg q12hr; may increase to 500 mg q12hr for serious infections</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8530">
						<label>•</label>
						<sec_title>Adult<route> IM/IV</route></sec_title>
						<para>
							<list id="lidelem4x8530">
								<item>
									<label>•</label>
									<para> 750 mg-1.5 g q8hr for 5-10 days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8535">
						<sec_title>Urinary tract infections</sec_title>
						<section type="none" id="sidelem4x8543">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8543">
									<item>
										<label>•</label>
										<para> 125 mg q12hr; may increase to 250 mg q12hr if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8547">
						<sec_title>Otitis media</sec_title>
						<section type="none" id="sidelem4x8555">
							<label>•</label>
							<sec_title>Child &lt;2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8555">
									<item>
										<label>•</label>
										<para> 125 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8562">
							<label>•</label>
							<sec_title>Child &gt;2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8562">
									<item>
										<label>•</label>
										<para> 250 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8566">
						<sec_title>Surgical prophylaxis</sec_title>
						<section type="none" id="sidelem4x8574">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8574">
									<item>
										<label>•</label>
										<para> 1.5 g <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8584">
						<sec_title>Severe infections</sec_title>
						<section type="none" id="sidelem4x8592">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x8592">
									<item>
										<label>•</label>
										<para> 1.5 g q6hr; may give up to 3 g q8hr for bacterial meningitis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8599">
							<label>•</label>
							<sec_title>Child &gt;3 mo<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x8599">
									<item>
										<label>•</label>
										<para> 50-100 mg/kg/day or IM in divided doses q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8603">
						<sec_title>Uncomplicated gonorrhea</sec_title>
						<section type="none" id="sidelem4x8611">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x8611">
									<item>
										<label>•</label>
										<para> 1.5 g as single dose in 2 separate sites with oral probenecid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8615">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x8623">
							<label>•</label>
							<sec_title>
								<route>Dosage reduction indicated with severe renal impairment (CCr &lt;20 ml/min)</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8626">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500 mg; solution for inj 1.5 g/50 ml, 750 mg/50 ml; susp 125, 250 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x8631">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8635">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel tabs or caps</para>
								</item>
								<item>
									<label>•</label>
									<para>On an empty stomach 1 hr before or 2 hr after a meal</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x8646">
					<sec_title>
						<emphasis style="italic">cefaclor</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x8651">
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Obtain C&amp;S specimen before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Shake susp, refrigerate, discard after 2 wk</para>
							</item>
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>With food if needed for GI symptoms</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S completed</para>
							</item>
							<item>
								<label>•</label>
								<para>Swallow ext rel whole</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8687">
					<sec_title>
						<emphasis style="italic">cefoTEtan</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x8692">
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Obtain C&amp;S specimen before use</para>
							</item>
							<item>
								<label>•</label>
								<para>IV direct after diluting 1 g/10 ml sterile water for inj, give over 3-5 min; may be diluted further with 50-100 ml NS or D<emphasis style="inf">5</emphasis>W; shake; run over <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-1 hr by <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; discontinue primary infusion during administration</para>
							</item>
							<item>
								<label>•</label>
								<para>May be stored 96 hr refrigerated or 24 hr at room temperature</para>
							</item>
						</list>
					</para>
					<para>
						<emphasis style="bold">Y-site compatibilities:</emphasis> Allopurinol, amifostine, aztreonam, diltiazem, famotidine, filgrastim, fluconazole, fludarabine, heparin, insulin (regular), melphalan, meperidine, morphine, PACLitaxel, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa</para>
				</section>
				<section type="none" id="sidelem4x8729">
					<sec_title>
						<emphasis style="italic">cefOXitin</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x8733">
						<section type="none" id="sidelem4x8734">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x8738">
									<item>
										<label>•</label>
										<para>After diluting 1 g/10 ml or more D<emphasis style="inf">5</emphasis>W, NS and give over 3-5 min; may be diluted further with 50-100 ml NS or D<emphasis style="inf">5</emphasis>W; run over <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-1 hr by <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; discontinue primary infusion during administration; give by cont infusion at prescribed rate; may store 96 hr refrigerated or 24 hr at room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>For 10-14 days to ensure organism death, prevent superinfection</para>
									</item>
									<item>
										<label>•</label>
										<para>After C&amp;S completed</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Heparin, insulin</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, cyclophosphamide, diltiazem, DOXOrubicin liposome, famotidine, fluconazole, foscarnet, HYDROmorphone, magnesium sulfate, meperidine, morphine, ondansetron, perphenazine, remifentanil, teniposide, thiotepa</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x8777">
					<sec_title>
						<emphasis style="italic">cefprozil</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x8782">
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Obtain C&amp;S specimen before use</para>
							</item>
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S</para>
							</item>
							<item>
								<label>•</label>
								<para>Refrigerate/shake susp before use, discard after 14 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8808">
					<sec_title>
						<emphasis style="italic">cefuroxime</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x8813">
							<item>
								<label>•</label>
								<para>Identify allergies before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Obtain C&amp;S specimen before use</para>
							</item>
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>With food if needed for GI symptoms</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S obtained</para>
							</item>
						</list>
					</para>
					<para>
						<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, allopurinol, amifostine, atracurium, aztreonam, cyclophosphamide, diltiazem, famotidine, fludarabine, foscarnet, HYDROmorphone, melphalan, meperidine, morphine, ondansetron, pancuronium, perphenazine, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium</para>
				</section>
			</section>
			<section type="effects" id="sidelem4x8845">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8848">
					<section type="none" id="sidelem4x8849">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, fatigue, paresthesia, fever, chills, confusion</para>
					</section>
					<section type="none" id="sidelem4x8854">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> nausea, vomiting, anorexia, dysgeusia, glossitis, bleeding; increased AST, ALT, bilirubin, LDH, alk phos; abdominal pain, loose stools, flatulence, heartburn, stomach cramps, colitis, jaundice, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8864">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, pruritus, candidiasis, increased BUN, <emphasis style="bold">nephrotoxicity, renal failure,</emphasis> pyuria, dysuria, reversible interstitial nephritis</para>
					</section>
					<section type="none" id="sidelem4x8872">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, agranulocytosis,</emphasis> anemia, <emphasis style="bold">neutropenia, lymphocytosis, eosinophilia, pancytopenia, hemolytic anemia, leukocytosis, granulocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8882">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, dermatitis, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8889">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
					<section type="none" id="sidelem4x8894">
						<sec_title>SYST:</sec_title>
						<para> Anaphylaxis, <emphasis style="bold">serum sickness,</emphasis> superinfection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8902">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8905">
					<section type="none" id="sidelem4x8906">
						<sec_title>cefaclor</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x8910">
						<sec_title>PO:</sec_title>
						<para> Peak <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-1 hr, half-life 36-54 min, 25% bound by plasma proteins, 60%-85% eliminated unchanged in urine in 8 hr, crosses placenta, excreted in breast milk (low concentrations)</para>
					</section>
					<section type="none" id="sidelem4x8921">
						<sec_title>cefoTEtan</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x8925">
						<sec_title>IM/IV:</sec_title>
						<para> Peak 1<emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-3 hr, half-life 3-5 hr, 75%-90% bound by plasma proteins, 50%-80% eliminated unchanged in urine, crosses placenta, excreted in breast milk</para>
					</section>
					<section type="none" id="sidelem4x8936">
						<sec_title>cefOXitin</sec_title>
						<para>Half-life 0.75-1 hr; 65%-80% bound by plasma proteins; 90%-100% eliminated unchanged in urine; crosses placenta, blood-brain barrier; eliminated in breast milk; not metabolized</para>
					</section>
					<section type="none" id="sidelem4x8941">
						<sec_title>IM:</sec_title>
						<para> Peak 15-30 min</para>
					</section>
					<section type="none" id="sidelem4x8946">
						<sec_title>IV:</sec_title>
						<para> Peak 5 min</para>
					</section>
					<section type="none" id="sidelem4x8951">
						<sec_title>cefprozil</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x8955">
						<sec_title>PO:</sec_title>
						<para> Peak 1.5 hr, protein binding 36%, elimination half-life 1.3 hr (normal renal function), 2 hr (hepatic disease), 5<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-6 hr (end-stage renal disease), extensively metabolized to an active metabolite, eliminated in urine 60%</para>
					</section>
					<section type="none" id="sidelem4x8966">
						<sec_title>cefuroxime</sec_title>
						<para>Peak PO 2 hr, IM 45 min, IV 2-3 min, 66% excreted unchanged in urine, half-life 1-2 hr in normal renal function</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8971">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect/toxicity—aminoglycosides, furosemide, probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk (cefoTEtan)—anticoagulants, thrombolytics, NSAIDs, antiplatelets, plicamycin, valproic acid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> oral contraceptive, possible—use additional form of contraception</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of cephalosporin —antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of cephalosporin—H<emphasis style="inf">2</emphasis>-blockers</para>
				<section type="none" id="sidelem4x8997">
					<section type="none" id="sidelem4x8998">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False increase:</emphasis> creatinine (serum urine), urinary 17-KS</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urinary protein, direct Coombs’ test, urine glucose testing (Clinitest)</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> cross-matching</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9013">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9016">
					<section type="none" id="sidelem4x9017">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9023">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity: increased BUN, creatinine</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9028">
								<item>
									<label>•</label>
									<para>I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9033">
								<item>
									<label>•</label>
									<para>Blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alk phos, Coombs’ test monthly if patient is on long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9038">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chlorine monthly if patient is on long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9043">
								<item>
									<label>•</label>
									<para>Bowel pattern daily; if severe diarrhea occurs, product should be discontinued; may indicate pseudomembranous colitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9048">
								<item>
									<label>•</label>
									<para>Urine output; if decreasing, notify prescriber (may indicate nephrotoxicity)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9054">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, flushing, urticaria, pruritus, dyspnea; discontinue product, notify prescriber, have emergency equipment available</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9062">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x9062">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> ecchymosis, bleeding gums, hematuria, stool guaiac daily</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9068">
								<item>
									<para>
										<emphasis alert="nurse">Overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9073">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9077">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9083">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9088">
								<item>
									<label>•</label>
									<para>If diabetic, to use blood glucose testing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9093">
								<item>
									<label>•</label>
									<para>To complete full course of product therapy; to report persistent diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9098">
								<item>
									<label>•</label>
									<para>To use yogurt, buttermilk to maintain intestinal flora, decrease diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9103">
								<item>
									<label>•</label>
									<para>To notify prescriber if breastfeeding or of any side effects</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9109">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, bruising, bleeding, joint pain (may indicate blood dyscrasias [rare]); diarrhea with mucus, blood (pseudomembranous colitis); symptoms of hypersensitivity</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>CEPHALOSPORINS—3RD/4TH GENERATION</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x91900">Do not confuse: cefTAZidime/ceftizoxime Vantin/Ventolin</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9190">
				<para>
					<confusion>
						<tradename id="tnidelem4x91900">cefTAZidime</tradename>
						<drug type="generic" refid="idelem4x91900">ceftizoxime</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9199">
				<sec_title>Action:</sec_title>
				<para>Inhibits bacterial cell wall synthesis, renders cell wall osmotically unstable, leads to cell death</para>
			</section>
			<section type="uses" id="sidelem4x9204">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">cefdinir:</emphasis> Community-acquired pneumonia, otitis media, sinusitis, pharyngitis, skin and skin-structure infections, acute exacerbations of chronic bronchitis, pneumonia, tonsillitis, citrobacter diversus, escherichia coli, Klebsiella pneumonial, proteus mirabilis, Staphylococcus epidermidis, streptococcus agalactial (group B), viridans Streptococci alpha: <emphasis style="italic">Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus</emphasis> (MSSA)</para>
				<para>
					<emphasis style="bold">cefditoren pivoxil:</emphasis> Acute bacterial exacerbations of chronic bronchitis caused by <emphasis style="italic">Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae, Moraxella catarrhalis</emphasis>; pharyngitis/tonsillitis caused by <emphasis style="italic">Streptococcus pyogenes</emphasis>; uncomplicated skin and skin-structure infections caused by <emphasis style="italic">Staphylococcus aureus, Streptococcus pyogenes;</emphasis> community-acquired pneumonia, viridans streptococci</para>
				<para>
					<emphasis style="bold">cefepime:</emphasis>
					<emphasis style="italic">Escherichia coli, Proteus, Klebsiella; Acinetobacter calcoaceticus, Acinetobacter lwoffii, Aeromonas hydrophilia, Citrobacter diversus, Citrobacter freundii, Enterobacter sp., Escherichia coli, Gardnerella vaginalis, Hafnia alvei, moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeal, Meningitidis, Providencia rettgeri, Stuartii, Pseudomonas aeruginosa, Salmonella sp., Serratia liquefaciens, Serratia marcescens, Shigella sp., Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactial, Bovis, Viridans streptococci, Yersinia entercolitica: Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> lower respiratory tract, urinary tract, skin, bone infections; febrile neutropenia intraabdominal infection</para>
				<para>
					<emphasis style="bold">cefixime:</emphasis> Uncomplicated UTI <emphasis style="italic">(Escherichia coli, Proteus mirabilis),</emphasis> pharyngitis and tonsillitis <emphasis style="italic">(Streptococcus pyogenes),</emphasis> otitis media <emphasis style="italic">(Haemophilus influenzae), Moraxella catarrhalis,</emphasis> acute bronchitis and acute exacerbations of chronic bronchitis <emphasis style="italic">(Streptococcus pneumoniae, H. influenzae),</emphasis> uncomplicated gonorrhea</para>
				<para>
					<emphasis style="bold">cefotaxime:</emphasis>
					<emphasis style="italic">Haemophilus influenzae, Haemophilus parainfluenzae, Escherichia coli, Enterococcus faecalis, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus mirabilis, Klebsiella, Citrobacter, Serratia, Salmonella, Shigella Pseudomonas; Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> serious lower respiratory tract, urinary tract, skin, bone, gonococcal infections; bacteremia, septicemia, meningitis, skin, skin-structure infections; CNS infections; perioperative prophylaxis, intraabdominal infections, PID, UTI, ventriculitis</para>
				<para>
					<emphasis style="bold">cefpodoxime:</emphasis> Bacteroides, <emphasis style="italic">Neisseria gonorrhoeae, Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Klebsiella;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> upper and lower respiratory tract, urinary tract, skin infections; otitis media; sexually transmitted diseases</para>
				<para>
					<emphasis style="bold">cefTAZidime:</emphasis>
					<emphasis style="italic">Haemophilus influenzae, Escherichia coli, Enterobacter aerogenes, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella, Citrobacter, Enterobacter, Salmonella, Shigella, Acinetobacter, Bacteroides fragilis, Neisseria, Serratia; Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> serious lower respiratory tract, urinary tract, skin, gynecologic, bone, joint, intraabdominal infections; septicemia, meningitis</para>
				<para>
					<emphasis style="bold">ceftibuten:</emphasis> Pharyngitis/tonsillitis, otitis media, secondary bacterial infection of acute bronchitis</para>
				<para>
					<emphasis style="bold">cefTRIAXone:</emphasis> Gram-negative bacilli: <emphasis style="italic">Haemophilus influenzae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Klebsiella, Citrobacter, Enterobacter, Salmonella, Shigella, Acinetobacter, Bacteroides fragilis, Neisseria, Serratia;</emphasis> gram-positive organisms: <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus;</emphasis> serious lower respiratory tract, urinary tract, skin, gonococcal, intraabdominal infections; septicemia, meningitis, bone, joint infections; otitis media; PID</para>
			</section>
			<section type="contra" id="sidelem4x9291">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to cephalosporins, infants &lt;1 mo</para>
				<section type="none" id="sidelem4x9296">
					<section type="none" id="sidelem4x9297">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, hypersensitivity to penicillins, GI/renal disease, geriatric patients, pseudomembranous colitis, viral infection, vit K deficiencies, diabetes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9302">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9305">
					<sec_title>
						<emphasis style="italic">cefdinir</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9309">
						<sec_title>Uncomplicated skin and skin-structure infections/community-acquired pneumonia</sec_title>
						<section type="none" id="sidelem4x9317">
							<label>•</label>
							<sec_title>Adult and child ≥13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9317">
									<item>
										<label>•</label>
										<para> 300 mg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9324">
							<label>•</label>
							<sec_title>Child 6 mo-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9324">
									<item>
										<label>•</label>
										<para> 7 mg/kg q12hr or 14 mg/kg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9328">
						<sec_title>Acute exacerbations of chronic bronchitis/acute maxillary sinusitis</sec_title>
						<section type="none" id="sidelem4x9336">
							<label>•</label>
							<sec_title>Adult and child ≥13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9336">
									<item>
										<label>•</label>
										<para> 300 mg q12hr or 600 mg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9340">
						<sec_title>Pharyngitis/tonsillitis</sec_title>
						<section type="none" id="sidelem4x9348">
							<label>•</label>
							<sec_title>Adult and child ≥13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9348">
									<item>
										<label>•</label>
										<para> 300 mg q12hr or 600 mg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9355">
							<label>•</label>
							<sec_title>Child 6 mo-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9355">
									<item>
										<label>•</label>
										<para> 7 mg/kg q12hr × 5-10 days or 14 mg/kg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9359">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9367">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, 300 mg/day (adult); 7 mg/kg/day (child)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9370">
						<sec_title>Available forms:</sec_title>
						<para> Caps 300 mg; susp 125 mg, 250 mg/5 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9375">
					<sec_title>
						<emphasis style="italic">cefditoren pivoxil</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9384">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x9384">
								<item>
									<label>•</label>
									<para> 200-400 mg bid × 10-14 days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9388">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9396">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min, max 200 mg bid; CCr &lt;30 ml/min, max 200 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9399">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200, 400 mg</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9404">
					<sec_title>
						<emphasis style="italic">cefepime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9408">
						<sec_title>Febrile neutropenia</sec_title>
						<section type="none" id="sidelem4x9416">
							<label>•</label>
							<sec_title>Adult/adolescent &gt;16 yrs/child ≥ 40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9416">
									<item>
										<label>•</label>
										<para> 2 g q8hr × 7 days or until neutropenia resolves</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9423">
							<label>•</label>
							<sec_title>Infant ≥2 mo/child/adolescent ≤16 yr and ≤40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9423">
									<item>
										<label>•</label>
										<para> 50 mg/kg/dose q8hr × 7 days or until neutropenia resolves</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9427">
						<sec_title>Urinary tract infections (mild to moderate)</sec_title>
						<section type="none" id="sidelem4x9435">
							<label>•</label>
							<sec_title>Adult<route> IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x9435">
									<item>
										<label>•</label>
										<para> 0.5-1 g q12hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9439">
						<sec_title>Urinary tract infections (severe)</sec_title>
						<section type="none" id="sidelem4x9447">
							<label>•</label>
							<sec_title>Adult/adolescent &gt;16 yr/child ≥40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9447">
									<item>
										<label>•</label>
										<para> 2 g q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9451">
						<sec_title>Pneumonia (moderate to severe)</sec_title>
						<section type="none" id="sidelem4x9459">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9459">
									<item>
										<label>•</label>
										<para> 1-2 g q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9463">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 500 mg, 1, 2 g; 1 g/50 ml, 2 g/100 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9468">
					<sec_title>
						<emphasis style="italic">cefixime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9472">
						<sec_title>Mild to moderate pharyngitis, tonsillitis, bronchitis</sec_title>
						<section type="none" id="sidelem4x9480">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9480">
									<item>
										<label>•</label>
										<para> 400 mg/day divided q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9487">
							<label>•</label>
							<sec_title>Children ≤45 kg infants ≥6 months<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9487">
									<item>
										<label>•</label>
										<para> 8 mg/kg/day divided q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9491">
						<sec_title>Uncomplicated urinary tract infection (UTI)</sec_title>
						<section type="none" id="sidelem4x9499">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9499">
									<item>
										<label>•</label>
										<para> 400 mg/day divided q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9506">
							<label>•</label>
							<sec_title>Children ≤45 kg and infants ≥6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9506">
									<item>
										<label>•</label>
										<para> 8 mg/kg/day divided q12-24hr max: 400 mg/day × 7-14 days is recommended by the American Academy of Pediatrics (AAP) for the treatment of initial UTI in febrile infants and young children 2-24 mo</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9513">
							<label>•</label>
							<sec_title>Infants 2-5 mo (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9513">
									<item>
										<label>•</label>
										<para> 8 mg/kg/day × 7-14 days is recommended by the American Academy of Pediatrics (AAP) for the treatment of initial UTI in febrile infants and young children</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9517">
						<sec_title>Mild to moderate otitis media</sec_title>
						<section type="none" id="sidelem4x9525">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9525">
									<item>
										<label>•</label>
										<para> 400 mg/day divided q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9532">
							<label>•</label>
							<sec_title>Children ≤45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9532">
									<item>
										<label>•</label>
										<para> 8 mg/kg/day divided q12-24hr, max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9539">
							<label>•</label>
							<sec_title>Infants ≥6 months<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9539">
									<item>
										<label>•</label>
										<para> 8 mg/kg/day divided q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9543">
						<sec_title>Gonorrhea of uncomplicated cervicitis, or urethritis due to <emphasis style="bold">
								<emphasis style="italic">N. gonorrhoeae</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x9554">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9554">
									<item>
										<label>•</label>
										<para> as alternative therapy, 400 mg as a single dose with a regimen effective against uncomplicated genital <emphasis style="italic">C. trachomatis</emphasis> infection (e.g., azithromycin as a single dose or doxycycline for 7 days) if chlamydial infection is not ruled out; the CDC states that cefixime is only acceptable if IM cefTRIAXone is not an option because of rising cefixime MICs for gonorrhea; if cefixime is used, test-of-cure should be done at the infected site 1 wk after treatment; cefixime is not recommended for infections of the pharynx</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9566">
							<label>•</label>
							<sec_title>Children ≥45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9566">
									<item>
										<label>•</label>
										<para> 400 mg as a single dose with a regimen effective against uncomplicated genital <emphasis style="italic">C. trachomatis</emphasis> infection (e.g., azithromycin as a single dose or doxycycline for 7 days) if chlamydial infection is not ruled out; cefixime is not recommended for infections of the pharynx; cefixime is an alternative to cefTRIAXone per AAP</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9573">
						<sec_title>Gonorrhea prophylaxis (victims of sexual assault) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9581">
							<label>•</label>
							<sec_title>Adult/adolescent</sec_title>
							<para>
								<list id="lidelem4x9581">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent:</emphasis> The CDC recommends 400 mg as a single dose with metroNIDAZOLE (for trichomoniasis and bacterial vaginosis prophylaxis) plus either azithromycin or doxycycline (for chlamydia prophylaxis); the CDC states that cefixime is only acceptable if IM cefTRIAXone is not an option because of rising cefixime MICs for gonorrhea</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9585">
						<sec_title>Typhoid fever caused by multidrug-resistant <emphasis style="bold">
								<emphasis style="italic">Salmonella typhi</emphasis>
							</emphasis> (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9597">
							<label>•</label>
							<sec_title>Adult/adolescent/child</sec_title>
							<para>
								<list id="lidelem4x9597">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child:</emphasis> 100-200 mg  or 15-20 mg/kg/day  in 2 divided doses for 7-14 days; for quinolone-resistant organisms, 20 mg/kg/day  in 2 divided doses for 7-14 days should be used</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9613">
							<label>•</label>
							<sec_title>Children &lt;50 kg</sec_title>
							<para>
								<list id="lidelem4x9613">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Children &lt;50 kg:</emphasis> should receive weight-based dosing, max adult dosages</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9617">
						<sec_title>Acute bacterial sinusitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9625">
							<label>•</label>
							<sec_title>Infants ≥6 mo/child/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9625">
									<item>
										<label>•</label>
										<para> 8 mg/kg/day  divided q12hr, max 400 mg/day, with clindamycin for 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9632">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9640">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 21-59 ml/min, give 65% of dose; CCr &lt;20 ml/min, give 50% of dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9643">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 400 mg; powder for oral susp 100 mg/5 ml, chew tabs 100, 200 mg, 200 mg/5 ml, cap 400 mg</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9648">
					<sec_title>
						<emphasis style="italic">cefotaxime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9657">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥50 kg<route> IV/IM</route></sec_title>
						<para>
							<list id="lidelem4x9657">
								<item>
									<label>•</label>
									<para> (uncomplicated infections) 1 g q12hr, (moderate-severe infection) 1-2 g q8hr, (severe infections) 2 g q6-8hr, (life-threatening infections) 2 g q4hr, max 12 g/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9664">
						<label>•</label>
						<sec_title>Adolescent/child &lt;50 kg and infants<route> IV/IM</route></sec_title>
						<para>
							<list id="lidelem4x9664">
								<item>
									<label>•</label>
									<para> 50-180 mg/kg/day divided q6-8hr, max 2 g/dose; (severe infections) 200-225 mg/kg/day divided q4-6hr max 12 g</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9671">
						<label>•</label>
						<sec_title>Neonates &gt;7 days<route> IV/IM</route></sec_title>
						<para>
							<list id="lidelem4x9671">
								<item>
									<label>•</label>
									<para> 50 mg/kg/dose q8-12hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9675">
						<sec_title>Uncomplicated gonorrhea</sec_title>
						<section type="none" id="sidelem4x9683">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x9683">
									<item>
										<label>•</label>
										<para> 500 mg as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9687">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x9695">
							<label>•</label>
							<sec_title>Adult<route> IM CCr &lt;20 ml/min 50% dose reduction</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9698">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 500 mg, 1, 2, 10 g; inj 1, 2 g premixed frozen</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9703">
					<sec_title>
						<emphasis style="italic">cefpodoxime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9707">
						<sec_title>Pneumonia</sec_title>
						<section type="none" id="sidelem4x9715">
							<label>•</label>
							<sec_title>Adult &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9715">
									<item>
										<label>•</label>
										<para> 200 mg q12hr × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9719">
						<sec_title>Skin and skin structure</sec_title>
						<section type="none" id="sidelem4x9727">
							<label>•</label>
							<sec_title>Adult &gt;13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9727">
									<item>
										<label>•</label>
										<para> 400 mg q12hr × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9731">
						<sec_title>Pharyngitis and tonsillitis</sec_title>
						<section type="none" id="sidelem4x9739">
							<label>•</label>
							<sec_title>Adult &gt;13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9739">
									<item>
										<label>•</label>
										<para> 100 mg q12hr × 5-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9746">
							<label>•</label>
							<sec_title>Child 5 mo-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9746">
									<item>
										<label>•</label>
										<para> 5 mg/kg q12hr (max 100 mg/dose or 200 mg/day) × 5-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9750">
						<sec_title>Uncomplicated UTI</sec_title>
						<section type="none" id="sidelem4x9758">
							<label>•</label>
							<sec_title>Adult &gt;13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9758">
									<item>
										<label>•</label>
										<para> 100 mg q12hr × 7 days; dosing interval increased with severe renal impairment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9762">
						<sec_title>Acute otitis media</sec_title>
						<section type="none" id="sidelem4x9770">
							<label>•</label>
							<sec_title>Child 5 mo-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9770">
									<item>
										<label>•</label>
										<para> 5 mg/kg q12hr × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9774">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200 mg; granules for susp 50 mg, 100 mg/5 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9780">
					<sec_title>
						<emphasis style="italic">cefTAZidime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9789">
						<label>•</label>
						<sec_title>Adult<route> IV/IM</route></sec_title>
						<para>
							<list id="lidelem4x9789">
								<item>
									<label>•</label>
									<para> 1-2 g q8</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9796">
						<label>•</label>
						<sec_title>Child<route> IV</route></sec_title>
						<para>
							<list id="lidelem4x9796">
								<item>
									<label>•</label>
									<para> 30-50 mg/kg q8hr, max 6 g/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9803">
						<label>•</label>
						<sec_title>Neonate<route> IV</route></sec_title>
						<para>
							<list id="lidelem4x9803">
								<item>
									<label>•</label>
									<para> 30-50 mg/kg q8-12hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9807">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9815">
							<label>•</label>
							<sec_title>Adult<route> IM/IV CCr 31-50 ml/min 1 g q12hr; CCr 16-30 ml/min 1 g q24hr;</route></sec_title>
						</section>
						<para>
							<emphasis alert="lifethreat">CCR 6-15 ml/min 1 g loading dose, then 0.5 g q24hr; CCr &lt;5 ml/min 1 g loading dose, then 0.5 g q48hr</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x9821">
						<sec_title>Available forms:</sec_title>
						<para> Inj 250, 500 mg, 1, 2, 6 g</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9826">
					<sec_title>
						<emphasis style="italic">ceftibuten</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9835">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x9835">
								<item>
									<label>•</label>
									<para> 400 mg/day × 10 days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9842">
						<label>•</label>
						<sec_title>Child 6 mo-12 yr<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x9842">
								<item>
									<label>•</label>
									<para> 9 mg/kg/day × 10 days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9846">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9854">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min, give 200 mg q24hr; CCr 5-29 ml/min, give 100 mg q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9857">
						<sec_title>Available forms:</sec_title>
						<para> Caps 400 mg; susp 90 mg, 180 mg/5 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9862">
					<sec_title>
						<emphasis style="italic">cefTRIAXone</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9871">
						<label>•</label>
						<sec_title>Adult<route> IM/IV</route></sec_title>
						<para>
							<list id="lidelem4x9871">
								<item>
									<label>•</label>
									<para> 1-2 g/day, max 4 g/24 hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9878">
						<label>•</label>
						<sec_title>Child<route> IM/IV</route></sec_title>
						<para>
							<list id="lidelem4x9878">
								<item>
									<label>•</label>
									<para> 50-75 mg/kg/day in equal doses q12-24hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9882">
						<sec_title>Uncomplicated gonorrhea</sec_title>
						<section type="none" id="sidelem4x9890">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x9890">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 250 mg  as single dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9897">
								<item>
									<label>•</label>
									<para>Reduce dosage in severe renal impairment (CCr &lt;10 ml/min)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9902">
						<sec_title>Available forms:</sec_title>
						<para> Inj 250, 500 mg, 1, 2, 10 g</para>
					</section>
					<section type="none" id="sidelem4x9907">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9911">
								<item>
									<label>•</label>
									<para>Change IV site q72hr</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x9917">
					<sec_title>
						<emphasis style="italic">cefdinir</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x9922">
							<item>
								<label>•</label>
								<para>Oral susp after adding 39 ml water to the 60-ml bottle or 65 ml water to the 120-ml bottle; discard unused portion after 10 days; give without regard to food, do not give within 2 hr of antacids, iron supplements</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S completed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9933">
					<sec_title>
						<emphasis style="italic">cefditoren pivoxil</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x9938">
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>With food; do not give with antacids</para>
							</item>
							<item>
								<label>•</label>
								<para>After C&amp;S completed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9954">
					<sec_title>
						<emphasis style="italic">cefepime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x9958">
						<section type="none" id="sidelem4x9959">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9963">
									<item>
										<label>•</label>
										<para>IV after diluting in 50-100 ml or more D<emphasis style="inf">5</emphasis>, NS; give over 30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>For 7-10 days to ensure organism death, prevent superinfection</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> 0.9% NaCl, D<emphasis style="inf">5</emphasis>, D<emphasis style="inf">5</emphasis>W, 0.5%, 10% lidocaine, bacteriostatic water for inj with parabens/benzyl alcohol</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> DOXOrubicin liposome</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x9991">
					<sec_title>
						<emphasis style="italic">cefixime</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x9996">
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>Without regard to food</para>
							</item>
							<item>
								<label>•</label>
								<para>Chew tabs before swallowing</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10012">
					<sec_title>
						<emphasis style="italic">cefotaxime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x10016">
						<section type="none" id="sidelem4x10017">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x10025">
								<label>•</label>
								<sec_title>
									<route>diluting</route>
								</sec_title>
								<para>
									<list id="lidelem4x10025">
										<item>
											<label>•</label>
											<para>IV after  1 g/10 ml D<emphasis style="inf">5</emphasis>W, NS, sterile water for inj,  over 3-5 min by <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; may be  with 50-100 ml NS or D<emphasis style="inf">5</emphasis>W;  over <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-1 hr; discontinue primary infusion during administration; may be  in larger vol of sol, given as a cont infusion</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x10057">
									<item>
										<label>•</label>
										<para>For 10-14 days to ensure organism death, prevent superinfection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10062">
									<item>
										<label>•</label>
										<para>Thaw frozen container at room temperature or refrigeration; do not force thaw by immersion or microwave; visually inspect container for leaks</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Caffeine, diphenhyDRINATE, heparin, ofloxacin</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, alprostadil, amifostine, amikacin, aminocaproic acid, aminophylline, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, caffeine, calcium chloride/gluconate, CARBOplatin, cefamandole, cefmetazole, cefonicid, cefoperazone, cefoTEtan, cefOXitin, cefTAZidime (L-arginine), cefTRIAXone sodium, cefuroxime, cimetidine, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, DOCEtaxel, DOPamine, doxacurium, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fludarabine, fluorouracil, folic acid, furosemide, gatifloxacin, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, insulin (regular), isoproterenol, ketorolac, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, normal saline, octreotide, ofloxacin, ondansetron, ornidazole, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, pefloxacin, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, peritoneal dialysis solution, perphenazine, PHENobarbital, phenylephrine, phenytoin, phytonadione, piperacillin, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin, ranitidine, remifentanil, Ringer’s injection, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, sodium fusidate, sodium lactate, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x10077">
					<sec_title>
						<emphasis style="italic">cefpodoxime</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x10082">
							<item>
								<label>•</label>
								<para>Do not break, crush, or chew tabs due to taste</para>
							</item>
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>With food for better absorption; do not give within 2 hr of antacids, H<emphasis style="inf">2</emphasis>-receptor antagonists</para>
							</item>
							<item>
								<label>•</label>
								<para>Shake susp well, refrigerate, discard after 2 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10106">
					<sec_title>
						<emphasis style="italic">cefTAZidime</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x10110">
						<section type="none" id="sidelem4x10111">
							<sec_title>IM route</sec_title>
							<section type="none" id="sidelem4x10119">
								<label>•</label>
								<sec_title>Fortaz, Tazidime vials</sec_title>
								<para>
									<list id="lidelem4x10119">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Fortaz, Tazidime vials:</emphasis> reconstitute 500 mg or 1 g with 1.5 or 3 ml, respectively, of sterile or bacteriostatic water for inj or 0.5%-1% lidocaine (approx 280 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10126">
								<label>•</label>
								<sec_title>Tazicef vials</sec_title>
								<para>
									<list id="lidelem4x10126">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Tazicef vials:</emphasis> reconstitute 1 g/3 ml sterile water for inj (approx 280 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10133">
								<label>•</label>
								<sec_title>Ceptaz vials</sec_title>
								<para>
									<list id="lidelem4x10133">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Ceptaz vials:</emphasis> reconstitute 1 g/3 ml sterile or bacteriostatic water for inj or 0.5%-1% lidocaine (approx 250 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10140">
								<label>•</label>
								<sec_title>
									<route>Withdraw</route>
								</sec_title>
								<para>
									<list id="lidelem4x10140">
										<item>
											<label>•</label>
											<para> dose while making sure needle remains in vial;  no CO<emphasis style="inf">2</emphasis> bubbles present;  deeply in large muscle mass,  before injection</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x10156">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x10161">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter, discoloration, if possible</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x10169">
								<label>•</label>
								<sec_title>Fortaz, Tazicef, Tazidime packs<route> reconstitute</route></sec_title>
								<para>
									<list id="lidelem4x10169">
										<item>
											<label>•</label>
											<para> 1 or 2 g/100 ml sterile water for inj or other compatible IV sol (10 or 20 mg/ml, respectively); reconstitution is done in two stages: first,  10 ml of the diluent into the pack and  well to dissolve and become clear; CO<emphasis style="inf">2</emphasis> pressure inside container will occur,  vent needle to release pressure;  remaining diluents,  vent needle</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10194">
								<label>•</label>
								<sec_title>Fortaz, Tazicef, Tazidime vials<route> reconstitute</route></sec_title>
								<para>
									<list id="lidelem4x10194">
										<item>
											<label>•</label>
											<para> 500 mg, 1 g, 2 g with 5, 10, 10 ml, respectively, of sterile water for inj or other compatible IV solution (100, 95-100, or 170-180 mg/ml, respectively);  well to dissolve</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10204">
								<label>•</label>
								<sec_title>Fortaz, Tazidime ADD-Vantage vials (for IV only)<route> reconstitute</route></sec_title>
								<para>
									<list id="lidelem4x10204">
										<item>
											<label>•</label>
											<para> 1 or 2 g with NS, <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> NS, D<emphasis style="inf">5</emphasis>W in either 50- or 100-ml flexible diluent container; to release CO<emphasis style="inf">2</emphasis> pressure,  vent needle after dissolving,  vent before using</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10231">
								<label>•</label>
								<sec_title>Ceptaz packs<route> reconstitute</route></sec_title>
								<para>
									<list id="lidelem4x10231">
										<item>
											<label>•</label>
											<para> 1 or 2 g/100 ml sterile water for inj or compatible IV sol (10 or 20 mg/ml, respectively); reconstitution is done in two stages: first,  10 ml of the diluent into the pack and  well to dissolve,  the remaining diluent,  vent needle before giving</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10250">
								<label>•</label>
								<sec_title>Ceptaz vials<route> reconstitute</route></sec_title>
								<para>
									<list id="lidelem4x10250">
										<item>
											<label>•</label>
											<para> 1 or 2 g/10 ml of sterile water for inj or compatible IV sol (90-95, or 170-180 mg/ml, respectively)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x10257">
								<label>•</label>
								<sec_title>Ceptaz ADD-Vantage vials (for IV only)<route> reconstitute</route></sec_title>
								<para>
									<list id="lidelem4x10257">
										<item>
											<label>•</label>
											<para> 1 or 2 g with NS, ½ NS, or D<emphasis style="inf">5</emphasis>W in either 50- or 100-ml diluent container</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x10264">
							<sec_title>Direct Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x10272">
								<label>•</label>
								<sec_title>Vials<route> withdraw</route></sec_title>
								<para>
									<list id="lidelem4x10272">
										<item>
											<label>•</label>
											<para> dose while making sure needle remains in sol; make sure there are no CO<emphasis style="inf">2</emphasis> bubbles in syringe before inj;  directly over 3-5 min or slowly into tubing of a free-flowing compatible IV solution</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x10282">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x10290">
								<label>•</label>
								<sec_title>Vials<route> withdraw</route></sec_title>
								<para>
									<list id="lidelem4x10290">
										<item>
											<label>•</label>
											<para> dose while making sure needle opening remains in sol; make sure there are no CO<emphasis style="inf">2</emphasis> bubbles in syringe before inj; infusion packs and ADD-Vantage systems ready for infusion after reconstitution,  over 15-30 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Cimetidine, dimenhyDRINATE, HYDROmorphone</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, anakinra, anidulafungin, atenolol, atropine sulfate, aztreonam, benzotropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, cefamandole, ceFAZolin, cefonicid, cefoperazone, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, cephapirin, cimetidine, ciprofloxacin, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, DOCEtaxel, DOPamine, doxacurium, doxapram, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, eptifibatide, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fludarabine, fluorouracil, folic acid, foscarnet, furosemide, gallium, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, HYDROmorphone, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), irinotecan, isepamicin, isoproterenol, isosorbide, ketamine, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, milrinone, morphine, moxalactam, multiple vitamin inj, nafcillin, nalbuphine, PACLitaxel, ranitidine, remifentanil, tacrolimus, teniposide, theophylline, thiotepa, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x10308">
					<sec_title>
						<emphasis style="italic">ceftibuten</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x10313">
							<item>
								<label>•</label>
								<para>For 10 days to ensure organism death, prevent superinfection</para>
							</item>
							<item>
								<label>•</label>
								<para>On empty stomach</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10324">
					<sec_title>
						<emphasis style="italic">cefTRIAXone</emphasis>
					</sec_title>
					<para>
						<list id="lidelem4x10330">
							<item>
								<label>•</label>
								<para>For 10-14 days to ensure organism death, prevent superinfection</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x10338">
						<label>•</label>
						<sec_title>
							<route>IM</route>
						</sec_title>
						<para>
							<list id="lidelem4x10338">
								<item>
									<label>•</label>
									<para> inj deeply in large muscle mass</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10342">
						<section type="none" id="sidelem4x10343">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x10351">
								<label>•</label>
								<sec_title>
									<route>IV</route>
								</sec_title>
								<para>
									<list id="lidelem4x10351">
										<item>
											<label>•</label>
											<para> after  250 mg/2.4 ml, 500 mg/4.8 ml, 1 g/9.6 ml, 2 g/19.2 ml D<emphasis style="inf">5</emphasis>W, water for inj, 0.9% NaCl; may be  with 50-100 ml NS, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">10</emphasis>W; shake;  over ½ hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x10373">
									<item>
										<label>•</label>
										<para>Do not mix with calcium salts</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B liposome, anidulafungin, argatroban, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, CARBOplatin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefoTAXime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefuroxime, cephalothin, cephapirin, cimetidine, cisatracurium, CISplatin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin liposomal, doxycycline, drotrecogin alfa, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, eptifibatide, erythromycin, esmolol, etoposide, fenoldopam, fludarabine, fluorouracil, folic acid, foscarnet, furosemide, gallium, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, indomethacin, insulin (regular), isoproterenol, ketorolac, lansoprazole, levofloxacin, lidocaine, linezolid, LORazepam, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, morphine, moxalactam, multiple vitamins injection, nafcillin, nalbuphine, naloxone, nesiritide, netilimicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium/sodium, PHENobarbital, phenylephrine, phytonadione, piperacillin, polymyxin B, potassium chloride, procainamide, propofol, propranolol, pyridoxine, ranitidine, remifentanil, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tolazoline, trastuzumab, trimetaphan, urokinase, vasopressin, vecuronium, verapamil, vinCRIStine, voriconazole, warfarin, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10384">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10387">
					<section type="none" id="sidelem4x10388">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, weakness, paresthesia, fever, chills, <emphasis style="bold">seizures,</emphasis> dyskinesia (cefdinir); <emphasis style="bold">neurotoxicity (renal disease) cefepime</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10398">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure,</emphasis> syncope (cefdinir)</para>
					</section>
					<section type="none" id="sidelem4x10406">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Oral candidiasis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10413">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia,</emphasis> pain, glossitis, <emphasis style="bold">bleeding;</emphasis> increased AST, ALT, bilirubin, LDH, alk phos; abdominal pain, <emphasis style="bold">pseudomembranous colitis;</emphasis> cholestasis (cefotaxime)</para>
					</section>
					<section type="none" id="sidelem4x10427">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Proteinuria,</emphasis> vaginitis, pruritus, <emphasis style="italic">candidiasis,</emphasis> increased BUN, <emphasis style="bold">nephrotoxicity, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10440">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, agranulocytosis,</emphasis> anemia, <emphasis style="bold">neutropenia, lymphocytosis, eosinophilia, pancytopenia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10450">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x10455">
						<sec_title>MS:</sec_title>
						<para> Arthralgia (cefditoren)</para>
					</section>
					<section type="none" id="sidelem4x10460">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
					<section type="none" id="sidelem4x10465">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, serum sickness, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10472">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10475">
					<section type="none" id="sidelem4x10476">
						<sec_title>cefdinir</sec_title>
						<para>Unchanged in urine; crosses placenta, blood-brain barrier; eliminated in breast milk, not metabolized; 60%-70% protein binding, half-life 1.7 hr</para>
					</section>
					<section type="none" id="sidelem4x10481">
						<sec_title>cefditoren pivoxil</sec_title>
						<para>Well absorbed when broken down (prodrug), wide distribution, half-life 100 min, onset rapid, peak 1.5-3 hr, duration 12 hr, 88% protein binding</para>
					</section>
					<section type="none" id="sidelem4x10486">
						<sec_title>cefepime</sec_title>
						<para>Peak 79 min; half-life 2 hr; 20% bound by plasma proteins; 90% excreted unchanged in urine; crosses placenta, blood-brain barrier; excreted in breast milk, not metabolized</para>
					</section>
					<section type="none" id="sidelem4x10491">
						<sec_title>cefixime</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x10495">
						<sec_title>PO:</sec_title>
						<para> Peak 2-8 hr, half-life 3-4 hr, 65%-70% protein binding, 50% eliminated unchanged in urine, crosses placenta, excreted in breast milk</para>
					</section>
					<section type="none" id="sidelem4x10500">
						<sec_title>cefotaxime</sec_title>
						<para>Half-life 1 hr, 35%-65% is bound by plasma proteins, 40%-65% is eliminated unchanged in urine in 24 hr, 25% metabolized in the liver to active metabolites, excreted in breast milk (small amounts)</para>
					</section>
					<section type="none" id="sidelem4x10507">
						<sec_title>IM:</sec_title>
						<para> Onset 30 min</para>
					</section>
					<section type="none" id="sidelem4x10512">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min</para>
					</section>
					<section type="none" id="sidelem4x10517">
						<sec_title>cefpodoxime</sec_title>
						<para>Half-life 1-1.5 hr, 13%-38% bound by plasma proteins, 30% eliminated unchanged in urine in 8 hr, crosses placenta, excreted in breast milk</para>
					</section>
					<section type="none" id="sidelem4x10522">
						<sec_title>cefTAZidime</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x10526">
						<sec_title>IM/IV:</sec_title>
						<para>Half-life 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, 10% bound by plasma proteins, 80% eliminated unchanged in urine, crosses placenta, excreted in breast milk</para>
					</section>
					<section type="none" id="sidelem4x10537">
						<sec_title>ceftibuten</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x10541">
						<sec_title>PO:</sec_title>
						<para> Peak 2-3 hr; plasma protein binding 65%, elimination half-life 2 hr, extensively metabolized to an active metabolite</para>
					</section>
					<section type="none" id="sidelem4x10546">
						<sec_title>IM:</sec_title>
						<para> Peak 1 hr</para>
					</section>
					<section type="none" id="sidelem4x10551">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min</para>
					</section>
					<section type="none" id="sidelem4x10556">
						<sec_title>cefTRIAXone</sec_title>
						<para>Half-life 6-9 hr, 58%-96%, eliminated unchanged in urine, crosses placenta, excreted in breast milk</para>
					</section>
					<section type="none" id="sidelem4x10561">
						<sec_title>IM:</sec_title>
						<para> Peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr</para>
					</section>
					<section type="none" id="sidelem4x10572">
						<sec_title>IV:</sec_title>
						<para> Peak 30 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10577">
				<sec_title>Interactions</sec_title>
				<para>Many products should not be used with calcium salts (mixed or administered) or H2 blockers antacids (PO)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cycloSPORINE levels—cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants, thrombolytics, plicamycin, valproic acid, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—aminoglycosides, furosemide, probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of cefdinir—iron</para>
				<section type="none" id="sidelem4x10598">
					<section type="none" id="sidelem4x10599">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—iron-rich cereal, infant formula</para>
					</section>
					<section type="none" id="sidelem4x10606">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, alk phos, LDH, bilirubin, BUN, creatinine</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> creatinine (serum urine), urinary 17-KS</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urinary protein, direct Coombs’ test, urine glucose</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> cross-matching</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10625">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10628">
					<section type="none" id="sidelem4x10629">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10634">
								<item>
									<label>•</label>
									<para>Sensitivity to penicillin, other cephalosporins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10640">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity: increased BUN, creatinine; urine output: if decreasing, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10645">
								<item>
									<label>•</label>
									<para>Blood studies: AST, ALT, CBC, Hct, bilirubin, LDH, alk phos, Coombs’ test monthly if patient is on long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10650">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride monthly if patient is on long-term therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10658">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> bowel pattern daily; if severe diarrhea occurs, product should be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10661">
								<item>
									<label>•</label>
									<para>IV site for extravasation, phlebitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10667">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: rash, urticaria, pruritus, chills, fever, joint pain, angioedema; may occur a few days after therapy begins</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10672">
								<item>
									<label>•</label>
									<para>Bleeding: ecchymosis, bleeding gums, hematuria, stool guaiac</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10678">
								<item>
									<para>
										<emphasis alert="nurse">Overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10683">
								<item>
									<label>•</label>
									<para>Monitor heart rate during direct IV infusion (cefotaxime)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10688">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10692">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection; negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10698">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10703">
								<item>
									<label>•</label>
									<para>If diabetic, to check blood glucose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10709">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, bruising, bleeding, joint pain, may indicate blood dyscrasias (rare); diarrhea with mucus, blood, may indicate pseudomembranous colitis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10714">
								<item>
									<label>•</label>
									<para>That cefditoren can be taken with oral contraceptives</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="1" status="active">
			<mono_name>cephradine</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x107300">See cephalosporins—1st generation</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="2" status="active">
			<mono_name>certolizumab pegol (Rx)</mono_name>
			<info>
				<pronunciation>(ser′tue-liz′oo-mab pegh′ol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107390">Cimzia</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier</class>
				<class type="chem"> Antitissue necrosis factor (anti-TNF) agent</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x10749">
				<sec_title>Action:</sec_title>
				<para>Monoclonal antibody that neutralizes the activity of tumor necrosis factor α (TNF-α) found in Crohn’s disease; decreases infiltration of inflammatory cells</para>
			</section>
			<section type="uses" id="sidelem4x10754">
				<sec_title>Uses:</sec_title>
				<para>Crohn’s disease (moderate to severe) that has not responded to conventional therapy, rheumatoid arthritis (moderate to severe), psoriatic arthritis, ankylosing spondylitis</para>
				<section type="none" id="sidelem4x10759">
					<section type="none" id="sidelem4x10760">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Moderate to severe chronic plaque psoriasis, fistulizing Crohn’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10765">
				<sec_title>Contraindications:</sec_title>
				<para>Influenza, IV administration, sepsis, hypersensitivity</para>
				<section type="none" id="sidelem4x10770">
					<section type="none" id="sidelem4x10771">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, AIDS, coagulopathy, diabetes, fungal infection, heart failure, hepatitis, human antichimeric antibody, immunosuppression, leukopenia, MS, cancer, neurologic/renal disease, surgery, thrombocytopenia, TB, vaccinations</para>
						<para>
							<bbw>Infection, neoplastic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10786">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10789">
					<section type="none" id="sidelem4x10790">
						<sec_title>Crohn’s disease (moderate to severe)</sec_title>
						<section type="none" id="sidelem4x10798">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10798">
									<item>
										<label>•</label>
										<para> 400 mg given as 2 inj at wk 0, 2, 4; if clinical response occurs, give 400 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10802">
						<sec_title>Rheumatoid arthritis (moderate to severe)</sec_title>
						<section type="none" id="sidelem4x10810">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10810">
									<item>
										<label>•</label>
										<para> 400 mg q2wk × 3 doses, then 200 mg q2wk; given with methotrexate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10814">
						<sec_title>Crohn’s disease (fistulizing)/intolerant to infliximab (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10822">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10822">
									<item>
										<label>•</label>
										<para> 400 mg wk 0, 2, 4, then 400 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10826">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 200-, 400-mg kit</para>
					</section>
					<section type="none" id="sidelem4x10831">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10834">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x10838">
									<item>
										<label>•</label>
										<para>Give by subcut inj only</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitution: allow to warm to room temperature; add 1 ml sterile water for inj to each vial; 2 vials will be needed for patients with Crohn’s disease</para>
									</item>
									<item>
										<label>•</label>
										<para>Gently swirl; do not shake; full reconstitution may take up to 30 min; reconstituted product may remain at room temperature for up to 2 hr or refrigerated up to 24 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>If reconstituted product has been refrigerated, allow to warm to room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>Use 2 syringes and two 20G needles</para>
									</item>
									<item>
										<label>•</label>
										<para>Withdraw reconstituted sol from each vial into separate syringes; each will contain 200 mg; switch 20G to 23G needle; inject into 2 separate sites in abdomen or thigh</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10874">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10877">
					<section type="none" id="sidelem4x10878">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> syncope, peripheral neuropathy, fever, <emphasis style="bold">seizures, demyelinating disease of CNS</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10888">
						<sec_title>CV:</sec_title>
						<para>
							<emphasis alert="lifethreat">Heart failure, MI, cardiac dysrhythmia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x10894">
						<sec_title>EENT:</sec_title>
						<para> Optic neuritis, retinal hemorrhage, uveitis</para>
					</section>
					<section type="none" id="sidelem4x10899">
						<sec_title>GI:</sec_title>
						<para> Increased LFTs, <emphasis style="bold">hepatitis, bowel obstruction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10906">
						<sec_title>GU:</sec_title>
						<para> UTI, renal disease</para>
					</section>
					<section type="none" id="sidelem4x10911">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, aplastic anemia, pancytopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10918">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria,</emphasis><emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10927">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> antibody formation, arthralgia, bleeding, infection, lupuslike symptoms, lymphadenopathy, <emphasis style="bold">malignancies, serum sickness, suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10938">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, upper respiratory tract infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10943">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 54-171 hr, terminal half-life 14 days</para>
			</section>
			<section type="interactions" id="sidelem4x10948">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x10956">
					<label>•</label>
					<sec_title>
						<route>Do not administer live vaccines, toxoids concurrently</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> possible infections—abatacept, adalimumab, anakinra, etanercept, immunosuppressive agents, infliximab, rilonacept; do not use concurrently</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> possible malignancies—adalimumab, etanercept, infliximab</para>
			</section>
			<section type="considerations" id="sidelem4x10967">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10970">
					<section type="none" id="sidelem4x10971">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10976">
								<item>
									<label>•</label>
									<para>Antinuclear antibody test (ANA), hepatitis B serology, CBC</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10981">
								<item>
									<label>•</label>
									<para>For rheumatoid arthritis, ROM, pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10986">
								<item>
									<label>•</label>
									<para>GI symptoms: nausea, vomiting, abdominal pain, hepatitis, increased LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10991">
								<item>
									<label>•</label>
									<para>Periodic blood counts (CBC)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10996">
								<item>
									<label>•</label>
									<para>CV status: B/P, pulse, chest pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11002">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reaction, anaphylaxis: rash, dermatitis, urticaria, dyspnea, hypotension, fever, chills; discontinue if severe; administer EPINEPHrine, corticosteroids, antihistamines; assess for allergies to murine proteins before starting therapy</emphasis>
<bbw>Infection: discontinue if infection occurs; do not administer to patients with active infection</bbw>

<bbw>Identify TB, risk for HBV before beginning treatment; TB test should be obtained; if present, TB should be treated before certolizumab treatment</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11025">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11029">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, mucus in stools</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11035">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11039">
								<item>
									<label>•</label>
									<para>Not to breastfeed while taking this product
<bbw>To notify prescriber of GI symptoms, hypersensitivity reactions, infections, fluid retention; redness, pain, swelling at inj site</bbw>

<bbw>Not to operate machinery, drive if dizziness, vertigo occur</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>cetirizine (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(se-teer′i-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x110714">All Day Allergy</tradename>
					<tradename id="tnidelem4x110713">All Day Allergy Children’s</tradename>
					<tradename id="tnidelem4x110712">
						<country code="CAN">Reactine </country>
					</tradename>
					<tradename id="tnidelem4x110711">ZyrTEC</tradename>
					<tradename id="tnidelem4x110710">ZyrTEC Children’s</tradename>
				</tradenames>
				<class type="func"> Antihistamine (2nd generation, peripherally selective)</class>
				<class type="chem"> Piperazine, H-histamine antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11087">
				<para>
					<confusion>
						<tradename id="tnidelem4x110870">ZyrTEC</tradename>
						<drug type="generic" refid="idelem4x110870">Xanax/Zantac</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11091">
				<sec_title>Action:</sec_title>
				<para>Acts on blood vessels, GI, respiratory system by competing with histamine for H<emphasis style="inf">1</emphasis>-receptor site; decreases allergic response by blocking pharmacologic effects of histamine; minimal anticholinergic, sedative action</para>
			</section>
			<section type="uses" id="sidelem4x11099">
				<sec_title>Uses:</sec_title>
				<para>Rhinitis, allergy symptoms, chronic idiopathic urticaria</para>
				<section type="none" id="sidelem4x11104">
					<section type="none" id="sidelem4x11105">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Asthma, atopic dermatitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11110">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, newborn or premature infants, hypersensitivity to this product or hydrOXYzine, severe hepatic disease</para>
				<section type="none" id="sidelem4x11115">
					<section type="none" id="sidelem4x11116">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), children, geriatric patients, respiratory disease, angle-closure glaucoma, prostatic hypertrophy, bladder neck obstruction, asthma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11121">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11124">
					<section type="none" id="sidelem4x11125">
						<sec_title>Perennial/seasonal allergic rhinitis or idiopathic urticaria</sec_title>
						<section type="none" id="sidelem4x11133">
							<label>•</label>
							<sec_title>Adult and child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11133">
									<item>
										<label>•</label>
										<para> 5-10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11141">
							<label>•</label>
							<sec_title>Child 2-5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11141">
									<item>
										<label>•</label>
										<para> 2.5 mg/day, may increase to 5 mg/day or 2.5 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11148">
							<label>•</label>
							<sec_title>Child 1-2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11148">
									<item>
										<label>•</label>
										<para> 2.5 mg/day, may increase to 2.5 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11155">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11155">
									<item>
										<label>•</label>
										<para> 5 mg/day, may increase to 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11159">
						<sec_title>Self-treatment of hay fever/other respiratory allergies</sec_title>
						<section type="none" id="sidelem4x11167">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11167">
									<item>
										<label>•</label>
										<para> 10 mg/day;  5-10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11174">
						<sec_title>Renal dose/hemodialysis/hepatic dose</sec_title>
						<section type="none" id="sidelem4x11182">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 11-31 ml/min, 5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11185">
						<sec_title>Atopic dermatitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11193">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11193">
									<item>
										<label>•</label>
										<para> 5-10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11200">
							<label>•</label>
							<sec_title>Child 1-2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11200">
									<item>
										<label>•</label>
										<para> 0.25 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11204">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg; syr 5 mg/5 ml, prefilled spoons 1 mg/ml; oral sol 5 mg/ml; liquid-filled caps 10 mg; chew tabs 5, 10 mg; oral disintegrating tab 10 mg</para>
					</section>
					<section type="none" id="sidelem4x11209">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11214">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11219">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11227">
							<label>•</label>
							<sec_title>Caps</sec_title>
							<para>
								<list id="lidelem4x11227">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Caps:</emphasis> swallow whole; do not break, cut, chew, crush</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11234">
							<label>•</label>
							<sec_title>Chew tabs</sec_title>
							<para>
								<list id="lidelem4x11234">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Chew tabs:</emphasis> chew before swallowing; may use with or without water</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11241">
							<label>•</label>
							<sec_title>Oral liquid</sec_title>
							<para>
								<list id="lidelem4x11241">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral liquid:</emphasis> use calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11245">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11248">
					<section type="none" id="sidelem4x11249">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> stimulation, <emphasis style="italic">drowsiness,</emphasis> sedation, <emphasis style="italic">fatigue,</emphasis> confusion, blurred vision, tinnitus, restlessness, tremors; paradoxical excitation in children, geriatric patients</para>
					</section>
					<section type="none" id="sidelem4x11263">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dry mouth,</emphasis> increased LFTs, constipation</para>
					</section>
					<section type="none" id="sidelem4x11271">
						<sec_title>INTEG:</sec_title>
						<para> Rash, eczema, photosensitivity, urticaria</para>
					</section>
					<section type="none" id="sidelem4x11276">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Thickening of bronchial secretions,</emphasis> dry nose, throat</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11284">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption rapid; onset <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr; peak 1-2 hr; duration 24 hr; protein binding 93%; half-life decreased in children, increased in renal/hepatic disease</para>
			</section>
			<section type="interactions" id="sidelem4x11295">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, opiates, sedative/hypnotics, other CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic/sedative effect—MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cetirizine effect—ritonavir</para>
				<section type="none" id="sidelem4x11310">
					<section type="none" id="sidelem4x11311">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x11315">
								<item>
									<label>•</label>
									<para>Food prolongs absorption by 1.7 hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11321">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11328">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11331">
					<section type="none" id="sidelem4x11332">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11340">
							<label>•</label>
							<sec_title>Allergy symptoms</sec_title>
							<para>
								<list id="lidelem4x11340">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergy symptoms:</emphasis> pruritus, urticaria, watering eyes at baseline and during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11344">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, increase in bronchial secretions, wheezing, chest tightness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11349">
								<item>
									<label>•</label>
									<para>Blood studies: LFTs, BUN, creatinine at baseline, periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11354">
								<item>
									<label>•</label>
									<para>Hard candy, gum, frequent rinsing of mouth for dryness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11359">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11363">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running or congested nose, rashes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11369">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11373">
								<item>
									<label>•</label>
									<para>About all aspects of product use; to notify prescriber if confusion, sedation, hypotension occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activity if drowsiness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants, OTC antihistamines</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid exposure to sunlight; burns may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sugarless gum, candy, frequent sips of water to minimize dry mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to breastfeed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active" ha="yes">
			<mono_name>cetrorelix (Rx)</mono_name>
			<info>
				<pronunciation>(set-roe-ree′lix)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x114170">Cetrotide</tradename>
				</tradenames>
				<class type="func"> Gonadotropin-releasing hormone antagonist</class>
				<class type="chem"> Synthetic decapeptide</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x11427">
				<sec_title>Action:</sec_title>
				<para>Inhibitor of pituitary gonadotropin secretion; initially increases LH and FSH; induces a rapid suppression of gonadotropin secretion</para>
			</section>
			<section type="uses" id="sidelem4x11432">
				<sec_title>Uses:</sec_title>
				<para>For inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation</para>
				<section type="none" id="sidelem4x11437">
					<section type="none" id="sidelem4x11438">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Benign prostatic hyperplasia (BPH), endometriosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11443">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, latex allergy, renal disease, KRA5 mutation</para>
				<section type="none" id="sidelem4x11448">
					<section type="none" id="sidelem4x11449">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, bronchospasm</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11454">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11457">
					<section type="none" id="sidelem4x11458">
						<sec_title>Single-dose regimen</sec_title>
						<section type="none" id="sidelem4x11466">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x11466">
									<item>
										<label>•</label>
										<para> 3 mg when serum estradiol level at appropriate stimulation response, usually on stimulation day 7; if hCG not given within 4 days after inj of 3 mg cetrorelix, give 0.25 mg daily until day of hCG administration</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11470">
						<sec_title>Multiple-dose regimen</sec_title>
						<section type="none" id="sidelem4x11478">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x11478">
									<item>
										<label>•</label>
										<para> 0.25 mg given on stimulation day 5 (either morning or evening) or 6 (morning) and continued daily until day hCG is given</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11482">
						<sec_title>BPH (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11490">
							<label>•</label>
							<sec_title>Adult (male)<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x11490">
									<item>
										<label>•</label>
										<para> 5 mg bid × 2 days, then 1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11494">
						<sec_title>Endometriosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11502">
							<label>•</label>
							<sec_title>Adult (female)<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x11502">
									<item>
										<label>•</label>
										<para> 3 mg weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11506">
						<sec_title>Available forms:</sec_title>
						<para> Inj 0.25 mg</para>
					</section>
					<section type="none" id="sidelem4x11511">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11514">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x11518">
									<item>
										<label>•</label>
										<para>Attach yellow-marked needle to dilutent syringe; dilute powder by injecting liquid from syringe into vial, leaving syringe on vial; gently swirl until clear, avoid bubbles; withdraw contents of vial back into syringe, replace yellow-marked needle with gray-marked needle</para>
									</item>
									<item>
										<label>•</label>
										<para>SUBCUT using abdomen, 1 inch away from navel or upper thigh; swab inj area with disinfectant; clean a 2-inch circle and allow to dry; pinch up area between thumb and finger; insert needle 45-90 degrees to surface; if positioned correctly, no blood will be drawn back into syringe; reposition needle without removing it; rotate inj sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11534">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11537">
					<section type="none" id="sidelem4x11538">
						<sec_title>CNS:</sec_title>
						<para> Headache, hot flashes</para>
					</section>
					<section type="none" id="sidelem4x11543">
						<sec_title>CV:</sec_title>
						<para> Edema</para>
					</section>
					<section type="none" id="sidelem4x11548">
						<sec_title>ENDO:</sec_title>
						<para> Ovarian hyperstimulation syndrome, abdominal pain (gyn)</para>
					</section>
					<section type="none" id="sidelem4x11553">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x11558">
						<sec_title>INTEG:</sec_title>
						<para> Pain on inj; local site reactions, bruising, pruritus</para>
					</section>
					<section type="none" id="sidelem4x11563">
						<sec_title>Other:</sec_title>
						<para> Rapid weight gain</para>
					</section>
					<section type="none" id="sidelem4x11568">
						<sec_title>RESP:</sec_title>
						<para> Shortness of breath</para>
					</section>
					<section type="none" id="sidelem4x11573">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Fetal death, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11580">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in feces/urine, half-life depends on dosage, metabolized to metabolites, protein binding 86%</para>
			</section>
			<section type="considerations" id="sidelem4x11585">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11588">
					<section type="none" id="sidelem4x11589">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11594">
								<item>
									<label>•</label>
									<para>Serum progesterone, LH; ovarian ultrasound day 7-14; pelvic exam, serum estradiol/gonadotropin; weight</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11602">
							<label>•</label>
							<sec_title>
								<route>For suspected pregnancy, product should not be used, pregnancy (X)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x11608">
							<label>•</label>
							<sec_title>
								<route>For latex allergy, product should not be used</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11612">
								<item>
									<para>
										<emphasis alert="nurse">For anaphylaxis during first infusion</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11617">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11621">
								<item>
									<label>•</label>
									<para>Therapeutic response: pregnancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11627">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11631">
								<item>
									<label>•</label>
									<para>To report abdominal pain, vaginal bleeding, nausea, vomiting, diarrhea, SOB, peripheral edema</para>
								</item>
								<item>
									<label>•</label>
									<para>How to perform self-administration technique if needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active" ha="yes">
			<mono_name>cetuximab (Rx)</mono_name>
			<info>
				<pronunciation>(se-tux′i-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x116500">Erbitux</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous, monoclonal antibody</class>
				<class type="chem"> Epidermal growth factor receptor inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11660">
				<sec_title>Action:</sec_title>
				<para>Not fully understood; binds to epidermal growth factor receptors (EGFRs); inhibits phosphorylation and activation of receptor-associated kinase, thereby resulting in inhibition of cell growth</para>
			</section>
			<section type="uses" id="sidelem4x11665">
				<sec_title>Uses:</sec_title>
				<para>Alone or in combination with irinotecan for EGFRs expressing metastatic colorectal carcinoma, head/neck cancer</para>
				<section type="none" id="sidelem4x11670">
					<section type="none" id="sidelem4x11671">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Front-line use for non–small-cell lung cancer in combination with CISplatin and vinorelbine</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11676">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, murine proteins</para>
				<section type="none" id="sidelem4x11681">
					<section type="none" id="sidelem4x11682">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients; CV/renal/hepatic disease; ocular, pulmonary disorders</para>
						<para>
							<bbw>Arrhythmias, CAD, infusion-related reactions, radiation/platinum-based therapy, cardiac, respiratory arrest</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11697">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11705">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x11705">
							<item>
								<label>•</label>
								<para> 400 mg/m<emphasis style="sup">2</emphasis> loading dose given over 120 min, max infusion rate 5 ml/min; weekly maintenance dose (all other infusion) is 250 mg/m<emphasis style="sup">2</emphasis> given over 60 min, max infusion rate 5 ml/min (10 mg/min); premedicate with an H<emphasis style="inf">1</emphasis>-antagonist (diphenhydrAMINE 50 mg IV); dosage adjustments made for infusion reactions or dermatologic toxicity; other protocols used</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11718">
					<section type="none" id="sidelem4x11719">
						<sec_title>Non–small-cell lung cancer (NSCLC) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x11727">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11727">
									<item>
										<label>•</label>
										<para> 400 mg/m<emphasis style="sup">2</emphasis> over 120 min (max 5 ml/min) week 1 with weekly infusion of 250 mg/m<emphasis style="sup">2</emphasis> over 60 min (max 5 ml/min) with CISplatin 80 mg/m<emphasis style="sup">2</emphasis> on day 1 and vinorelbine 25 mg/m<emphasis style="sup">2</emphasis> on days 1, 8</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11743">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 100 mg/50 ml, 200 mg/100 ml</para>
					</section>
					<section type="none" id="sidelem4x11748">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11751">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x11756">
									<item>
										<label>•</label>
										<para>Use cytoxic handling procedures</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11761">
									<item>
										<label>•</label>
										<para>By IV infusion only; do not give by IV push or bolus; do not shake or dilute</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11766">
									<item>
										<label>•</label>
										<para>Do not dilute with other products</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11771">
									<item>
										<label>•</label>
										<para>Store refrigerated at 36° F-46° F, discard unused portions</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11779">
								<label>•</label>
								<sec_title>Infusion pump</sec_title>
								<para>
									<list id="lidelem4x11779">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Infusion pump:</emphasis> draw up volume of vial using appropriate syringe/needle (vented spike or other appropriate transfer device); fill Erbitux into sterile evacuated container/bag, repeat until calculated volume put into the container; use new needle for each vial; give through in-line filter (low protein binding 0.22 micrometer); affix infusion line and prime before starting infusion, max rate 5 ml/min; flush line at end of infusion with 0.9% NaCl, use a low protein binding 0.22-micrometer in-line filter</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11786">
								<label>•</label>
								<sec_title>Syringe pump</sec_title>
								<para>
									<list id="lidelem4x11786">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Syringe pump:</emphasis> draw up volume of vial using appropriate syringe/needle (vented spike); place syringe into syringe driver of syringe pump and set rate; use in-line filter (low protein binding 0.22-micrometer); connect infusion line, start infusion after priming; repeat until calculated volume given</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x11790">
									<item>
										<label>•</label>
										<para>Use new needle and filter for each vial, max 5 ml/min rate; use 0.9% NaCl to flush line after infusion</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11795">
									<item>
										<label>•</label>
										<para>Do not piggyback to patient infusion line</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11800">
									<item>
										<label>•</label>
										<para>Observe patient for adverse reactions for 1 hr after infusion
<bbw>Infusion reactions: if mild (grade 1 or 2), reduce all doses by 50%; if severe (grade 3 or 4), permanently discontinue</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11815">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11818">
					<section type="none" id="sidelem4x11819">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia, depression,</emphasis><emphasis style="bold">aseptic meningitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11828">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11835">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting, anorexia, mouth ulceration, dehydration, constipation, abdominal pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11842">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11849">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, acne, dry skin, <emphasis style="bold">toxic epidermal necrolysis, angioedema,</emphasis><emphasis style="italic">blepharitis, cheilitis, cellulitis, cysts, alopecia, skin/nail disorder,</emphasis><emphasis style="bold">acute</emphasis> infusion <emphasis style="bold">reactions, other skin toxicities</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11863">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Conjunctivitis, asthma, malaise, fever,</emphasis><emphasis style="bold">renal failure,</emphasis> hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x11873">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Back pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11880">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Interstitial lung disease,</emphasis><emphasis style="italic">cough, dyspnea,</emphasis><emphasis style="bold">pulmonary embolus,</emphasis><emphasis style="italic">peripheral edema,</emphasis><emphasis style="bold">respiratory arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11895">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, sepsis, infection, mucosal inflammation, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11902">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 114 hr, steady state by 3rd wkly infusion, peak 168-235 g/ml</para>
			</section>
			<section type="interactions" id="sidelem4x11907">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x11910">
					<section type="none" id="sidelem4x11911">
						<sec_title>Drug/Lab:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11918">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11921">
					<section type="none" id="sidelem4x11922">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Pulmonary changes:</emphasis> lung sounds, cough, dyspnea; interstitial lung disease may occur, may be fatal; discontinue therapy if confirmed</bbw>
						</para>
						<section type="none" id="sidelem4x11941">
							<label>•</label>
							<sec_title>Cardiac arrest<route> monitor electrolytes, in those undergoing radiation therapy, electrolytes may be decreased; monitor cardiac patients that receive this product and radiation therapy or platinum based therapy with 5-FU (head, neck, cancer)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11945">
								<item>
									<para>
										<emphasis alert="nurse">Serious hypersensitivity reactions: toxic epidermal necrosis, angioedema, anaphylaxis, Stevens-Johnson syndrome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11950">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, dehydration, abdominal pain, stomatitis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11958">
							<label>•</label>
							<sec_title>
								<route>K-RAS mutations</route>
							</sec_title>
							<para>
								<list id="lidelem4x11958">
									<item>
										<label>•</label>
										<para> with metastatic colorectal carcinoma; if K-RAS mutation on codon 12 or 13 detected, patient should not receive anti-EGFR antibody therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11962">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11966">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased growth, spread of EGFR-expressing metastatic colorectal, head/neck carcinoma</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11972">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To report adverse reactions immediately: shortness of breath, severe abdominal pain, skin eruptions</bbw>
						</para>
						<para>
							<list id="lidelem4x11985">
								<item>
									<label>•</label>
									<para>About the reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To use contraception during treatment (pregnancy [C]), not to breastfeed</bbw>
						</para>
						<para>
							<list id="lidelem4x12001">
								<item>
									<label>•</label>
									<para>To wear sunscreen and hats to limit sun exposure; sun exposure can exacerbate any skin reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infections</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>chlordiazePOXIDE (Rx)</mono_name>
			<info>
				<pronunciation>(klor-dye-az-e-pox′ide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x120171">Librium</tradename>
					<tradename id="tnidelem4x120170">
						<country code="CAN">Solium</country>
					</tradename>
				</tradenames>
				<class type="func"> Antianxiety</class>
				<class type="chem"> Benzodiazepine, long-acting</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x12032">
				<para>
					<confusion>
						<tradename id="tnidelem4x120320">Librium</tradename>
						<drug type="generic" refid="idelem4x120320">Librax</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12036">
				<sec_title>Action:</sec_title>
				<para>Potentiates the actions of GABA, especially in the limbic system, reticular formation</para>
			</section>
			<section type="uses" id="sidelem4x12041">
				<sec_title>Uses:</sec_title>
				<para>Short-term management of anxiety, acute alcohol withdrawal, preoperatively for relaxation</para>
			</section>
			<section type="contra" id="sidelem4x12047">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children &lt;6 yr, hypersensitivity to benzodiazepines, closed-angle glaucoma, psychosis</para>
				<section type="none" id="sidelem4x12052">
					<section type="none" id="sidelem4x12053">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, debilitated, renal/hepatic disease, suicidal ideation, abrupt discontinuation, respiratory depression, Parkinson’s disease, myasthenia gravis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12058">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12061">
					<section type="none" id="sidelem4x12062">
						<sec_title>Mild anxiety</sec_title>
						<section type="none" id="sidelem4x12070">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12070">
									<item>
										<label>•</label>
										<para> 5-10 mg tid-qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12077">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12077">
									<item>
										<label>•</label>
										<para> 5 mg bid initially, increase as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12084">
							<label>•</label>
							<sec_title>Child &gt;6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12084">
									<item>
										<label>•</label>
										<para> 5 mg bid-qid, max 10 mg bid-tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12088">
						<sec_title>Severe anxiety</sec_title>
						<section type="none" id="sidelem4x12096">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12096">
									<item>
										<label>•</label>
										<para> 25-50 mg tid-qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12100">
						<sec_title>Preoperatively</sec_title>
						<section type="none" id="sidelem4x12108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12108">
									<item>
										<label>•</label>
										<para> 5-10 mg tid-qid on day before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12112">
						<sec_title>Alcohol withdrawal</sec_title>
						<section type="none" id="sidelem4x12120">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12120">
									<item>
										<label>•</label>
										<para> 50-100 mg q4-6hr prn, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12124">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x12132">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;10 ml/min, give 50% dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12135">
						<sec_title>Available forms:</sec_title>
						<para> Caps 5, 10, 25 mg</para>
					</section>
					<section type="none" id="sidelem4x12140">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x12143">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x12147">
									<item>
										<label>•</label>
										<para>With food or milk for GI symptoms</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12153">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12156">
					<section type="none" id="sidelem4x12157">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, fatigue, depression, insomnia, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x12165">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> edema, <emphasis style="bold">ECG changes, tachycardia,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x12176">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x12184">
						<sec_title>GI:</sec_title>
						<para> Constipation, dry mouth, nausea, vomiting, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x12189">
						<sec_title>GU:</sec_title>
						<para> Irregular periods, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x12194">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12201">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, itching</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12206">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x12209">
					<section type="none" id="sidelem4x12210">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min, peak within 2 hr, duration 4-6 hr, metabolized by liver, excreted by kidneys, crosses placenta, excreted in breast milk, half-life 5-30 hr (increased in geriatric patients)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12215">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> chlordiazePOXIDE—cimetidine, disulfiram, FLUoxetine, isoniazid, ketoconazole, metoprolol, oral contraceptives, propranolol, valproic acid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of levodopa</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of chlordiazePOXIDE—CYP3A4 inhibitors (protease inhibitors, barbiturates, rifamycins)</para>
				<section type="none" id="sidelem4x12234">
					<section type="none" id="sidelem4x12235">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> 17-OHCS</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> pregnancy test (some methods)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12250">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12253">
					<section type="none" id="sidelem4x12254">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12259">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse; if systolic B/P drops 20 mm Hg, hold product, notify prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12267">
							<label>•</label>
							<sec_title>
								<route>blood dyscrasias</route>
							</sec_title>
							<para>
								<list id="lidelem4x12267">
									<item>
										<label>•</label>
										<para>Blood studies: CBC during long-term therapy;  have occurred rarely</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12272">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine, LDH, alk phos during long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12277">
								<item>
									<label>•</label>
									<para>For ataxia, oversedation of geriatric patients, debilitated patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12282">
								<item>
									<label>•</label>
									<para>Physical dependency, withdrawal symptoms: headache, nausea, vomiting, muscle pain, weakness after long-term use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12290">
							<label>•</label>
							<sec_title>Mental status<route> mood, sensorium, affect, sleeping pattern, drowsiness, dizziness; suicidal tendencies; paradoxic reactions such as excitement, stimulation, acute rage</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12296">
							<label>•</label>
							<sec_title>
								<route>For pregnancy; product should not be used during pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12299">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy because drowsiness, dizziness occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12304">
								<item>
									<label>•</label>
									<para>Check to confirm that PO medication has been swallowed if patient is depressed, suicidal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12310">
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12315">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12319">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, restlessness, sleeplessness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12325">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12330">
								<item>
									<label>•</label>
									<para>That product may be taken with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12335">
								<item>
									<label>•</label>
									<para>Not to use product for everyday stress or use for more than 4 mo unless directed by prescriber, tolerance occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12340">
								<item>
									<label>•</label>
									<para>Not to take more than prescribed amount; may be habit forming</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12345">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12350">
								<item>
									<label>•</label>
									<para>To avoid driving, activities that require alertness because drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12355">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, other psychotropic medications unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12363">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication abruptly after long-term use because this may precipitate seizures</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12366">
								<item>
									<label>•</label>
									<para>To rise slowly because fainting may occur, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12371">
								<item>
									<label>•</label>
									<para>That drowsiness may be worse at beginning of treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12379">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is suspected or planned</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x12385">
							<label>•</label>
							<sec_title>
								<route>To immediately report suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>chloroquine (Rx)</mono_name>
			<info>
				<pronunciation>(klor′oh-kwin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x123980">Aralen</tradename>
				</tradenames>
				<class type="func"> Antimalarial</class>
				<class type="chem"> Synthetic 4-amino-quinoline derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x12408">
				<sec_title>Action:</sec_title>
				<para>Inhibits parasite replication, transcription of DNA to RNA by forming complexes with DNA of parasite</para>
			</section>
			<section type="uses" id="sidelem4x12413">
				<sec_title>Uses:</sec_title>
				<para>Malaria of <emphasis style="italic">Plasmodium vivax, P. malariae, P. ovale, P. falciparum</emphasis> (some strains); amebiasis</para>
				<section type="none" id="sidelem4x12421">
					<section type="none" id="sidelem4x12422">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Discoid lupus erythematosus, polymorphous light eruption, rheumatoid arthritis, ulcerative colitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12427">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, retinal field changes</para>
				<section type="none" id="sidelem4x12432">
					<section type="none" id="sidelem4x12433">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, blood dyscrasias, severe GI/neurologic/cardiac disease, alcoholism, hepatic disease, G6PD deficiency, psoriasis, eczema, seizures, preexisting auditory damage, torsades de pointes</para>
						<para>
							<bbw>Infection</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12448">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12451">
					<section type="none" id="sidelem4x12452">
						<sec_title>Acute malaria attacks</sec_title>
						<section type="none" id="sidelem4x12460">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12460">
									<item>
										<label>•</label>
										<para> 1000 mg (600-mg base), then 500 mg (300-mg base) in 6-8 hr, then 500 mg (300-mg base) daily × 2 days for a total of 2.5 g (1.5-g base) in 3 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12467">
							<label>•</label>
							<sec_title>Adult/adolescent of low body weight, child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12467">
									<item>
										<label>•</label>
										<para> 16.5 mg (10-mg base)/kg, max 600-mg base, then 8.3 mg (5-mg base)/kg, max 300-mg base 6 hr after 1st dose, then 8.3 mg (5-mg base)/kg, max 300-mg base 24 hr after 1st dose, then 8.3 mg (5-mg base)/kg, max 300-mg base 36 hr after 1st dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12471">
						<sec_title>Malaria prophylaxis (in areas with chloroquine-sensitive <emphasis style="bold">
								<emphasis style="italic">P. falciparum</emphasis>
							</emphasis>)</sec_title>
						<section type="none" id="sidelem4x12483">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x12483">
									<item>
										<label>•</label>
										<para>Adult:  500 mg (300-mg base) weekly on same day of each wk starting 2 wk before travel and for 8 wk after leaving</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12488">
						<sec_title>Extraintestinal amebiasis</sec_title>
						<section type="none" id="sidelem4x12496">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12496">
									<item>
										<label>•</label>
										<para> 1 g (600-mg base) daily × 2 days, then 500 mg (300-mg base) for ≥2-3 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12503">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12503">
									<item>
										<label>•</label>
										<para> 16.6 mg (10-mg base)/kg (max 300-mg base) daily × 2-3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12507">
						<sec_title>Rheumatoid arthritis/discoid lupus erythematosus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12515">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12515">
									<item>
										<label>•</label>
										<para> 250 mg (150-mg base) daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12519">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250 mg (150-mg base), 500 mg (300-mg base) phosphate</para>
					</section>
					<section type="none" id="sidelem4x12525">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12529">
								<item>
									<label>•</label>
									<para>Product in mg or base; they are different</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12535">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x12539">
									<item>
										<label>•</label>
										<para>Before or after meals at same time each day to maintain product level</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container at room temperature; keep inj in cool environment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12550">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12553">
					<section type="none" id="sidelem4x12554">
						<sec_title>CNS:</sec_title>
						<para> Headache, stimulation, fatigue, <emphasis style="bold">seizures,</emphasis> psychosis, hallucinations, insomnia</para>
					</section>
					<section type="none" id="sidelem4x12562">
						<sec_title>CV:</sec_title>
						<para> Hypotension, <emphasis style="bold">heart block, asystole with syncope,</emphasis> ECG changes, cardiomyopathy</para>
					</section>
					<section type="none" id="sidelem4x12570">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision, corneal changes, retinal changes, difficulty focusing,</emphasis> tinnitus, vertigo, deafness, photophobia, corneal edema</para>
					</section>
					<section type="none" id="sidelem4x12578">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> diarrhea, cramps</para>
					</section>
					<section type="none" id="sidelem4x12586">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis, hemolytic anemia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12593">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, pigmentary changes, skin eruptions, lichen-planus–like eruptions, eczema, <emphasis style="bold">exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12600">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver; excreted in urine, feces, breast milk; crosses placenta</para>
				<section type="none" id="sidelem4x12605">
					<section type="none" id="sidelem4x12606">
						<sec_title>PO:</sec_title>
						<para> Peak 1-3 hr, half-life 3-5 days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12611">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x12615">
						<item>
							<label>•</label>
							<para>Reduced oral clearance and metabolism of chloroquine: cimetidine</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation, torsades de pointes—class IA, III antidysrhythmics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—2D6 inhibitors (amiodarone, chlorpheniramine, FLUoxetine, haloperidol, ritonavir, PARoxetine, terbinafine, ticlopidine); CYP3A4 inhibitors (diltiazem, verapamil, itraconazole, ketoconazole, erythromycin, doxycycline, clarithromycin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of chloroquine—magnesium, aluminum compounds, kaolin; do not use concurrently</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of ampicillin, rabies vaccine (ID)</para>
				<section type="none" id="sidelem4x12636">
					<section type="none" id="sidelem4x12637">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12644">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12647">
					<section type="none" id="sidelem4x12648">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Infection:</emphasis> resistance is common, not to be used for P. falciparum acquired in areas of resistance or where prophylaxis has failed•Ophthalmic test if long-term treatment or dosage of &gt;150 mg/day, baseline and periodically•Blood studies: CBC, as blood dyscrasias occur•<emphasis alert="lifethreat">ECG during therapy; watch for depression of T waves, widening of QRS complex</emphasis>•<emphasis alert="lifethreat">Allergic reactions:</emphasis> pruritus, rash, urticaria•<emphasis alert="lifethreat">Blood dyscrasias:</emphasis> malaise, fever, bruising, bleeding (rare)•<emphasis alert="lifethreat">For ototoxicity (tinnitus, vertigo, change in hearing); audiometric testing should be done before, after treatment</emphasis><emphasis alert="lifethreat">For toxicity: blurring vision; difficulty focusing; headache; dizziness; decreased knee, ankle reflexes; seizures, CV collapse; product should be discontinued immediately and IV fluids given</emphasis></bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x12709">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12713">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12719">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12724">
								<item>
									<label>•</label>
									<para>To take with meals or immediately after meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12729">
								<item>
									<label>•</label>
									<para>To use sunglasses in bright sunlight to decrease photophobia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12734">
								<item>
									<label>•</label>
									<para>That urine may turn rust or brown color</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12742">
							<label>•</label>
							<sec_title>
								<route>To report hearing, visual problems; fever, fatigue, bruising, bleeding; may indicate blood dyscrasias</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>chlorpheniramine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(klor-fen-ir′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x1276613">AHIST</tradename>
					<tradename id="tnidelem4x1276612">Aller-Chlor</tradename>
					<tradename id="tnidelem4x1276611">Allergy</tradename>
					<tradename id="tnidelem4x1276610">Chlor-Pheniton</tradename>
					<tradename id="tnidelem4x127669">Chlor-Trimeton</tradename>
					<tradename id="tnidelem4x127668">Diabetic Tussin Allergy Relief</tradename>
					<tradename id="tnidelem4x127667">ED-Chlor-Tann</tradename>
					<tradename id="tnidelem4x127666">Equaline Allergy</tradename>
					<tradename id="tnidelem4x127665">Equate Chlortabs Allergy</tradename>
					<tradename id="tnidelem4x127664">
						<country code="CAN">Novo-Pheniram</country>
					</tradename>
					<tradename id="tnidelem4x127663">P-Tann</tradename>
					<tradename id="tnidelem4x127662">Tana Hist-PD</tradename>
					<tradename id="tnidelem4x127661">Teldrin</tradename>
					<tradename id="tnidelem4x127660">
						<country code="CAN">Tripolon</country>
					</tradename>
				</tradenames>
				<class type="func"> Antihistamine (1st generation, nonselective)</class>
				<class type="chem"> Alkylamine, H-receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12784">
				<para>
					<confusion>
						<tradename id="tnidelem4x127840">Teldrin</tradename>
						<drug type="generic" refid="idelem4x127840">Tedral</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12788">
				<sec_title>Action:</sec_title>
				<para>Acts on blood vessels, GI system, respiratory system by competing with histamine for H<emphasis style="inf">1</emphasis>-receptor site; decreases allergic response by blocking histamine</para>
			</section>
			<section type="uses" id="sidelem4x12796">
				<sec_title>Uses:</sec_title>
				<para>Allergy symptoms, rhinitis, conjunctivitis (allergic)</para>
				<section type="none" id="sidelem4x12801">
					<section type="none" id="sidelem4x12802">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Nausea, vomiting due to motion sickness, pruritus, urticaria</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12807">
				<sec_title>Contraindications:</sec_title>
				<para>Newborns/neonates</para>
				<section type="none" id="sidelem4x12812">
					<section type="none" id="sidelem4x12813">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, increased intraocular pressure, cardiac/renal disease, hypertension, asthma, seizure disorder, hyperthyroidism, prostatic hypertrophy, GI obstruction, peptic ulcer disease, emphysema, hypersensitivity to H<emphasis style="inf">1</emphasis>-receptor antagonists, lower respiratory tract disease, stenosed peptic ulcers, bladder neck obstruction, closed-angle glaucoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12821">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12829">
					<label>•</label>
					<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12829">
							<item>
								<label>•</label>
								<para> 4 mg tid-qid, max 24 mg/day;  8-12 mg bid-tid, max 24 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12839">
					<label>•</label>
					<sec_title>Child 6-12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12839">
							<item>
								<label>•</label>
								<para> 2 mg q4-6hr, max 12 mg/day;  8 mg bedtime or daily;  not recommended for child &lt;6 yr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12849">
					<section type="none" id="sidelem4x12850">
						<sec_title>Available forms:</sec_title>
						<para> Chewable tabs 2 mg; tabs 4, 8, 12 mg; ext rel tabs 8, 12 mg; ext rel caps 8, 12 mg; syr 1 mg/5 ml, 2 mg/5 ml, 2.5 mg/5 ml; 2 mg/ml drops</para>
					</section>
					<section type="none" id="sidelem4x12855">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12860">
								<item>
									<label>•</label>
									<para>Avoid concurrent use with other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12865">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel forms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12870">
								<item>
									<label>•</label>
									<para>Without regard to meal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12875">
								<item>
									<label>•</label>
									<para>Avoid use in children &lt;6 yr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12880">
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12888">
							<label>•</label>
							<sec_title>Syrup</sec_title>
							<para>
								<list id="lidelem4x12888">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Syrup:</emphasis> Use dosing utensil to measure correct dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12892">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12895">
					<section type="none" id="sidelem4x12896">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> poor coordination, fatigue, anxiety, euphoria, confusion, paresthesia, neuritis</para>
					</section>
					<section type="none" id="sidelem4x12904">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision; dilated pupils; tinnitus; nasal stuffiness; dry nose, throat, mouth</para>
					</section>
					<section type="none" id="sidelem4x12909">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x12914">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Retention,</emphasis> dysuria, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x12922">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12929">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x12934">
						<sec_title>RESP:</sec_title>
						<para> Increased thick secretions, wheezing, chest tightness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12939">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Detoxified in liver, excreted by kidneys (metabolites/free drug), half-life 12-15 hr</para>
				<section type="none" id="sidelem4x12944">
					<section type="none" id="sidelem4x12945">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr, duration 4-12 hr</para>
					</section>
					<section type="none" id="sidelem4x12956">
						<sec_title>PO-ER:</sec_title>
						<para> Duration 8-24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12961">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—barbiturates, opiates, hypnotics, tricyclics, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of chlorpheniramine—MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic action—atropine, phenothiazines, quiNIDine, haloperidol</para>
				<section type="none" id="sidelem4x12977">
					<section type="none" id="sidelem4x12978">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12985">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12988">
					<section type="none" id="sidelem4x12989">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12993">
								<item>
									<label>•</label>
									<para>Be alert for urinary retention, frequency, dysuria; product should be discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, increase in bronchial secretions, wheezing, chest tightness</para>
								</item>
								<item>
									<label>•</label>
									<para>Hard candy, gum, frequent rinsing of mouth for dryness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13009">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13013">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running, congested nose, rashes, conjunctivitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13019">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13023">
								<item>
									<label>•</label>
									<para>About all aspects of product use; to notify prescriber of confusion, sedation, hypotension, difficulty voiding</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activity if drowsiness occurs, especially geriatric patients</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid concurrent use of alcohol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>chlorproMAZINE (Rx)</mono_name>
			<info>
				<pronunciation>(klor-proe′ma-zeen)</pronunciation>
				<class type="func"> Antipsychotic/antiemetic</class>
				<class type="chem"> Phenothiazine-aliphatic</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13057">
				<para>
					<confusion>
						<tradename id="tnidelem4x130570">chlorproMAZINE</tradename>
						<drug type="generic" refid="idelem4x130570">chlorproPAMIDE/prochlorperazine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13061">
				<sec_title>Action:</sec_title>
				<para>Depresses cerebral cortex, hypothalamus, limbic system, which control activity aggression; blocks neurotransmission produced by DOPamine at synapse; exhibits a strong α-adrenergic, anticholinergic blocking action; mechanism for antipsychotic effects is unclear</para>
			</section>
			<section type="uses" id="sidelem4x13066">
				<sec_title>Uses:</sec_title>
				<para>Psychotic disorders, mania, schizophrenia, anxiety, intractable hiccups in adults, nausea, vomiting; preoperatively for relaxation; acute intermittent porphyria, behavioral problems in children, nonpsychotic, demented patients, Tourette’s syndrome</para>
				<section type="none" id="sidelem4x13071">
					<section type="none" id="sidelem4x13072">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Vascular headache, agitation, dementia, neonatal abstinence syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13077">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;6 mo, hypersensitivity, circulatory collapse, liver damage, cerebral arteriosclerosis, coronary disease, coma</para>
				<section type="none" id="sidelem4x13082">
					<section type="none" id="sidelem4x13083">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, seizure disorders, hypertension, hepatic/cardiac disease, prostatic enlargement, Parkinson’s disease, pulmonary disease, severe hypo/hypertension, blood dyscrasias, brain damage, bone marrow depression, alcohol/barbiturate withdrawal, closed-angle glaucoma</para>
						<para>
							<bbw>Dementia; increased mortality in geriatric patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13098">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13101">
					<section type="none" id="sidelem4x13102">
						<sec_title>Psychosis</sec_title>
						<section type="none" id="sidelem4x13110">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13110">
									<item>
										<label>•</label>
										<para> 10-50 mg q1-4hr initially then increase up to 2 g/day if necessary;  10-50 mg q1-4hr, usual dose 300-800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13120">
							<label>•</label>
							<sec_title>Geriatric</sec_title>
							<para>
								<list id="lidelem4x13120">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Geriatric:</emphasis> 10-25 mg daily-bid, increase by 10-25 mg/day q4-7days, max 800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13127">
							<label>•</label>
							<sec_title>Child &gt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13127">
									<item>
										<label>•</label>
										<para> 0.55 mg/kg q4-6hr;  0.5 mg/kg q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13134">
						<sec_title>Nausea and vomiting</sec_title>
						<section type="none" id="sidelem4x13142">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13142">
									<item>
										<label>•</label>
										<para> 10-25 mg q4-6hr prn;  12.5-25 mg, then 25-50 mg if no hypotension q3hr prn; q6-8hr prn, max 400 mg/day;  25-50 mg daily-qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13155">
							<label>•</label>
							<sec_title>Child ≥6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13155">
									<item>
										<label>•</label>
										<para> 0.55 mg/kg q4-6hr;  q6-8hr;  ≤5 yr or ≤22.7 kg, 40 mg; max  5-10 yr or 22.7-45.5 kg, 75 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13168">
						<sec_title>Intractable hiccups/acute intermittent porphyria</sec_title>
						<section type="none" id="sidelem4x13176">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13176">
									<item>
										<label>•</label>
										<para> 25-50 mg tid-qid;  25-50 mg (only if PO dose does not work);  25-50 mg in 500-1000 ml (only for severe hiccups)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13190">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25, 50, 100, 200 mg; inj 25 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x13195">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13199">
								<item>
									<label>•</label>
									<para>Anticholinergic agent for EPS if ordered</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13205">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x13210">
									<item>
										<label>•</label>
										<para>With full glass of water, milk or with food to decrease GI upset</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13215">
									<item>
										<label>•</label>
										<para>Periodically attempt dosage reduction in those with behavioral problems</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13220">
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x13228">
								<label>•</label>
								<sec_title>Syrup</sec_title>
								<para>
									<list id="lidelem4x13228">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Syrup:</emphasis> Use calibrated measuring device, do not spill on skin or clothes</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x13232">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x13236">
									<item>
										<label>•</label>
										<para>Use gloves to prepare product; if product touches skin, wash with soap and water to prevent contact dermatitis</para>
									</item>
									<item>
										<label>•</label>
										<para>IM, inject in deep muscle mass with patient recumbent, do not give SUBCUT, no dilution needed; if irritation occurs, may dilute in NS or procaine 2%</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid skin contact with injection solution—may cause contact dermatitis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13252">
							<sec_title>IV route</sec_title>
							<para>
								<emphasis style="bold">Direct IV:</emphasis> After <emphasis style="bold">diluting</emphasis> 1 mg/1 ml with NS, <emphasis style="bold">give</emphasis> 1 mg or less/2 min or more with patient recumbent, never give undiluted</para>
							<para>
								<emphasis style="bold">Intermittent IV INFUSION: Dilute</emphasis> 25-50 mg/500-1000 NS or other compatible large IV sol, <emphasis style="bold">give</emphasis> over ½ hour, protect from light</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Atropine, benztropine, butorphanol, diphenhydrAMINE, doxapram, droperidol, fentaNYL, glycopyrrolate, HYDROmorphone, hydrOXYzine, meperidine, metoclopramide, midazolam, morphine, pentazocine, perphenazine, prochlorperazine, promazine, promethazine, scopolamine</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, amphotericin B lipid complex, amsacrine, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, benztropine, bleomycin sulfate, buprenorphine, butorphanol, calcium chloride/gluconate, caspofungin, cimetidine, cisatracurium, CISplatin, cladribine, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, isoproterenol, labetalol, levofloxacin, lidocaine, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, meperidine, methicillin, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, netilmicin, nitroglycerin, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, palonosetron, pamidronate, pancuronium, papaverine, penicillin G potassium, pentamidine, pentazocine, phytonadione, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine sulfate, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, Ringer’s injection, ritodrine, riTUXimab, rocuronium, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, tirofiban, TNA, tolazoline, TPN, trimetaphan, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex with C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13280">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13283">
					<section type="none" id="sidelem4x13284">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">EPS: pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">headache,</emphasis><emphasis style="bold">neuroleptic malignant syndrome,</emphasis> dizziness</para>
					</section>
					<section type="none" id="sidelem4x13298">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> hypertension, <emphasis style="bold">cardiac arrest,</emphasis> ECG changes, <emphasis style="bold">tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13312">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, glaucoma, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x13317">
						<sec_title>ENDO:</sec_title>
						<para> SIADH</para>
					</section>
					<section type="none" id="sidelem4x13322">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dry mouth, nausea, vomiting, anorexia, constipation,</emphasis> diarrhea, <emphasis style="bold">cholestatic jaundice,</emphasis> weight gain</para>
					</section>
					<section type="none" id="sidelem4x13333">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, enuresis, impotence, amenorrhea, gynecomastia, breast engorgement</para>
					</section>
					<section type="none" id="sidelem4x13338">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">leukopenia, leukocytosis, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13345">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> photosensitivity, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x13353">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Laryngospasm,</emphasis> dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13363">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Death in geriatric patients with dementia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13370">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine (metabolites), crosses placenta, enters breast milk, 95% bound to plasma proteins, elimination half-life 23-37 hr</para>
				<section type="none" id="sidelem4x13375">
					<section type="none" id="sidelem4x13376">
						<sec_title>PO:</sec_title>
						<para> Absorption variable, widely distributed, onset erratic 30-60 min, duration 4-6 hr</para>
					</section>
					<section type="none" id="sidelem4x13381">
						<sec_title>PO-ER:</sec_title>
						<para> Onset 30-60 min, peak unknown, duration 10-12 hr</para>
					</section>
					<section type="none" id="sidelem4x13386">
						<sec_title>IM:</sec_title>
						<para> Well absorbed, peak 15-20 min, duration 4-8 hr</para>
					</section>
					<section type="none" id="sidelem4x13391">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min, peak 10 min, duration unknown</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13396">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—other CNS depressants, alcohol, barbiturate anesthetics, antihistamines, sedatives/hypnotics, antidepressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—EPINEPHrine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> agranulocystosis—antithyroid agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of both products—β-adrenergic blockers, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—anticholinergics, antidepressants, antiparkinsonian agents, MAOIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> valproic acid level</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> seizure threshold—anticonvulsants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—aluminum hydroxide, magnesium hydroxide antacids, cimetidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antiparkinson activity—levodopa, bromocriptine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> serum chlorproMAZINE—lithium, barbiturates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> anticoagulant effect—warfarin</para>
				<section type="none" id="sidelem4x13443">
					<section type="none" id="sidelem4x13444">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hepatic studies</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets, Hgb/HcT</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> pregnancy tests, PKU</para>
					</section>
					<section type="none" id="sidelem4x13459">
						<sec_title>False negative:</sec_title>
						<para> urinary steroids, 17-OHCS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13464">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13467">
					<section type="none" id="sidelem4x13468">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13473">
								<item>
									<label>•</label>
									<para>Mental status: orientation, mood, behavior, presence and type of hallucinations before initial administration and monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13478">
								<item>
									<label>•</label>
									<para>Any potentially reversible causes of behavior problems in geriatric patients before and during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13483">
								<item>
									<label>•</label>
									<para>Swallowing of PO medication; check for hoarding or giving of medication to other patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13488">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; palpate bladder if low urinary output occurs, especially in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13493">
								<item>
									<label>•</label>
									<para>Bilirubin, CBC, LFTs, ocular exam; agranulocytosis, glaucoma, cholestatic jaundice may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13498">
								<item>
									<label>•</label>
									<para>Respirations q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; obtain baseline ECG; Q-wave and T-wave changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13503">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13509">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: hyperpyrexia, muscle rigidity, increased CPK, altered mental status, for acute dystonia (check chewing, swallowing, eyes, pill rolling)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13517">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x13517">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13521">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; increase bulk, water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13527">
								<item>
									<label>•</label>
									<para>Supervised ambulation until stabilized on medication; do not involve in strenuous exercise program because fainting is possible; patient should not stand still for long periods</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13532">
								<item>
									<label>•</label>
									<para>Increased fluids, roughage to prevent constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13537">
								<item>
									<label>•</label>
									<para>Candy, gum, sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13542">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13546">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech; increase in target behaviors</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13552">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13557">
								<item>
									<label>•</label>
									<para>To use good oral hygiene; to use frequent rinsing of mouth, sugarless gum, candy, ice chips for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13562">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until product response is determined</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13567">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension occurs often; to rise gradually from sitting or lying position</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13572">
								<item>
									<label>•</label>
									<para>To remain lying down for at least 30 min after IM inj</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13577">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths because hypotension may occur; that, during hot weather, heat stroke may occur; to take extra precautions to stay cool</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13582">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of product or EPS may result; product should be withdrawn slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13587">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber since serious product interactions may occur; avoid use with alcohol, increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13592">
								<item>
									<label>•</label>
									<para>To use a sunscreen and sunglasses to prevent burns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13597">
								<item>
									<label>•</label>
									<para>To take antacids 2 hr before or after this product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13605">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, malaise, fever, bleeding, mouth sores; CBC should be drawn and product discontinued</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13608">
								<item>
									<label>•</label>
									<para>To employ contraceptive measures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13613">
								<item>
									<label>•</label>
									<para>That urine may turn pink or reddish brown</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>cholestyramine (Rx)</mono_name>
			<info>
				<pronunciation>(koe-less-tir′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x136302">Prevalite</tradename>
					<tradename id="tnidelem4x136301">Questran</tradename>
					<tradename id="tnidelem4x136300">Questran Light</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> Bile acid sequestrant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13640">
				<para>
					<confusion>
						<tradename id="tnidelem4x136400">Questran</tradename>
						<drug type="generic" refid="idelem4x136400">Quarzan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13644">
				<sec_title>Action:</sec_title>
				<para>Adsorbs, combines with bile acids to form insoluble complex that is excreted through feces; loss of bile acids lowers LDL, cholesterol levels</para>
			</section>
			<section type="uses" id="sidelem4x13649">
				<sec_title>Uses:</sec_title>
				<para>Primary hypercholesterolemia (esp. type IIa/IIb hyperlipoproteinemia), pruritus associated with biliary obstruction</para>
				<section type="none" id="sidelem4x13654">
					<section type="none" id="sidelem4x13655">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Diarrhea caused by excess bile acid</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13660">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; complete biliary obstruction; hyperlipidemia III, IV, V</para>
				<section type="none" id="sidelem4x13665">
					<section type="none" id="sidelem4x13666">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, PKU, renal disease, coagulopathy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13671">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13679">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13679">
							<item>
								<label>•</label>
								<para> 4 g/day or bid, max 24 g/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13686">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13686">
							<item>
								<label>•</label>
								<para> 240 mg/kg/day in 3 divided doses with food or drink, max 8 g/day titrated up over several weeks to decrease GI effects</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13690">
					<section type="none" id="sidelem4x13691">
						<sec_title>Available forms:</sec_title>
						<para> Powder for susp 4 g cholestyramine/packet or scoop; tab 1 g</para>
					</section>
					<section type="none" id="sidelem4x13696">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13700">
								<item>
									<label>•</label>
									<para>Product daily or bid; give all other medications 1 hr before or 4-6 hr after cholestyramine to avoid poor absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>Product mixed with applesauce or stirred into beverage (2-6 oz), let stand for 2 min; do not take dry, avoid inhaling powder, avoid GI tube administration, take with food</para>
								</item>
								<item>
									<label>•</label>
									<para>Supplemental doses of vit A, D, K if levels are low</para>
								</item>
								<item>
									<label>•</label>
									<para>Doses are expressed in anhydrous cholestyramine resin; amount of resin varies with each product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13722">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13725">
					<section type="none" id="sidelem4x13726">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, drowsiness, vertigo, tinnitus, anxiety</para>
					</section>
					<section type="none" id="sidelem4x13731">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, abdominal pain, nausea,</emphasis> fecal impaction, hemorrhoids, flatulence, vomiting, steatorrhea, peptic ulcer</para>
					</section>
					<section type="none" id="sidelem4x13739">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding,</emphasis> increased PT</para>
					</section>
					<section type="none" id="sidelem4x13747">
						<sec_title>INTEG:</sec_title>
						<para> Rash, irritation of perianal area, tongue, skin</para>
					</section>
					<section type="none" id="sidelem4x13752">
						<sec_title>META:</sec_title>
						<para> Decreased vit A, D, K, red cell folate content; <emphasis style="bold">hyperchloremic acidosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13759">
						<sec_title>MS:</sec_title>
						<para> Muscle, joint pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13764">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13767">
					<section type="none" id="sidelem4x13768">
						<sec_title>PO:</sec_title>
						<para> Excreted in feces, LDL lowered within 4-7 days, serum cholesterol lowered within 1 mo, duration 2-4 wk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13773">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of warfarin; thiazides; cardiac glycosides; propranolol; corticosteroids; iron; thyroid hormones; acetaminophen; amiodarone; penicillin G; tetracyclines; clofibrate; gemfibrozil; oral vancomycin, glipiZIDE; vit A, D, E, K</para>
				<section type="none" id="sidelem4x13780">
					<section type="none" id="sidelem4x13781">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13792">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13795">
					<section type="none" id="sidelem4x13796">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13801">
								<item>
									<label>•</label>
									<para>Cardiac glycoside level if both products administered, may need to adjust dose of cardiac glycoside, if this product is increased or decreased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13806">
								<item>
									<label>•</label>
									<para>For signs of vit A, D, K deficiency</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13814">
							<label>•</label>
							<sec_title>Hypercholesterolemia</sec_title>
							<para>
								<list id="lidelem4x13814">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercholesterolemia:</emphasis> fasting LDL, HDL, total cholesterol, triglyceride levels, electrolytes if receiving extended therapy; diet history</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13821">
							<label>•</label>
							<sec_title>Pruritus</sec_title>
							<para>
								<list id="lidelem4x13821">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pruritus:</emphasis> for signs of itching</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13825">
								<item>
									<label>•</label>
									<para>Bowel pattern daily; increase bulk, water in diet for constipation; diarrhea may also occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13830">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13834">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased LDL, cholesterol level (hyperlipidemia); diarrhea, pruritus (excess bile acids)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13840">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13846">
								<item>
									<para>
										<emphasis alert="nurse">About the symptoms of hypoprothrombinemia: bleeding mucous membranes, dark tarry stools, hematuria, petechiae; report immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13851">
								<item>
									<label>•</label>
									<para>To take with food, never use dry</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13859">
							<label>•</label>
							<sec_title>
								<route>That PKU patients should avoid Questran Light (contains aspartame and phenylalanine)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13862">
								<item>
									<label>•</label>
									<para>About the importance of compliance</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13867">
								<item>
									<label>•</label>
									<para>That risk factors should be decreased: high-fat diet, smoking, alcohol consumption, absence of exercise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13872">
								<item>
									<label>•</label>
									<para>That GI side effects will resolve with continued use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>cidofovir (Rx)</mono_name>
			<info>
				<pronunciation>(si-doh-foh′veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x138820">Vistide</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Nucleotide analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13892">
				<sec_title>Action:</sec_title>
				<para>Suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis</para>
			</section>
			<section type="uses" id="sidelem4x13897">
				<sec_title>Uses:</sec_title>
				<para>CMV retinitis in patients with HIV; used with probenecid</para>
				<section type="none" id="sidelem4x13902">
					<section type="none" id="sidelem4x13903">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adenovirus, condylomata acuminata, eczema vaccination, Epstein-Barr virus, generalized vaccinia, herpes genitalis/simplex, HPV, molluscum contagiosum, vaccinia necrosum, vaccinia, varicella-zoster, variola</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13908">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, probenecid, sulfa products; direct intraocular injection</para>
				<para>
					<bbw>Proteinuria, renal disease/failure</bbw>
				</para>
				<section type="none" id="sidelem4x13923">
					<section type="none" id="sidelem4x13924">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;6 mo, geriatric patients, preexisting cytopenias, renal function impairment, platelet count &lt;25,000/mm<emphasis style="sup">3</emphasis>, dehydration</para>
						<para>
							<bbw>Neutropenia, infertility, secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13944">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13952">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x13952">
							<item>
								<label>•</label>
								<para> 5 mg/kg weekly × 2 wk then 3 mg/kg q2wk, give with probenecid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13956">
					<section type="none" id="sidelem4x13957">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x13965">
							<label>•</label>
							<sec_title>Adult<route> IV CCr ≤55 ml/min, do not use; SCr increase of 0.3-0.4 mg/dl above baseline, decrease dose to 3 mg/kg; SCr increase of ≥0.5 mg/dl above baseline or ≥221 proteinuria, discontinue</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13968">
						<sec_title>Available forms:</sec_title>
						<para> Inj 75 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x13973">
						<sec_title>Administer:</sec_title>
						<para>
							<bbw>Use cytotoxic handling procedures</bbw>
						</para>
						<para>
							<list id="lidelem4x13986">
								<item>
									<label>•</label>
									<para>Allow to warm to room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>If product comes in contact with skin, wash with soap and water immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>If zidovudine is used, reduce dose to 50% on cidofovir treatment days</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14002">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x14010">
								<label>•</label>
								<sec_title>
									<route>Dilute</route>
								</sec_title>
								<para>
									<list id="lidelem4x14010">
										<item>
											<label>•</label>
											<para> in 100 ml 0.9% saline sol before administration; probenecid must be given PO 2 g 3 hr before the cidofovir infusion and 1 g at 2 and 8 hr after ending the cidofovir infusion;  1 L of 0.9% saline sol IV with each INFUSION of cidofovir, give saline INFUSION over 1-2 hr period immediately before cidofovir; patient should be given a 2nd L if the patient can tolerate the fluid load (2nd L given at time of cidofovir or immediately afterward, should be given over 1-3 hr)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x14020">
								<label>•</label>
								<sec_title>
									<route>Give</route>
								</sec_title>
								<para>
									<list id="lidelem4x14020">
										<item>
											<label>•</label>
											<para> slowly; do not give by bolus IV, SUBCUT inj</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x14024">
									<item>
										<label>•</label>
										<para>Use diluted sol within 24 hr, do not freeze; do not use sol with particulate matter or discoloration</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x14029">
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14034">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14037">
					<section type="none" id="sidelem4x14038">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever, chills,</emphasis><emphasis style="bold">coma,</emphasis> confusion, abnormal thoughts, <emphasis style="italic">dizziness</emphasis>, bizarre dreams, <emphasis style="italic">headache</emphasis>, psychosis, tremors, somnolence, paresthesia, <emphasis style="italic">amnesia, anxiety, insomnia</emphasis>, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14059">
						<sec_title>CV:</sec_title>
						<para> Dysrhythmias, hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x14064">
						<sec_title>EENT:</sec_title>
						<para> Retinal detachment with CMV retinitis</para>
					</section>
					<section type="none" id="sidelem4x14069">
						<sec_title>GI:</sec_title>
						<para> Abnormal LFTs, <emphasis style="italic">nausea, vomiting, anorexia, diarrhea</emphasis>, abdominal pain, <emphasis style="bold">hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14079">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria,</emphasis> increased creatinine, BUN, <emphasis style="bold">nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14089">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Granulocytopenia, thrombocytopenia, irreversible neutropenia, anemia, eosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14096">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, alopecia, pruritus</emphasis>, <emphasis style="italic">acne</emphasis>, urticaria, pain at inj site, phlebitis</para>
					</section>
					<section type="none" id="sidelem4x14107">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14112">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 2.6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x14117">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Nephrotoxicity:</emphasis> amphotericin B, foscarnet, aminoglycosides, pentamidine IV, NSAIDs, salicylates; wait 7 days after use to begin cidofovir</bbw>
				</para>
			</section>
			<section type="considerations" id="sidelem4x14132">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14135">
					<section type="none" id="sidelem4x14136">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14141">
								<item>
									<label>•</label>
									<para>Culture before treatment is initiated; cultures of blood, urine, and throat may all be taken; CMV not confirmed by this method; diagnosis made by ophthalmic exam
<bbw>Renal, hepatic, increased hemopoietic studies, BUN; serum creatinine, AST, ALT, creatinine, CCr, A-G ratio, baseline and drip treatment, blood counts should be done q2wk; watch for decreasing granulocytes, Hgb; if low, therapy may have to be discontinued and restarted after hematologic recovery; blood transfusions may be required, renal failure can occur also, Fanconi syndrome</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14156">
								<item>
									<label>•</label>
									<para>For GI symptoms: severe nausea, vomiting, diarrhea; severe symptoms may necessitate discontinuing product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14165">
							<para>
								<list id="lidelem4x14165">
									<item>
										<label>•</label>
										<para>Electrolytes and minerals: calcium, phosphorus, magnesium, sodium, potassium; watch closely for tetany during 1st administration
<bbw>
												<emphasis alert="lifethreat">Blood dyscrasias</emphasis> (anemia, granulocytopenia); bruising, fatigue, bleeding, poor healing; leukopenia, neutropenia, thrombocytopenia: WBCs, platelets q2days during 2×/day dosing and every wk thereafter; check for leukopenias with daily WBC count in patients with prior leukopenia, with other nucleoside analogs, or for whom leukopenia counts are &lt;1000 cells/mm3 at start of treatment</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x14181">
								<item>
									<label>•</label>
									<para>Allergic reactions: flushing, rash, urticaria, pruritus</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14186">
								<item>
									<label>•</label>
									<para>Monitor serum creatinine or CCr at least q2wk; give only to those with creatinine levels ≤1.5 mg/dl, CCr &gt;55 ml/min, urine protein &lt;100 mg/dl</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14191">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14195">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of CMV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14201">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14206">
								<item>
									<label>•</label>
									<para>To notify prescriber if sore throat, swollen lymph nodes, malaise, fever occur; may indicate other infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14211">
								<item>
									<label>•</label>
									<para>To report perioral tingling, numbness in extremities, paresthesias; report rash immediately, mental/vision changes, urinary problems, abnormal bleeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14219">
							<label>•</label>
							<sec_title>
								<route>That serious product interactions may occur if OTC products are ingested; check with prescriber</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14222">
								<item>
									<label>•</label>
									<para>That product is not a cure but will control symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14227">
								<item>
									<label>•</label>
									<para>That regular ophthalmic exams, renal studies must be continued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14232">
								<item>
									<label>•</label>
									<para>That major toxicities may necessitate discontinuing product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14240">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment, that infertility may occur, and that men should use barrier contraception for 90 days after treatment</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>cilostazol (Rx)</mono_name>
			<info>
				<pronunciation>(sih-los′tah-zol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x142530">Pletal</tradename>
				</tradenames>
				<class type="func"> Platelet aggregation inhibitor</class>
				<class type="chem"> Quinolinone derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x14263">
				<para>
					<confusion>
						<tradename id="tnidelem4x142630">Pletal</tradename>
						<drug type="generic" refid="idelem4x142630">Plendil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x14267">
				<sec_title>Action:</sec_title>
				<para>Multifactorial effects (antithrombotic, antiplatelet vasodilation)</para>
			</section>
			<section type="uses" id="sidelem4x14272">
				<sec_title>Uses:</sec_title>
				<para>Intermittent claudication associated with PVD</para>
				<section type="none" id="sidelem4x14277">
					<section type="none" id="sidelem4x14278">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Buerger’s disease, percutaneous coronary intervention (PCI)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14283">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, acute MI, active bleeding conditions, hemostatic conditions</para>
				<para>
					<bbw>CHF</bbw>
				</para>
				<section type="none" id="sidelem4x14298">
					<section type="none" id="sidelem4x14299">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, previous hepatic disease, cardiac/renal disease, increased bleeding risk, low platelet count, platelet dysfunction, smoking</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14304">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14312">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14312">
							<item>
								<label>•</label>
								<para> 100 mg bid taken ≥30 min before or 2 hr after breakfast and dinner or 50 mg bid if using products that inhibit CYP3A4 and CYP2C19; 12 wk of treatment may be needed for beneficial effect</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14316">
					<section type="none" id="sidelem4x14317">
						<sec_title>PCI to prevent acute coronary thrombosis/Buerger’s disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14325">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14325">
									<item>
										<label>•</label>
										<para> 100 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14329">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x14334">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14338">
								<item>
									<label>•</label>
									<para>Give bid 30 min before or 2 hr after meals with a full glass of water; do not give with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14345">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14348">
					<section type="none" id="sidelem4x14349">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14356">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, tachycardia,</emphasis> nodal dysrhythmia, postural hypotension, chest pain</para>
					</section>
					<section type="none" id="sidelem4x14364">
						<sec_title>EENT:</sec_title>
						<para> Blindness, diplopia, ear pain, tinnitus, retinal hemorrhage</para>
					</section>
					<section type="none" id="sidelem4x14369">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="italic">diarrhea,</emphasis> GI discomfort, colitis, cholelithiasis, ulcer, esophagitis, gastritis, anorexia, <emphasis style="italic">flatulence, dyspepsia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14382">
						<sec_title>GU:</sec_title>
						<para> Cystitis, frequency, vaginitis, <emphasis style="bold">vaginal hemorrhage,</emphasis> hematuria</para>
					</section>
					<section type="none" id="sidelem4x14390">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding (epistaxis, hematuria, retinal hemorrhage, GI bleeding), thrombocytopenia,</emphasis> anemia, <emphasis style="bold">polycythemia, aplastic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14400">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, dry skin, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14410">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Back pain, headache, infection, myalgia, peripheral edema,</emphasis> chills, fever, malaise, diabetes mellitus</para>
					</section>
					<section type="none" id="sidelem4x14418">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, pharyngitis, rhinitis,</emphasis> asthma, pneumonia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14426">
				<sec_title>Pharmacokinetics</sec_title>
				<para>95%-98% protein binding; metabolism: hepatic extensively by CYP3A4, 2C19 enzymes (active metabolite); excreted in urine (74%), feces (20%); half-life 11-13 hr</para>
			</section>
			<section type="interactions" id="sidelem4x14431">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding tendencies—anticoagulants, NSAIDs, thrombolytics, abciximab, eptifibatide, tirofiban, ticlopidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cilostazol levels—CYP3A4, CYP2C19 inhibitors; diltiazem, erythromycin, clarithromycin, verapamil, protease inhibitors, omeprazole; exercise caution when coadministering with fluvoxaMINE, FLUoxetine, ketoconazole, isoniazid, gemfibrozil, omeprazole, itraconazole, voriconazole, fluconazole; reduce dose to 50 mg bid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> cilostazol levels—CYP3A4 inducers</para>
				<section type="none" id="sidelem4x14446">
					<section type="none" id="sidelem4x14447">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> action—chamomile, coenzyme Q10, feverfew, garlic, ginger, ginko biloba, flax, goldenseal, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x14454">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x14458">
								<item>
									<label>•</label>
									<para>Do not use with grapefruit juice, toxicity may occur</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> cilostazol action—fatty meal, avoid giving with food</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14468">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14471">
					<section type="none" id="sidelem4x14472">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>For underlying CV disease because CV risk is great; for CV lesions with repeated oral administration; do not administer to patients with CHF of any severity; for severe headache, signs of toxicity</bbw>
						</para>
						<para>
							<list id="lidelem4x14486">
								<item>
									<label>•</label>
									<para>Blood studies: CBC q2wk, Hct, Hgb, PT</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14492">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14496">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved walking distance, duration; decreased pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14502">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14507">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until effect is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14512">
								<item>
									<label>•</label>
									<para>To report any unusual bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14517">
								<item>
									<label>•</label>
									<para>To report side effects such as diarrhea, skin rashes, subcutaneous bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14522">
								<item>
									<label>•</label>
									<para>That effects may take 2-4 wk; treatment of up to 12 wk may be required for necessary effect</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14527">
								<item>
									<label>•</label>
									<para>That reading the patient package insert is necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14532">
								<item>
									<label>•</label>
									<para>That it is best to discontinue tobacco use, not to use grapefruit juice</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14540">
							<label>•</label>
							<sec_title>
								<route>That there are many drug and herb interactions; obtain approval from prescriber before use</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>cimetidine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(sye-met′i-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x145514">Acid Reducer</tradename>
					<tradename id="tnidelem4x145513">Equaline Acid Reducer</tradename>
					<tradename id="tnidelem4x145512">
						<country code="CAN">Nu-Cimet </country>
					</tradename>
					<tradename id="tnidelem4x145511">Tagamet</tradename>
					<tradename id="tnidelem4x145510">Tagamet HB</tradename>
				</tradenames>
				<class type="func"> H-histamine receptor antagonist</class>
				<class type="chem"> Imidazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x14567">
				<sec_title>Action:</sec_title>
				<para>Inhibits histamine at H<emphasis style="inf">2</emphasis>-receptor site in the gastric parietal cells, which inhibits gastric acid secretion</para>
			</section>
			<section type="uses" id="sidelem4x14576">
				<sec_title>Uses:</sec_title>
				<para>Short-term treatment of duodenal and gastric ulcers and maintenance; management of GERD (PO) and Zollinger-Ellison syndrome; prevention of upper GI bleeding; prevent, relieve heartburn, acid indigestion, upper GI bleeding</para>
				<section type="none" id="sidelem4x14581">
					<section type="none" id="sidelem4x14582">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prevention of aspiration pneumonitis, stress ulcers, angioedema, molluscum contagiosum, NSAID-induced ulcer prophylaxis, verruca vulgaris</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14587">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, H2 blockers, benzyl alcohol</para>
				<section type="none" id="sidelem4x14592">
					<section type="none" id="sidelem4x14593">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;16 yr, geriatric patients, organic brain syndrome, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14598">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14601">
					<section type="none" id="sidelem4x14602">
						<sec_title>Short-term treatment of active ulcers</sec_title>
						<section type="none" id="sidelem4x14610">
							<label>•</label>
							<sec_title>Adult/adolescents ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14610">
									<item>
										<label>•</label>
										<para> 300 mg qid with meals, at bedtime × 8-12 wk or 400 mg bid, 800 mg at bedtime; after 8 wk, give bedtime dose only;  300 mg/20 ml 0.9% NaCl over 1-2 min q6hr;  300 mg/50 ml D<emphasis style="inf">5</emphasis>W over 15-20 min;  300 mg q6hr, max 2400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14629">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14629">
									<item>
										<label>•</label>
										<para> 20-40 mg/kg/day, divided q6hr;  5-10 mg/kg q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14636">
						<sec_title>Prophylaxis of duodenal ulcer</sec_title>
						<section type="none" id="sidelem4x14644">
							<label>•</label>
							<sec_title>Adult and child &gt;16 yr</sec_title>
							<para>
								<list id="lidelem4x14644">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult and child &gt;16 yr:</emphasis> 400 mg at bedtime or 300 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14648">
						<sec_title>GERD</sec_title>
						<section type="none" id="sidelem4x14656">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14656">
									<item>
										<label>•</label>
										<para> 800-1600 mg/day in divided doses × up to 12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14660">
						<sec_title>Hypersecretory conditions (Zollinger-Ellison syndrome)</sec_title>
						<section type="none" id="sidelem4x14668">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x14668">
									<item>
										<label>•</label>
										<para> 300-600 mg q6hr; may increase to 12 g/day if needed; OTC use ≤200 mg daily or bid, max 2×/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14672">
						<sec_title>Upper GI bleeding prophylaxis</sec_title>
						<section type="none" id="sidelem4x14680">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14680">
									<item>
										<label>•</label>
										<para> 50 mg/hr; lowered in renal disease</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14684">
						<sec_title>Heartburn</sec_title>
						<section type="none" id="sidelem4x14692">
							<label>•</label>
							<sec_title>Adult/child ≥12 yrs<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14692">
									<item>
										<label>•</label>
										<para> 200 mg Tagamet Hb up to bid, may use before eating, max 400 mg/day, max daily use up to 2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14696">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x14704">
							<label>•</label>
							<sec_title>Adult<route> PO/IV CCr &lt;30 ml/min, 300 mg q12hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14707">
						<sec_title>Verruca vulgaris (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14715">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14715">
									<item>
										<label>•</label>
										<para> 30-40 mg/kg/day divided tid × 2 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14719">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200, 300, 400, 800 mg; liq 200, 300 mg/5 ml; inj 300 mg/2 ml, 300 mg/50 ml 0.9% NaCl</para>
					</section>
					<section type="none" id="sidelem4x14724">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x14727">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x14731">
									<item>
										<label>•</label>
										<para>With meals for prolonged product effect; antacids 1 hr before or 1 hr after cimetidine</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14737">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x14741">
									<item>
										<label>•</label>
										<para>May give undiluted</para>
									</item>
									<item>
										<label>•</label>
										<para>Give at end of dialysis</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject deeply in large muscle mass, aspirate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14757">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x14765">
								<label>•</label>
								<sec_title>
									<route>diluting</route>
								</sec_title>
								<para>
									<list id="lidelem4x14765">
										<item>
											<label>•</label>
											<para>After  300 mg/20 ml of 0.9% NaCl for inj; give by  ≥5 min;  may be  300 mg/50 ml of D<emphasis style="inf">5</emphasis>W;  ≥30 min; or total daily dose (900 mg) diluted in 100-1000 ml D<emphasis style="inf">5</emphasis>W given over 24 hr </para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x14790">
									<item>
										<label>•</label>
										<para>Storage of diluted sol at room temperature up to 48 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex/liposome, anakinra, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, cephapirin, chlorproMAZINE, cisatracurium, CISplatin, cladribine, clarithromycin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin, DOXOrubicin liposome, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, foscarnet, gallium, gatifloxacin, gemcitabine, gentamicin, gycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, meropenem, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactum, multiple vitamin injection, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G sodium/potassium, pentamidine, pentazocine, phenylephrine, phytonadione, pipercillin, piperacillin/tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, Ringers’ ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, topotecan, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14801">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14804">
					<section type="none" id="sidelem4x14805">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Confusion, headache,</emphasis> depression, dizziness, anxiety, weakness, psychosis, tremors, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14815">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, tachycardia, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14822">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> abdominal cramps, <emphasis style="bold">paralytic ileus, jaundice</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14832">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia, galactorrhea, impotence, increase in BUN, creatinine</para>
					</section>
					<section type="none" id="sidelem4x14837">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, neutropenia, aplastic anemia, increase in PT</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14844">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, rash, alopecia, sweating, flushing, <emphasis style="bold">exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14851">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pneumonia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14858">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr; 30%-40% metabolized by liver, excreted in urine (unchanged), crosses placenta, enters breast milk</para>
				<section type="none" id="sidelem4x14869">
					<section type="none" id="sidelem4x14870">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min, peak 45-90 min; duration 4-5 hr, well absorbed</para>
					</section>
					<section type="none" id="sidelem4x14875">
						<sec_title>IM/IV:</sec_title>
						<para> Onset 10 min, peak <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr, duration 4-5 hr, well absorbed (IM)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14886">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity due to CYP450 pathway—benzodiazepines, β-blockers, calcium channel blockers, carBAMazepine, chloroquine, lidocaine, metroNIDAZOLE, moricizine, phenytoin, quiNIDine, quiNINE, sulfonylureas, theophylline, tricyclics, valproic acid, warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow suppression—carmustine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of cimetidine—antacids, sucralfate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—ketoconazole, itraconazole</para>
				<section type="none" id="sidelem4x14905">
					<section type="none" id="sidelem4x14906">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, AST, creatinine, prolactin</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> gastroccult, hemoccult tests</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> TB skin tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14922">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14925">
					<section type="none" id="sidelem4x14926">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x14934">
							<label>•</label>
							<sec_title>Ulcer symptoms</sec_title>
							<para>
								<list id="lidelem4x14934">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ulcer symptoms:</emphasis> epigastric pain, duration, intensity; aggravating, ameliorating factors</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14938">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14942">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain in abdomen; healing of ulcers; absence of gastroesophageal reflux, gastric pH of 5</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14948">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14953">
								<item>
									<label>•</label>
									<para>That gynecomastia, impotence may occur, are reversible</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14958">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until stabilized on this medication; drowsiness or dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14963">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations: aspirin; cough, cold preparations; condition may worsen, OTC therapy is used for short term (2 wk)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14968">
								<item>
									<label>•</label>
									<para>That smoking decreases effectiveness of product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14973">
								<item>
									<label>•</label>
									<para>That product must be taken exactly as prescribed and continued for prescribed time to be effective; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14978">
								<item>
									<label>•</label>
									<para>To report bruising, fatigue, malaise; blood dyscrasias may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14986">
							<label>•</label>
							<sec_title>
								<route>To report diarrhea, black tarry stools, sore throat, rash to prescriber</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>cinacalcet (Rx)</mono_name>
			<info>
				<pronunciation>(sin-a-kal′set)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x149940">Sensipar</tradename>
				</tradenames>
				<class type="func"> Calcium receptor agonist</class>
				<class type="chem"> Polypeptide hormone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15004">
				<sec_title>Action:</sec_title>
				<para>Directly lowers PTH levels by increasing sensitivity of calcium-sensing receptors to extracellular calcium</para>
			</section>
			<section type="uses" id="sidelem4x15009">
				<sec_title>Uses:</sec_title>
				<para>Hypercalcemia with parathyroid carcinoma, secondary hyperparathyroidism with chronic kidney disease for patient on dialysis, primary hyperparathyroidism</para>
			</section>
			<section type="contra" id="sidelem4x15014">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypocalcemia</para>
				<section type="none" id="sidelem4x15019">
					<section type="none" id="sidelem4x15020">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, seizure disorders, hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15025">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15028">
					<section type="none" id="sidelem4x15029">
						<sec_title>Parathyroid carcinoma</sec_title>
						<section type="none" id="sidelem4x15037">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15037">
									<item>
										<label>•</label>
										<para> 30 mg bid, titrate q2-4wk, with sequential doses of 30 mg bid, 60 mg bid, 90 mg bid, 90 mg tid-qid to normalize calcium levels</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15041">
						<sec_title>Secondary hyperparathyroidism</sec_title>
						<section type="none" id="sidelem4x15049">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15049">
									<item>
										<label>•</label>
										<para> 30 mg/day, titrate no more frequently than q2-4wk with sequential doses of 30, 60, 90, 120, 180 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15053">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 30, 60, 90 mg</para>
					</section>
					<section type="none" id="sidelem4x15058">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15062">
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, or chew; use with food or right after a meal</para>
								</item>
								<item>
									<label>•</label>
									<para>Can be used alone or in combination with vit D sterols, phosphate binders</para>
								</item>
								<item>
									<label>•</label>
									<para>Storage at &lt;77° F (25° C)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15078">
						<sec_title>Secondary hyperthyroidism</sec_title>
						<para>
							<list id="lidelem4x15082">
								<item>
									<label>•</label>
									<para>Titrate q2-4wk to target iPTH consistent with National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) for chronic kidney disease patient on dialysis of 150-300 pg/ml; if iPTH &lt;150-300 pg/ml, reduce dose of cinacalcet and/or vit D sterols or discontinue treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15088">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15091">
					<section type="none" id="sidelem4x15092">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, asthenia, <emphasis style="bold">seizures,</emphasis> tetany, hallucinations, depression, headache</para>
					</section>
					<section type="none" id="sidelem4x15100">
						<sec_title>CV:</sec_title>
						<para> Hypertension, dysrhythmia exacerbation</para>
					</section>
					<section type="none" id="sidelem4x15105">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, vomiting, anorexia</para>
					</section>
					<section type="none" id="sidelem4x15110">
						<sec_title>MISC:</sec_title>
						<para> Access infection, noncardiac chest pain, hypocalcemia</para>
					</section>
					<section type="none" id="sidelem4x15115">
						<sec_title>MS:</sec_title>
						<para> Myalgia, bone fractures</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15120">
				<sec_title>Pharmacokinetics</sec_title>
				<para>93%-97% bound to plasma; proteins metabolized by CYP3A4, 2D6, 1A2; half-life 30-40 hr; renal excretion of metabolites (80% renal, 15% in feces)</para>
			</section>
			<section type="interactions" id="sidelem4x15125">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> cinacalcet levels: CYP3A4 inhibitors (ketoconazole, erythromycin, itraconazole)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of CYP2D6 inhibitors (flecainide, vinBLAStine, thioridazine, tricyclics)</para>
				<section type="none" id="sidelem4x15137">
					<section type="none" id="sidelem4x15138">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> action by high-fat meal</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15145">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15148">
					<section type="none" id="sidelem4x15149">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15157">
							<label>•</label>
							<sec_title>Hypocalcemia</sec_title>
							<para>
								<list id="lidelem4x15157">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypocalcemia:</emphasis> cramping, seizures, tetany, myalgia, paresthesia; calcium, phosphorous within 1 wk and iPTH 1-4 wk after initiation or dosage adjustment when maintenance established; measure calcium, phosphorus monthly; iPTH q1-3mo, target range 150-300 pg/ml for iPTH level; biochemical markers of bone formation/resorption; radiologic evidence of fracture; serum testosterone</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15164">
							<label>•</label>
							<sec_title>Renal disease (without dialysis)<route> these patients should not receive treatment with this product, high risk of hypocalcemia</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15170">
							<label>•</label>
							<sec_title>
								<route>If calcium &lt;8.4 mg/dl, do not start therapy</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15173">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15177">
								<item>
									<label>•</label>
									<para>Therapeutic response: calcium levels 9-10 mg/dl, decreasing symptoms of hypercalcemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15183">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15188">
								<item>
									<label>•</label>
									<para>To take with food or shortly after a meal; to take tabs whole, not to take any other meds, supplements without prescriber approval</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15196">
							<label>•</label>
							<sec_title>
								<route>To report cramping, seizures, muscle pain, tingling, tetany immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>ciprofloxacin (Rx)</mono_name>
			<info>
				<pronunciation>(sip-ro-floks′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x152041">Cipro</tradename>
					<tradename id="tnidelem4x152040">Cipro XR</tradename>
				</tradenames>
				<class type="func"> Antiinfective—broad spectrum</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15214">
				<para>
					<confusion>
						<tradename id="tnidelem4x152140">ciprofloxacin</tradename>
						<drug type="generic" refid="idelem4x152140">cephalexin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15218">
				<sec_title>Action:</sec_title>
				<para>Interferes with conversion of intermediate DNA fragments into high-molecular-weight DNA in bacteria; DNA gyrase inhibitor</para>
			</section>
			<section type="uses" id="sidelem4x15223">
				<sec_title>Uses:</sec_title>
				<para>Infection caused by susceptible <emphasis style="italic">Escherichia coli, Enterobacter cloacae, Proteus mirabilis, Klebsiella pneumoniae, Proteus vulgaris, Citrobacter freundii, Serratia marcescens, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Enterobacter, Campylobacter jejuni, Salmonella;</emphasis> chronic bacterial prostatitis, acute sinusitis, postexposure inhalation anthrax, infectious diarrhea, typhoid fever, complicated intraabdominal infections, nosocomial pneumonia, urinary tract infections</para>
				<section type="none" id="sidelem4x15231">
					<section type="none" id="sidelem4x15232">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Acinetobacter/woffii, Aeromonas hydrophila,</emphasis> brucellosis, <emphasis style="italic">Burkholderia, pseudomallei,</emphasis> chancroid, cholera, dental infection, <emphasis style="italic">Edwardsiella tarda,</emphasis> endocarditis, <emphasis style="italic">Enterobacter aerogenes,</emphasis> granuloma inguinale, <emphasis style="italic">Klebsiella oxytoca,</emphasis> Legionnaire’s disease, melioidosis, meningococcal infection prophylaxis, <emphasis style="italic">Pasteurella multocida,</emphasis> PID, periodontitis, pharyngitis, <emphasis style="italic">Salmonella sp., Stenotrophomonas maltophilia,</emphasis> tularemia, <emphasis style="italic">Vibrio cholerae/parahaemolyticus/vulnificus, Yersinia enterocolitica</emphasis></para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15260">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to quinolones</para>
				<section type="none" id="sidelem4x15265">
					<section type="none" id="sidelem4x15266">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal disease, seizure disorder, stroke, CV disease, hepatic disease, QT prolongation, hypokalemia, colitis</para>
						<para>
							<bbw>Tendon pain/rupture, tendinitis, myasthenia gravis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15280">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15283">
					<section type="none" id="sidelem4x15284">
						<sec_title>Uncomplicated urinary tract infections</sec_title>
						<section type="none" id="sidelem4x15292">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15292">
									<item>
										<label>•</label>
										<para> 250 mg q12hr × 3 days or XL 500 mg q24hr × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15296">
						<sec_title>Complicated/severe urinary tract infections</sec_title>
						<section type="none" id="sidelem4x15304">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15304">
									<item>
										<label>•</label>
										<para> 500 mg q12hr or XL 1000 mg q24hr × 7-14 days;  400 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15312">
						<sec_title>Respiratory, bone, skin, joint infections (mild-moderate)</sec_title>
						<section type="none" id="sidelem4x15320">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15320">
									<item>
										<label>•</label>
										<para> 500-750 mg q12hr × 7-14 days;  400 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15327">
						<sec_title>Nosocomial pneumonia</sec_title>
						<section type="none" id="sidelem4x15335">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15335">
									<item>
										<label>•</label>
										<para> 400 mg q8hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15339">
						<sec_title>Intraabdominal infections, complicated</sec_title>
						<section type="none" id="sidelem4x15347">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15347">
									<item>
										<label>•</label>
										<para> 500 mg q12hr × 7-14 days;  400 mg q12hr × 7-14 days, usually given with metroNIDAZOLE</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15354">
						<sec_title>Acute sinusitis, mild/moderate</sec_title>
						<section type="none" id="sidelem4x15362">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15362">
									<item>
										<label>•</label>
										<para> 500 mg q12hr × 10 days;  400 mg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15369">
						<sec_title>Inhalational anthrax (postexposure)</sec_title>
						<section type="none" id="sidelem4x15377">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15377">
									<item>
										<label>•</label>
										<para> 500 mg q12hr × 60 days;  400 mg q12hr × 60 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15387">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15387">
									<item>
										<label>•</label>
										<para> 15 mg/kg/dose q12hr × 60 days, max 500 mg/dose;  10 mg/kg q12hr, max 400 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15394">
						<sec_title>Infectious diarrhea</sec_title>
						<section type="none" id="sidelem4x15402">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15402">
									<item>
										<label>•</label>
										<para> 500-750 mg q12hr × 5-7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15406">
						<sec_title>Chronic bacterial prostatis</sec_title>
						<section type="none" id="sidelem4x15414">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15414">
									<item>
										<label>•</label>
										<para> 500 mg q12hr × 28 days;  400 mg q12hr × 28 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15421">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x15429">
							<label>•</label>
							<sec_title>Adult<route> CCr 30-50 ml/min, PO 250-500 mg q12hr; CCr 5-29 ml/min, PO 250-500 mg q18hr; IV 200-400 mg q18-24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15432">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 250, 500, 750 mg; ext rel tabs (XR) 500, 1000 mg; inj 200 mg/100 ml D<emphasis style="inf">5</emphasis>, 400 mg/200 ml D<emphasis style="inf">5</emphasis>; inj 200, 400 mg; oral susp 250 mg, 500 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x15443">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15447">
								<item>
									<label>•</label>
									<para>Obtain C&amp;S before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Use caution when giving with antidysrhythmics IA, III</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15458">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x15462">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew XR (ext rel) product, use adequate fluids to prevent crystalluria</para>
									</item>
									<item>
										<label>•</label>
										<para>2 hr before or 6 hr after antacids, zinc, iron, calcium</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give oral susp by GI tube</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15478">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x15482">
									<item>
										<label>•</label>
										<para>Over 1 hr as an infusion, comes in premixed plastic infusion container or diluted 20- or 40-ml vial to a final concentration of 0.5-2 mg/ml of NS or D<emphasis style="inf">5</emphasis>W; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock, diluted vials can be stored for 14 days at room temperature or refrigerator; do not freeze</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, anakinra, anidulafungin, argatroban, arsenic, atenolol, aztreonam, bivalirudin, bleomycin, calcium gluconate, CARBOplatin, caspofungin, cefTAZidime, cisatracurium, CISplatin, clarithromycin, codeine, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, doripenem, DOPamine, doxacurium, DOXOrubicin, epirubicin, eptifibatide, ertapenem, etoposide, fenoldopam, fludarabine, gallium, gemcitabine, gentamicin, granisetron, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, irinotecan, lidocaine, linezolid, LORazepam, LR, mechlorethamine, meperidine, methotrexate, metoclopramide, metroNIDAZOLE, midazolam, midodrine, milrinone, mitoXANtrone, mycophenolate, nesiritide, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, piperacillin, potassium acetate/chloride, promethazine, ranitidine, remifentanil, rocuronium, sodium chloride, tacrolimus, teniposide, thiotepa, tigecycline, tirofiban, TNA, tobramycin, trastuzumab, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15498">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15501">
					<section type="none" id="sidelem4x15502">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis>, dizziness, fatigue, insomnia, depression, <emphasis style="italic">restlessness,</emphasis><emphasis style="bold">seizures,</emphasis> confusion, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x15515">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea</emphasis>, increased ALT/AST, dry mouth, flatulence, heartburn, <emphasis style="italic">vomiting</emphasis>, oral candidiasis, dysphagia, <emphasis style="bold">pseudomembranous colitis, abdominal pain, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15528">
						<sec_title>GU:</sec_title>
						<para> Crystalluria, interstitial neuritis</para>
					</section>
					<section type="none" id="sidelem4x15533">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bone marrow depression,</emphasis> agranulocytosis, eosinophils</para>
					</section>
					<section type="none" id="sidelem4x15541">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis>, pruritus, urticaria, photosensitivity, flushing, fever, chills, <emphasis style="bold">toxic epidermal necrolysis,</emphasis> injection site reactions</para>
					</section>
					<section type="none" id="sidelem4x15552">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome,</emphasis> visual impairment, <emphasis style="bold">QT prolongation, pseudotumor cerebri</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15563">
						<sec_title>MS:</sec_title>
						<para> Tremor, arthralgia, tendinitis, <emphasis style="bold">tendon rupture</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15570">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x15573">
					<section type="none" id="sidelem4x15574">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr; half-life 4 hr; excreted in urine as active product, metabolites 35%-40%, 20%-40% protein binding</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x15579">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> tendonitis, tendon rupture—corticosteroids</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ciprofloxacin levels—probenecid; monitor for toxicity</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of theophylline, warfarin, monitor blood levels, reduce dose</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of CYP1A2 inhibitors</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—astemizole, droperidol, class IA/III antidysrhythmics, tricyclics, tetracyclines, local anesthetics, phenothiazines, haloperidol, risperiDONE, sertindole, ziprasidone, alfuzosin, arsenic trioxide, β-agonists, chloroquine, cloZAPine, cyclobenzapine, dasatinib, dolasetron, droperidol, flecainide, halogenated anesthetics, lapatinib, levomethadyl, macrolides, methadone, octreotide, ondansetron, paliperidone, palonosetron, pentamidine, propafenone, ranolazine, SUNItinib, tacrolimus, terfenadine, vardenafil, vorinostat; less likely than other quinolones</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ciprofloxacin absorption—antacids that contain magnesium, aluminum; zinc, iron, sucralfate, enteral feedings, calcium, sevelamer</para>
				<section type="none" id="sidelem4x15617">
					<section type="none" id="sidelem4x15618">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect of caffeine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—dairy products, food</para>
					</section>
					<section type="none" id="sidelem4x15629">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, BUN, creatinine, LDH, bilirubin, alk phos, glucose, proteinuria, albuminuria</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15640">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15643">
					<section type="none" id="sidelem4x15644">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15652">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x15652">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> WBC, temperature before treatment, periodically</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15659">
							<label>•</label>
							<sec_title>QT Prolongation<route> Monitor for changes in QTc if taking other products that increase QT</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15676">
							<label>•</label>
							<sec_title>CNS symptoms</sec_title>
							<para>
								<list id="lidelem4x15676">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS symptoms:</emphasis> headache, dizziness, fatigue, insomnia, depression, seizures</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15680">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies: BUN, creatinine, AST, ALT</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15688">
							<para>
								<list id="lidelem4x15688">
									<item>
										<label>•</label>
										<para>I&amp;O ratio, urine pH &lt;5.5 is ideal
<bbw>
												<emphasis alert="lifethreat">Tendonitis, tendon rupture:</emphasis> discontinue at first sign of tendon pain, inflammation; increased in those &gt;60 yr, those taking corticosteroids, organ transplants</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15702">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: fever, flushing, rash, urticaria, pruritus, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15710">
							<label>•</label>
							<sec_title>Pseudomotor Cerebri<route> may occur at excessive doses</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15713">
								<item>
									<label>•</label>
									<para>Limited intake of alkaline foods, products: milk, dairy products, alkaline antacids, sodium bicarbonate; caffeine intake if excessive cardiac or CNS stimulation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15718">
								<item>
									<label>•</label>
									<para>Increase fluids to 3 L/day to avoid crystallization in kidneys</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15723">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15727">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, frequency, urgency, C&amp;S; absence of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15733">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15738">
								<item>
									<label>•</label>
									<para>Not to take any products that contain magnesium, calcium (such as antacids), iron, aluminum with this product or 2 hr before, 6 hr after product; to drink fluids to prevent crystals in urine
<bbw>To report tendon pain, chest pain, palpitations</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15752">
								<item>
									<label>•</label>
									<para>To ambulate, perform activities with assistance if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15757">
								<item>
									<label>•</label>
									<para>To complete full course of product therapy; not to double or miss doses</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15766">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if rash occurs, discontinue product</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15769">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected pregnancy (C); not to breastfeed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15774">
								<item>
									<label>•</label>
									<para>To frequently rinse mouth; use sugarless candy, gum for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15779">
								<item>
									<label>•</label>
									<para>To contact prescriber if taking theophylline, warfarin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15784">
								<item>
									<label>•</label>
									<para>Extended release and regular release are not interchangeable</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15789">
								<item>
									<label>•</label>
									<para>Not to add or stop products without prescriber’s approval</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15794">
								<item>
									<label>•</label>
									<para>To use calibrated measuring device for suspension</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>ciprofloxacin (ophthalmic)</mono_name>
			<info>
				<pronunciation>(sip-roe-flox′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x158040">Ciloxan</tradename>
				</tradenames>
				<class type="func"> ophthalmic antiinfective</class>
				<class type="chem"> fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15814">
				<para>
					<confusion>
						<tradename id="tnidelem4x158140">ciprofloxacin</tradename>
						<drug type="generic" refid="idelem4x158140">gatifloxacin/levofloxacin/moxifloxacin/ofloxacin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15818">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA gyrase, thereby decreasing bacterial replication</para>
			</section>
			<section type="uses" id="sidelem4x15823">
				<sec_title>Uses:</sec_title>
				<para>Corneal ulcers, bacterial conjunctivitis</para>
			</section>
			<section type="contra" id="sidelem4x15828">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or fluoroquinolones</para>
				<section type="none" id="sidelem4x15833">
					<section type="none" id="sidelem4x15834">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15839">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15842">
					<section type="none" id="sidelem4x15843">
						<sec_title>Bacterial conjunctivitis</sec_title>
						<section type="none" id="sidelem4x15851">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥1 yr</sec_title>
							<para>
								<list id="lidelem4x15851">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child ≥1 yr:</emphasis> Ophthalmic (sol): 1-2 drops in affected eye(s) every 2 hr while awake × 2 days, then every 4 hr while awake for the next 5 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15858">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥2 yr</sec_title>
							<para>
								<list id="lidelem4x15858">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child ≥2 yr:</emphasis> Ophthalmic (ointment): <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-inch ribbon to conjunctival sac tid × 2 days, then <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> inch bid for next 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15874">
						<sec_title>Ophthalmic infection associated with corneal ulcer</sec_title>
						<section type="none" id="sidelem4x15882">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥1 yr</sec_title>
							<para>
								<list id="lidelem4x15882">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child ≥1 yr:</emphasis> Ophthalmic (solution): 2 drops in affected eye(s) every 15 min × 6 hr, then every 30 min for the remainder of the first day; for the second day, 2 drops every hr; for days 3-14, 2 drops every 4 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15886">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic ointment, solution 0.3%</para>
					</section>
					<section type="none" id="sidelem4x15891">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15895">
								<item>
									<label>•</label>
									<para>Commercially available ophthalmic solutions are not for injection subconjunctivally or into the anterior chamber of the eye</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15901">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x15905">
									<item>
										<label>•</label>
										<para>Apply topically to the eye, taking care to avoid contamination</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid wearing contact lens(es) while treating eye infection</para>
									</item>
									<item>
										<label>•</label>
										<para>Protect from light, store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15931">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15934">
					<section type="none" id="sidelem4x15935">
						<sec_title>EENT:</sec_title>
						<para> Burning, hypersensitivity, pruritus, precipitate in those with corneal ulcers, lid margin crusting</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15940">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15943">
					<section type="none" id="sidelem4x15944">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15947">
							<sec_title>Allergic reaction:</sec_title>
							<para>
								<list id="lidelem4x15951">
									<item>
										<label>•</label>
										<para>Assess for hypersensitivity, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15957">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15961">
								<item>
									<label>•</label>
									<para>Decreased ophthalmic infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15967">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x15970">
							<sec_title>Ophthalmic route:</sec_title>
							<para>
								<list id="lidelem4x15974">
									<item>
										<label>•</label>
										<para>To apply topically to the eye, taking care to avoid contamination; for ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>To apply pressure to lacrimal sac for 1 min after instillation</para>
									</item>
									<item>
										<label>•</label>
										<para>To avoid wearing contact lens(es) while treating eye infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active" ha="yes">
			<mono_name>cisatracurium</mono_name>
			<info>
				<pronunciation>(sis-ah-trah-kyoo′ree-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x160030">Nimbex</tradename>
				</tradenames>
				<class type="func"> Skeletal muscle relaxant</class>
				<class type="chem"> Nondepolarizing neuromuscular blocker</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x16013">
				<sec_title>Action:</sec_title>
				<para>Antagonizes acetylcholine by binding to cholinergic receptors on the motor end plate, resulting in neuromuscular blockade</para>
			</section>
			<section type="uses" id="sidelem4x16018">
				<sec_title>Uses:</sec_title>
				<para>To maintain neuromuscular blockade during mechanical ventilation and as an adjunct to general anesthesia</para>
			</section>
			<section type="contra" id="sidelem4x16023">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x16028">
					<section type="none" id="sidelem4x16029">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, benzyl alcohol hypersensitivity, electrolyte imbalances, long-term use in ICU, trauma, or burns, dehydration, metabolic alkalosis, respiratory acidosis, myopathy, myasthenia gravis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16034">
				<sec_title>Dosage and routes</sec_title>
				<para>For neuromuscular blockade, as an adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU</para>
				<section type="none" id="sidelem4x16039">
					<section type="none" id="sidelem4x16040">
						<sec_title>Endotracheal intubation</sec_title>
						<section type="none" id="sidelem4x16048">
							<label>•</label>
							<sec_title>Adult/adolescent (healthy)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16048">
									<item>
										<label>•</label>
										<para> 0.15-0.2 mg/kg, one time</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16055">
							<label>•</label>
							<sec_title>Adult with myasthenia gravis<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16055">
									<item>
										<label>•</label>
										<para> use peripheral nerve stimulator monitoring and an initial dose ≤0.02 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16062">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16062">
									<item>
										<label>•</label>
										<para> 0.1-0.15 mg/kg over 5-10 sec during either halothane or opioid anesthesia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16069">
							<label>•</label>
							<sec_title>Infant/child ≤23 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16069">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg over 5-10 sec during either halothane or opioid anesthesia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16073">
						<sec_title>To maintain neuromuscular blockade during prolonged surgical procedures:</sec_title>
						<section type="none" id="sidelem4x16081">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥2 yr (healthy)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16081">
									<item>
										<label>•</label>
										<para> Maintenance dose 0.03 mg/kg; maintenance dosing is generally required 40-50 min after an initial dose of 0.15 mg/kg IV or 50-60 min after an initial dose of 0.2 mg/kg; the need for maintenance doses should be determined by clinical criteria</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16085">
						<sec_title>Available forms:</sec_title>
						<para>  Injection solution 2, 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x16090">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x16093">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x16097">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Only experienced clinicians, familiar with the use of neuromuscular blocking drugs, should administer or supervise the use of this product</para>
									</item>
									<item>
										<label>•</label>
										<para>Use by rapid IV injection or by continuous IV infusion</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16113">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x16117">
									<item>
										<label>•</label>
										<para>Inject IV over 5-10 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16123">
							<sec_title>
								<emphasis style="bold">Continuous IV INFUSION route</emphasis>
							</sec_title>
							<para>
								<list id="lidelem4x16128">
									<item>
										<label>•</label>
										<para>Dilute with NS, D<emphasis style="inf">5</emphasis>W, or D<emphasis style="inf">5</emphasis>NS (0.1-0.4 mg/ml); adjust the rate of infusion according to peripheral nerve stimulation</para>
									</item>
									<item>
										<label>•</label>
										<para>The amount of infusion sol required per minute depends on the concentration of cisatracurium in the infusion sol, the desired dose of cisatracurium, and the patient’s weight</para>
									</item>
									<item>
										<label>•</label>
										<para>Store Nimbex injection diluted to 0.1 mg/ml either under refrigeration or at room temperature for 24 hr; dilutions to 0.1 mg/ml or 0.2 mg/ml in D<emphasis style="inf">5</emphasis>W/LR injection may be stored under refrigeration for 24 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Not an analgesic, treat pain with other agents</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16158">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16161">
					<section type="none" id="sidelem4x16162">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Bradycardia,</emphasis> flushing, hypotension</para>
					</section>
					<section type="none" id="sidelem4x16171">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Apnea, bronchospasm, prolonged neuromuscular block</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16178">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 2 min, peak 3-5 min, duration 25-44 min, half-life 22-30 min</para>
			</section>
			<section type="interactions" id="sidelem4x16183">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade—aminoglycosides, clindamycin, lithium, local anesthetics, magnesium salts, colistin, colistimethate, procainamide, quiNIDine, tetracyclines, bacitracin, capreomycin, polymyxin B, vancomycin; amphotericin B, CISplatin, corticosteroids, loop/thiazide diuretics (if hypokalemia is present)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> neuromuscular blockade—carBAMazepine, phenytoin</para>
			</section>
			<section type="considerations" id="sidelem4x16194">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16197">
					<section type="none" id="sidelem4x16198">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x16201">
							<sec_title>Neuromuscular function:</sec_title>
							<section type="none" id="sidelem4x16209">
								<label>•</label>
								<sec_title>
									<route>not to be used for rapid-sequence endotracheal intubation</route>
								</sec_title>
								<para>
									<list id="lidelem4x16209">
										<item>
											<label>•</label>
											<para>Use nerve stimulator to monitor neuromuscular function; if no response, stop until response; </para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x16213">
							<sec_title>Electrolyte:</sec_title>
							<para>
								<list id="lidelem4x16217">
									<item>
										<label>•</label>
										<para>Electrolytes and acid-base balance may be altered</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16223">
						<sec_title>Malignant hyperthermia:</sec_title>
						<para>
							<emphasis alert="lifethreat">Assess for malignant hyperthermia; those with a family history of this condition should not receive this product or it should be used cautiously</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x16229">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16233">
								<item>
									<label>•</label>
									<para>Maintenance of neuromuscular blockade</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16239">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16243">
								<item>
									<label>•</label>
									<para>Reason for product and expected results</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name>CISplatin (Rx) <country code="CAN">FIX_STRUCTURECISplatin (Rx)</country></mono_name>
			<info>
				<pronunciation>(sis′pla-tin)</pronunciation>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Platinum complex</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x16266">
				<para>
					<confusion>
						<tradename id="tnidelem4x162660">CISplatin</tradename>
						<drug type="generic" refid="idelem4x162660">CARBOplatin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x16270">
				<sec_title>Action:</sec_title>
				<para>Alkylates DNA, RNA; inhibits enzymes that allow for the synthesis of amino acids in proteins; activity not cell-cycle–phase specific</para>
			</section>
			<section type="uses" id="sidelem4x16275">
				<sec_title>Uses:</sec_title>
				<para>Advanced bladder cancer; adjunct in metastatic testicular cancer; adjunct in metastatic ovarian cancer</para>
				<section type="none" id="sidelem4x16280">
					<section type="none" id="sidelem4x16281">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Astrocytoma; breast, gastric, head, neck, hepatocellular, lung, penile cancer; carcinoid, desmoid tumor; Hodgkin’s disease, malignant glioma, malignant melanoma, neuroblastoma, non-Hodgkin’s lymphoma (NHL), osteogenic sarcoma, osteosarcoma; soft-tissue sarcomas; head, neck cancer; esophagus, prostate, lung, cervical cancer; lymphoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16286">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding</para>
				<para>
					<bbw>Preexisting hearing impairment, bone marrow suppression, platinum compound hypersensitivity, renal disease/failure</bbw>
				</para>
				<section type="none" id="sidelem4x16301">
					<section type="none" id="sidelem4x16302">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, vaccination, infections, extravasation, peripheral neuropathy, radiation therapy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16307">
				<sec_title>Dosage and routes</sec_title>
				<para>Dosage protocols may vary</para>
				<section type="none" id="sidelem4x16312">
					<section type="none" id="sidelem4x16313">
						<sec_title>Metastatic testicular cancer</sec_title>
						<section type="none" id="sidelem4x16321">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16321">
									<item>
										<label>•</label>
										<para> 20 mg/m<emphasis style="sup">2</emphasis>/day × 5 days, repeat q3wk for 2 cycles or more, depending on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16328">
						<sec_title>Advanced bladder cancer</sec_title>
						<section type="none" id="sidelem4x16336">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16336">
									<item>
										<label>•</label>
										<para> 50-70 mg/m<emphasis style="sup">2</emphasis> q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16343">
						<sec_title>Metastatic ovarian cancer</sec_title>
						<section type="none" id="sidelem4x16351">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16351">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis> q4wk or 75-100 mg/m<emphasis style="sup">2</emphasis> q3wk with cyclophosphamide</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16361">
						<sec_title>Hodgkin’s/non-Hodgkin’s lymphoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16369">
							<label>•</label>
							<sec_title>Adult and child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x16369">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis> 24 hr continuous infusion day 1 of 4-day regimen with cytarabine/dexamethasone q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16376">
						<sec_title>Gastric cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16384">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16384">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis> on day 1 with DOCEtaxel 75 mg/m<emphasis style="sup">2</emphasis> and fluorouracil 750 mg/m<emphasis style="sup">2</emphasis> on days 1-5, q21days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16398">
						<sec_title>Available forms:</sec_title>
						<para> Inj 0.5 <country code="CAN">FIX_STRUCTURE Inj 0.5 </country>, 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x16406">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x16409">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x16417">
								<label>•</label>
								<sec_title>
									<route>Do not use aluminum equipment during any preparation or administration, will form precipitate; do not refrigerate unopened powder or solution; protect from sunlight</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x16423">
								<label>•</label>
								<sec_title>
									<route>Prepare in biologic cabinet using gown, gloves, mask; do not allow product to come in contact with skin; use soap and water if contact occurs; use cytotoxic handling procedures</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x16426">
									<item>
										<label>•</label>
										<para>Hydrate patient with 0.9% NaCl over 8-12 hr before treatment</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x16431">
									<item>
										<label>•</label>
										<para>EPINEPHrine, antihistamines, corticosteroids for hypersensitivity reaction</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x16436">
									<item>
										<label>•</label>
										<para>Antiemetic 30-60 min before product and prn; allopurinol to maintain uric acid levels, alkalinization of urine; diuretic (furosemide 40 mg IV) or mannitol after INFUSION</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16441">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x16449">
								<label>•</label>
								<sec_title>
									<route>Dilute</route>
								</sec_title>
								<para>
									<list id="lidelem4x16449">
										<item>
											<label>•</label>
											<para> 10 mg/10 ml or 50 mg/50 ml sterile water for inj, withdraw prescribed dose; <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> dose with 1000 ml D<emphasis style="inf">5</emphasis> 0.2 NaCl, D<emphasis style="inf">5</emphasis> 0.45 NaCl with 37.5 g mannitol; IV INFUSION is  over 3-4 hr; use a 0.45-μm filter; total dose 2 L over 6-8 hr; check site for irritation, phlebitis</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x16470">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x16478">
								<label>•</label>
								<sec_title>
									<route>Give</route>
								</sec_title>
								<para>
									<list id="lidelem4x16478">
										<item>
											<label>•</label>
											<para> over 24 hr × 5 days</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>/0.225% NaCl, D<emphasis style="inf">5</emphasis>/0.45% NaCl, D<emphasis style="inf">5</emphasis>/0.9% NaCl, D<emphasis style="inf">5</emphasis>/0.45% NaCl with mannitol 1.875%, D<emphasis style="inf">5</emphasis>/0.33% NaCl with KCl 20 mEq and mannitol 1.875%, 0.9% NaCl, 0.45% NaCl, 0.3% NaCl, 0.225% NaCl</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amikacin, aminophylline, amiodarone, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, carmustine, caspofungin, ceFAZolin, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, cladribine, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, indomethacin, irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, nafcillin, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phenytoin, piperacillin, polymyxin B, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propofol, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, riTUXimab, sargramostim, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, topotecan, trastuzumab, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16507">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16510">
					<section type="none" id="sidelem4x16511">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis><emphasis style="italic">peripheral neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16520">
						<sec_title>CV:</sec_title>
						<para> Cardiac abnormalities</para>
					</section>
					<section type="none" id="sidelem4x16525">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Tinnitus, hearing loss, vestibular toxicity,</emphasis> blurred vision, altered color perception</para>
					</section>
					<section type="none" id="sidelem4x16533">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Severe nausea, vomiting, diarrhea, weight loss</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16540">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal tubular damage,</emphasis><emphasis style="italic">renal insufficiency,</emphasis> impotence, sterility, amenorrhea, gynecomastia, hyperuremia</para>
					</section>
					<section type="none" id="sidelem4x16550">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16557">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> dermatitis</para>
					</section>
					<section type="none" id="sidelem4x16565">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypomagnesemia,</emphasis> hypocalcemia, hypokalemia, hypophosphatemia</para>
					</section>
					<section type="none" id="sidelem4x16573">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16580">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16587">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption complete, metabolized in liver, excreted in urine, half-life 20 min first phase, 48-70 min second phase, 24 hr terminal phase, accumulates in body tissues for several months, enters breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x16592">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—aspirin, NSAIDs, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ototoxicity—bumetanide, ethacrynic acid, furosemide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—myelosuppressive agents, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—aminoglycosides, loop diuretics, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<section type="none" id="sidelem4x16619">
					<section type="none" id="sidelem4x16620">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, BUN, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> CCr, calcium, phosphate, potassium, magnesium</para>
						<para>
							<emphasis style="bold">Positive:</emphasis> Coombs’ test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16635">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16638">
					<section type="none" id="sidelem4x16639">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> CBC, differential, platelet count weekly; withhold product if WBC is &lt;4000 or platelet count is &lt;100,000; notify prescriber of results</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Renal toxicity:</emphasis> BUN, creatinine, serum uric acid, urine CCr before, electrolytes during therapy; dose should not be given if BUN &lt;25 mg/dl; creatinine &lt;1.5 mg/dl; I&amp;O ratio; report fall in urine output of &lt;30 ml/hr</bbw>
						</para>
						<para>
							<list id="lidelem4x16667">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: wheezing, tachycardia, facial swelling, fainting; discontinue product, report to prescriber; resuscitation equipment should be nearby, may occur within minutes; often EPINEPHrine, corticosteroids, antihistamines may alleviate symptoms</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16672">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr; may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16677">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16683">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding: hematuria, guaiac, bruising, petechiae, mucosa, or orifices q8hr; obtain prescription for viscous lidocaine (Xylocaine)</emphasis>
<bbw>
											<emphasis alert="lifethreat">Ototoxicity:</emphasis> more common in genetic variants TPMT 3B and 3C in children; use audiometric testing baseline and before each dose</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16699">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16704">
								<item>
									<label>•</label>
									<para>Comprehensive oral hygiene</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16709">
								<item>
									<label>•</label>
									<para>All medications PO, if possible; avoid IM inj when platelets &lt;100,000/mm<emphasis style="sup">3</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16719">
							<label>•</label>
							<sec_title>Hyperuricemia in lymphoma</sec_title>
							<para>
								<list id="lidelem4x16719">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperuricemia in lymphoma:</emphasis> Increase fluid intake to 2-3 L/day to prevent urate deposits, calculi formation; promote elimination of product, usually occurs between 3-5 days after a dose, may use allopurinol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16723">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16727">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16734">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x16742">
							<label>•</label>
							<sec_title>To report signs of infection<route> increased temperature, sore throat, flulike symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x16748">
							<label>•</label>
							<sec_title>To report signs of anemia<route> fatigue, headache, faintness, SOB, irritability</route></sec_title>
						</section>
						<section type="none" id="sidelem4x16754">
							<label>•</label>
							<sec_title>
								<route>To report bleeding, bruising, petechiae; to avoid use of razors, commercial mouthwash; to avoid aspirin, ibuprofen, NSAIDs, alcohol; may cause GI bleeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x16760">
							<para>
								<list id="lidelem4x16760">
									<item>
										<label>•</label>
										<para>That impotence or amenorrhea can occur but is reversible after discontinuing treatment
<bbw>
												<emphasis alert="lifethreat">Ototoxicity:</emphasis> to report loss of hearing, ringing or roaring in the ears</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x16773">
								<item>
									<label>•</label>
									<para>To maintain adequate fluids; to report decreased urine output, flank pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16778">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; a wig or hairpiece may make patient feel better; new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16783">
								<item>
									<label>•</label>
									<para>To report numbness, tingling in face or extremities; poor hearing; joint pain, swelling</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16788">
								<item>
									<label>•</label>
									<para>Not to receive vaccinations during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16796">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment and for 4 mo after (pregnancy [D]); product may cause infertility; to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>citalopram (Rx)</mono_name>
			<info>
				<pronunciation>(sigh-tal′oh-pram)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x168040">CeleXA</tradename>
				</tradenames>
				<class type="func"> Antidepressant</class>
				<class type="chem"> Selective serotonin reuptake inhibitor (SSRI)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x16814">
				<para>
					<confusion>
						<tradename id="tnidelem4x168140">CeleXA</tradename>
						<drug type="generic" refid="idelem4x168140">CeleBREX/Cerebyx/Cerebra/Zyprexa</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x16818">
				<sec_title>Action:</sec_title>
				<para>Inhibits CNS neuron uptake of serotonin but not of norepinephrine; weak inhibitor of CYP450 enzyme system, thus making it more appealing than other products</para>
			</section>
			<section type="uses" id="sidelem4x16823">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder</para>
				<section type="none" id="sidelem4x16828">
					<section type="none" id="sidelem4x16829">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Premenstrual disorders, panic disorder, social phobia, obsessive-compulsive disorder in adolescents; anxiety, hot flashes, menopause; adjunct in schizophrenia, PTSD</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16834">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x16839">
					<section type="none" id="sidelem4x16840">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal/hepatic disease, seizure disorder, hypersensitivity to escitalopram, bradycardia, recent MI, abrupt discontinuation, QT prolongation</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16854">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16857">
					<section type="none" id="sidelem4x16858">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x16866">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16866">
									<item>
										<label>•</label>
										<para> 20 mg/day <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis>, may increase if needed to 40 mg/day after 1 wk; maintenance: after 6-8 wk of initial treatment, continue for 24 wk (32 wk total), reevaluate long-term usefulness (max 40 mg/day)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16876">
						<sec_title>Hepatic dose/geriatric</sec_title>
						<section type="none" id="sidelem4x16884">
							<label>•</label>
							<sec_title>Adult<route> PO 20 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16887">
						<sec_title>Panic disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16895">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16895">
									<item>
										<label>•</label>
										<para> 20-40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16899">
						<sec_title>Premenstrual dysphoria/social phobia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16907">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16907">
									<item>
										<label>•</label>
										<para> 10-30 mg/day, used intermittently in premenstrual dysphoria</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16911">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20, 40 mg; oral sol 10 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x16916">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16921">
								<item>
									<label>•</label>
									<para>With food or milk for GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16926">
								<item>
									<label>•</label>
									<para>Crushed if patient is unable to swallow medication whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16931">
								<item>
									<label>•</label>
									<para>Dosages at bedtime if oversedation occurs during the day; may take entire dose at bedtime</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16939">
							<label>•</label>
							<sec_title>
								<route>Do not give within 14 days of MAOIs</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x16942">
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16948">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16951">
					<section type="none" id="sidelem4x16952">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, fatigue, sedation, poor concentration, abnormal dreams, agitation,</emphasis><emphasis style="bold">seizures,</emphasis> apathy, euphoria, hallucinations, delusions, psychosis, <emphasis style="bold">suicidal attempts, neuroleptic malignant-like syndrome reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16964">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hot flashes, palpitations,</emphasis> angina pectoris, <emphasis style="bold">hemorrhage,</emphasis> hypertension, tachycardia, 1st-degree AV block, bradycardia, <emphasis style="bold">MI, thrombophlebitis, QT prolongation,</emphasis> orthostatic hypotension, <emphasis style="bold">torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16980">
						<sec_title>EENT:</sec_title>
						<para> Visual changes, ear/eye pain, photophobia, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x16985">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, dry mouth, anorexia, dyspepsia, constipation, cramps, vomiting, taste changes, flatulence, decreased appetite</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16992">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Dysmenorrhea, decreased libido, urinary frequency, UTI,</emphasis> amenorrhea, cystitis, impotence, urine retention</para>
					</section>
					<section type="none" id="sidelem4x17000">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Sweating, rash, pruritus,</emphasis> acne, alopecia, urticaria, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x17008">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Pain,</emphasis> arthritis, twitching</para>
					</section>
					<section type="none" id="sidelem4x17016">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Infection, pharyngitis, nasal congestion, sinus headache, sinusitis, cough, dyspnea, bronchitis,</emphasis> asthma, hyperventilation, pneumonia</para>
					</section>
					<section type="none" id="sidelem4x17024">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="italic">Asthenia, viral infection, fever, allergy, chills;</emphasis> hyponatremia (geriatric patients), <emphasis style="bold">serotonin syndrome, neonatal abstinence syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17034">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver by CYP3A4, CYP2C19; excreted in urine; steady state 1 wk; peak 4 hr; half-life 35 hr</para>
			</section>
			<section type="interactions" id="sidelem4x17039">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Fatal reactions: do not use with MAOIs</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: QTc interval—dofetilide, halofantrine, probucol, pimoside, quinolones, ziprasidone; do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of tricyclics; use cautiously</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serotonin syndrome—serotonin receptor agonists, SSRIs, traMADol, lithium, MAOIs, traZODone, SNRIs (venlafaxine, DULoxetine)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, salicylates, thrombolytics, anticoagulants, antiplatelets</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS effects—barbiturates, sedative/hypnotics, other CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> citalopram levels—macrolides, azole antifungals</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma levels of β-blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> citalopram levels—carBAMazepine, cloNIDine</para>
				<section type="none" id="sidelem4x17080">
					<section type="none" id="sidelem4x17081">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="nurse">Increase: serotonin syndrome—St. John’s wort, SAM-e; fatal reaction may occur; do not use concurrently</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS stimulation—yohimbe</para>
					</section>
					<section type="none" id="sidelem4x17093">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA, 5-HIAA</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17108">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17111">
					<section type="none" id="sidelem4x17112">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms, depression, panic</bbw>
						</para>
						<para>
							<list id="lidelem4x17128">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome: increased heart rate, sweating, dilated pupils, tremors, twitching, hyperthermia, agitation</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17133">
								<item>
									<label>•</label>
									<para>B/P lying, standing, pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take vital signs q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17138">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may decrease or increase with product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17146">
							<label>•</label>
							<sec_title>Torsades de pointes, QT prolongation<route> is dose-dependent, ECG for flattening of T wave, bundle branch, AV block, dysrhythmias in cardiac patients</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x17149">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol is consumed, hold dose until <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17156">
								<item>
									<label>•</label>
									<para>Sexual dysfunction: erectile dysfunction, decreased libido</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17161">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during therapy, as drowsiness, dizziness occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17166">
								<item>
									<label>•</label>
									<para>Safety measures, primarily for geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17172">
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17177">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17181">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17187">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17192">
								<item>
									<label>•</label>
									<para>That therapeutic effect may take 4-6 wk; that patient may have increased anxiety 1st 5-7 days of therapy; not to discontinue abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17197">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities that require alertness because of drowsiness, dizziness, blurred vision; to report signs, symptoms of bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17202">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants
<bbw>That suicidal ideas, behavior may occur in children or young adults</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17216">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnant, planning to become pregnant, or breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17222">
								<item>
									<para>
										<emphasis alert="nurse">About the effects of serotonin syndrome: nausea/vomiting, tremors; if symptoms occur, to discontinue immediately, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>clarithromycin (Rx)</mono_name>
			<info>
				<pronunciation>(klare-ith′row-my-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x172321">Biaxin</tradename>
					<tradename id="tnidelem4x172320">Biaxin XL</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Macrolide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17242">
				<sec_title>Action:</sec_title>
				<para>Binds to 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis</para>
			</section>
			<section type="uses" id="sidelem4x17247">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate infections of the upper and lower respiratory tract, uncomplicated skin and skin-structure infections caused by <emphasis style="italic">Streptococcus pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Moraxella catarrhalis, Neisseria gonorrhoeae, Corynebacterium diphtheriae, Listeria monocytogenes, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus, Mycobacterium avium</emphasis> complex (MAC); complex infection in AIDS patients; <emphasis style="italic">Mycobacterium avium intracellulare, Helicobacter pylori</emphasis> in combination with omeprazole, <emphasis style="italic">H. parainfluenzae</emphasis></para>
				<section type="none" id="sidelem4x17260">
					<section type="none" id="sidelem4x17261">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Endocarditis prophylaxis, dyspepsia, gastric ulcer, Legionnaire’s disease, pertussis, SARS</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17266">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or macrolide antibiotics, torsades de pointes, QT prolongation</para>
				<section type="none" id="sidelem4x17271">
					<section type="none" id="sidelem4x17272">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17277">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17280">
					<section type="none" id="sidelem4x17281">
						<sec_title>Acute exacerbation of chronic bronchitis</sec_title>
						<section type="none" id="sidelem4x17289">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17289">
									<item>
										<label>•</label>
										<para> 250-500 mg q12hr × 7-14 days or 1000 mg/day × 7 days (XL)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17293">
						<sec_title>Pharyngitis/tonsillitis</sec_title>
						<section type="none" id="sidelem4x17301">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17301">
									<item>
										<label>•</label>
										<para> 250 mg q12hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17305">
						<sec_title>Community-acquired pneumonia</sec_title>
						<section type="none" id="sidelem4x17313">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17313">
									<item>
										<label>•</label>
										<para> 250 mg q12hr × 7-14 days or 1000 mg/day × 7 days (XL)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17317">
						<sec_title>MAC prophylaxis/treatment</sec_title>
						<section type="none" id="sidelem4x17325">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17325">
									<item>
										<label>•</label>
										<para> 500 mg bid; will require an additional antiinfective for active infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17329">
						<sec_title>
							<emphasis style="italic">H. pylori</emphasis> infection</sec_title>
						<section type="none" id="sidelem4x17339">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17339">
									<item>
										<label>•</label>
										<para> 500 mg with 30 mg lansoprazole and 1 g amoxicillin together q12hr × 10-14 days or 500 mg with omeprazole 20 mg and 1 g amoxicillin together q12hr × 10 days or 500 mg q8hr and omeprazole 40 mg daily × 14 days, continue omeprazole for 14 more days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17343">
						<sec_title>Acute maxillary sinusitis</sec_title>
						<section type="none" id="sidelem4x17351">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17351">
									<item>
										<label>•</label>
										<para> 500 mg q12hr × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17355">
						<sec_title>Most infections</sec_title>
						<section type="none" id="sidelem4x17363">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17363">
									<item>
										<label>•</label>
										<para> 7.5 mg/kg q12hr × 10 days, max 500 mg/dose for MAC</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17368">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x17376">
							<label>•</label>
							<sec_title>Adult and child<route> PO CCr 30-60 ml/min decrease dose by 50% if using with ritonavir; &lt;30 ml/min, reduce dose by 50%, if used with ritonavir reduce by 75%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17379">
						<sec_title>Legionnaire’s disease/SARS/whooping cough/gastric ulcer/dyspepsia <emphasis style="italic">(H. pylori)</emphasis> (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17390">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17390">
									<item>
										<label>•</label>
										<para> 500 mg q12hr; may be used in combination for some of these conditions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17394">
						<sec_title>Endocarditis prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17402">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17402">
									<item>
										<label>•</label>
										<para> 500 mg 1 hr before procedure</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17406">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500 mg; oral susp 125 mg/5 ml, 250 mg/5 ml; ext rel tab (XL) 500 mg</para>
					</section>
					<section type="none" id="sidelem4x17411">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17415">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel</para>
								</item>
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L) during diarrhea episodes</para>
								</item>
								<item>
									<label>•</label>
									<para>q12hr to maintain serum levels</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Susp:</emphasis> Shake well, store at room temperature, discard after 2 wk</para>
						<para>
							<emphasis style="bold">Ext Rel:</emphasis> Give with food</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17444">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17447">
					<section type="none" id="sidelem4x17448">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Ventricular dysrhythmias, QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17455">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis><emphasis style="italic">abdominal pain,</emphasis> stomatitis, heartburn, anorexia, <emphasis style="italic">abnormal taste</emphasis>, <emphasis style="bold">pseudomembranous colitis, tooth/tongue discoloration, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17472">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, moniliasis, interstitial nephritis, azotemia</para>
					</section>
					<section type="none" id="sidelem4x17477">
						<sec_title>HEMA:</sec_title>
						<para> Leukopenia, <emphasis style="bold">thrombocytopenia,</emphasis> increased INR</para>
					</section>
					<section type="none" id="sidelem4x17485">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17492">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> hearing loss</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17500">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Regular release: peak 2-2.5 hr; duration 12 hr; Ext release: peak 5-7 hr; half-life 5-7 hr; metabolized by liver; excreted in bile, feces; possible inhibition of P-glycoprotein</para>
			</section>
			<section type="interactions" id="sidelem4x17505">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—cisapride, pimozide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels, increase toxicity—ALPRAZolam, busPIRone, carBAMazepine, cycloSPORINE, digoxin, disopyramide, ergots, felodipine, fluconazole, omeprazole, tacrolimus, theophylline, antidiabetics, digoxin, theophylline, carBAMazepine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of HMG-CoA reductase inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action, risk for toxicity—all products metabolized by CYP3A enzyme system</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of calcium channel blockers, midazolam, benzodiazepines, tacrolimus</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA, III antidysrhythmics or other products that prolong QT</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase or decrease action:</emphasis> zidovudine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clarithromycin action—CYP3A4 substrates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels—rifampin, rifabutin, nevirapine, etravirine, benzodiazepine</para>
				<section type="none" id="sidelem4x17543">
					<section type="none" id="sidelem4x17544">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x17548">
								<item>
									<label>•</label>
									<para>Do not use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17554">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> 17-OHCS/17-KS, AST, ALT, BUN, creatinine, LDH, total bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> folate assay, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17565">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17568">
					<section type="none" id="sidelem4x17569">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17577">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x17577">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> wound characteristics, urine, stool, sputum, WBC, temperature; C&amp;S before product therapy; product may be given as soon as culture is taken; C&amp;S may be repeated after treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17581">
								<item>
									<label>•</label>
									<para>For ulcers: abdominal pain, bleeding in stools, emesis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17586">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies; report hematuria, oliguria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17591">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17596">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest; discontinue product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17601">
								<item>
									<label>•</label>
									<para>Bleeding: check INR if anticoagulants are taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17606">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction to each medication</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17615">
							<label>•</label>
							<sec_title>QT prolongation, ventricular dysrhythmias<route> monitor ECG, cardiac status in those with underlying cardiac abnormalities</route></sec_title>
						</section>
						<section type="none" id="sidelem4x17621">
							<label>•</label>
							<sec_title>Serious skin reaction<route> Stevens-Johnson syndrome, toxic epidermal necrolysis; product should be discontinued immediately</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17624">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17628">
								<item>
									<label>•</label>
									<para>Therapeutic response: C&amp;S negative for infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17634">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17639">
								<item>
									<label>•</label>
									<para>To take with full glass of water; may give with food to decrease GI symptoms, ext rel with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17645">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue; may indicate superinfection</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17651">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of diarrhea, dark urine, pale stools, yellow discoloration of eyes or skin, severe abdominal pain</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17656">
								<item>
									<label>•</label>
									<para>To take at evenly spaced intervals; to complete dosage regimen; to notify prescribers of all products used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17661">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected or planned</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>clevidipine (Rx)</mono_name>
			<info>
				<pronunciation>(klev-id’i-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x176790">Cleviprex</tradename>
				</tradenames>
				<class type="func"> Calcium channel blocker (L-type)</class>
				<class type="chem"> Dihydropyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17689">
				<sec_title>Action:</sec_title>
				<para>L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle; reduces mean arterial B/P by decreasing systemic vascular resistance</para>
			</section>
			<section type="uses" id="sidelem4x17694">
				<sec_title>Uses:</sec_title>
				<para>Reduction of B/P when oral therapy not feasible</para>
			</section>
			<section type="contra" id="sidelem4x17699">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, eggs, soya lecithin; defective lipid metabolism; severe aortic stenosis, pancreatitis</para>
				<section type="none" id="sidelem4x17704">
					<section type="none" id="sidelem4x17705">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), labor, breastfeeding, children &lt;18 yr, heart failure, hyperlipidemia, chronic hypertension, pheochromocytoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17710">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17718">
					<label>•</label>
					<sec_title>Adult<route> CONT IV</route></sec_title>
					<para>
						<list id="lidelem4x17718">
							<item>
								<label>•</label>
								<para> 1-2 mg/hr; dose may be doubled q90sec initially; as B/P reaches goal, adjust dose less frequently (q5-10min) with smaller increases in dose; most patients require 4-6 mg/hr, max 32 mg/hr; no more than 1000 ml should be infused per 24-hr period due to lipid load restrictions</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x17722">
					<section type="none" id="sidelem4x17723">
						<sec_title>Available forms:</sec_title>
						<para> Single-dose vial 50, 100 ml (0.5 mg/ml)</para>
					</section>
					<section type="none" id="sidelem4x17728">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17731">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x17735">
									<item>
										<label>•</label>
										<para>Do not give through same line as other medications; do not dilute, do not filter</para>
									</item>
									<item>
										<label>•</label>
										<para>Gently invert several times before use; do not use if discolored or if particulate matter is present</para>
									</item>
									<item>
										<label>•</label>
										<para>Give through central or peripheral line at 1-2 mg/hr; use infusion device</para>
									</item>
									<item>
										<label>•</label>
										<para>Store vials in refrigerator; do not freeze; leave vials in carton until use; product is photosensitive, but protection from light during administration is not required</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17756">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17759">
					<section type="none" id="sidelem4x17760">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x17765">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, sinus tachycardia,</emphasis> syncope, <emphasis style="bold">reflex tachycardia, atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17775">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17780">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 2-4 min; half-life initially 1 min, terminal 15 min; metabolized via esterases in blood, extravascular tissues; excreted in urine 63%-74%, feces 7%-22%; protein binding &gt;99%</para>
			</section>
			<section type="considerations" id="sidelem4x17786">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17789">
					<section type="none" id="sidelem4x17790">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17794">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, pulse, respiration, ECG; some patients have developed severe angina, acute MI after calcium channel blockers if obstructive CAD is severe; if not transitioned to other antihypertensive therapies after clevidipine infusion, patients should be monitored ≥8 hr for rebound hypertension; monitor for rebound hypertension after product stoppage</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17800">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17804">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17810">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x17818">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately if neurological symptoms, visual changes, or symptoms of CHF occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17821">
								<item>
									<label>•</label>
									<para>To continue follow-up for hypertension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17826">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned, suspected, or if breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>clindamycin HCI (Rx)</mono_name>
			<info>
				<pronunciation>(klin-da-my′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x178361">Cleocin HCl</tradename>
					<tradename id="tnidelem4x178360">
						<country code="CAN">Dalacin C </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="23" status="active">
			<mono_name>clindamycin palmitate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x178431">Cleocin Pediatric</tradename>
					<tradename id="tnidelem4x178430">
						<country code="CAN">Dalacin C Flavored Granules </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="24" status="active">
			<mono_name>clindamycin phosphate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x178501">Cleocin Phosphate</tradename>
					<tradename id="tnidelem4x178500">
						<country code="CAN">Dalacin C Phosphate Sterile Solution </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Lincomycin derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x17862">
				<sec_title>Action:</sec_title>
				<para>Binds to 50S subunit of bacterial ribosomes, suppresses protein synthesis</para>
			</section>
			<section type="uses" id="sidelem4x17867">
				<sec_title>Uses:</sec_title>
				<para>Infections caused by staphylococci, streptococci, <emphasis style="italic">Rickettsia, Fusobacterium, Actinomyces, Peptococcus, Bacteroides, Pneumocystis jiroveci</emphasis></para>
				<section type="none" id="sidelem4x17874">
					<section type="none" id="sidelem4x17875">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acne rosacea, <emphasis style="italic">Bacillus anthracis,</emphasis> dental infections, folliculitis, malaria, pemphigus, periodontitis, <emphasis style="italic">Pneumocystis jiroveci</emphasis> pneumonia (PCP), toxoplasmosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17886">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or lincomycin, tartrazine dye; ulcerative colitis/enteritis</para>
				<para>
					<bbw>Pseudomembranous colitis</bbw>
				</para>
				<section type="none" id="sidelem4x17901">
					<section type="none" id="sidelem4x17902">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, GI/hepatic disease, asthma, allergy</para>
						<para>
							<bbw>Diarrhea</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17917">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17925">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x17925">
							<item>
								<label>•</label>
								<para> 150-450 mg q6hr, max 2700 mg/day;  1.2-2.7 g/day in 2-4 divided doses, max 4800mg/day severe infections</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x17935">
					<label>•</label>
					<sec_title>Child &gt;1 mo<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x17935">
							<item>
								<label>•</label>
								<para> 8-25 mg/kg/day in divided doses q6-8hr;  20-40 mg/kg/day in 3-4 equal divided doses q6-8hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x17945">
					<label>•</label>
					<sec_title>Neonate<route> IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x17945">
							<item>
								<label>•</label>
								<para> 15-20 mg/kg/day divided doses q6-8hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x17949">
					<section type="none" id="sidelem4x17950">
						<sec_title>PID</sec_title>
						<section type="none" id="sidelem4x17958">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x17958">
									<item>
										<label>•</label>
										<para> 900 mg q8hr plus gentamicin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17962">
						<sec_title>Bacterial endocarditis prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17970">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x17970">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 600 mg 1 hr before procedure</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17974">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">P. jiroveci pneumonia</emphasis>
							</emphasis> (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17985">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17985">
									<item>
										<label>•</label>
										<para> 1200-1800 mg/day in divided doses with 15-30 mg primaquine/day × 21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17989">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">HCl:</emphasis> caps 75, 150, 300 mg; <emphasis style="bold">palmitate:</emphasis> oral sol 75 mg/5 ml; <emphasis style="bold">phosphate:</emphasis> inj 150, 300, 600 mg base/16 ml; 900 mg base/ml; inj infusion in D<emphasis style="inf">5</emphasis> 300 mg, 600 mg, 900 mg/16 ml</para>
					</section>
					<section type="none" id="sidelem4x18006">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18010">
								<item>
									<label>•</label>
									<para>In equal intervals around the clock to maintain blood levels</para>
								</item>
								<item>
									<label>•</label>
									<para>Obtain C&amp;S before use</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18022">
						<sec_title>PO route</sec_title>
						<para>
							<list id="lidelem4x18026">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew caps</para>
								</item>
								<item>
									<label>•</label>
									<para>Orally with at least 8 oz of water</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18037">
							<sec_title>Oral solution</sec_title>
							<para>
								<list id="lidelem4x18041">
									<item>
										<label>•</label>
										<para>Do not refrigerate reconstituted product; store at room temperature ≤2 wk</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute granules with most of 75 ml of water, shake well, add remaining water, shake well (75 mg/5 ml)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18052">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x18056">
									<item>
										<label>•</label>
										<para>IM deep inj; rotate sites; do not give &gt;600 mg in single IM inj</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18062">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x18067">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18075">
								<label>•</label>
								<sec_title>Vials</sec_title>
								<para>
									<list id="lidelem4x18075">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Vials:</emphasis> dilute 300 and 600 mg doses with 50 ml of a compatible diluent; dilute 900 mg doses with 50-100 ml of a compatible diluent; dilute 1200 mg doses with 100 ml of a compatible diluent, final concentration max 18 mg/ml</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18082">
								<label>•</label>
								<sec_title>ADD-vantage vials</sec_title>
								<para>
									<list id="lidelem4x18082">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">ADD-vantage vials:</emphasis> dilute 600 and 900 mg ADD-vantage containers with 50 or 100 mg, respectively, of NS or D<emphasis style="inf">5</emphasis>W</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18092">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x18092">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> when diluted in D<emphasis style="inf">5</emphasis>W, NS, or LR, solutions with concentrations of 6, 9, or 12 mg/ml are stable for 16 days at room temperature or 32 days under refrigeration when stored in glass bottles or minibags; when diluted in D<emphasis style="inf">5</emphasis>W, solutions with a concentration of 18 mg/ml are stable for 16 days at room temperature</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x18102">
							<sec_title>Intermittent IV infusion route</sec_title>
							<para>
								<list id="lidelem4x18106">
									<item>
										<label>•</label>
										<para>Infuse over at least 10-60 min, infusion rates max 30 mg/min and ≤1.2 g should be infused in a 1 hr period</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse 300 mg doses over 10 min; 600 mg doses over 20 min, 900 mg doses over 30 min, and 1200 mg doses over 40 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18117">
							<sec_title>Continuous IV infusion route</sec_title>
							<para>
								<list id="lidelem4x18121">
									<item>
										<label>•</label>
										<para>Give first dose rapidly, then follow with continuous infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Rate is based on desired serum clindamycin levels:</para>
									</item>
									<item>
										<label>•</label>
										<para>To maintain serum concentrations above 4 mcg/ml, use a rapid infusion rate of 10 mg/min for 30 min and a maintenance rate of 0.75 mg/min; to maintain serum concentrations above 5 mcg/ml, use a rapid infusion rate of 15 mg/min for 30 min and a maintenance rate of 1 mg/min; to maintain serum concentrations above 5 mcg/ml, use a rapid infusion rate of 20 mg/min for 30 min and a maintenance rate of 1.25 mg/min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B cholesteryl, amphotericin B lipid complex, amsacrine, anakinra, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefpirome, cefTAZidime, ceftizoxime, ceftobiprole, cefuroxime, cephalothin, cephapirin, chloramphenicol, cimetidine, cisatracurium, CISplatin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fludarabine, fluorouracil, folic acid, foscarnet, furosemide, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, milrinone, morphine, moxalactam, multiple vitamins injection, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium/sodium, pentazocine, perphenazine, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, potassium chloride, procainamide, propofol, propranolol, protamine, pyridoxine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18143">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18146">
					<section type="none" id="sidelem4x18147">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain, diarrhea,</emphasis><emphasis style="bold">pseudomembranous colitis,</emphasis> anorexia, weight loss, increased AST/ALT, bilirubin, alk phos; jaundice</para>
					</section>
					<section type="none" id="sidelem4x18157">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Vaginitis,</emphasis> urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x18165">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, erythema, pain, abscess at inj site</para>
					</section>
					<section type="none" id="sidelem4x18170">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18177">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x18180">
					<section type="none" id="sidelem4x18181">
						<sec_title>PO:</sec_title>
						<para> Peak 45 min, duration 6-8 hr</para>
					</section>
					<section type="none" id="sidelem4x18186">
						<sec_title>IM:</sec_title>
						<para> Peak 3 hr (adult), 1 hr (child); duration 8-12 hr; half-life 2½ hr; metabolized in liver; excreted in urine, bile, feces as inactive metabolites; crosses placenta; excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x18191">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x18195">
						<item>
							<label>•</label>
							<para>May block clindamycin effect: erythromycin, chloramphenicol</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade—neuromuscular blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—kaolin</para>
				<section type="none" id="sidelem4x18209">
					<section type="none" id="sidelem4x18210">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, bilirubin, CPK, AST, ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18217">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18220">
					<section type="none" id="sidelem4x18221">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x18229">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x18229">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> C&amp;S before product therapy; product may be given as soon as culture is taken</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18233">
								<item>
									<label>•</label>
									<para>VS, urine, stools, sputum</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18238">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT if on long-term therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18246">
							<para>
								<list id="lidelem4x18246">
									<item>
										<label>•</label>
										<para>B/P, pulse in patient receiving product parenterally
<bbw>
												<emphasis alert="lifethreat">Pseudomembranous colitis:</emphasis> bowel pattern before, during treatment; if severe diarrhea occurs, product should be discontinued, may occur several wk after therapy is terminated</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18259">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18267">
							<label>•</label>
							<sec_title>Serious skin reactions<route> Stevens-Johnson syndrome, exfoliative dermatitis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x18270">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18274">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased temperature, negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18280">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18285">
								<item>
									<label>•</label>
									<para>To take oral product with full glass of water; that antiperistaltic products may worsen diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18290">
								<item>
									<label>•</label>
									<para>About all aspects of product therapy; to complete entire course of medication to ensure organism death (10-14 days); culture may be taken after medication course completed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18296">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue; may indicate superinfection</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18301">
								<item>
									<label>•</label>
									<para>To take with food to reduce GI symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18309">
							<label>•</label>
							<sec_title>
								<route>To notify nurse or prescriber of diarrhea with pus, mucous</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>clindamycin (topical, vaginal)</mono_name>
			<info>
				<pronunciation>(klin-da-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x1833110">Cleocin</tradename>
					<tradename id="tnidelem4x183319">Cleocin-T</tradename>
					<tradename id="tnidelem4x183318">Clindacin-P</tradename>
					<tradename id="tnidelem4x183317">Clindagel</tradename>
					<tradename id="tnidelem4x183316">ClindaMax</tradename>
					<tradename id="tnidelem4x183315">
						<country code="CAN">Clindasol </country>
					</tradename>
					<tradename id="tnidelem4x183314">
						<country code="CAN">Clinda-T </country>
					</tradename>
					<tradename id="tnidelem4x183313">Clindesse</tradename>
					<tradename id="tnidelem4x183312">Clindets</tradename>
					<tradename id="tnidelem4x183311">
						<country code="CAN">Dalacin </country>
					</tradename>
					<tradename id="tnidelem4x183310">Evoclin</tradename>
				</tradenames>
				<class type="func"> Topical antiinfective</class>
				<class type="chem"> Lincosamide derivative</class>
			</info>
			<section type="actions" id="sidelem4x18350">
				<sec_title>Action:</sec_title>
				<para>Antibacterial activity results from inhibition of protein synthesis; bacteriostatic</para>
			</section>
			<section type="uses" id="sidelem4x18355">
				<sec_title>Uses:</sec_title>
				<para>For the treatment of acne vulgaris; treatment of bacterial vaginosis and anaerobic bacteria</para>
			</section>
			<section type="contra" id="sidelem4x18360">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or lincomycin, history of antibiotic-associated colitis or ulcerative colitis</para>
				<section type="none" id="sidelem4x18365">
					<section type="none" id="sidelem4x18366">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children &lt;12 yr</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18371">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18374">
					<section type="none" id="sidelem4x18375">
						<sec_title>Acne vulgaris</sec_title>
						<section type="none" id="sidelem4x18383">
							<label>•</label>
							<sec_title>Adult/adolescent<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x18383">
									<item>
										<label>•</label>
										<para> (gel, lotion, solution) Apply a thin film of 1% to affected areas bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18390">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr<route> TOP (foam)</route></sec_title>
							<para>
								<list id="lidelem4x18390">
									<item>
										<label>•</label>
										<para> Apply 1% topical foam to affected areas once daily; if there is no improvement after 6-8 weeks or if the condition worsens, discontinue treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18397">
							<label>•</label>
							<sec_title>
								<route>TOP</route>
							</sec_title>
							<para>
								<list id="lidelem4x18397">
									<item>
										<label>•</label>
										<para> (medicated pledgets) Use a pledget to apply a thin film to the affected area bid; more than one pledget may be used, but each pledget should be used only once and then discarded</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18401">
						<sec_title>Bacterial vaginosis and anaerobic bacteria</sec_title>
						<section type="none" id="sidelem4x18404">
							<sec_title>Nonpregnant adult/adolescent/postmenarchal females:</sec_title>
							<section type="none" id="sidelem4x18412">
								<label>•</label>
								<sec_title>Intravaginal cream</sec_title>
								<para>
									<list id="lidelem4x18412">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Intravaginal cream:</emphasis> one applicatorful (100 mg clindamycin/5 g cream) intravaginally, preferably at bedtime, for 3 or 7 consecutive days in nonpregnant women and for 7 consecutive days in pregnant women; clindesse is administered as a single dose at any time of the day</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18419">
								<label>•</label>
								<sec_title>Intravaginal ovules/suppositories</sec_title>
								<para>
									<list id="lidelem4x18419">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Intravaginal ovules/suppositories:</emphasis> as an alternative to first-line therapies, the CDC recommends one ovule (100 mg clindamycin) inserted intravaginally at bedtime for 3 days</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x18423">
						<sec_title>Available forms:</sec_title>
						<para> Topical gel, foam, lotion, pledget, solution 1%; vaginal cream 2%, vaginal suppositories 100 mg</para>
					</section>
					<section type="none" id="sidelem4x18428">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18431">
							<sec_title>Topical route:</sec_title>
							<para>
								<list id="lidelem4x18435">
									<item>
										<label>•</label>
										<para>Improvement occurs after 6 wk but can require 8-12 wk</para>
									</item>
									<item>
										<label>•</label>
										<para>Topical skin products are not for intravaginal therapy and are for external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
									<item>
										<label>•</label>
										<para>Wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18451">
						<sec_title>Cream/ointment/lotion:</sec_title>
						<para>
							<list id="lidelem4x18455">
								<item>
									<label>•</label>
									<para>Shake well before use (lotion); apply a thin film to the cleansed affected area; massage gently into affected areas</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18461">
							<sec_title>Foam formulations:</sec_title>
							<para>
								<list id="lidelem4x18465">
									<item>
										<label>•</label>
										<para>Do not dispense foam directly onto hands or face; the warmth of the skin will cause the foam to melt; instead, dispense desired amount directly into the cap or onto a cool surface; make sure enough foam is dispensed to cover the affected area(s); if the can feels warm or the foam seems runny, run the can under cold water; to apply, pick up small amounts of the foam with the fingertips and gently massage into the affected areas until the foam disappears</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18471">
							<sec_title>Solution formulations:</sec_title>
							<para>
								<list id="lidelem4x18475">
									<item>
										<label>•</label>
										<para>Shake well before use; apply a thin film to the cleansed affected area; massage gently into affected areas; if using a solution-soaked pledget, patient may use more than 1 pledget per application as needed to treat affected areas, but each pledget should be used only once and then discarded</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18481">
							<sec_title>Intravaginal route:</sec_title>
							<para>
								<list id="lidelem4x18485">
									<item>
										<label>•</label>
										<para>Only use dosage formulations specified for intravaginal use; intravaginal dosage forms are not for topical therapy; do not ingest</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18492">
							<sec_title>Suppository:</sec_title>
							<para>
								<list id="lidelem4x18496">
									<item>
										<label>•</label>
										<para>Unwrap vaginal ovule (suppository) before insertion; use applicator(s) supplied by the manufacturer</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18502">
							<sec_title>Cream:</sec_title>
							<para>
								<list id="lidelem4x18506">
									<item>
										<label>•</label>
										<para>Use applicator(s) supplied by the manufacturer</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18512">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18515">
					<section type="none" id="sidelem4x18516">
						<sec_title>GU:</sec_title>
						<para> Colitis, diarrhea, overgrowth, vaginitis, vaginal moniliasis, UTI</para>
					</section>
					<section type="none" id="sidelem4x18521">
						<sec_title>INTEG:</sec_title>
						<para> Redness, burning, dermatitis, rash, pruritus</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18526">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18529">
					<section type="none" id="sidelem4x18530">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x18541">
							<label>•</label>
							<sec_title>
								<route>Contact prescriber immediately if severe diarrhea, stomach cramps/pain, or bloody stools occur</route>
							</sec_title>
						</section>
						<para>
							<emphasis style="bold">Infection:</emphasis> Assess for number of lesions, severity in acne, itching in vaginosis</para>
					</section>
					<section type="none" id="sidelem4x18548">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18552">
								<item>
									<label>•</label>
									<para>Decreased lesions in acne, infection in vaginosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18558">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x18561">
							<sec_title>Topical route:</sec_title>
							<para>
								<list id="lidelem4x18565">
									<item>
										<label>•</label>
										<para>That improvement occurs after 6 wk but can require 8-12 wk</para>
									</item>
									<item>
										<label>•</label>
										<para>That topical skin products are not for intravaginal therapy and are for external use only; not to use skin products near the eyes, nose, or mouth</para>
									</item>
									<item>
										<label>•</label>
										<para>To wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18581">
							<sec_title>Cream/ointment/lotion:</sec_title>
							<section type="none" id="sidelem4x18589">
								<label>•</label>
								<sec_title>lotion</sec_title>
								<para>
									<list id="lidelem4x18589">
										<item>
											<label>•</label>
											<para>Shake well before use; <emphasis style="bold">lotion:</emphasis> apply a thin film to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x18594">
							<sec_title>Foam formulations:</sec_title>
							<para>
								<list id="lidelem4x18598">
									<item>
										<label>•</label>
										<para>Do not dispense foam directly onto hands or face; the warmth of the skin will cause the foam to melt; instead, dispense desired amount directly into the cap or onto a cool surface; make sure enough foam is dispensed to cover the affected area(s); if the can feels warm or the foam seems runny, run the can under cold water; to apply, pick up small amounts of the foam with the fingertips and gently into the affected areas until the foam disappears</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18604">
							<sec_title>Solution formulations:</sec_title>
							<para>
								<list id="lidelem4x18608">
									<item>
										<label>•</label>
										<para>Shake well before use; apply a thin film to the cleansed affected area; massage gently into affected areas; if using a solution-soaked pledget, patient may use more than one pledget per application as needed to treat affected areas, but each pledget should be used only once and then discarded</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18614">
							<sec_title>Intravaginal route:</sec_title>
							<para>
								<list id="lidelem4x18618">
									<item>
										<label>•</label>
										<para>Only use dosage formulations specified for intravaginal use; intravaginal dosage forms are not for topical therapy; do not ingest</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18624">
							<sec_title>Suppository:</sec_title>
							<para>
								<list id="lidelem4x18628">
									<item>
										<label>•</label>
										<para>Unwrap vaginal ovule (suppository) before insertion; use applicator(s) supplied by the manufacturer</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18634">
							<sec_title>Cream:</sec_title>
							<para>
								<list id="lidelem4x18638">
									<item>
										<label>•</label>
										<para>Use applicator(s) supplied by the manufacturer</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>clobetasol</mono_name>
			<info>
				<pronunciation>(kloe-bay′ta-sol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x186495">Clobex</tradename>
					<tradename id="tnidelem4x186494">Cormax</tradename>
					<tradename id="tnidelem4x186493">Olux</tradename>
					<tradename id="tnidelem4x186492">Olux-E</tradename>
					<tradename id="tnidelem4x186491">Temovate</tradename>
					<tradename id="tnidelem4x186490">Temovate-E</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, topical</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x18655">
				<sec_title>Action:</sec_title>
				<para>Crosses cell membrane to attach to receptors to decrease inflammation, itching</para>
			</section>
			<section type="uses" id="sidelem4x18660">
				<sec_title>Uses:</sec_title>
				<para>Inflammation/itching in corticosteroid-responsive dermatoses on the skin/scalp</para>
			</section>
			<section type="contra" id="sidelem4x18665">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, use of some preparations on face, axilla, groin; monotherapy for primary bacterial infections</para>
				<section type="none" id="sidelem4x18670">
					<section type="none" id="sidelem4x18671">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18676">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18684">
					<label>•</label>
					<sec_title>Adult<route> TOP</route></sec_title>
					<para>
						<list id="lidelem4x18684">
							<item>
								<label>•</label>
								<para> Apply to infected areas bid (shampoo: daily up to 4×/wk)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18689">
					<section type="none" id="sidelem4x18690">
						<sec_title>Available forms:</sec_title>
						<para> Gel, lotion, ointment, cream, shampoo, solution, spray, foam 0.05%</para>
					</section>
					<section type="none" id="sidelem4x18695">
						<sec_title>Administer</sec_title>
						<section type="none" id="sidelem4x18698">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x18704">
									<item>
										<para>
											<emphasis alert="nurse">Do not use with occlusive dressings</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18710">
									<item>
										<para>
											<emphasis alert="nurse">Treatment should be limited to 2 wk</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18718">
								<label>•</label>
								<sec_title>Cream/Ointment/Lotion</sec_title>
								<para>
									<list id="lidelem4x18718">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Ointment/Lotion:</emphasis> using gloves, apply sparingly in a thin film and rub gently into the cleansed, slightly moist affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18725">
								<label>•</label>
								<sec_title>Gel</sec_title>
								<para>
									<list id="lidelem4x18725">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gel:</emphasis> using gloves, apply sparingly in a thin film and rub gently into the cleansed, slightly moist affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18732">
								<label>•</label>
								<sec_title>Scalp foam</sec_title>
								<para>
									<list id="lidelem4x18732">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Scalp foam:</emphasis> invert can and dispense a small amount of foam onto a saucer or other cool surface; do not dispense directly onto hands; pick up small amounts of foam with fingers and gently massage into affected area until foam disappears; repeat until entire affected scalp area is treated</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18739">
								<label>•</label>
								<sec_title>Shampoo</sec_title>
								<para>
									<list id="lidelem4x18739">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Shampoo:</emphasis> apply onto dry scalp in thin film, leave lather on scalp for 15 min, rinse off</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18743">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18746">
					<section type="none" id="sidelem4x18747">
						<sec_title>GU:</sec_title>
						<para> Glycosuria</para>
					</section>
					<section type="none" id="sidelem4x18752">
						<sec_title>INTEG:</sec_title>
						<para> Burning, folliculitis, pruritus, dermatitis, irritation, erythema, hypertrichosis, acne</para>
					</section>
					<section type="none" id="sidelem4x18757">
						<sec_title>MISC:</sec_title>
						<para> Hyperglycemia, HPA axis suppression</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18762">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18765">
					<section type="none" id="sidelem4x18766">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18770">
								<item>
									<label>•</label>
									<para>Skin reactions: burning, pruritus, folliculitis, dermatitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18776">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18780">
								<item>
									<label>•</label>
									<para>Decreasing itching, inflammation on the skin, scalp</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18786">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x18789">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x18795">
									<item>
										<para>
											<emphasis alert="nurse">Do not use with occlusive dressings</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18801">
									<item>
										<para>
											<emphasis alert="nurse">Treatment should be limited to 2 wk</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18809">
								<label>•</label>
								<sec_title>Cream/Ointment/Lotion</sec_title>
								<para>
									<list id="lidelem4x18809">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Ointment/Lotion:</emphasis> to apply sparingly in a thin film and rub gently into the cleansed, affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18816">
								<label>•</label>
								<sec_title>Gel</sec_title>
								<para>
									<list id="lidelem4x18816">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gel:</emphasis> to apply sparingly in a thin film and rub gently into the cleansed, slightly moist affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18823">
								<label>•</label>
								<sec_title>Scalp foam</sec_title>
								<para>
									<list id="lidelem4x18823">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Scalp foam:</emphasis> to invert can and dispense a small amount of foam onto a saucer or other cool surface; not to dispense directly onto hands; to pick up small amounts of foam with fingers and gently massage into affected area until foam disappears; repeat until entire affected scalp area is treated</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>clomiPHENE (Rx)</mono_name>
			<info>
				<pronunciation>(kloe′mi-feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x188321">Clomid</tradename>
					<tradename id="tnidelem4x188320">Serophene</tradename>
				</tradenames>
				<class type="func"> Ovulation stimulant</class>
				<class type="chem"> Selective estrogen receptor modulator (SERM)</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x18842">
				<para>
					<confusion>
						<tradename id="tnidelem4x188420">clomiPHENE</tradename>
						<drug type="generic" refid="idelem4x188420">clomiPRAMINE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x18849">
				<sec_title>Action:</sec_title>
				<para>Increases LH, FSH release from the pituitary, which increases the maturation of the ovarian follicle, ovulation, and the development of the corpus luteum</para>
			</section>
			<section type="uses" id="sidelem4x18854">
				<sec_title>Uses:</sec_title>
				<para>Female infertility (ovulatory failure)</para>
				<section type="none" id="sidelem4x18859">
					<section type="none" id="sidelem4x18860">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Oligospermia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x18865">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), hypersensitivity, hepatic disease, undiagnosed uterine bleeding, uncontrolled thyroid or adrenal dysfunction, intracranial lesion, ovarian cysts, endometrial carcinoma</para>
				<section type="none" id="sidelem4x18870">
					<section type="none" id="sidelem4x18871">
						<sec_title>Precautions:</sec_title>
						<para> Hypertension, depression, seizures, diabetes mellitus, abnormal ovarian enlargement, ovarian hyperstimulation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18876">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18884">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x18884">
							<item>
								<label>•</label>
								<para> 50 mg/day × 5 days or 50 mg/day beginning on day 5 of menstrual cycle, may increase to 100 mg daily × 5 days with next cycle; may be repeated until conception occurs or max 6 cycles of therapy</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18889">
					<section type="none" id="sidelem4x18890">
						<sec_title>Oligospermia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18898">
							<label>•</label>
							<sec_title>Adult (men)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18898">
									<item>
										<label>•</label>
										<para> 25 mg/day × 25 days, then 5 days off cycle each mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18902">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg</para>
					</section>
					<section type="none" id="sidelem4x18907">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18911">
								<item>
									<label>•</label>
									<para>After discontinuing estrogen therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>At same time daily to maintain product level, without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid heat, moisture, light; store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18927">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18930">
					<section type="none" id="sidelem4x18931">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, depression,</emphasis> restlessness, anxiety, nervousness, fatigue, insomnia, dizziness, flushing</para>
					</section>
					<section type="none" id="sidelem4x18939">
						<sec_title>CV:</sec_title>
						<para> Vasomotor flushing, phlebitis, <emphasis style="bold">deep venous thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18946">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, diplopia, photophobia</para>
					</section>
					<section type="none" id="sidelem4x18951">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, constipation,</emphasis> abdominal pain, bloating, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18961">
						<sec_title>GU:</sec_title>
						<para> Polyuria, urinary frequency, <emphasis style="bold">birth defects, spontaneous abortions,</emphasis> multiple ovulation, breast pain, oliguria, abnormal uterine bleeding, ovarian cyst, hypertrophy of ovary, hot flashes</para>
					</section>
					<section type="none" id="sidelem4x18969">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, dermatitis,</emphasis> urticaria, alopecia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18977">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in feces</para>
			</section>
			<section type="interactions" id="sidelem4x18982">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x18985">
					<section type="none" id="sidelem4x18986">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> clomiPHENE effect—DHEA, black cohosh, chaste tree fruit</para>
					</section>
					<section type="none" id="sidelem4x18993">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> clomiPHENE effect—soy</para>
						<para>
							<emphasis alert="lifethreat">Drug/Lab Test</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19007">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19010">
					<section type="none" id="sidelem4x19011">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19015">
								<item>
									<label>•</label>
									<para>Verify infertility workup, pelvic exam</para>
								</item>
								<item>
									<label>•</label>
									<para>LFTs before therapy: AST, ALT, alk phos</para>
								</item>
								<item>
									<label>•</label>
									<para>Serum progesterone, urinary excretion of pregnanediol to identify occurrence of ovulation</para>
								</item>
								<item>
									<label>•</label>
									<para>Ovarian size, cervical condition by pelvic examination</para>
								</item>
								<item>
									<label>•</label>
									<para>Rule out endometrial carcinoma in women &gt;35 yr by endometrial biopsy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19041">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19045">
								<item>
									<label>•</label>
									<para>Therapeutic response: fertility</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19051">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19056">
								<item>
									<label>•</label>
									<para>That multiple births are common</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19064">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately if low abdominal pain occurs; may indicate ovarian cyst, cyst rupture</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19070">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of photophobia, blurred vision, diplopia, abnormal bleeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19073">
								<item>
									<label>•</label>
									<para>That, if dose is missed, to double it next time; if more than one dose is missed, to call prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19078">
								<item>
									<label>•</label>
									<para>That response usually occurs 4-10 days after last day of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19083">
								<item>
									<label>•</label>
									<para>About the method for taking, recording basal body temperature to determine whether ovulation has occurred</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19088">
								<item>
									<label>•</label>
									<para>If ovulation can be determined (there is a slight decrease in temperature then a sharp increase with ovulation), to attempt coitus 3 days before and every other day until after ovulation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19096">
							<label>•</label>
							<sec_title>
								<route>If pregnancy is suspected, to notify prescriber immediately (X)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>clomiPRAMINE (Rx)</mono_name>
			<info>
				<pronunciation>(kloe-mip′ra-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x191040">Anafranil</tradename>
				</tradenames>
				<class type="func"> Antidepressant, tricyclic</class>
				<class type="chem"> Tertiary amine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x19114">
				<para>
					<confusion>
						<tradename id="tnidelem4x191140">clomiPRAMINE</tradename>
						<drug type="generic" refid="idelem4x191140">clomiPHENE/chlorproMAZINE/desipramine/Norpramin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x19118">
				<sec_title>Action:</sec_title>
				<para>Potentiates serotonin and norepinephrine; moderate anticholinergic effect</para>
			</section>
			<section type="uses" id="sidelem4x19123">
				<sec_title>Uses:</sec_title>
				<para>Obsessive-compulsive disorder</para>
				<section type="none" id="sidelem4x19128">
					<section type="none" id="sidelem4x19129">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Autism, depression, premature ejaculation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x19134">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, carBAMazepine, tricyclics, immediate post-MI, MAOI therapy</para>
				<section type="none" id="sidelem4x19139">
					<section type="none" id="sidelem4x19140">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, seizures, cardiac disease, glaucoma, prostatic hypertrophy, urinary retention</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19157">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19160">
					<section type="none" id="sidelem4x19161">
						<sec_title>Obsessive-compulsive disorder</sec_title>
						<section type="none" id="sidelem4x19169">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19169">
									<item>
										<label>•</label>
										<para> 25 mg at bedtime, increase gradually over 4 wk to 75-250 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19176">
							<label>•</label>
							<sec_title>Child 10-18 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19176">
									<item>
										<label>•</label>
										<para> 25 mg/day gradually increase over 2 wk; max 3 mg/kg/day or 200 mg/day, whichever is smaller</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19180">
						<sec_title>Autism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19188">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19188">
									<item>
										<label>•</label>
										<para> 25 mg/day, may increase to 75-100 mg/day, max 250 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19195">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19195">
									<item>
										<label>•</label>
										<para> 25 mg/day, may increase if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19199">
						<sec_title>Premature ejaculation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19207">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19207">
									<item>
										<label>•</label>
										<para> 25-50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19211">
						<sec_title>Depression (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19219">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19219">
									<item>
										<label>•</label>
										<para> 25 mg at bedtime and increase gradually over 4 wk to 75-250 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19226">
							<label>•</label>
							<sec_title>Child 10-18 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19226">
									<item>
										<label>•</label>
										<para> 25-50 mg/day gradually increased; max 3 mg/kg/day or 200 mg/day, whichever is smaller</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19230">
						<sec_title>Available forms:</sec_title>
						<para> Caps 25, 50, 75 mg</para>
					</section>
					<section type="none" id="sidelem4x19235">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x19239">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew caps</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation, especially for geriatric patients</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food, during initial dosing and titration give with meals</para>
								</item>
								<item>
									<label>•</label>
									<para>After titration, may be given as a single dose at bedtime to reduce daytime sedation</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container, at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19265">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19268">
					<section type="none" id="sidelem4x19269">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, tremors, mania,</emphasis><emphasis style="bold">seizures,</emphasis> aggressiveness, EPS, drowsiness, headache, <emphasis style="bold">neuroleptic malignant syndrome,</emphasis> insomnia, agitation, anxiety, impaired memory</para>
					</section>
					<section type="none" id="sidelem4x19282">
						<sec_title>CV:</sec_title>
						<para> Hypotension, tachycardia, <emphasis style="bold">cardiac arrest,</emphasis> hypertension, palpitations</para>
					</section>
					<section type="none" id="sidelem4x19290">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, altered taste, tinnitus, increased intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x19295">
						<sec_title>ENDO:</sec_title>
						<para> Galactorrhea, hyperprolactinemia</para>
					</section>
					<section type="none" id="sidelem4x19300">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, dry mouth, nausea, dyspepsia,</emphasis> weight gain, <emphasis style="bold">hepatic toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19310">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Delayed ejaculation, anorgasmia,</emphasis> urinary retention, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x19318">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, neutropenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19325">
						<sec_title>INTEG:</sec_title>
						<para> Diaphoresis, photosensitivity, abnormal skin order, flushing, rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x19330">
						<sec_title>META:</sec_title>
						<para> Hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x19335">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pharyngitis, rhinitis, bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19342">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Suicide in children, adolescents</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19349">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset ≥2 wk (depression), 4-10 wk (OCD); peak 2-6 hr; extensively bound to tissue and plasma proteins; demethylated in liver; active metabolites excreted in urine (50%-60%), feces (24%-32%); half-life 32 hr; steady state 1-2 wk</para>
			</section>
			<section type="interactions" id="sidelem4x19354">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: hypertensive crisis, seizures, hypertensive episode—MAOIs</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs serotonin syndrome, linezolid, methylene blue IV</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> clomiPRAMINE levels—cimetidine, FLUoxetine, fluvoxaMINE, sertraline; do not use together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypertensive effect—cloNIDine, EPINEPHrine, norepinephrine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> clomiPRAMINE level—CYP1A2, CYP2D6</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, CNS depressants, general anesthetics</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—other tricyclics, phenothiazines, quinolones, antidysrhythmics, droperidol, mefloquine, mesoridazine, moxifloxacin, pentamidine, pimozide, tacrolimus, ziprasidone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of cloNIDine, levodopa, skeletal muscle relaxants, haloperidol, opiates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clomiPRAMINE levels—barbiturates, carBAMazepine, phenytoin</para>
				<section type="none" id="sidelem4x19390">
					<section type="none" id="sidelem4x19391">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serotonin syndrome—St. John’s wort; do not use concurrently</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—hops, kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x19403">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> prolactin, TBG, AST, ALT, blood glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum thyroid hormone (T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19420">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19423">
					<section type="none" id="sidelem4x19424">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19429">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse q4hr; if systolic B/P drops 20 mm Hg, withhold product, notify prescriber; take VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19437">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> hyperpyrexia, rigidity, irregular pulse, diaphoresis</route></sec_title>
						</section>
						<section type="none" id="sidelem4x19443">
							<label>•</label>
							<sec_title>
								<route>ECG for flattening of T wave, QTc prolongation, bundle branch block, AV block, dysrhythmias in cardiac patients, may lead to cardiac collapse</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19446">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, leukocytes, differential, cardiac enzymes if patient is receiving long-term therapy and signs of blood dyscrasias</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19451">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin
<bbw>Mental status: mood, sensorium, affect, suicidal tendencies; increase in psychiatric symptoms: depression, panic, frequency of obsessive-compulsive behaviors; watch closely for evidence of suicidal thoughts in children, adolescents; seizure disorders</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19465">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation more likely in children</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19473">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x19473">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not usual unless product discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19477">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol consumed, withhold dose until <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19484">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy, since drowsiness, dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19489">
								<item>
									<label>•</label>
									<para>Gum, hard candy, or frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19494">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19498">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19504">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19509">
								<item>
									<label>•</label>
									<para>That the effects may take 4-6 wk to appear</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19514">
								<item>
									<label>•</label>
									<para>About risk for seizures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19519">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities that require alertness because drowsiness, dizziness, blurred vision may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19524">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19529">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use because this may cause nausea, headache, malaise
<bbw>That suicidal thoughts/behaviors may occur in children, young adults; report immediately</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19543">
								<item>
									<label>•</label>
									<para>To wear sunscreen, protective clothing to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19548">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned, suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19553">
								<item>
									<label>•</label>
									<para>That men may experience a high incidence of sexual dysfunction</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19561">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> report immediately sweating, diarrhea, twitching</route></sec_title>
						</section>
						<section type="none" id="sidelem4x19567">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> do not stop abruptly</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active" ha="yes">
			<mono_name>clonazePAM (Rx)</mono_name>
			<info>
				<pronunciation>(kloe-na′zi-pam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x195821">KlonoPIN</tradename>
					<tradename id="tnidelem4x195820">
						<country code="CAN">Rivotril</country>
					</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> Benzodiazepine derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x19596">
				<para>
					<confusion>
						<tradename id="tnidelem4x195960">clonazePAM</tradename>
						<drug type="generic" refid="idelem4x195960">LORazepam/clorazepate/cloNIDine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x19604">
				<sec_title>Action:</sec_title>
				<para>Inhibits spike, wave formation during absence seizures (petit mal); decreases amplitude, frequency, duration, spread of discharge during minor motor seizures</para>
			</section>
			<section type="uses" id="sidelem4x19609">
				<sec_title>Uses:</sec_title>
				<para>Absence, atypical absence, akinetic, myoclonic seizures; Lennox-Gastaut syndrome, panic disorder</para>
				<section type="none" id="sidelem4x19614">
					<section type="none" id="sidelem4x19615">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Anxiety, insomnia, nystagmus, restless leg syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x19620">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to benzodiazepines, acute closed-angle glaucoma, psychosis, severe hepatic disease</para>
				<section type="none" id="sidelem4x19625">
					<section type="none" id="sidelem4x19626">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, geriatric patients, open-angle glaucoma, chronic respiratory disease, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19631">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19634">
					<section type="none" id="sidelem4x19635">
						<sec_title>Lennox-Gastaut syndrome/atypicals absence seizures/akinetic and myclonic seizures</sec_title>
						<section type="none" id="sidelem4x19643">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19643">
									<item>
										<label>•</label>
										<para> up to 1.5 mg/day in 3 divided doses; may be increased 0.5-1 mg q3days until desired response, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19650">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19650">
									<item>
										<label>•</label>
										<para> 0.25 daily-bid initially, increase by 0.25/day q7-14days as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19657">
							<label>•</label>
							<sec_title>Child &lt;10 yr or &lt;30 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19657">
									<item>
										<label>•</label>
										<para> initial 0.01-0.03 mg/kg/day in divided doses q8hr, max 0.05 mg/kg/day; may be increased 0.25-0.5 mg q3days until desired response, max 0.1-0.2 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19661">
						<sec_title>Panic disorder</sec_title>
						<section type="none" id="sidelem4x19669">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19669">
									<item>
										<label>•</label>
										<para> 0.25 mg bid increase to 1 mg daily after 3 days, max 4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19673">
						<sec_title>Restless leg syndrome (RLS) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19681">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19681">
									<item>
										<label>•</label>
										<para> 0.5 mg tid or 0.5 mg in the evening and 30 min before bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19685">
						<sec_title>Insomnia/anxiety (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19693">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19693">
									<item>
										<label>•</label>
										<para> 0.125-0.25 mg at bedtime, titrate up q3-4days as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19697">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1, 2 mg; orally disintegrating tabs 0.125, 0.25, 0.5, 1, 2 mg</para>
					</section>
					<section type="none" id="sidelem4x19702">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19705">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19710">
									<item>
										<label>•</label>
										<para>With food, milk for GI symptoms</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x19718">
								<label>•</label>
								<sec_title>Orally disintegrating tablets</sec_title>
								<para>
									<list id="lidelem4x19718">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Orally disintegrating tablets:</emphasis> open pouch by peeling back foil on blister pack (do not push tab through foil), place on tongue, allow to dissolve; may be swallowed with/without water</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x19722">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19727">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19730">
					<section type="none" id="sidelem4x19731">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness,</emphasis> dizziness, confusion, behavioral changes, tremors, insomnia, headache, <emphasis style="bold">suicidal tendencies,</emphasis> slurred speech, anterograde amnesia, fatigue, poor coordination</para>
					</section>
					<section type="none" id="sidelem4x19742">
						<sec_title>CV:</sec_title>
						<para> Palpitations, bradycardia, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x19747">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Increased salivation, nystagmus, diplopia,</emphasis> abnormal eye movements</para>
					</section>
					<section type="none" id="sidelem4x19755">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, constipation,</emphasis> polyphagia, anorexia, xerostomia, diarrhea, gastritis, sore gums, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x19763">
						<sec_title>GU:</sec_title>
						<para> Dysuria, enuresis, nocturia, retention, libido changes</para>
					</section>
					<section type="none" id="sidelem4x19768">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukocytosis, eosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19775">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia, hirsutism</para>
					</section>
					<section type="none" id="sidelem4x19780">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression,</emphasis> dyspnea, congestion</para>
					</section>
					<section type="none" id="sidelem4x19788">
						<sec_title>MS:</sec_title>
						<para> myalgia, muscle weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19793">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x19796">
					<section type="none" id="sidelem4x19797">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr, metabolized by liver, excreted in urine, half-life 18-50 hr, duration 6-12 hr, protein binding 85%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x19802">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> clonazePAM effects—CYP3A4 inhibitors (azoles, cimetidine, clarithromycin, diltiazem, erythromycin, FLUoxetine), oral contraceptives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, barbiturates, opiates, antidepressants, other anticonvulsants, general anesthetics, hypnotics, sedatives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clonazePAM effect—CYP3A4 inducers (carBAMazepine, PHENobarbital, phenytoin)</para>
				<section type="none" id="sidelem4x19817">
					<section type="none" id="sidelem4x19818">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, chamomile, valerian</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> clonazePAM effect—ginkgo, melatonin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> clonazePAM effect—ginseng, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x19834">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, alk phos, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19845">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19848">
					<section type="none" id="sidelem4x19849">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x19857">
							<label>•</label>
							<sec_title>Seizures<route> duration, type, intensity, with/without aura</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19860">
								<item>
									<label>•</label>
									<para>Blood studies: RBC, Hct, Hgb, reticulocyte counts every wk for 4 wk, then monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19865">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin, creatinine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19873">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> do not discontinue abruptly; seizures may increase</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19876">
								<item>
									<label>•</label>
									<para>Signs of physical withdrawal if medication suddenly discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19882">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, oversedation, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19887">
								<item>
									<label>•</label>
									<para>Eye problems: need for ophthalmic exam before, during, after treatment (slit lamp, funduscopy, tonometry)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19895">
							<label>•</label>
							<sec_title>Allergic reaction<route> red, raised rash; product should be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19899">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: fever, sore throat, bruising, rash, jaundice</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19907">
							<label>•</label>
							<sec_title>Toxicity<route> bone marrow depression, nausea, vomiting, ataxia, diplopia, CV collapse; drug levels during initial treatment (therapeutic 20-80 ng/ml)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19910">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during early part of treatment; dizziness occurs, especially among geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19915">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19919">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19925">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19930">
								<item>
									<label>•</label>
									<para>To carry emergency ID bracelet stating name, products taken, condition; prescriber’s name, phone number, discuss tolerance, withdrawal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19935">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19940">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants; increased sedation may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19948">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication quickly after long-term use; to taper off over several wk</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19954">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of yellowing of skin/eyes, clay-colored stools, bleeding, fever, extreme fatigue, sore throat, suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>cloNIDine (Rx)</mono_name>
			<info>
				<pronunciation>(klon′i-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x199673">Catapres</tradename>
					<tradename id="tnidelem4x199672">Catapres-TTS</tradename>
					<tradename id="tnidelem4x199671">Duraclon</tradename>
					<tradename id="tnidelem4x199670">Kapvay</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Central α-adrenergic agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x19977">
				<para>
					<confusion>
						<tradename id="tnidelem4x199770">cloNIDine</tradename>
						<drug type="generic" refid="idelem4x199770">KlonoPIN/clonazePAM</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x19984">
				<sec_title>Action:</sec_title>
				<para>Inhibits sympathetic vasomotor center in CNS, which reduces impulses in sympathetic nervous system; blood pressure, pulse rate, cardiac output decrease, prevents pain signal transmission in CNS by α-adrenergic receptor stimulation of the spinal cord</para>
			</section>
			<section type="uses" id="sidelem4x19989">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension, used alone or in combination; severe pain in cancer patients (epidural), attention-deficit/hyperactivity disorder (ADHD)</para>
				<section type="none" id="sidelem4x19994">
					<section type="none" id="sidelem4x19995">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Opioid withdrawal, prevention of vascular headaches, treatment of menopausal symptoms, dysmenorrhea, autism, cycloSPORINE nephrotoxicity prophylaxis, diabetic neuropathy, ethanol/nicotine/opiate agonist withdrawal, Tourette’s syndrome, hypertensive emergency, neonatal abstinence syndrome, scleroderma renal crisis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x20000">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; (epidural) bleeding disorders, anticoagulants</para>
				<section type="none" id="sidelem4x20006">
					<section type="none" id="sidelem4x20007">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr (transdermal), geriatric patients, noncompliant patients, MI (recent), diabetes mellitus, chronic renal failure, Raynaud’s disease, thyroid disease, depression, COPD, asthma, pheochromocytoma</para>
						<para>
							<bbw>Labor (epidermal clonidine)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20022">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20025">
					<section type="none" id="sidelem4x20026">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x20034">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20034">
									<item>
										<label>•</label>
										<para> 0.1 mg bid then increase by 0.1-0.2 mg/day at weekly intervals until desired response; max 2.4 mg; range 0.2-0.6 mg/day in divided doses or  q7days, start 0.1 mg and adjust q1-2wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20044">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20044">
									<item>
										<label>•</label>
										<para> 0.1 mg at bedtime; may increase gradually</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20051">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20051">
									<item>
										<label>•</label>
										<para> 5-10 mcg/kg/day in divided doses q8-12hr, max 0.9 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20055">
						<sec_title>Severe pain</sec_title>
						<section type="none" id="sidelem4x20063">
							<label>•</label>
							<sec_title>Adult<route> CONT EPIDURAL INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x20063">
									<item>
										<label>•</label>
										<para> 30 mcg/hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20070">
							<label>•</label>
							<sec_title>Child<route> CONT EPIDURAL INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x20070">
									<item>
										<label>•</label>
										<para> 0.5 mcg/kg/hr, then titrate to response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20074">
						<sec_title>Opioid withdrawal (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20082">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20082">
									<item>
										<label>•</label>
										<para> 0.3-1.2 mg/day; may decrease by 50% × 3 days, then decrease by 0.1-0.2 mg/day or discontinue</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20086">
						<sec_title>ADHD</sec_title>
						<section type="none" id="sidelem4x20094">
							<label>•</label>
							<sec_title>Adolescent/child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20094">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg/day in 3-4 divided doses may increase in 0.1 mg/day weekly up to 0.4 mg/day; ext rel 0.1 mg at bedtime, increase dose by 0.1 mg/day up to 0.4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20098">
						<sec_title>Menopausal symptoms (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20106">
							<label>•</label>
							<sec_title>Adult<route> TRANSDERMAL</route></sec_title>
							<para>
								<list id="lidelem4x20106">
									<item>
										<label>•</label>
										<para> 0.1-mg patch q1wk;  0.05-0.4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20113">
						<sec_title>Tourette’s syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20121">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20121">
									<item>
										<label>•</label>
										<para> 0.15-0.2 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20125">
						<sec_title>Hypertensive emergency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20133">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20133">
									<item>
										<label>•</label>
										<para> 0.1-0.2 mg q1hr to a total of 0.6 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20137">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.025 <country code="CAN">FIX_STRUCTURE Tabs 0.025 </country>, 0.1, 0.2, 0.3 mg; transdermal 2.5, 5, 7.5 mg delivering 0.1, 0.2, 0.3 mg/24 hr, respectively; inj 100, 500 mcg/ml; ext rel tab 0.1 mg (Kapvay)</para>
					</section>
					<section type="none" id="sidelem4x20145">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20149">
								<item>
									<label>•</label>
									<para>Store patches in cool environment, tablets in tight container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20155">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x20159">
									<item>
										<label>•</label>
										<para>Give last dose at bedtime</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not crush, cut, chew, or break ext rel tabs; Kapvay is not interchangeable with other products</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20170">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x20174">
									<item>
										<label>•</label>
										<para>Once weekly; apply to site without hair; best absorption over chest or upper arm; rotate sites with each application; clean site before application; apply firmly, especially around edges; may secure with adhesive tape if loosen, fold sticky sides together and discard</para>
									</item>
									<item>
										<label>•</label>
										<para>Should be removed before MRI</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20185">
							<sec_title>Epidural route</sec_title>
							<para>
								<list id="lidelem4x20189">
									<item>
										<label>•</label>
										<para>Used for severe cancer pain</para>
									</item>
									<item>
										<label>•</label>
										<para>May be used with opiates</para>
									</item>
									<item>
										<label>•</label>
										<para>Use only if familiar with epidural infusion devices
<bbw>Do not use for labor</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20214">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20217">
					<section type="none" id="sidelem4x20218">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, sedation, headache, fatigue,</emphasis> nightmares, insomnia, mental changes, anxiety, depression, hallucinations, delirium, syncope, dizziness</para>
					</section>
					<section type="none" id="sidelem4x20226">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension, palpitations,</emphasis><emphasis style="bold">CHF,</emphasis> ECG abnormalities, sinus tachycardia</para>
					</section>
					<section type="none" id="sidelem4x20236">
						<sec_title>EENT:</sec_title>
						<para> Taste change, parotid pain</para>
					</section>
					<section type="none" id="sidelem4x20241">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x20246">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, malaise,</emphasis> constipation, <emphasis style="italic">dry mouth</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20256">
						<sec_title>GU:</sec_title>
						<para> Impotence, dysuria, nocturia, gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x20261">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> alopecia, facial pallor, pruritus, hives, edema, burning papules, excoriation (transdermal patches)</para>
					</section>
					<section type="none" id="sidelem4x20269">
						<sec_title>MISC:</sec_title>
						<para> Withdrawal symptoms</para>
					</section>
					<section type="none" id="sidelem4x20274">
						<sec_title>MS:</sec_title>
						<para> Muscle, joint pain; leg cramps</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20279">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorbed well</para>
				<section type="none" id="sidelem4x20284">
					<section type="none" id="sidelem4x20285">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> to 1 hr, peak 2-4 hr, duration 8-12 hr, half-life 6-12 hr</para>
					</section>
					<section type="none" id="sidelem4x20297">
						<sec_title>TRANSDERMAL:</sec_title>
						<para> Onset 3 days; duration 1 wk; metabolized by liver (metabolites); excreted in urine (45% unchanged, inactive metabolites), feces; crosses blood-brain barrier; excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x20302">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x20310">
					<label>•</label>
					<sec_title>AV block<route> verapamil, diltiazem</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x20314">
						<item>
							<para>
								<emphasis alert="nurse">Life-threatening elevations of B/P: tricyclics, β-blockers</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—opiates, sedatives, hypnotics, anesthetics, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effects—diuretics, other antihypertensive nitrates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypotensive effects—tricyclics, MAOIs, appetite suppressants, amphetamines, prazosin, antipsychotics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of levodopa</para>
				<section type="none" id="sidelem4x20335">
					<section type="none" id="sidelem4x20336">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra, ginseng</para>
					</section>
					<section type="none" id="sidelem4x20347">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> blood glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA, urinary catecholamines, aldosterone</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20358">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20361">
					<section type="none" id="sidelem4x20362">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x20370">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x20370">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse; report significant changes</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20377">
							<label>•</label>
							<sec_title>Opiate withdrawal (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x20377">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Opiate withdrawal (unlabeled):</emphasis> fever, diarrhea, nausea, vomiting, cramps, insomnia, shivering, dilated pupils</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20384">
							<label>•</label>
							<sec_title>Cancer pain</sec_title>
							<para>
								<list id="lidelem4x20384">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cancer pain:</emphasis> location, intensity, character; alleviating, aggravating factors at baseline and frequently</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20388">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily; monitor I&amp;O; check for falling output</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20396">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x20396">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, fever, pruritus, urticaria; product should be discontinued if antihistamines fail to help</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20403">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x20403">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema, dyspnea, wet crackles, B/P, more common in geriatric patients</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20410">
							<label>•</label>
							<sec_title>ADHD</sec_title>
							<para>
								<list id="lidelem4x20410">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">ADHD:</emphasis> B/P, pulse, palpitations, syncope</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20414">
								<item>
									<label>•</label>
									<para>Renal symptoms: polyuria, oliguria, frequency</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20419">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20423">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P with hypertension, decrease in withdrawal symptoms (opioid), decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20429">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20434">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities, since product may cause drowsiness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20439">
								<item>
									<label>•</label>
									<para>To notify all health care providers of medication use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20447">
							<label>•</label>
							<sec_title>Not to discontinue product abruptly or withdrawal symptoms may occur<route> anxiety, increased B/P, headache, insomnia, increased pulse, tremors, nausea, sweating; to comply with dosage schedule even if feeling better</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x20450">
								<item>
									<label>•</label>
									<para>Not to use OTC (cough, cold, or allergy), alcohol or CNS depressant products unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20455">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20463">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, signs of angioedema</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x20466">
								<item>
									<label>•</label>
									<para>About excessive perspiration, dehydration, vomiting; diarrhea may lead to fall in B/P; consult prescriber if these occur; that product may cause dizziness, fainting; that light-headedness may occur during first few days of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20471">
								<item>
									<label>•</label>
									<para>That product may cause dry mouth; to use hard candy, saliva product, sugarless gum, or frequent rinsing of mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20476">
								<item>
									<label>•</label>
									<para>That compliance is necessary; not to skip or stop product unless directed by prescriber; tolerance may develop with long-term use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20484">
							<label>•</label>
							<sec_title>Transdermal</sec_title>
							<para>
								<list id="lidelem4x20484">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Transdermal:</emphasis> how to use patch; that patch comes in two parts: product patch and overlay to keep patch in place; not to trim or cut patch; that response may take 2-3 days if product is given transdermally; on administration of patch, if switching from tabs to patch, to taper tabs to avoid withdrawal, remove for MRI, can use during bathing, swimming</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>clopidogrel (Rx)</mono_name>
			<info>
				<pronunciation>(klo-pid′oh-grel)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x204990">Plavix</tradename>
				</tradenames>
				<class type="func"> Platelet aggregation inhibitor</class>
				<class type="chem"> Thienopyridine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x20509">
				<para>
					<confusion>
						<tradename id="tnidelem4x205090">Plavix</tradename>
						<drug type="generic" refid="idelem4x205090">Paxil/Elavil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x20513">
				<sec_title>Action:</sec_title>
				<para>Inhibits ADP-induced platelet aggregation</para>
			</section>
			<section type="uses" id="sidelem4x20518">
				<sec_title>Uses:</sec_title>
				<para>Reducing the risk of stroke, MI, vascular death, peripheral arterial disease in high-risk patients, acute coronary syndrome, transient ischemic attack (TIA), unstable angina</para>
				<section type="none" id="sidelem4x20523">
					<section type="none" id="sidelem4x20524">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cardiac surgery (infant and child), Kawasaki disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x20529">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active bleeding</para>
				<section type="none" id="sidelem4x20534">
					<section type="none" id="sidelem4x20535">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, previous hepatic disease, increased bleeding risk, neutropenia, agranulocytosis, renal disease, Asian/Black/Caucasian patients</para>
						<para>
							<bbw>CYP2C19 allele (poor metabolizers)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20550">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20553">
					<section type="none" id="sidelem4x20554">
						<sec_title>Recent MI, stroke, peripheral arterial disease, TIA</sec_title>
						<section type="none" id="sidelem4x20562">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20562">
									<item>
										<label>•</label>
										<para> 75 mg/day with/without aspirin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20566">
						<sec_title>Acute coronary syndrome</sec_title>
						<section type="none" id="sidelem4x20574">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20574">
									<item>
										<label>•</label>
										<para> loading dose 300 mg, then 75 mg/day with aspirin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20578">
						<sec_title>Cardiac surgery/other cardiac conditions (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20586">
							<label>•</label>
							<sec_title>Child ≤2 yr, infant, neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20586">
									<item>
										<label>•</label>
										<para> 0.2 mg/kg/day for platelet inhibition</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20590">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 75, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x20595">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20599">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Should be discontinued 5 days before elective surgery if an antiplatelet action is not desired</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20610">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20613">
					<section type="none" id="sidelem4x20614">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, depression, syncope, hypesthesia, neuralgia, confusion, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x20619">
						<sec_title>CV:</sec_title>
						<para> Edema, hypertension, chest pain</para>
					</section>
					<section type="none" id="sidelem4x20624">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, constipation, GI discomfort, <emphasis style="bold">GI bleeding, pancreatitis, hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20631">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Glomerulonephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20638">
						<sec_title>HEMA:</sec_title>
						<para> Epistaxis, purpura, <emphasis style="bold">bleeding (major/minor from any site), neutropenia, aplastic anemia, agranulocytosis, thrombotic thrombocytopenic purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20645">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20652">
						<sec_title>MISC:</sec_title>
						<para> UTI, hypercholesterolemia, chest pain, fatigue, <emphasis style="bold">intracranial hemorrhage, toxic epidermal necrolysis, Stevens-Johnson syndrome,</emphasis> flulike syndrome</para>
					</section>
					<section type="none" id="sidelem4x20660">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x20665">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory tract infection, dyspnea, rhinitis, bronchitis, cough, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20672">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; metabolized by liver (CYP3A4, CYP2B6, CYP1A2, CYP2C8); excreted in urine, feces; half-life 6 hr; plasma protein binding 95%; effect on platelets after 3-7 days</para>
			</section>
			<section type="interactions" id="sidelem4x20677">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>Avoid use with CYP2C19 inhibitors (omeprazole, esomeprazole)</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, aspirin, NSAIDs, abciximab, eptifibatide, tirofiban, thrombolytics, ticlopidine, SSRIs, treprostinil, rifampin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of some NSAIDs, phenytoin, TOLBUTamide, tamoxifen, torsemide, fluvastatin, warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clopidogrel effect—proton pump inhibitor (PPIs)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> CYP3A4 inhibitors/substrates —atorvastatin, simvastatin, cerivastatin</para>
				<section type="none" id="sidelem4x20707">
					<section type="none" id="sidelem4x20708">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> clopidogrel effect—feverfew, fish oil, omega-3 fatty acid, garlic, ginger, ginkgo biloba, green tea, horse chestnut</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> clopidogrel effect—bilberry, saw palmetto</para>
					</section>
					<section type="none" id="sidelem4x20719">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, bilirubin, uric acid, total cholesterol, nonprotein nitrogen (NPN)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20726">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20729">
					<section type="none" id="sidelem4x20730">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="nurse">Thrombotic/thrombocytic purpura, fever, thrombocytopenia, neurolytic anemia</emphasis>
						</para>
						<para>
							<bbw>CYP2C19 Allele (poor metabolizers): Consider using another antiplatelet product, higher CV reaction occurs after acute coronary syndrome or PCI, tests are available to determine CYP2C19 allele</bbw>
						</para>
						<para>
							<list id="lidelem4x20748">
								<item>
									<label>•</label>
									<para>Symptoms of stroke, MI during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine (long-term therapy)</para>
								</item>
								<item>
									<label>•</label>
									<para>Blood studies: CBC, differential, Hct, Hgb, PT, cholesterol (long-term therapy)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20764">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20768">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of stroke, MI</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20774">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20779">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20787">
							<label>•</label>
							<sec_title>
								<route>To report any unusual bruising, bleeding to prescriber; that it may take longer to stop bleeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x20790">
								<item>
									<label>•</label>
									<para>To take without regard to food</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20798">
							<label>•</label>
							<sec_title>
								<route>To report diarrhea, skin rashes, subcutaneous bleeding, chills, fever, sore throat</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x20801">
								<item>
									<label>•</label>
									<para>To tell all health care providers that clopidogrel is being used; may be held for 5 days before surgery</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active">
			<mono_name>clotrimazole (topical, vaginal, oral)</mono_name>
			<info>
				<pronunciation>(kloe-trim′a-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x208117">Cruex</tradename>
					<tradename id="tnidelem4x208116">Gyne-Lotrimin</tradename>
					<tradename id="tnidelem4x208115">Lotrimin</tradename>
					<tradename id="tnidelem4x208114">Lotrimin AF</tradename>
					<tradename id="tnidelem4x208113">MyCelex</tradename>
					<tradename id="tnidelem4x208112">MyCelex-7</tradename>
					<tradename id="tnidelem4x208111">Trivagizole 3</tradename>
					<tradename id="tnidelem4x208110">Desenex</tradename>
				</tradenames>
				<class type="func"> Topical antifungal</class>
				<class type="chem"> Imidazole derivative</class>
			</info>
			<section type="confusion" id="sidelem4x20821">
				<para>
					<confusion>
						<tradename id="tnidelem4x208210">clotrimazole</tradename>
						<drug type="generic" refid="idelem4x208210">miconazole/clobetasol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x20825">
				<sec_title>Action:</sec_title>
				<para>Antifungal activity results from altering cell wall permeability</para>
			</section>
			<section type="uses" id="sidelem4x20830">
				<sec_title>Uses:</sec_title>
				<para>Vulvovaginal, oropharyngeal candidiasis; topical fungal infections</para>
			</section>
			<section type="contra" id="sidelem4x20835">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, ophthalmic use</para>
				<section type="none" id="sidelem4x20840">
					<section type="none" id="sidelem4x20841">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic impairment (oral)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20846">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20849">
					<section type="none" id="sidelem4x20850">
						<sec_title>Tinea corporis, cruris, pedis, versicolor; candidiasis</sec_title>
						<section type="none" id="sidelem4x20858">
							<label>•</label>
							<sec_title>Adult/child ≥2 yr</sec_title>
							<para>
								<list id="lidelem4x20858">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/child ≥2 yr:</emphasis> Apply to affected area and rub into area <emphasis style="smallcaps">am</emphasis>/<emphasis style="smallcaps">pm</emphasis> × 2-4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20868">
						<sec_title>Vulvovaginal candidiasis</sec_title>
						<section type="none" id="sidelem4x20876">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> Vag cream</route></sec_title>
							<para>
								<list id="lidelem4x20876">
									<item>
										<label>•</label>
										<para> 1 applicator at bedtime × 3 days (2%) or 7 days (1%)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20880">
						<sec_title>Oropharyngeal candidiasis</sec_title>
						<section type="none" id="sidelem4x20888">
							<label>•</label>
							<sec_title>Adult/child ≥3 yr<route> Lozenge</route></sec_title>
							<para>
								<list id="lidelem4x20888">
									<item>
										<label>•</label>
										<para> 1 PO dissolved 5×/day × 2 wk or adults 1 lozenge dissolved tid (prevention)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20892">
						<sec_title>Available forms:</sec_title>
						<para> Topical cream, solution, 1%; vaginal cream 1%, 2%; lozenges, troches 10 mg</para>
					</section>
					<section type="none" id="sidelem4x20897">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x20900">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x20905">
									<item>
										<label>•</label>
										<para>Topical skin products are not for intravaginal therapy and are for external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x20910">
									<item>
										<label>•</label>
										<para>Wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x20919">
								<label>•</label>
								<sec_title>Cream/solution</sec_title>
								<para>
									<list id="lidelem4x20919">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/solution:</emphasis> apply to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x20926">
								<label>•</label>
								<sec_title>Troches</sec_title>
								<para>
									<list id="lidelem4x20926">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Troches:</emphasis> allow to dissolve; do not chew or swallow whole</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x20930">
							<sec_title>Intravaginal route</sec_title>
							<para>
								<list id="lidelem4x20935">
									<item>
										<label>•</label>
										<para>Only use dosage formulations specified for intravaginal use; intravaginal dosage forms are not for topical therapy; do not ingest</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x20943">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x20943">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20947">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20950">
					<section type="none" id="sidelem4x20951">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x20956">
						<sec_title>GU:</sec_title>
						<para> Vaginal burning, irritation</para>
					</section>
					<section type="none" id="sidelem4x20961">
						<sec_title>INTEG:</sec_title>
						<para> Burning, peeling, rash, pruritus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20966">
				<sec_title>Pharmacokinetics</sec_title>
				<para>PO duration 3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x20971">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x20974">
					<section type="none" id="sidelem4x20975">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20982">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20985">
					<section type="none" id="sidelem4x20986">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x20994">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x20994">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> assess for hypersensitivity; product might need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21001">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x21001">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> assess for severity of infection, itching</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21005">
								<item>
									<label>•</label>
									<para>Hepatic function studies periodically if using oral troches</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21010">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x21014">
								<item>
									<label>•</label>
									<para>Decreased infection, itching</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21020">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x21023">
							<sec_title>Topical route:</sec_title>
							<para>
								<list id="lidelem4x21028">
									<item>
										<label>•</label>
										<para>That topical skin products are not for intravaginal therapy and are for external use only; do not use skin products near the eyes, nose, or mouth; do not use occlusive dressings</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x21033">
									<item>
										<label>•</label>
										<para>To wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x21041">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x21041">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> to shake well before use; apply a thin film to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x21045">
							<sec_title>PO route:</sec_title>
							<section type="none" id="sidelem4x21053">
								<label>•</label>
								<sec_title>
									<route>Troches</route>
								</sec_title>
								<para>
									<list id="lidelem4x21053">
										<item>
											<label>•</label>
											<para>: allow to dissolve; do not chew or swallow whole</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x21065">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x21065">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> to use applicator(s) supplied by the manufacturer</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>cloZAPine (Rx)</mono_name>
			<info>
				<pronunciation>(kloz′a-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x210742">Clozaril</tradename>
					<tradename id="tnidelem4x210741">FazaClo</tradename>
					<tradename id="tnidelem4x210740">Versacloz</tradename>
				</tradenames>
				<class type="func"> Antipsychotic</class>
				<class type="chem"> Tricyclic dibenzodiazepine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x21084">
				<para>
					<confusion>
						<tradename id="tnidelem4x210840">Clozaril</tradename>
						<drug type="generic" refid="idelem4x210840">Colazal cloZAPine/cloNIDine/clofazimine/clonazePAM/Klonopin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x21088">
				<sec_title>Action:</sec_title>
				<para>Interferes with DOPamine receptor binding with lack of EPS; also acts as an adrenergic, cholinergic, histaminergic, serotonergic antagonist</para>
			</section>
			<section type="uses" id="sidelem4x21093">
				<sec_title>Uses:</sec_title>
				<para>Management of psychotic symptoms for schizophrenic patients for whom other antipsychotics have failed; recurrent suicidal behavior</para>
				<section type="none" id="sidelem4x21098">
					<section type="none" id="sidelem4x21099">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Agitation, bipolar disorder, psychosis in dementia, psychosis in Parkinson’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x21104">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe granulocytopenia (WBC &lt;3500 before therapy), coma</para>
				<para>
					<bbw>Myeloproliferative disorders, severe CNS depression, agranulocytosis, leukopenia, neutropenia, seizure disorder</bbw>
				</para>
				<section type="none" id="sidelem4x21119">
					<section type="none" id="sidelem4x21120">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;16 yr, geriatric patients; CV, pulmonary, cardiac, renal, hepatic disease; seizures, prostatic enlargement, closed-angle glaucoma, stroke</para>
						<para>
							<bbw>Bone marrow suppression, hypotension, myocarditis, orthostatic hypotension, geriatric patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x21136">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21139">
					<section type="none" id="sidelem4x21140">
						<sec_title>Schizophrenia</sec_title>
						<section type="none" id="sidelem4x21148">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21148">
									<item>
										<label>•</label>
										<para> 12.5 mg daily or bid; may increase by 25-50 mg/day; normal range 300-450 mg/day after 2 wk; dose &gt;500 mg require 3 divided doses; do not increase dose more than 2×/wk; max 900 mg/day; use lowest dose to control symptoms; if dose is to be discontinued, taper over 1-2 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21155">
							<label>•</label>
							<sec_title>Child ≥9 yr, adolescents (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21155">
									<item>
										<label>•</label>
										<para> 6.25-12.5 mg initially slowly titrate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21159">
						<sec_title>Dementia with multiple behavioral disturbances (unlabeled)</sec_title>
						<section type="none" id="sidelem4x21167">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21167">
									<item>
										<label>•</label>
										<para> 12.5 mg daily at bedtime, may increase by 12.5 mg every other day, max 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21171">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 12.5, 25, 50, 100, 200 mg; orally disintegrating tabs 12.5, 25, 100, 150, 200 mg; oral suspension 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x21176">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x21181">
								<item>
									<label>•</label>
									<para>May be taken with or without food</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21189">
							<label>•</label>
							<sec_title>
								<route>Patient-specific registration required before administration; if WBC &lt;3500 cells/mm3 or ANC &lt;2000 cells/mm3, therapy should not be started; may only dispense the 7, 14, 28 day supply upon receipt of lab report that is appropriate</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x21198">
								<item>
									<label>•</label>
									<para>Check to confirm PO medication swallowed; monitor for hoarding or giving of medication to other patients, if hospitalized; avoid giving patient &gt;7 days’ worth of medication if outpatient</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21203">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21211">
							<label>•</label>
							<sec_title>Orally disintegrating tab</sec_title>
							<para>
								<list id="lidelem4x21211">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tab:</emphasis> do not push through foil; leave in foil blister until ready to take, peel back foil, place tab in mouth; allow to dissolve, swallow; water is not needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21218">
							<label>•</label>
							<sec_title>Oral suspension</sec_title>
							<para>
								<list id="lidelem4x21218">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral suspension:</emphasis> Shake before using, use oral syringe and syringe adapter</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x21222">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x21225">
					<section type="none" id="sidelem4x21226">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Neuroleptic malignant syndrome,</emphasis><emphasis style="italic">sedation, salivation, dizziness, headache, tremors, sleep problems, akinesia, fever,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">sweating, akathisia, confusion, fatigue, insomnia,</emphasis> depression, slurred speech, anxiety, <emphasis style="italic">agitation,</emphasis> dystonia, obsessive-compulsive symptoms</para>
					</section>
					<section type="none" id="sidelem4x21243">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Tachycardia, hypo/hypertension,</emphasis> chest pain, ECG changes, orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x21251">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21258">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Drooling or excessive salivation, constipation, nausea, abdominal discomfort, vomiting, diarrhea,</emphasis> anorexia, <emphasis style="italic">weight gain, dry mouth,</emphasis> heartburn, <emphasis style="italic">dyspepsia, gastroesophageal reflux</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21271">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary abnormalities,</emphasis> incontinence, ejaculation dysfunction; frequency, urgency, retention, dysuria</para>
					</section>
					<section type="none" id="sidelem4x21279">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, agranulocytosis, eosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21286">
						<sec_title>MS:</sec_title>
						<para> Weakness; pain in back, neck, legs; spasm, <emphasis style="italic">rigidity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21293">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="italic">Diaphoresis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21300">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, nasal congestion, lower respiratory tract infection</para>
					</section>
					<section type="none" id="sidelem4x21305">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Death among geriatric patients with dementia,</emphasis> aggravation of diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x21313">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 27%-47%; 97% protein bound; completely metabolized by liver enzymes involved in metabolism CYP1A2, 2D6, 3A4; excreted in urine (50%), feces (30%) (metabolites); half-life 8-12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x21318">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants, psychoactives, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cloZAPine level—caffeine, citalopram, FLUoxetine, sertraline, ritonavir, risperiDONE, CYP1A2 inhibitors (fluvoxaMINE), CYP3A4 inhibitors (ketoconazole, erythromycin)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentration—warfarin, digoxin, other highly protein-bound products</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—β blockers, class IA/III antidysrhythmias, and other drugs that increase QT</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension, respiratory, cardiac arrest, collapse—benzodiazepines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> cloZAPine level—CYP1A2 inducers (carBAMazepine, omeprazole, rifampin); PHENobarbital</para>
				<section type="none" id="sidelem4x21345">
					<section type="none" id="sidelem4x21346">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, cardiac enzymes, cholesterol, blood glucose, bilirubin, PBI, cholinesterase,<emphasis style="sup">131</emphasis>I, Hct/Hgb, erythrocyte sedimentation rate</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> pregnancy tests, PKU</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> urinary steroids, 17-OHCS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x21368">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x21371">
					<section type="none" id="sidelem4x21372">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Myocarditis; if suspected, discontinue use; myocarditis usually occurs during 1st month of treatment</bbw>
						</para>
						<para>
							<bbw>Seizures; usually occur with higher doses &gt;600 mg/day or dosage change &gt;100 mg/day; do not use in uncontrolled seizure disorder, use cautiously in those with a predisposition to seizures</bbw>
						</para>
						<para>
							<list id="lidelem4x21394">
								<item>
									<label>•</label>
									<para>AIMS assessment, blood glucose, CBC differential, glycosylated hemoglobin A1c, LFTs, neurologic function, pregnancy test, serum creatinine, electrolytes, lipid profile, prolactin, thyroid function tests, weight</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> bilirubin, CBC, LFTs monthly; discontinue treatment if WBC &lt;3000-3500/mm3 or ANC &lt;1500/mm3; test weekly; may resume when normal; if WBC &lt;2000/mm3 or ANC &lt;1000/mm3, discontinue; <emphasis alert="lifethreat">if agranulocytosis develops, never restart product</emphasis></bbw>
						</para>
						<para>
							<list id="lidelem4x21425">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hypotension:</emphasis> B/P standing and lying; take pulse, respirations q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg</bbw>
						</para>
						<para>
							<list id="lidelem4x21443">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21451">
							<label>•</label>
							<sec_title>
								<route>EPS</route>
							</sec_title>
							<para>
								<list id="lidelem4x21451">
									<item>
										<label>•</label>
										<para> including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21456">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: tachycardia, seizures, fever, dyspnea, diaphoresis, increased/decreased B/P; notify prescriber immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21461">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk, water in diet, especially for geriatric patients; stool softeners, laxatives may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21466">
								<item>
									<label>•</label>
									<para>Do not involve patient in strenuous exercise program fainting is possible; patient should not stand still for long periods</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21471">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x21475">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia, reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21481">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x21489">
							<label>•</label>
							<sec_title>
								<route>About symptoms of agranulocytosis and need for blood tests weekly for 6 mo, then q2wk; to report flulike symptoms</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x21492">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension often occurs; to rise gradually from sitting or lying position; to avoid hot tubs, hot showers, tub baths; hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21497">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of this product because EPS may result; that product should be withdrawn over 1-2 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21502">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber, since serious product interactions may occur; to avoid use with alcohol or CNS depressants, increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21507">
								<item>
									<label>•</label>
									<para>About compliance with product regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21512">
								<item>
									<label>•</label>
									<para>About EPS and necessity for meticulous oral hygiene, since oral candidiasis may occur
<bbw>To report sore throat, malaise, fever, bleeding, mouth sores; if these occur, CBC should be drawn and product discontinued</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21530">
							<label>•</label>
							<sec_title>
								<route>That heat stroke may occur in hot weather; to take extra precautions to stay cool</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x21533">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities; seizures may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21541">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnant or if pregnancy is intended; not to breastfeed</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>codeine (Rx)</mono_name>
			<info>
				<pronunciation>(koe′deen)</pronunciation>
				<class type="func"> Opiate analgesic, antitussive</class>
				<class type="chem"> Opiate, phenathrene derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule><schedule num="3">III</schedule><schedule num="4">IV</schedule><schedule num="5">V</schedule> (depends on content)</class>
			</info>
			<section type="confusion" id="sidelem4x21564">
				<para>
					<confusion>
						<tradename id="tnidelem4x215640">codeine</tradename>
						<drug type="generic" refid="idelem4x215640">Lodine/iodine/Cardene</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x21568">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors; decreases cough reflex, GI motility</para>
			</section>
			<section type="uses" id="sidelem4x21573">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate pain</para>
				<section type="none" id="sidelem4x21578">
					<section type="none" id="sidelem4x21579">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Diarrhea, arthralgia, bone/dental pain, headache, migraine, myalgia, nonproductive cough</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x21584">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity to opiates, respiratory depression, increased intracranial pressure, seizure disorders, severe respiratory disorders</para>
				<para>
					<bbw>Children (tonsillectomy/adenoidectomy)</bbw>
				</para>
				<section type="none" id="sidelem4x21599">
					<section type="none" id="sidelem4x21600">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, cardiac dysrhythmias, prostatic hypertrophy, bowel impaction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x21605">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21608">
					<section type="none" id="sidelem4x21609">
						<sec_title>Pain</sec_title>
						<section type="none" id="sidelem4x21617">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x21617">
									<item>
										<label>•</label>
										<para> 15-60 mg q4hr prn, use phosphate product for IM/IV</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21624">
							<label>•</label>
							<sec_title>Child 6-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21624">
									<item>
										<label>•</label>
										<para> 3 mg/kg/day in divided doses q4hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21628">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x21636">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-50 ml/min, 75% of dose; CCr &lt;10 ml/min, 50% of dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x21639">
						<sec_title>Cough (unlabeled)</sec_title>
						<section type="none" id="sidelem4x21647">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21647">
									<item>
										<label>•</label>
										<para> 10-20 mg q4-6hr, max 120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21651">
						<sec_title>Diarrhea (unlabeled)</sec_title>
						<section type="none" id="sidelem4x21659">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21659">
									<item>
										<label>•</label>
										<para> 30 mg; may repeat qid prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21663">
						<sec_title>Arthralgia/bone pain/back pain/dental pain/headache/migraine/myalgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x21671">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21671">
									<item>
										<label>•</label>
										<para> 15-60 mg q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x21678">
							<label>•</label>
							<sec_title>Child ≥3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21678">
									<item>
										<label>•</label>
										<para> 0.5-1 mg/kg or 15 mg/m<emphasis style="sup">2</emphasis> (max 60 mg/dose) q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21685">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 15, 30 mg; inj 15, 30, 60 mg/ml; oral sol 30 mg/5 ml; syrup 5 mg/ml <country code="CAN">FIX_STRUCTURE Tabs 15, 30 mg; inj 15, 30, 60 mg/ml; oral sol 30 mg/5 ml; syrup 5 mg/ml </country></para>
					</section>
					<section type="none" id="sidelem4x21692">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x21696">
								<item>
									<label>•</label>
									<para>Discontinue gradually after long-term use, use stool softener, laxative for constipation</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x21707">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x21710">
					<section type="none" id="sidelem4x21711">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, sedation,</emphasis> dizziness, agitation, dependency, lethargy, restlessness, euphoria, <emphasis style="bold">seizures,</emphasis> hallucinations, headache, confusion</para>
					</section>
					<section type="none" id="sidelem4x21722">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, palpitations, orthostatic hypotension, tachycardia, <emphasis style="bold">circulatory collapse</emphasis></para>
					</section>
					<section type="none" id="sidelem4x21729">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation,</emphasis> dry mouth</para>
					</section>
					<section type="none" id="sidelem4x21737">
						<sec_title>GU:</sec_title>
						<para> Urinary retention</para>
					</section>
					<section type="none" id="sidelem4x21742">
						<sec_title>INTEG:</sec_title>
						<para> Flushing, rash, urticaria, pruritus</para>
					</section>
					<section type="none" id="sidelem4x21747">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression, respiratory paralysis,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x21755">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x21762">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 60%-90%; peak <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-1 hr; duration 4-6 hr; metabolized by liver (CYP3A4 to morphine); excreted by kidneys, in breast milk; crosses placenta; half-life 3 hr; protein binding 7%; altered codeine metabolism occurs in different ethnic groups</para>
				<section type="none" id="sidelem4x21775">
					<section type="none" id="sidelem4x21776">
						<sec_title>PO:</sec_title>
						<para> Onset 30-60 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x21781">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CYP2D6, alcohol, opiates, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity—MAOIs; use cautiously</emphasis>
				</para>
				<section type="none" id="sidelem4x21793">
					<section type="none" id="sidelem4x21794">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> lipase, amylase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x21801">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x21804">
					<section type="none" id="sidelem4x21805">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x21813">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x21813">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> intensity, type, location, aggravating, alleviating factors; need for pain medication, tolerance; use pain scoring</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21817">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21822">
								<item>
									<label>•</label>
									<para>GI function: nausea, vomiting, constipation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x21830">
							<label>•</label>
							<sec_title>Cough</sec_title>
							<para>
								<list id="lidelem4x21830">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cough:</emphasis> type, duration, ability to raise secretion for productive cough; do not use to suppress productive cough</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x21834">
								<item>
									<label>•</label>
									<para>CNS changes, dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21839">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria
<bbw>Children (tonsillectomy/adenoidectomy): Deaths have occurred; use is contraindicated</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x21854">
								<item>
									<para>
										<emphasis alert="nurse">Respiratory dysfunction: respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min, shallow; obstructive sleep apnea (children) (tonsillectomy/adenoidectomy)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21859">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x21863">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain, absence of grimacing, decreased cough, decreased diarrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x21869">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x21873">
								<item>
									<label>•</label>
									<para>Not to breastfeed</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>That physical dependency may result after extended periods</para>
								</item>
								<item>
									<label>•</label>
									<para>To decrease dry mouth use sugarless gum, rinse mouth often</para>
								</item>
								<item>
									<label>•</label>
									<para>To change position slowly; orthostatic hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness, dizziness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants unless directed by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active">
			<mono_name>colchicine (Rx)</mono_name>
			<info>
				<pronunciation>(kol′chih-seen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x219190">Colcrys</tradename>
				</tradenames>
				<class type="func"> Antigout agent</class>
				<class type="chem"> alkaloid</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x21929">
				<sec_title>Action:</sec_title>
				<para>Inhibits microtubule formation of lactic acid in leukocytes, which decreases phagocytosis and inflammation in joints</para>
			</section>
			<section type="uses" id="sidelem4x21934">
				<sec_title>Uses:</sec_title>
				<para>Gout, gouty arthritis (prevention, treatment); to arrest the progression of neurologic disability in those with MS, Mediterranean fever</para>
				<section type="none" id="sidelem4x21939">
					<section type="none" id="sidelem4x21940">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hepatic cirrhosis, pericarditis, amyloidosis, Behçet’s syndrome, biliary cirrhosis, dermatitis herpetiformis, idiopathic thrombocytopenic purpura, Paget’s disease, pseudogout, pulmonary fibrosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x21945">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) (injectable), serious GI, severe cardiac/renal/hepatic disorders, hypersensitivity</para>
				<section type="none" id="sidelem4x21950">
					<section type="none" id="sidelem4x21951">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (PO), breastfeeding, children, geriatric patients, blood dyscrasias, hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x21956">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x21959">
					<section type="none" id="sidelem4x21960">
						<sec_title>Gout prevention</sec_title>
						<section type="none" id="sidelem4x21968">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21968">
									<item>
										<label>•</label>
										<para> 0.6-1.2 mg/day in 1-2 divided doses, depending on severity</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21973">
						<sec_title>Gout treatment</sec_title>
						<section type="none" id="sidelem4x21981">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x21981">
									<item>
										<label>•</label>
										<para> 1.2 mg initially, then 0.6 mg 1 hr later (1.8 mg); for those on strong CYP3A4 inhibitor (during past 14 days), 0.6 mg initially, then 0.3 mg 1 hr later</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x21985">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x21993">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, for acute gout, do not repeat course for 2 wk; for familial Mediterranean fever, 0.3 mg daily, increase cautiously</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x21996">
						<sec_title>Pericarditis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x22004">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22004">
									<item>
										<label>•</label>
										<para> 0.5 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22008">
						<sec_title>Mediterranean fever (unlabeled)</sec_title>
						<section type="none" id="sidelem4x22016">
							<label>•</label>
							<sec_title>Adult on no interacting products<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22016">
									<item>
										<label>•</label>
										<para> 1.2-2.4 mg/day in 1-2 divided doses; strong CYP3A4 inhibitor; P-glycoprotein inhibitors within 14 day: max 0.6 mg/day in 1-2 divided doses; moderate CYP3A4 inhibitors with 14 day: max 1.2 mg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22023">
							<label>•</label>
							<sec_title>Adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22023">
									<item>
										<label>•</label>
										<para> 1.2-2.4 mg/day in 1-2 divided doses, titrate by 0.3 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22030">
							<label>•</label>
							<sec_title>Child &gt; 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22030">
									<item>
										<label>•</label>
										<para> 0.9-1.8 mg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22037">
							<label>•</label>
							<sec_title>Child 4-6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22037">
									<item>
										<label>•</label>
										<para> 0.3-1.8 mg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22041">
						<sec_title>Amyloidosis/biliary cirrhosis/dermatitis herpetiformis/Paget’s disease/Behçet’s syndrome/chronic idiopathic thrombocytopenic purpura/pulmonary fibrosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x22049">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22049">
									<item>
										<label>•</label>
										<para> 0.5-0.6 mg bid-tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22053">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.6 mg; cap 0.6 mg</para>
					</section>
					<section type="none" id="sidelem4x22058">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x22061">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x22066">
									<item>
										<label>•</label>
										<para>Without regard to food</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x22074">
								<label>•</label>
								<sec_title>
									<route>Cumulative doses ≤4 mg, renal patients ≤2 mg; when reached, administer only for 3 wk</route>
								</sec_title>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22077">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22080">
					<section type="none" id="sidelem4x22081">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, malaise,</emphasis> metallic taste, cramps, peptic ulcer, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x22089">
						<sec_title>GU:</sec_title>
						<para> Hematuria, <emphasis style="bold">oliguria, renal damage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22096">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, aplastic anemia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x22103">
						<sec_title>INTEG:</sec_title>
						<para> Chills, dermatitis, pruritus, purpura, erythema</para>
					</section>
					<section type="none" id="sidelem4x22108">
						<sec_title>MISC:</sec_title>
						<para> Myopathy, alopecia, reversible azoospermia, peripheral neuritis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x22113">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x22116">
					<section type="none" id="sidelem4x22117">
						<sec_title>PO:</sec_title>
						<para> Peak <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-2 hr, half-life 4.4 hr, deacetylates in liver, excreted in feces (metabolites/active product)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x22128">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: colchicine level/toxicity—moderate/strong CYP3A4 inhibitors, reduce dose</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI effects—NSAIDs, ethanol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depression—radiation, bone marrow depressants, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of vit B<emphasis style="inf">12</emphasis>; may cause reversible malabsorption</para>
				<section type="none" id="sidelem4x22149">
					<section type="none" id="sidelem4x22150">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> colchicine level—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x22157">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, AST</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC, granulocytes</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine Hgb</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> urinary 17-hydroxycorticosteroids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x22176">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x22179">
					<section type="none" id="sidelem4x22180">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x22185">
								<item>
									<label>•</label>
									<para>Relief of pain, uric acid levels returning to normal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22190">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; observe for decrease in urinary output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22196">
								<item>
									<para>
										<emphasis alert="nurse">CBC, platelets, reticulocytes before, during therapy (q3mo); may cause aplastic anemia, agranulocytosis, decreased platelets</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22204">
							<label>•</label>
							<sec_title>Toxicity<route> weakness, abdominal pain, nausea, vomiting, diarrhea; product should be discontinued, report symptoms immediately</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x22207">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x22211">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased stone formation, decreased pain in kidney region, absence of hematuria, decreased pain in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22217">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x22221">
								<item>
									<label>•</label>
									<para>To avoid alcohol, OTC preparations that contain alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any pain, redness, hard areas, usually in legs; rash, sore throat, fever, bleeding, bruising, weakness, numbness, tingling, nausea, vomiting, abdominal pain</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of complying with medical regimen (diet, weight loss, product therapy); about the possibility of bone marrow depression occurring</para>
								</item>
								<item>
									<label>•</label>
									<para>Advise all providers of product use; surgery may increase possibility of acute gout symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>colesevelam (Rx)</mono_name>
			<info>
				<pronunciation>(koe-leh-seve′eh-lam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x222530">WelChol</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> Bile acid sequestrant</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x22263">
				<sec_title>Action:</sec_title>
				<para>Adsorbs, combines with bile acids to form insoluble complex excreted through feces; loss of bile acids lowers cholesterol levels</para>
			</section>
			<section type="uses" id="sidelem4x22268">
				<sec_title>Uses:</sec_title>
				<para>Elevated LDL cholesterol, alone or in combination with HMG-COA reductase inhibitor; type 2 diabetes (adjunct)</para>
			</section>
			<section type="contra" id="sidelem4x22273">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, bowel disease, primary biliary cirrhosis, triglycerides &gt;500 mg/dl, bowel obstruction, pancreatitis, biliary obstruction, dysphagia, fat-soluble vitamin deficiency</para>
				<section type="none" id="sidelem4x22278">
					<section type="none" id="sidelem4x22279">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x22284">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x22287">
					<section type="none" id="sidelem4x22288">
						<sec_title>Monotherapy</sec_title>
						<section type="none" id="sidelem4x22296">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22296">
									<item>
										<label>•</label>
										<para> three 625-mg tabs bid with meals or 6 tabs daily with meal; may increase to 7 tabs if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22300">
						<sec_title>Combination therapy</sec_title>
						<section type="none" id="sidelem4x22308">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22308">
									<item>
										<label>•</label>
										<para> 3 tabs bid with meals or 6 tabs daily with meal given with an HMG-CoA reductase inhibitor</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22312">
						<sec_title>Type 2 diabetes, adjunct (to improve glycemic control)</sec_title>
						<section type="none" id="sidelem4x22320">
							<label>•</label>
							<sec_title>Adult and geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22320">
									<item>
										<label>•</label>
										<para> Approx 3.8 g (6 tabs)/day or approx 1.9 g (3 tabs) bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22324">
						<sec_title>Heterozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x22332">
							<label>•</label>
							<sec_title>Females (postmenarchal and &gt;10 yr) and males ≥10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22332">
									<item>
										<label>•</label>
										<para> 1.875-g packet bid or 3.75-g packet daily dissolved in 4-8 oz of water with meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22336">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 625 mg; powder for oral susp 3.75 g/packet</para>
					</section>
					<section type="none" id="sidelem4x22341">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x22346">
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, or chew</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22351">
								<item>
									<label>•</label>
									<para>Give product daily or bid with meals; give all other medications 4 hr before colesevelam; with liquid to avoid poor absorption</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x22359">
							<label>•</label>
							<sec_title>Powder for oral susp</sec_title>
							<para>
								<list id="lidelem4x22359">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Powder for oral susp:</emphasis> empty contents of packet into a cup/glass, add <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 cup (4-8 oz) of water, fruit juice, diet soda; stir well before drinking</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22369">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22372">
					<section type="none" id="sidelem4x22373">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, abdominal pain, nausea,</emphasis> fecal impaction, hemorrhoids, flatulence, vomiting, GI obstruction</para>
					</section>
					<section type="none" id="sidelem4x22381">
						<sec_title>MISC:</sec_title>
						<para> Hypertriglycerides, hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x22386">
						<sec_title>MS:</sec_title>
						<para> Muscle, joint pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x22391">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in feces, peak response 2 wk</para>
			</section>
			<section type="interactions" id="sidelem4x22396">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of diltiazem, gemfibrozil, mycophenolate, phenytoin, propranolol, warfarin, thiazides, digoxin, penicillin G, tetracyclines, corticosteroids, iron, thyroid, fat-soluble vitamins, glyBURIDE, fluoroquinolones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of—oral contraceptives</para>
				<section type="none" id="sidelem4x22407">
					<section type="none" id="sidelem4x22408">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x22415">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x22418">
					<section type="none" id="sidelem4x22419">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x22423">
								<item>
									<label>•</label>
									<para>Cardiac glycoside level, if both products administered</para>
								</item>
								<item>
									<label>•</label>
									<para>Fasting LDL, HDL, total cholesterol, triglyceride levels, electrolytes if on extended therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Bowel pattern daily; increase bulk, water in diet for constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22440">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x22444">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased total cholesterol level, LDL cholesterol, apolipoproteins</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22450">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x22454">
								<item>
									<label>•</label>
									<para>About the importance of compliance; toxicity may result if doses missed; timing of dose 4 hr after other meds</para>
								</item>
								<item>
									<label>•</label>
									<para>That risk factors should be decreased: high-fat diet, smoking, alcohol consumption, absence of exercise</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>conivaptan (Rx)</mono_name>
			<info>
				<pronunciation>(kon-ih-vap′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x224700">Vaprisol</tradename>
				</tradenames>
				<class type="func"> Vasopressin receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x22476">
				<sec_title>Action:</sec_title>
				<para>Dual arginine vasopressin (AVP) antagonist with affinity for V<emphasis style="inf">1A</emphasis>, V<emphasis style="inf">2</emphasis> receptors; level of AVP in circulating blood is critical for regulation of water, electrolyte balance and is usually elevated in euvolemic/hypervolemic hyponatremia</para>
			</section>
			<section type="uses" id="sidelem4x22487">
				<sec_title>Uses:</sec_title>
				<para>Euvolemia hyponatremia in hospitalized patients; not indicated for CHF, hypervolemic hyponatremia</para>
			</section>
			<section type="contra" id="sidelem4x22492">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypovolemia</para>
				<section type="none" id="sidelem4x22497">
					<section type="none" id="sidelem4x22498">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, orthostatic disease, renal disease, heart failure, rapid correction of serum sodium</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x22503">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x22511">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x22511">
							<item>
								<label>•</label>
								<para> loading dose 20 mg given over 30 min then  over 24 hr; after 1 day, give for an additional 1-3 days as a  of 20 mg/day total; can be titrated up to 40 mg/day if serum sodium is not rising at desired rate; max time 4 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x22521">
					<section type="none" id="sidelem4x22522">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x22530">
							<label>•</label>
							<sec_title>Adult<route> IV Child-Pugh A-C or CCr 30-60 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x22533">
						<sec_title>Available forms:</sec_title>
						<para> Injection (premixed) 0.2 mg/ml in 100 ml D<emphasis style="inf">5</emphasis>W</para>
					</section>
					<section type="none" id="sidelem4x22541">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x22544">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x22548">
									<item>
										<label>•</label>
										<para>Withdraw 4 ml (20 mg), add to 100 ml D<emphasis style="inf">5</emphasis>W, gently invert several times to mix, give over 30 min; in large vein, change site every 24 hr to minimize vascular irritation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x22557">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x22561">
									<item>
										<label>•</label>
										<para>Withdraw 4 ml (20 mg), add to 250 ml D<emphasis style="inf">5</emphasis>W, gently invert several times to mix, give over 24 hr; or give 40 mg in 250 ml D<emphasis style="inf">5</emphasis>W, gently invert several times to mix, give over 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x22573">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x22576">
					<section type="none" id="sidelem4x22577">
						<sec_title>CNS:</sec_title>
						<para> Headache, confusion, insomnia</para>
					</section>
					<section type="none" id="sidelem4x22582">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Atrial fibrillation,</emphasis> hypo/hypertension, <emphasis style="italic">orthostatic hypotension,</emphasis> phlebitis</para>
					</section>
					<section type="none" id="sidelem4x22593">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, constipation, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x22598">
						<sec_title>GU:</sec_title>
						<para> Hematuria, polyuria, UTI, pollakiuria</para>
					</section>
					<section type="none" id="sidelem4x22603">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x22608">
						<sec_title>INTEG:</sec_title>
						<para> Erythemia, inj site reaction</para>
					</section>
					<section type="none" id="sidelem4x22613">
						<sec_title>META:</sec_title>
						<para> Dehydration, hypo/hyperglycemia, hypokalemia, hypomagnesia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x22618">
						<sec_title>MISC:</sec_title>
						<para> Oral candidiasis, pain, peripheral edema, pneumonia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x22623">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 99%, metabolized by CYP3A4, terminal half-life 5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x22629">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: effect of—CYP3A4 substrates (alfuzosin, ARIPiprazole, bexarolene, bortezomib, bosentan, bupivacaine, buprenorphine, carBAMazepine, cevimeline, cilostazol, cinacalcet, clopidogrel, colchicine, cyclobenzaprine, dapsone, darifenacin, disopyramide, DOCEtaxel, donepezil, DOXOrubicin, dutasteride, eletriptan, eplerenone, ergots, erlotinib, eszopiclone, ethinyl estradiol, ethosuximide, etoposide, fentaNYL, galantamine, gefitinib, ifosfamide, irinotecan, lidocaine, loperimide, loratadine, mefloquine, methadone, modafinil, PACLitaxel, paricalcitrol, pimozide, praziquantel, quiNIDine, quiNINE, ramelteon, repaglinide, rifabutin, sibutramine, sildenafil, sirolimus, SUFentanil, SUNItinib, tacrolimus, tamoxifen, teniposide, testosterone, tiaGABine, tinidazole, trimetrexate, vardenafil, vinca alkaloids, ziprasidone, zolpidem, zonisamide); do not use concurrently</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x22635">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x22638">
					<section type="none" id="sidelem4x22639">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x22647">
							<label>•</label>
							<sec_title>
								<route>Renal, hepatic function</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x22653">
							<label>•</label>
							<sec_title>
								<route>Frequent sodium volume status; overly rapid correction of sodium concentration (&gt;12 mEq/L per 24 hr) may result in osmotic demyelination syndrome</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x22656">
								<item>
									<label>•</label>
									<para>Neurologic status: confusion, headache</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22661">
								<item>
									<label>•</label>
									<para>CV status: atrial fibrillation, hypo/hypertension, orthostatic hypotension; monitor B/P, pulse</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x22666">
								<item>
									<label>•</label>
									<para>Monitor other electrolytes (magnesium and potassium)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22671">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x22675">
								<item>
									<label>•</label>
									<para>Therapeutic response: correction of serum sodium levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x22681">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x22685">
								<item>
									<label>•</label>
									<para>To report neurologic changes: headache, insomnia, confusion</para>
								</item>
								<item>
									<label>•</label>
									<para>About administration procedure and expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>To report inj site pain, redness, swelling</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>CONTRACEPTIVES, HORMONAL</mono_name>
			<info>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x22855">
				<sec_title>Action:</sec_title>
				<para>Prevents ovulation by suppressing FSH and LH; <emphasis style="italic">monophasic:</emphasis> estrogen/progestin (fixed dose) used during a 21-day cycle; ovulation is inhibited by suppression of FSH and LH; thickness of cervical mucus and endometrial lining prevents pregnancy; <emphasis style="italic">biphasic:</emphasis> ovulation is inhibited by suppression of FSH and LH; alteration of cervical mucus, endometrial lining prevents pregnancy; <emphasis style="italic">triphasic:</emphasis> ovulation is inhibited by suppression of FSH and LH; change of cervical mucus, endometrial lining prevents pregnancy; variable doses of estrogen/progestin combinations may be similar to natural hormonal fluctuations; <emphasis style="italic">extended cycle:</emphasis> estrogen/progestin continuous for 84 days, off for 7 days, results in 4 menstrual periods/yr; <emphasis style="italic">progressive estrogen:</emphasis> constant progestin with 3 progressive doses of estrogen; <emphasis style="italic">progestin-only pill, implant, intrauterine:</emphasis> change of cervical mucus and endometrial lining prevents pregnancy; ovulation may be suppressed</para>
			</section>
			<section type="uses" id="sidelem4x22880">
				<sec_title>Uses:</sec_title>
				<para>To prevent pregnancy, regulation of menstrual cycle, treatment of acne in women &gt;14 yr for whom other treatment has failed, emergency contraception; <emphasis style="italic">injection:</emphasis> inhibits gonadotropin secretion, ovulation, follicular maturation; <emphasis style="italic">emergency:</emphasis> inhibits ovulation and fertilization, decreases transport of sperm and egg from fallopian tube to uterus; <emphasis style="italic">vaginal ring, transdermal:</emphasis> inhibits ovulation, prevents sperm entry into uterus; <emphasis style="italic">antiacne:</emphasis> may decrease sex hormone binding globulin, results in decreased testosterone</para>
			</section>
			<section type="contra" id="sidelem4x22897">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, women ≥40 yr, reproductive cancer, thrombophlebitis, MI, hepatic tumors, hepatic disease, CAD, CVA, breast cancer, jaundice, stroke, vaginal bleeding</para>
				<section type="none" id="sidelem4x22902">
					<section type="none" id="sidelem4x22903">
						<sec_title>Precautions:</sec_title>
						<para> Depression, hypertension, renal disease, seizure disorders, lupus erythematosus, rheumatic disease, migraine headache, amenorrhea, irregular menses, gallbladder disease, diabetes mellitus, heavy smoking, acute mononucleosis, sickle cell disease</para>
						<para>
							<bbw>Tobacco smoking</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x22918">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x22921">
					<section type="none" id="sidelem4x22922">
						<sec_title>Monophasic</sec_title>
						<section type="none" id="sidelem4x22930">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22930">
									<item>
										<label>•</label>
										<para> Take first tab on Sunday after start of menses × 21 days; skip 7 days, then repeat cycle; start on 1st day of menses × 21 days; skip 7 days, then repeat cycle; may contain 7 placebo tabs when 1 tab is taken daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22934">
						<sec_title>Biphasic</sec_title>
						<section type="none" id="sidelem4x22942">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22942">
									<item>
										<label>•</label>
										<para> Take 10 days of small progestin, then large progestin; estrogen is the same during cycle; skip 7 days, then repeat cycle; may contain 7 placebo tabs when 1 tab is taken daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22946">
						<sec_title>Triphasic</sec_title>
						<section type="none" id="sidelem4x22954">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22954">
									<item>
										<label>•</label>
										<para> Estrogen dose remains constant; progestin changes throughout 21-day cycle; some products contain 28 tabs per month</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22958">
						<sec_title>Extended cycle</sec_title>
						<section type="none" id="sidelem4x22966">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22966">
									<item>
										<label>•</label>
										<para> Start taking on 1st day of menses; continue for 84 days of active tab, then 7 days of placebo; repeat cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22970">
						<sec_title>Progestin</sec_title>
						<section type="none" id="sidelem4x22978">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22978">
									<item>
										<label>•</label>
										<para> Start on 1st day of menses, then daily and continuously</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22982">
						<sec_title>Progressive estrogen</sec_title>
						<section type="none" id="sidelem4x22990">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x22990">
									<item>
										<label>•</label>
										<para> Progestin dose remains constant; estrogen increases q7days throughout 21-day cycle; may include 7 placebo tabs for 28-day cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x22994">
						<sec_title>Emergency</sec_title>
						<section type="none" id="sidelem4x23002">
							<label>•</label>
							<sec_title>Adult/adolescent</sec_title>
							<para>
								<list id="lidelem4x23002">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent:</emphasis> Give within 72 hr of intercourse, repeat 12 hr later;  1 tab, then 1 tab 12 hr later;  2 tab, then 2 tab 12 hr later;  2 white tabs;  4 white tabs;  4 orange tabs;  4 yellow tabs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23024">
						<sec_title>Injectable</sec_title>
						<section type="none" id="sidelem4x23032">
							<label>•</label>
							<sec_title>Adult<route> IM (Depo-Provera)</route></sec_title>
							<para>
								<list id="lidelem4x23032">
									<item>
										<label>•</label>
										<para> 150 mg within 5 days of start of menses or within 5 days postpartum (must not be breastfeeding); if breastfeeding, give 6 wk postpartum, repeat q3mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23036">
						<sec_title>Intrauterine</sec_title>
						<section type="none" id="sidelem4x23044">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x23044">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> To be inserted using the levonorgestrel-releasing intrauterine system (LRIS) by those trained in procedure; inserted into uterine cavity within 7 days of the onset of menstruation; use should not exceed 5 yr per implant</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23048">
						<sec_title>Vaginal ring</sec_title>
						<section type="none" id="sidelem4x23056">
							<label>•</label>
							<sec_title>Adult<route> VAG</route></sec_title>
							<para>
								<list id="lidelem4x23056">
									<item>
										<label>•</label>
										<para> Insert 1 ring on or before day 5 of cycle; leave in place 3 wk; remove for 1 wk, then repeat</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23061">
						<sec_title>Transdermal</sec_title>
						<section type="none" id="sidelem4x23069">
							<label>•</label>
							<sec_title>Adult<route> TD</route></sec_title>
							<para>
								<list id="lidelem4x23069">
									<item>
										<label>•</label>
										<para> Apply patch within 7 days of menses; change weekly × 3 wk; no patch wk 4; repeat cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23073">
						<sec_title>Implant</sec_title>
						<section type="none" id="sidelem4x23081">
							<label>•</label>
							<sec_title>Adult<route> SUBDERMAL</route></sec_title>
							<para>
								<list id="lidelem4x23081">
									<item>
										<label>•</label>
										<para> In inner side of upper arm on days 1-5 of menses, replace q3yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23085">
						<sec_title>Acne</sec_title>
						<section type="none" id="sidelem4x23093">
							<label>•</label>
							<sec_title>Adult<route> PO (Ortho Tri-Cyclen)</route></sec_title>
							<para>
								<list id="lidelem4x23093">
									<item>
										<label>•</label>
										<para> Take daily × 21 days, off 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23097">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x23101">
								<item>
									<label>•</label>
									<para>PO with food for GI symptoms; give at same time each day</para>
								</item>
								<item>
									<label>•</label>
									<para>Subdermal implant of 6 caps effective for 5 yr, then should be removed</para>
								</item>
								<item>
									<label>•</label>
									<para>IM inj deep in large muscle mass after shaking suspension; ensure patient not pregnant if inj are 2 wk or more apart</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x23117">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x23120">
					<section type="none" id="sidelem4x23121">
						<sec_title>CNS:</sec_title>
						<para> Depression, fatigue, dizziness, nervousness, anxiety, headache</para>
					</section>
					<section type="none" id="sidelem4x23126">
						<sec_title>CV:</sec_title>
						<para> Increased B/P, <emphasis style="bold">cerebral hemorrhage, thrombosis, pulmonary embolism,</emphasis> fluid retention, edema, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x23136">
						<sec_title>EENT:</sec_title>
						<para> Optic neuritis, retinal thrombosis, cataracts</para>
					</section>
					<section type="none" id="sidelem4x23141">
						<sec_title>ENDO:</sec_title>
						<para> Decreased glucose tolerance, increased TBG, PBI, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, temporary infertility</para>
					</section>
					<section type="none" id="sidelem4x23152">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, cramps, diarrhea, bloating, constipation, change in appetite, <emphasis style="bold">cholestatic jaundice,</emphasis> weight change</para>
					</section>
					<section type="none" id="sidelem4x23163">
						<sec_title>GU:</sec_title>
						<para> Breakthrough bleeding, amenorrhea, spotting, dysmenorrhea, galactorrhea, endocervical hyperplasia, vaginitis, cystitis-like syndrome, breast changes</para>
					</section>
					<section type="none" id="sidelem4x23168">
						<sec_title>HEMA:</sec_title>
						<para> Increased fibrinogen, clotting factor</para>
					</section>
					<section type="none" id="sidelem4x23173">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Chloasma, melasma,</emphasis> acne, rash, urticaria, erythema, pruritus, hirsutism, alopecia, photosensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x23181">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x23186">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Decrease: oral contraceptives effectiveness—anticonvulsants, rifampin, analgesics, antibiotics, antihistamines, griseofulvin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> oral anticoagulants action</para>
				<section type="none" id="sidelem4x23196">
					<section type="none" id="sidelem4x23197">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x23201">
								<item>
									<label>•</label>
									<para>Altered action: black cohosh</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> oral contraceptives effect—saw palmetto, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x23211">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> peak level—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x23218">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PT; clotting factors VII, VIII, IX, X; TBG, PBI, T<emphasis style="inf">4</emphasis>, platelet aggregability, BSP, triglycerides, bilirubin, AST, ALT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> T<emphasis style="inf">3</emphasis>, antithrombin III, folate, metyrapone test, GTT, 17-OHCS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x23235">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x23238">
					<section type="none" id="sidelem4x23239">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x23243">
								<item>
									<label>•</label>
									<para>Glucose, thyroid function, LFTs, BP</para>
								</item>
								<item>
									<label>•</label>
									<para>Reproductive changes: changes in breasts, tumors; positive Pap smear; product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23254">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x23258">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pregnancy, endometriosis, hypermenorrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23264">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x23269">
								<item>
									<label>•</label>
									<para>About detection of clots using Homan’s sign</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23274">
								<item>
									<label>•</label>
									<para>To use sunscreen or avoid sunlight; photosensitivity can occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23279">
								<item>
									<label>•</label>
									<para>To take at same time each day to ensure equal product level</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23284">
								<item>
									<label>•</label>
									<para>To report GI symptoms that occur after 4 mo</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x23292">
							<label>•</label>
							<sec_title>
								<route>To use another birth control method during 1st week of oral contraceptive use</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x23295">
								<item>
									<label>•</label>
									<para>To take another tablet as soon as possible if one is missed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23300">
								<item>
									<label>•</label>
									<para>That, after product is discontinued, pregnancy may not occur for several months</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x23308">
							<label>•</label>
							<sec_title>
								<route>To report abdominal pain, change in vision, shortness of breath, change in menstrual flow, spotting, breakthrough bleeding, breast lumps, swelling, headache, severe leg pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x23311">
								<item>
									<label>•</label>
									<para>That continuing medical care is needed: Pap smear and gynecologic examinations q6mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23316">
								<item>
									<label>•</label>
									<para>To notify health care providers and dentists of oral contraceptive use
<bbw>Do not smoke; increased risk of CV side effects</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="1" status="active" ha="yes">
			<mono_name>crizotinib</mono_name>
			<info>
				<pronunciation>(kriz-oh′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x233400">XALKORI</tradename>
				</tradenames>
				<class type="func"> Antineoplastic; biologic response modifiers</class>
				<class type="chem"> Signal transduction inhibitors (STIs)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x23350">
				<sec_title>Action:</sec_title>
				<para>Inhibits receptor tyrosine kinases (anaplastic lymphoma kinase (ALK), Hepatocyte Growth Factor Receptor (HGFR, c-Met), Recepteur d’Origine Nantais (RON)</para>
			</section>
			<section type="uses" id="sidelem4x23355">
				<sec_title>Uses:</sec_title>
				<para>Locally advanced or metastatic non–small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test</para>
			</section>
			<section type="contra" id="sidelem4x23360">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x23365">
					<section type="none" id="sidelem4x23366">
						<sec_title>Precautions:</sec_title>
						<para> Neonates, infants, children, adolescents, pneumonitis, severe hepatic disease, congenital long QT syndrome, severe renal impairment, end-stage renal disease, vision disorders</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x23371">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23379">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x23379">
							<item>
								<label>•</label>
								<para> 250 mg bid, continue as long as beneficial</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x23390">
					<label>•</label>
					<sec_title>For Grade 1-2<route> no dosage adjustment needed; Grade 3</route></sec_title>
				</section>
				<section type="none" id="sidelem4x23400">
					<label>•</label>
					<sec_title>For Grade 1<route> No dosage adjustment necessary; Grade 2 ALT/AST elevations with grade ≤1 total bilirubin elevations</route></sec_title>
				</section>
				<section type="none" id="sidelem4x23410">
					<label>•</label>
					<sec_title>For any grade pneumonitis<route> permanently discontinue</route></sec_title>
				</section>
				<section type="none" id="sidelem4x23420">
					<label>•</label>
					<sec_title>For Grade 1-2 QTc prolongation<route> no dosage adjustment necessary; For Grade 3 QTc prolongation</route></sec_title>
				</section>
				<section type="none" id="sidelem4x23423">
					<section type="none" id="sidelem4x23424">
						<sec_title>Available forms:</sec_title>
						<para> Cap 200, 250 mg</para>
					</section>
					<section type="none" id="sidelem4x23429">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x23433">
								<item>
									<label>•</label>
									<para>May be taken orally with or without food</para>
								</item>
								<item>
									<label>•</label>
									<para>Have the patient swallow capsule whole; do not crush or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>If a dose is missed, it can be taken up to 6 hr before the next dose is due to maintain the twice daily regimen; do not take both doses at the same time</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x23456">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x23459">
					<section type="none" id="sidelem4x23460">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, balance disorder, presyncope, neuropathy (motor and sensory), burning sensation, dysesthesia, hyperesthesia, hypoesthesia, neuralgia, paresthesias, peripheral neuropathy (motor and sensory), headache, insomnia</para>
					</section>
					<section type="none" id="sidelem4x23465">
						<sec_title>CV:</sec_title>
						<para>
							<emphasis alert="lifethreat"> QT prolongation, disseminated intravascular coagulation (DIC), septic shock, bradycardia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x23471">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Diplopia, photopsia,</emphasis> photophobia, <emphasis style="italic">blurred vision,</emphasis> visual field defect, <emphasis style="italic">vitreous floaters,</emphasis> visual brightness, reduced <emphasis style="italic">visual acuity;</emphasis> esophageal disorders</para>
					</section>
					<section type="none" id="sidelem4x23488">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting, constipation,</emphasis> decreased appetite, dysgeusia, abdominal pain, abdominal discomfort/ pain, stomatitis, oral ulceration, glossodynia, glossitis, cheilitis, mucosal inflammation, oropharyngeal pain/discomfort, oral pain, esophageal disorder, elevated hepatic enzymes and hyperbilirubinemia, <emphasis style="bold">hepatotoxicity,</emphasis> dyspepsia, dysphagia, epigastric discomfort/pain, burning, esophagitis, esophageal obstruction/pain/spasm, esophageal ulceration, gastroesophageal reflux, odynophagia, and reflux esophagitis</para>
					</section>
					<section type="none" id="sidelem4x23499">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Grade 3/4 neutropenia, thrombocytopenia,</emphasis> lymphopenia</para>
					</section>
					<section type="none" id="sidelem4x23507">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, fever, <emphasis style="italic">edema,</emphasis> localized/peripheral edema, chest pain (unspecified), chest discomfort, musculoskeletal chest pain, arthralgia, back pain, <emphasis style="italic">rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x23517">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Severe, life-threatening pneumonitis, pneumonia, hypoxia, acute respiratory distress syndrome (ARDS),</emphasis> dyspnea, empyema, pulmonary hemorrhage, <emphasis style="bold">pulmonary embolism,</emphasis> upper respiratory tract infection (nasopharyngitis, pharyngitis, rhinitis), cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x23528">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 91%; distribution into the tissues and plasma; metabolized by the CYP3A4/5; primary metabolic pathways are oxidation to metabolites; terminal half-life 42 hr; excreted 63% feces, 22% urine; unchanged drug 53% feces, 2.3% urine; absolute bioavailability is 43%; peak is 4-6 hr; steady state is reached within 15 days; dosage adjustments may need to be made in hepatic/renal disease and Asian patients</para>
			</section>
			<section type="interactions" id="sidelem4x23533">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CYP2B6 substrates (prasugrel, selegiline, cyclophosphamide)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CYP3A4 inhibitors (ketoconazole, atazanavir, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, voriconazole, boceprevir, delavirdine, isoniazid, dalfopristin-quinupristin, tipranavir)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> CYP3A4 inducers (rifampin, carBAMazepine, PHENobarbital, phenytoin, rifabutin); antacids, H2-blockers, proton pump inhibitors (PPIs)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of—midazolam</para>
				<para>Avoid use with CYP3A4 substrates( alfentanil, cycloSPORINE, ergotamine, dihydroergotamine fentaNYL, sirolimus, colchicine)</para>
				<para>
					<emphasis style="bold">Increase: QT prolongation, torsades de pointes—arsenic trioxide, certain phenothiazines (chlorproMAZINE, mesoridazine, thioridazine), grepafloxacin, pentamidine, probucol, sparfloxacin, troleandomycin, class IA antiarrhythmics (disopyramide, procainamide, quiNIDine), class III antiarrhythmics (amiodarone, dofetilide, ibutilide, sotalol), clarithromycin, ziprasidone, pimozide, haloperidol, halofantrine, quiNIDine, chloroquine, dronedarone, droperidol, erythromycin, methadone, posaconazole, propafenone, saquinavir, abarelix, amoxapine, apomorphine, asenapine, β-agonists, ofloxacin, eribulin, ezogabine, flecainide, gatifloxacin, gemifloxacin, halogenated anesthetics, iloperidone, levofloxacin, local anesthetics, magnesium sulfate, potassium sulfate, sodium, maprotiline, moxifloxacin, nilotinib, norfloxacin, ciprofloxacin, OLANZapine, paliperidone, some phenothiazines (fluPHENAZine, perphenazine, prochlorperazine, trifluoperazine), telavancin, tetrabenazine, tricyclic antidepressants, venlafaxine, vorinostat, citalopram, alfuzosin, cloZAPine, cyclobenzaprine, dolasetron, palonosetron, QUEtiapine, rilpivirine, SUNItinib, tacrolimus, tacrolimus, vardenafil, indacaterol, dasatinib, fluconazole, lapatinib, lopinavir/ritonavir, mefloquine, octreotide, ondansetron, ranolazine,</emphasis> risperiDONE, telithromycin, vemurafenib</para>
				<section type="none" id="sidelem4x23559">
					<section type="none" id="sidelem4x23560">
						<sec_title>Drug/Herb</sec_title>
						<para>Do not use with St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x23565">
						<sec_title>Drug/Food</sec_title>
						<para>Do not use with grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x23570">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x23573">
					<section type="none" id="sidelem4x23574">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x23582">
							<label>•</label>
							<sec_title>Severe, life-threatening, or fatal treatment-related pneumonitis<route> all cases occurred within 2 mo of treatment initiation; monitor for pulmonary symptoms that may indicate pneumonitis, other causes of pneumonitis should be excluded; permanently discontinue in patients with treatment-related pneumonitis l</route></sec_title>
						</section>
						<section type="none" id="sidelem4x23588">
							<label>•</label>
							<sec_title>Hepatic disease<route> liver function test (LFT) abnormalities, altered bilirubin levels may occur during treatment; monitor LFTs and bilirubin levels before treatment, then monthly; more frequent testing is needed in those presenting with grade 2 or greater toxicities; laboratory alterations should be managed with dose reduction, treatment interruption, or discontinuation</route></sec_title>
						</section>
						<section type="none" id="sidelem4x23594">
							<label>•</label>
							<sec_title>
								<route>QT prolongation has been reported with use of product; therefore, avoid crizotinib use in those patients; monitor ECG and electrolytes in patients with congestive heart failure, bradycardia, electrolyte imbalance (hypokalemia, hypomagnesemia), or in patients taking concomitant medications known to prolong the QT interval; treatment interruption, dosage adjustment, treatment discontinuation may be needed in patients who develop QT prolongation</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x23600">
							<label>•</label>
							<sec_title>
								<route>Vision disorders,</route>
							</sec_title>
							<para>
								<list id="lidelem4x23600">
									<item>
										<label>•</label>
										<para> generally start within 2 wk of the start of therapy; ophthalmological evaluation should be considered, particularly if patients experience photopsia or new or increased vitreous floaters; caution should be used when driving or operating machinery by patients who experience vision disorders</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23607">
							<label>•</label>
							<sec_title>Pregnancy/breastfeeding<route> identify if pregnancy is planned or suspected (pregnancy category D), do not breastfeed</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x23610">
								<item>
									<label>•</label>
									<para>CBC with differential; BUN/creatinine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23615">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x23619">
								<item>
									<label>•</label>
									<para>Decreasing spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23625">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x23630">
								<item>
									<label>•</label>
									<para>That missed doses can be taken up to 6 hr before the next dose is due to maintain the twice daily regimen</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x23638">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception; both women and men of childbearing age should use adequate contraceptive methods during therapy and for at least 90 days after completing treatment, pregnancy category D</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x23644">
							<label>•</label>
							<sec_title>
								<route>To report immediately shortness of breath, cough, fatigue, visual changes</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x23647">
								<item>
									<label>•</label>
									<para>Not to take with grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x23652">
								<item>
									<label>•</label>
									<para>To avoid activities requiring mental alertness until effects are known</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x23660">
							<label>•</label>
							<sec_title>
								<route>To report signs of QT prolongation (abnormal heartbeats, dizziness, syncope)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x23663">
								<item>
									<label>•</label>
									<para>To swallow caps whole and avoid contact with broken cap</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>crofelemer</mono_name>
			<info>
				<pronunciation>(kroe-fel′e-mer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x236730">Fulyzaq</tradename>
				</tradenames>
				<class type="func"> Antidiarrheal</class>
				<class type="chem"> Red sap of Croton lechleri plant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x23683">
				<sec_title>Action:</sec_title>
				<para>Blocks chloride channel and high volume water loss in diarrhea</para>
			</section>
			<section type="uses" id="sidelem4x23688">
				<sec_title>Uses:</sec_title>
				<para>Non-infectious diarrhea in those with HIV/AIDS using antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x23693">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x23698">
					<section type="none" id="sidelem4x23699">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, black patients, children/adolescents, GI disease, infection, malabsorption syndrome, pancreatitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x23705">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23713">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x23713">
							<item>
								<label>•</label>
								<para> 125 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x23717">
					<section type="none" id="sidelem4x23718">
						<sec_title>Available forms:</sec_title>
						<para> Delayed rel tabs 125 mg</para>
					</section>
					<section type="none" id="sidelem4x23723">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x23727">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x23738">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x23741">
					<section type="none" id="sidelem4x23742">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, depression</para>
					</section>
					<section type="none" id="sidelem4x23747">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, abdominal pain, anorexia, flatulence</para>
					</section>
					<section type="none" id="sidelem4x23752">
						<sec_title>INTEG:</sec_title>
						<para> Acne vulgaris, contact dermatitis</para>
					</section>
					<section type="none" id="sidelem4x23757">
						<sec_title>MISC:</sec_title>
						<para> Arthralgia, cough, increased urinary frequency</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x23762">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serious constipation, bowel obstruction—alosetron (IBS)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> constipation—may occur with antimuscarinics, opiate agonists</para>
			</section>
			<section type="considerations" id="sidelem4x23772">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x23775">
					<section type="none" id="sidelem4x23776">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x23780">
								<item>
									<label>•</label>
									<para>Stools: volume, color, characteristic, frequency; bowel pattern before protein rebound constipation</para>
								</item>
								<item>
									<label>•</label>
									<para>Electrolytes (K, Na, Cl), hydration status</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor effect in black patients; may be less effective</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23796">
						<sec_title>Evaluate:</sec_title>
						<para> Therapeutic response: decreased diarrhea</para>
					</section>
					<section type="none" id="sidelem4x23801">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x23805">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>If drowsiness occurs, not to operate machinery</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ru="yes">
			<mono_name>crotamiton</mono_name>
			<info>
				<pronunciation>(kroe-tam′-ih-tuhn)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x238230">Eurax</tradename>
				</tradenames>
				<class type="func"> Scabicide/pediculicide</class>
			</info>
			<section type="contra" id="sidelem4x23829">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; raw, inflamed skin</para>
			</section>
			<section type="doses" id="sidelem4x23834">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23842">
					<label>•</label>
					<sec_title>Adult<route> TOP</route></sec_title>
					<para>
						<list id="lidelem4x23842">
							<item>
								<label>•</label>
								<para> After routine bath, apply over the entire body from the chin to the soles; do not apply to the face or head; repeat in 24 hr; patient may take a cleansing bath 48 hr after the second dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x23846">
					<section type="none" id="sidelem4x23847">
						<sec_title>Treatment of pruritus</sec_title>
						<section type="none" id="sidelem4x23855">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x23855">
									<item>
										<label>•</label>
										<para> Apply topically by massaging gently into affected area until medication is completely absorbed; repeat if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x23859">
						<sec_title>Available forms:</sec_title>
						<para> Lotion, cream 10%</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>cyanocobalamin (vit B12) (<emphasis style="smallcaps">OTC</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(sye-an-oh-koe-bal′a-min)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x238751">Nascobal</tradename>
					<tradename id="tnidelem4x238750">Rubramin PC</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="5" status="active">
			<mono_name>hydroxocobalamin (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x238830">
						<country code="CAN">CytoKit </country>
					</tradename>
				</tradenames>
				<class type="func"> Vit B, water-soluble vitamin</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="actions" id="sidelem4x23894">
				<sec_title>Action:</sec_title>
				<para>Needed for adequate nerve functioning, protein and carbohydrate metabolism, normal growth, RBC development, cell reproduction</para>
			</section>
			<section type="uses" id="sidelem4x23899">
				<sec_title>Uses:</sec_title>
				<para>Vit B<emphasis style="inf">12</emphasis> deficiency, pernicious anemia, vit B<emphasis style="inf">12</emphasis> malabsorption syndrome, Schilling test, increased requirements with pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, renal/hepatic disease, nutritional supplementation</para>
			</section>
			<section type="contra" id="sidelem4x23910">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, cobalt, benzyl alcohol, optic nerve atrophy</para>
				<section type="none" id="sidelem4x23915">
					<section type="none" id="sidelem4x23916">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>), breastfeeding, children, renal/hepatic disease, folic acid/iron deficiency anemia, infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x23921">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x23924">
					<sec_title>
						<emphasis style="bold">
							<emphasis style="italic">Cyanocobalamin</emphasis>
						</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x23934">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x23934">
								<item>
									<label>•</label>
									<para> Up to 1000 mcg/day  30-100 mcg/day × 1 wk, then 100-200 mcg/mo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23942">
						<sec_title>Schilling test</sec_title>
						<section type="none" id="sidelem4x23950">
							<label>•</label>
							<sec_title>Adult and child<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x23950">
									<item>
										<label>•</label>
										<para> 1000 mcg in 1 dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x23957">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x23957">
									<item>
										<label>•</label>
										<para> Up to 1000 mcg/day  30-50 mcg/day × 2 wk, then 100 mcg/mo;  500 mcg weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x23967">
					<sec_title>
						<emphasis style="bold">
							<emphasis style="italic">Hydroxocobalamin</emphasis>
						</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x23977">
						<label>•</label>
						<sec_title>Adult<route> SUBCUT/IM</route></sec_title>
						<para>
							<list id="lidelem4x23977">
								<item>
									<label>•</label>
									<para> 30-50 mcg/day × 5-10 days, then 100-200 mcg/mo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23984">
						<label>•</label>
						<sec_title>Child<route> SUBCUT/IM</route></sec_title>
						<para>
							<list id="lidelem4x23984">
								<item>
									<label>•</label>
									<para> 30-50 mcg/day × 5-10 days, then 30-50 mcg/mo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x23988">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Cyanocobalamin:</emphasis> tabs 50, 100, 250, 500, 1000, 5000 mcg; ext rel tabs 1000 mcg; lozenges 100, 250, 500 mcg; nasal 500 mcg/spray; inj 100, 1000 mcg/ml; <emphasis style="italic">hydroxocobalamin:</emphasis> inj 1000 mcg/ml, powder for inj 5 g/vial</para>
					</section>
					<section type="none" id="sidelem4x23999">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x24002">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x24006">
									<item>
										<label>•</label>
										<para>With fruit juice to disguise taste; immediately after mixing</para>
									</item>
									<item>
										<label>•</label>
										<para>With meals if possible for better absorption; large doses should not be used because most is excreted</para>
									</item>
									<item>
										<label>•</label>
										<para>Protect from light, heat</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24022">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x24026">
									<item>
										<label>•</label>
										<para>By IM inj for pernicious anemia for life unless contraindicated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24032">
							<sec_title>Intranasal route</sec_title>
							<para>
								<list id="lidelem4x24036">
									<item>
										<label>•</label>
										<para>Avoid use within 1 hr of hot fluids, food, no primary needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24042">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x24046">
									<item>
										<label>•</label>
										<para>IV route not recommended but may be admixed in TPN solution</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Ascorbic acid, chloramphenicol, hydrocortisone, vit B/C</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> Dextrose/Ringer’s or LR combinations, dextrose/saline combinations, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">10</emphasis>W, 0.45% NaCl, Ringer’s or LR sol</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, aminophylline, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, ceFAZolin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, clindamycin, dexamethasone, digoxin, diphenhydrAMINE, DOBUTamine, DOPamine, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, erythromycin, esmolol, famotidine, fentaNYL, fluconazole, folic acid, furosemide, ganciclovir, gentamicin, glycopyrrolate, heparin, hydrocortisone, hydrOXYzine, imipenem-cilastatin, indomethacin, insulin (regular), isoproterenol hydrochloride, ketorolac, labetalol, lidocaine, magnesium, mannitol, meperidine, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, miconazole, midazolam, minocycline, morphine, moxalactam, multiple vitamins injection, nafcillin, nalbuphine, naloxone, netilmicin, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxytocin, papaverine, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, ritodrine, sodium bicarbonate, succinylcholine, SUFentanil, theophylline, thiamine, ticarcillin, ticarcillin-clavulanate, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, verapamil, vitamin B complex with C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x24070">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x24073">
					<section type="none" id="sidelem4x24074">
						<sec_title>CNS:</sec_title>
						<para> Flushing, optic nerve atrophy</para>
					</section>
					<section type="none" id="sidelem4x24079">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">CHF,</emphasis> peripheral vascular thrombosis, <emphasis style="bold">pulmonary edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24089">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24096">
						<sec_title>INTEG:</sec_title>
						<para> Itching, rash, pain at inj site</para>
					</section>
					<section type="none" id="sidelem4x24101">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x24106">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylactic shock</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x24113">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Gastric intrinsic factor must be present for absorption to occur; stored in liver, kidneys, stomach; 50%-90% excreted in urine; crosses placenta; excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x24118">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> absorption—predniSONE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—aminoglycosides, anticonvulsants, colchicine, chloramphenicol, aminosalicylic acid, potassium preparations, cimetidine</para>
				<section type="none" id="sidelem4x24130">
					<section type="none" id="sidelem4x24131">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> vit B<emphasis style="inf">12</emphasis> absorption—goldenseal</para>
					</section>
					<section type="none" id="sidelem4x24141">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> intrinsic factor</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x24148">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x24151">
					<section type="none" id="sidelem4x24152">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x24157">
								<item>
									<label>•</label>
									<para>For vit B<emphasis style="inf">12</emphasis> deficiency: red, beefy tongue; psychosis; pallor; neuropathy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24165">
								<item>
									<label>•</label>
									<para>GI function: diarrhea, constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24170">
								<item>
									<label>•</label>
									<para>Potassium levels during beginning treatment in megaloblastic anemia; q6mo in pernicious anemia; folic acid, plasma vit B<emphasis style="inf">12</emphasis> (after 1 wk), reticulocyte counts</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24178">
								<item>
									<label>•</label>
									<para>Nutritional status: egg yolks, fish, organ meats, dairy products, clams, oysters: good sources of vit B<emphasis style="inf">12</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x24188">
							<label>•</label>
							<sec_title>
								<route>For pulmonary edema, worsening of CHF in cardiac patients</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x24191">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x24195">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anorexia, dyspnea on exertion, palpitations, paresthesias, psychosis, visual disturbances</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x24201">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x24205">
								<item>
									<label>•</label>
									<para>That treatment must continue for life for pernicious anemia</para>
								</item>
								<item>
									<label>•</label>
									<para>To eat a well-balanced diet</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid contact with persons with infection; that infections are common</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>cyclobenzaprine (Rx)</mono_name>
			<info>
				<pronunciation>(sye-kloe-ben′za-preen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x242312">Amrix</tradename>
					<tradename id="tnidelem4x242311">Fexmid</tradename>
					<tradename id="tnidelem4x242310">Flexeril</tradename>
				</tradenames>
				<class type="func"> Skeletal muscle relaxant, central acting</class>
				<class type="chem"> Tricyclic amine salt</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x24241">
				<para>
					<confusion>
						<tradename id="tnidelem4x242410">cyclobenzaprine</tradename>
						<drug type="generic" refid="idelem4x242410">cyproheptadine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x24245">
				<sec_title>Action:</sec_title>
				<para>Reduces tonic muscle activity at the brain stem; may be related to antidepressant effects</para>
			</section>
			<section type="uses" id="sidelem4x24250">
				<sec_title>Uses:</sec_title>
				<para>Adjunct for relief of muscle spasm and pain in musculoskeletal conditions</para>
				<section type="none" id="sidelem4x24255">
					<section type="none" id="sidelem4x24256">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Fibromyalgia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x24261">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;12 yr, acute recovery phase of MI, dysrhythmias, heart block, CHF, hypersensitivity, intermittent porphyria, thyroid disease, QT prolongation</para>
				<section type="none" id="sidelem4x24266">
					<section type="none" id="sidelem4x24267">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, renal/hepatic disease, addictive personality</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x24272">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x24275">
					<section type="none" id="sidelem4x24276">
						<sec_title>Muscloskeletal disorders</sec_title>
						<section type="none" id="sidelem4x24284">
							<label>•</label>
							<sec_title>Adult/adolescent ≥15 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24284">
									<item>
										<label>•</label>
										<para> 5 mg tid × 1 wk, max 30 mg/day × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24291">
							<label>•</label>
							<sec_title>Adult<route> EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x24291">
									<item>
										<label>•</label>
										<para> 15 mg/day, max 30 mg/day × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24298">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24298">
									<item>
										<label>•</label>
										<para> 5 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24302">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x24310">
							<label>•</label>
							<sec_title>Adult (mild hepatic disease)<route> PO 5 mg, titrate slowly</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x24313">
						<sec_title>Fibromyalgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x24321">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24321">
									<item>
										<label>•</label>
										<para> 10 mg at bedtime, titrated up</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24325">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 7.5, 10 mg; ext rel tab 15, 30 mg</para>
					</section>
					<section type="none" id="sidelem4x24330">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x24334">
								<item>
									<label>•</label>
									<para>Without regard to meals, give with food for GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush, break, chew ext rel cap</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x24350">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x24353">
					<section type="none" id="sidelem4x24354">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, weakness, drowsiness,</emphasis> headache, tremor, depression, insomnia, confusion, paresthesia, nervousness</para>
					</section>
					<section type="none" id="sidelem4x24362">
						<sec_title>CV:</sec_title>
						<para> Postural hypotension, tachycardia, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24369">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, temporary loss of vision, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x24374">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, hiccups, dry mouth, constipation, hepatitis</para>
					</section>
					<section type="none" id="sidelem4x24382">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, frequency, change in libido</para>
					</section>
					<section type="none" id="sidelem4x24387">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, fever, facial flushing, sweating</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x24392">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x24395">
					<section type="none" id="sidelem4x24396">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, peak 3-8 hr, duration 12-24 hr, half-life 1-3 days, 32 hr ext rel, metabolized by liver, excreted in urine, crosses placenta, excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x24403">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x24411">
					<label>•</label>
					<sec_title>
						<route>Do not use within 14 days of MAOIs, traMADol</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: QT interval—Class IA/III antidysrhythmics, and other products that increase QT interval</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, tricyclics, opiates, barbiturates, sedatives, hypnotics</para>
				<section type="none" id="sidelem4x24424">
					<section type="none" id="sidelem4x24425">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x24432">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x24435">
					<section type="none" id="sidelem4x24436">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x24444">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> If using with SSRIs, SNRIs, monitor closely, if syndrome occurs, discontinue both products immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x24450">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x24450">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, duration, mobility, stiffness at baseline, periodically</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24457">
							<label>•</label>
							<sec_title>Allergic reactions<route> rash, fever, respiratory distress</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x24460">
								<item>
									<label>•</label>
									<para>Severe weakness, numbness in extremities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24465">
								<item>
									<label>•</label>
									<para>Assistance with ambulation if dizziness, drowsiness occur, especially for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x24470">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x24474">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, spasticity; muscle spasms of acute, painful musculoskeletal conditions generally short term; long-term therapy seldom warranted</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x24480">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x24488">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication abruptly; that insomnia, nausea, headache, spasticity, tachycardia will occur; that product should be tapered off over 1-2 wk</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x24491">
								<item>
									<label>•</label>
									<para>Not to take with alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24496">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness, dizziness occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24501">
								<item>
									<label>•</label>
									<para>To avoid using OTC medication (cough preparations, antihistamines) unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24506">
								<item>
									<label>•</label>
									<para>To use gum, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>cyclopentolate ophthalmic</mono_name>
			<section type="none" id="sidelem4x24519">
				<para>See <see refid="trapii:B978-0-323-44826-0.00036-7">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="8" status="active" ha="yes">
			<mono_name>cyclophosphamide (Rx)</mono_name>
			<info>
				<pronunciation>(sye-kloe-foss′fa-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x245301">Cytoxan</tradename>
					<tradename id="tnidelem4x245300">
						<country code="CAN">Procytox </country>
					</tradename>
				</tradenames>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Nitrogen mustard</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x24542">
				<para>
					<confusion>
						<tradename id="tnidelem4x245420">cyclophosphamide</tradename>
						<drug type="generic" refid="idelem4x245420">cycloSPORINE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x24549">
				<sec_title>Action:</sec_title>
				<para>Alkylates DNA is responsible for cross-linking DNA strands; activity is not cell-cycle–phase specific</para>
			</section>
			<section type="uses" id="sidelem4x24554">
				<sec_title>Uses:</sec_title>
				<para>Hodgkin’s disease, lymphomas, leukemia; cancer of female reproductive tract, breast, multiple myeloma; neuroblastoma; retinoblastoma; Ewing’s sarcoma; nephrotic syndrome</para>
				<section type="none" id="sidelem4x24559">
					<section type="none" id="sidelem4x24560">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Aplastic anemia, chronic idiopathic thrombocytopenic purpura, dermatomyositis, pneumonitis, polymyositis, SLE, scleroderma, RA, Behçet’s syndrome, Churg-Strauss syndrome, polyarteritis nodosa, Wegener’s granulomatosis, idiopathic pulmonary fibrosis, localized neuroblastoma, CLL</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x24565">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, prostatic hypertrophy, bladder neck obstruction</para>
				<section type="none" id="sidelem4x24570">
					<section type="none" id="sidelem4x24571">
						<sec_title>Precautions:</sec_title>
						<para> Radiation therapy, cardiac disease, anemia, dysrhythmias, child, dental disease/work, dialysis, geriatric patients, heart failure, hematuria, infections, leukopenia QT prolongation, secondary malignancy surgery, tumor lysis syndrome, vaccinations, breastfeeding, severely depressed bone marrow function</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x24578">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x24581">
					<section type="none" id="sidelem4x24582">
						<sec_title>Acute lymphocytic leukemia (ALL) (induction therapy)</sec_title>
						<section type="none" id="sidelem4x24590">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x24590">
									<item>
										<label>•</label>
										<para> Total doses of IV 300-1500mg/m<emphasis style="sup">2</emphasis> have been incorporated into induction, intensification, consolidation regimens, possibly using vinCRIStine, predniSONE, or others;  1-5mg/kg/day depending on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24600">
						<sec_title>Neuroblastoma</sec_title>
						<section type="none" id="sidelem4x24608">
							<label>•</label>
							<sec_title>Adult/Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x24608">
									<item>
										<label>•</label>
										<para> For induction, 40-50 mg/kg in divided doses over 2-5 days or 10-15 mg/kg q7-10days, 3-5 mg/kg 2×/wk or 1-5 mg/kg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24615">
							<label>•</label>
							<sec_title>Child and infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24615">
									<item>
										<label>•</label>
										<para> 150 mg/m<emphasis style="sup">2</emphasis>/day, days 1-7 with DOXOrubicin ( 35 mg/m<emphasis style="sup">2</emphasis> on day 8) q21days × 5 cycles</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24631">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x24631">
									<item>
										<label>•</label>
										<para> 70 mg/kg/day with hydration on days 1, 2 with DOXOrubicin and vinCRIStine q21days for courses 1, 2, 4, 6 alternating with CISplatin and etoposide q21days for courses 3, 5, 7</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24635">
						<sec_title>Breast cancer</sec_title>
						<section type="none" id="sidelem4x24643">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24643">
									<item>
										<label>•</label>
										<para> 100-200 mg/m<emphasis style="sup">2</emphasis>/day or 2 mg/kg/day × 4-14 days;  500-1000 mg/m<emphasis style="sup">2</emphasis> on day 1 in combination with fluorouracil and methotrexate or DOXOrubicin or DOXOrubicin alone, also cyclophosphamide 600 mg/m<emphasis style="sup">2</emphasis>; may be given dose-dense on day 1 of q14days with DOXOrubicin (60 mg/m<emphasis style="sup">2</emphasis>) with growth-factor support</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24662">
						<sec_title>Operable node-positive breast cancer IV (TAC regimen)</sec_title>
						<section type="none" id="sidelem4x24670">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x24670">
									<item>
										<label>•</label>
										<para> 500 mg/m<emphasis style="sup">2</emphasis> with DOXOrubicin (50 mg/m<emphasis style="sup">2</emphasis>), then DOCEtaxel (75 mg/m<emphasis style="sup">2</emphasis>)  given 1 hr later q3wk × 6 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24688">
						<sec_title>Nephrotic syndrome</sec_title>
						<section type="none" id="sidelem4x24696">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24696">
									<item>
										<label>•</label>
										<para> 2.5-3 mg/kg daily × 60-90 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24700">
						<sec_title>Aplastic anemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x24708">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x24708">
									<item>
										<label>•</label>
										<para> 45-50 mg/kg divided over 4 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24712">
						<sec_title>Behçet’s syndrome/Churg-Strauss syndrome/polyarteritis nodosa/uveitis/Wegener’s granulomatosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x24720">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24720">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/day,  0.5-1 g/m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24729">
						<sec_title>Rheumatoid arthritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x24737">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x24737">
									<item>
										<label>•</label>
										<para> 1.5-2.5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24741">
						<sec_title>CLL (unlabeled)</sec_title>
						<section type="none" id="sidelem4x24749">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x24749">
									<item>
										<label>•</label>
										<para> 250 mg/m<emphasis style="sup">2</emphasis>/day on days 1-3 with fludarabine 30 mg/m<emphasis style="sup">2</emphasis>/day on days 1-3</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x24759">
						<sec_title>Available forms:</sec_title>
						<para> Inj <country code="CAN">FIX_STRUCTURE Inj</country> 200, 500 mg, 1, 2 g vials; tabs 25, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x24767">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x24775">
							<label>•</label>
							<sec_title>
								<route>Use cytotoxic handling procedures</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x24778">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> so product can be eliminated before bedtime</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24786">
								<item>
									<label>•</label>
									<para>Fluids IV or PO before chemotherapy to hydrate patient</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24791">
								<item>
									<label>•</label>
									<para>Antacid before oral agent; give after evening meal, before bedtime</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24796">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product and prn</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x24801">
								<item>
									<label>•</label>
									<para>Allopurinol or sodium bicarbonate to maintain uric acid levels, alkalinization of urine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x24806">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x24810">
									<item>
										<label>•</label>
										<para>Take on empty stomach; do not crush, break, chew tabs; wash hands immediately if in contact with tab</para>
									</item>
									<item>
										<label>•</label>
										<para>May be taken as a single dose or divided doses</para>
									</item>
									<item>
										<label>•</label>
										<para>Take in <emphasis style="smallcaps">am</emphasis> or afternoon, avoid evening</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24834">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x24838">
									<item>
										<label>•</label>
										<para>Reconstitute with NS only</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x24844">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x24848">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures</para>
									</item>
									<item>
										<label>•</label>
										<para>IV after diluting 100 mg/5 ml of sterile water or bacteriostatic water; shake; let stand until clear; may be further diluted in ≤250 ml D<emphasis style="inf">5</emphasis> NS D<emphasis style="inf">5</emphasis>/NS; 0.45% NaCl give 100 mg or less/min through 3-way stopcock of glucose or saline infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Use 21, 23, 25G needle; check site for irritation, phlebitis</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> Amino acids 4.25%/D<emphasis style="inf">25</emphasis>, D<emphasis style="inf">5</emphasis>/0.9% NaCl, D<emphasis style="inf">5</emphasis>W, 0.9% NaCl</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Bleomycin, CISplatin, doxapram, DOXOrubicin, droperidol, fluorouracil, furosemide, heparin, leucovorin, methotrexate, metoclopramide, mitoMYcin, vinBLAStine, vinCRIStine</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, azlocillin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefepime, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, kanamycin, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium, pentamidine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propofol, propranolol, quinupristin-dalfopristin, ranitidine, rapacuronium, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, topotecan, TPN, trastuzumab, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x24893">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x24896">
					<section type="none" id="sidelem4x24897">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x24902">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiotoxicity (high doses), myocardial fibrosis, congestive heart failure, pericarditis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24909">
						<sec_title>ENDO:</sec_title>
						<para> SIADH, gonadal suppression</para>
					</section>
					<section type="none" id="sidelem4x24914">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, weight loss,</emphasis> colitis, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24924">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hemorrhagic cystitis,</emphasis><emphasis style="italic">hematuria, neoplasms, amenorrhea, azoospermia, sterility, ovarian fibrosis,</emphasis><emphasis style="bold">renal tubular fibrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24935">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, pancytopenia; myelosuppression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24942">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> dermatitis</para>
					</section>
					<section type="none" id="sidelem4x24950">
						<sec_title>META:</sec_title>
						<para> Hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x24955">
						<sec_title>MISC:</sec_title>
						<para> Secondary neoplasms, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x24962">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pulmonary fibrosis, interstitial pneumonia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x24969">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine, half-life 4-6<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, 50% bound to plasma proteins</para>
			</section>
			<section type="interactions" id="sidelem4x24980">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade—succinylcholine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cyclophosphamide toxicity—barbiturates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bone marrow depression—allopurinol, thiazides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—insulin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> digoxin levels—digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> cyclophosphamide effect—chloramphenicol, corticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<section type="none" id="sidelem4x25016">
					<section type="none" id="sidelem4x25017">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x25025">
							<label>•</label>
							<sec_title>Toxicity<route> St. John’s wort</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x25028">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> Pap smear</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> PPD, mumps, trichophytin, <emphasis style="italic">Candida, Trichophyton,</emphasis> Pap smear</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x25046">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x25049">
					<section type="none" id="sidelem4x25050">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x25058">
							<label>•</label>
							<sec_title>Hemorrhagic cystitis; renal studies<route> BUN, serum uric acid, urine CCr before, during therapy; I&amp;O ratio; report fall in urine output &lt;30 ml/hr</route></sec_title>
						</section>
						<section type="none" id="sidelem4x25064">
							<label>•</label>
							<sec_title>Bone marrow depression<route> CBC, differential, platelet count baseline, weekly; withhold product if WBC is &lt;2500 or platelet count is &lt;75,000; notify prescriber of results</route></sec_title>
						</section>
						<section type="none" id="sidelem4x25070">
							<label>•</label>
							<sec_title>
								<route>Pulmonary function tests, chest x-ray films before, during therapy; chest film should be obtained q2wk during treatment</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x25073">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr; elevated temperature may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25081">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> hepatic studies before, during therapy (bilirubin, AST, ALT, LDH), as needed; jaundice of skin, sclera; dark urine, clay-colored stools; itchy skin; abdominal pain; fever; diarrhea</route></sec_title>
						</section>
						<section type="none" id="sidelem4x25087">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x25087">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising or petechiae, mucosa or orifices q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x25091">
								<item>
									<label>•</label>
									<para>Dyspnea, crackles, unproductive cough, chest pain, tachypnea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25096">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image, discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25101">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores or ulceration, white patches, oral pain, bleeding, dysphagia; obtain prescription for viscous lidocaine (Xylocaine)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25107">
								<item>
									<para>
										<emphasis alert="nurse">Symptoms that indicate severe allergic reaction: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25112">
								<item>
									<label>•</label>
									<para>Increase fluid intake to 2-3 L/day to prevent urate deposits, calculi formation, reduce incidence of hemorrhagic cystitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25117">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25122">
								<item>
									<label>•</label>
									<para>Warm compresses at inj site for inflammation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x25127">
						<sec_title>Evaluate:</sec_title>
						<section type="none" id="sidelem4x25135">
							<label>•</label>
							<sec_title>
								<route>To take adequate fluids to eliminate product</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x25138">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x25143">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x25148">
								<item>
									<label>•</label>
									<para>That amenorrhea can occur and may last up to 1 yr after therapy but is reversible after stopping treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25153">
								<item>
									<label>•</label>
									<para>To report any changes in breathing or coughing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25158">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; a wig or hairpiece may make patient feel better; new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25163">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot, or rough texture</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25171">
							<label>•</label>
							<sec_title>To report signs of infection<route> increased temperature, sore throat, flulike symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x25177">
							<label>•</label>
							<sec_title>To report signs of anemia<route> fatigue, headache, faintness, SOB, irritability</route></sec_title>
						</section>
						<section type="none" id="sidelem4x25183">
							<label>•</label>
							<sec_title>
								<route>To report bleeding (bruising, hematuria, petechiae); to avoid use of razors, commercial mouthwash</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x25189">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception during and for 4 mo after treatment; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x25192">
								<item>
									<label>•</label>
									<para>To avoid use of aspirin products, ibuprofen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25197">
								<item>
									<label>•</label>
									<para>To avoid vaccinations during therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25206">
							<label>•</label>
							<sec_title>
								<route>Advise patient on proper handling and disposal of chemotherapy drugs</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>cycloSPORINE (Rx)</mono_name>
			<info>
				<pronunciation>(sye′kloe-spor-een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x252143">Cyclosporine (modified)</tradename>
					<tradename id="tnidelem4x252142">Gengraf</tradename>
					<tradename id="tnidelem4x252141">Neoral</tradename>
					<tradename id="tnidelem4x252140">Sandimmune</tradename>
				</tradenames>
				<class type="func"> Immunosuppressant</class>
				<class type="chem"> Fungus-derived peptide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x25224">
				<para>
					<confusion>
						<tradename id="tnidelem4x252240">cycloSPORINE</tradename>
						<drug type="generic" refid="idelem4x252240">cycloSERINE/cyclophosphamide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x25228">
				<sec_title>Action:</sec_title>
				<para>Produces immunosuppression by inhibiting lymphocytes (T)</para>
			</section>
			<section type="uses" id="sidelem4x25233">
				<sec_title>Uses:</sec_title>
				<para>Organ transplants (liver, kidney, heart) (GVHD) to prevent rejection, rheumatoid arthritis, psoriasis</para>
				<section type="none" id="sidelem4x25238">
					<section type="none" id="sidelem4x25239">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Recalcitrant ulcerative colitis, aplastic anemia, Crohn’s disease, thrombocytopenia purpura, lupus, nephritis, myasthenia gravis, psoriatic arthritis, atopic dermatitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x25244">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity to polyxyethylated castor oil (inj only); psoriasis or RA in renal disease (Neoral/Gengraf); Gengraf/Neoral used with PUVA/UVB, methotrexate, coal tar; ocular infections</para>
				<para>
					<bbw>Uncontrolled, malignant hypertension; radiation in psoriasis, neoplastic disease, sunlight (UV) exposure, renal disease/failure</bbw>
				</para>
				<section type="none" id="sidelem4x25259">
					<section type="none" id="sidelem4x25260">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, severe hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x25265">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x25268">
					<section type="none" id="sidelem4x25269">
						<sec_title>Prevention of transplant rejection (nonmodified)</sec_title>
						<section type="none" id="sidelem4x25277">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25277">
									<item>
										<label>•</label>
										<para> 15 mg/kg several hr before surgery, daily for 2 wk, reduce dosage by 2.5 mg/kg/wk to 5-10 mg/kg/day;  5-6 mg/kg several hr before surgery, daily, switch to PO form as soon as possible</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25284">
						<sec_title>Prevention of transplant rejection (modified)</sec_title>
						<section type="none" id="sidelem4x25292">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25292">
									<item>
										<label>•</label>
										<para> 4-12 mg/kg/day divided q12hr, depends on organ transplanted</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25296">
						<sec_title>Rheumatoid arthritis (Neoral/Gengraf)</sec_title>
						<section type="none" id="sidelem4x25304">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25304">
									<item>
										<label>•</label>
										<para> 2.5 mg/kg/day divided bid, may increase 0.5-0.75 mg/kg/day after 8-12 wk, max 4 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25308">
						<sec_title>Psoriasis (Neoral/Gengraf)</sec_title>
						<section type="none" id="sidelem4x25316">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25316">
									<item>
										<label>•</label>
										<para> 2.5 mg/kg/day divided bid, × 4 wk, then increase by 0.5 mg/kg/day q2wk, max 4 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25320">
						<sec_title>Idiopathic thrombocytopenia purpura (unlabeled)</sec_title>
						<section type="none" id="sidelem4x25328">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25328">
									<item>
										<label>•</label>
										<para> 1.25-2.5 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25332">
						<sec_title>Severe aplastic anemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x25340">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25340">
									<item>
										<label>•</label>
										<para> 12 mg/kg/day or 15 mg/kg/day (child) with antithymocyte globulin (ATG)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25344">
						<sec_title>Atopic dermatitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x25352">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25352">
									<item>
										<label>•</label>
										<para> 5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25356">
						<sec_title>Crohn’s disease that is resistant to/intolerant of corticosteroids (unlabeled)</sec_title>
						<section type="none" id="sidelem4x25364">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x25364">
									<item>
										<label>•</label>
										<para> 2.5-15 mg/kg/day (nonmodified)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25368">
						<sec_title>Available forms:</sec_title>
						<para> Oral sol 100 mg/ml; soft gel cap 25, 50, 100 mg; inj 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x25373">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x25376">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x25384">
								<label>•</label>
								<sec_title>
									<route>Some brands are not interchangeable</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x25387">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew caps</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x25392">
									<item>
										<label>•</label>
										<para>Use pipette provided to draw up oral sol; may mix with milk or juice; wipe pipette, do not wash (Neoral)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x25397">
									<item>
										<label>•</label>
										<para>For several days before transplant surgery; give at same time of day</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x25402">
									<item>
										<label>•</label>
										<para>With corticosteroids</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x25407">
									<item>
										<label>•</label>
										<para>With meals for GI upset or in chocolate milk, milk, or orange juice (SandIMMUNE)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25412">
						<sec_title>Rheumatoid arthritis</sec_title>
						<para>
							<list id="lidelem4x25416">
								<item>
									<label>•</label>
									<para>Give Neoral or Gengraf 2.5 mg/kg/day divided bid; may use with salicylates, NSAIDs, PO corticosteroids</para>
								</item>
								<item>
									<label>•</label>
									<para>Always give the daily dose of Neoral/Gengraf in 2 divided doses on consistent schedule</para>
								</item>
								<item>
									<label>•</label>
									<para>Give initial SandIMMUNE PO dose 4-12 hr before transplantation as a single dose of 15 mg/kg, continue the single daily dose for 1-2 wk, then taper 5%/wk to a maintenance dose of 5-10 mg/kg/day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25433">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x25437">
									<item>
										<label>•</label>
										<para>After diluting each 50 mg/20-100 ml of 0.9% NaCl or D<emphasis style="inf">5</emphasis>W; run over 2-6 hr, use an infusion pump, glass infusion bottles only</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x25446">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x25451">
									<item>
										<label>•</label>
										<para>May run over 24 hr</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x25459">
								<label>•</label>
								<sec_title>
									<route>For SandIMMUNE parenteral,</route>
								</sec_title>
								<para>
									<list id="lidelem4x25459">
										<item>
											<label>•</label>
											<para> give <emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> of PO dose, initial dose 4-12 hr before transplantation as a single IV dose 5-6 mg/kg/day, continue the single daily dose until PO can be used</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, NaCl 0.9%</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Abciximab, alatrofloxacin, alfentanil, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, indomethacin, irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, levofloxacin, lidocaine, linezolid, LORazepam, mannitol, mechlorethamine, meperidine, meropenem, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, multiple vitamins injection, nafcillin, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, phentolamine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium acetate/chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, ritodrine, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x25480">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x25483">
					<section type="none" id="sidelem4x25484">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, headache,</emphasis><emphasis style="bold">seizures, confusion, encephalopathy,</emphasis> migraine</para>
					</section>
					<section type="none" id="sidelem4x25494">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, <emphasis style="italic">oral candida, gum hyperplasia,</emphasis><emphasis style="bold">hepatotoxicity, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x25503">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Albuminuria, hematuria, proteinuria, renal failure, hemolytic uremic syndrome, nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x25510">
						<sec_title>INTEG:</sec_title>
						<para> Rash, acne, <emphasis style="italic">hirsutism,</emphasis> pruritus</para>
					</section>
					<section type="none" id="sidelem4x25518">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia, hypomagnesemia, hyperlipidemia, hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x25524">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Infection, hypertension</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x25531">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 4 hr; highly protein bound; half-life (biphasic) 1.2 hr, 25 hr; metabolized in liver; excreted in feces, 6% in urine; crosses placenta; excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x25536">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action, toxicity of cycloSPORINE—allopurinol, amiodarone, amphotericin B, androgens, azole antifungals, β-blockers, bromocriptine, calcium channel blockers, carvedilol, cimetidine, colchicine, corticosteroids, fluoroquinolones, foscarnet, imipenem-cilastatin, macrolides, metoclopramide, oral contraceptives, NSAIDs, melphalan, SSRIs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of aliskiren, digoxin, etoposide, HMG-CoA reductase inhibitors, methotrexate, potassium-sparing diuretics, sirolimus, tacrolimus</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action toxicity of—digoxin, colchicine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> cycloSPORINE action—anticonvulsants, nafcillin, orlistat, PHENobarbital, phenytoin, rifamycins, sulfamethoxazole-trimethoprim, terbinafine, ticlopidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody reaction—live virus vaccines</para>
				<section type="none" id="sidelem4x25559">
					<section type="none" id="sidelem4x25560">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x25564">
								<item>
									<label>•</label>
									<para>Slowed metabolism of product: grapefruit juice, food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x25570">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x25573">
					<section type="none" id="sidelem4x25574">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x25579">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine at least monthly during treatment, 3 mo after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25584">
								<item>
									<label>•</label>
									<para>Product blood level during treatment 12 hr after dose, toxic &gt;400 ng/ml</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25592">
							<label>•</label>
							<sec_title>
								<route>dark urine, jaundice, itching, light-colored stools; product should be discontinued</route>
							</sec_title>
							<para>
								<list id="lidelem4x25592">
									<item>
										<label>•</label>
										<para>Hepatic studies: alk phos, AST, ALT, bilirubin; hepatotoxicity: </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x25596">
								<item>
									<label>•</label>
									<para>Serum lipids, magnesium, potassium, cycloSPORINE blood concentrations, therapeutic range: 100-400 mg/ml</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25602">
								<item>
									<para>
										<emphasis alert="nurse">Encephalopathy: impaired cognition, seizures, visual changes including blindness, loss of motor function, movement disorders and psychiatric changes; dosage reduction or discontinuation may be needed in severe cases</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25608">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity: 6 wk after surgery, acute tubular necrosis, CyA trough level &gt;200 ng/ml, gradual rise in creatinine (0.15 mg/dl/day), creatinine plateau &lt;25% above baseline, intracapsular pressure &lt;40 mm Hg</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25614">
								<item>
									<para>
										<emphasis alert="nurse">Signs/symptoms of encephalopathy, lymphoma</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x25619">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x25623">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of rejection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x25629">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x25637">
							<label>•</label>
							<sec_title>
								<route>To report fever, chills, sore throat, fatigue, since serious infections may occur; tremors, bleeding gums, increased B/P</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x25640">
								<item>
									<label>•</label>
									<para>To use contraceptive measures during treatment, for 12 wk after ending therapy; to notify prescriber if pregnancy is planned or suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25645">
								<item>
									<label>•</label>
									<para>To take at same time of day, every day; not to skip doses or double dose; not to use with grapefruit juice or receive vaccines; that there are many drug interactions; not to add new products without approval of prescriber
<bbw>To limit UV exposure</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25659">
								<item>
									<label>•</label>
									<para>That treatment is lifelong to prevent rejection; to identify signs of rejection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25664">
								<item>
									<label>•</label>
									<para>To report severe diarrhea because drug loss may result</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25672">
							<label>•</label>
							<sec_title>About the signs of nephrotoxicity<route> increased B/P, tremors of the hands, changes in gums, increased hair on body, face</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x25675">
								<item>
									<label>•</label>
									<para>To continue with all lab work and follow-up appointments</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25680">
								<item>
									<label>•</label>
									<para>That types of products are not interchangeable</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x25685">
								<item>
									<label>•</label>
									<para>Not to wash syringe/container with water; variation in dose may result</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active" ha="yes">
			<mono_name>cytarabine (Rx)</mono_name>
			<info>
				<pronunciation>(sye-tare′a-been)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x256980">
						<country code="CAN">Cytosar </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="11" status="active">
			<mono_name>cytarabine liposomal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x257050">DepoCyt</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antimetabolite</class>
				<class type="chem"> Pyrimidine nucleoside analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x25715">
				<para>
					<confusion>
						<tradename id="tnidelem4x257150">Cytosar</tradename>
						<drug type="generic" refid="idelem4x257150">Cytoxan/Cytovene</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x25719">
				<sec_title>Action:</sec_title>
				<para>Competes with physiologic substrate of DNA synthesis, thus interfering with cell replication in the S phase of the cell cycle (before mitosis)</para>
			</section>
			<section type="uses" id="sidelem4x25724">
				<sec_title>Uses:</sec_title>
				<para>Acute myelocytic leukemia, acute nonlymphocytic leukemia, chronic myelocytic leukemia; lymphomatous meningitis (intrathecal/intraventricular)</para>
				<section type="none" id="sidelem4x25729">
					<section type="none" id="sidelem4x25730">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hodgkin’s/non-Hodgkin’s lymphoma, malignant meningitis, mantle cell lymphoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x25735">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x25740">
					<section type="none" id="sidelem4x25741">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, renal/hepatic disease, tumor lysis syndrome, infection, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia</para>
						<para>
							<bbw>Bone marrow suppression</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x25756">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x25759">
					<section type="none" id="sidelem4x25760">
						<sec_title>Acute myelogenous leukemia (AML)</sec_title>
						<section type="none" id="sidelem4x25768">
							<label>•</label>
							<sec_title>Adult<route> CONT IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x25768">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis>/day × 7 days q2wk as single agent or 2-6 mg/kg/day (100-200 mg/m<emphasis style="sup">2</emphasis>/day) as a single dose or 2-3 divided doses for 5-10 days until remission, used in combination; maintenance 70-200 mg/m<emphasis style="sup">2</emphasis>/day for 2-5 days monthly;  maintenance 100 mg/m<emphasis style="sup">2</emphasis>/day × 5 days q28days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25787">
						<sec_title>Meningeal leukemia</sec_title>
						<section type="none" id="sidelem4x25795">
							<label>•</label>
							<sec_title>Adult/Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x25795">
									<item>
										<label>•</label>
										<para> For induction, 40-50 mg/kg in divided doses over 2-5 days or 10-15 mg/kg q7-10days, 3-5 mg/kg 2×/wk or 1-5 mg/kg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x25802">
							<label>•</label>
							<sec_title>Adult/child<route> INTRATHECAL</route></sec_title>
							<para>
								<list id="lidelem4x25802">
									<item>
										<label>•</label>
										<para> For induction 50 mg (liposomal) q14days × 2 doses (wk 1, 3); consolidation 50 mg (liposomal) q14days × 3 doses (wk 5, 7, 9), then another dose at wk 13; maintenance 50 mg (liposomal) q28days (wk 17, 21, 25, 29)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25806">
						<sec_title>Refractory acute Hodgkin’s/refractory non-Hodgkin’s lymphoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x25814">
							<label>•</label>
							<sec_title>Adult/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x25814">
									<item>
										<label>•</label>
										<para> 2 g/m<emphasis style="sup">2</emphasis>/day; on day 5 q21days, with etoposide, methylPREDNISolone, and CISplatin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25821">
						<sec_title>Carcinomatous meningitis (liposoma)</sec_title>
						<section type="none" id="sidelem4x25829">
							<label>•</label>
							<sec_title>Adult<route> IT</route></sec_title>
							<para>
								<list id="lidelem4x25829">
									<item>
										<label>•</label>
										<para> 50 mg over 1-5 min q14days, during induction and consolidation wk 1, 3, 5, 7, 9, give another 50 mg  wk 13; maintenance 50 mg q28days on wk 17, 21, 25, 29 use with dexamethasone 4 mg  × 5 days on each day of cytarabine</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x25839">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x25847">
							<label>•</label>
							<sec_title>Adult CCr ≤60 ml/min, serum creatinine 1.5-1.9 mg/dl or increase of 0.5-1.2 mg/dl from baseline during treatment<route> reduce to 1 g/m2</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x25858">
						<sec_title>Available forms:</sec_title>
						<para> Solution for injection 20 mg/ml (DepoCyt) liposomal for intrathecal use 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x25863">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x25867">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product and prn</para>
								</item>
								<item>
									<label>•</label>
									<para>Allopurinol to maintain uric acid levels and alkalinization of the urine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x25878">
							<sec_title>IT route</sec_title>
							<para>
								<list id="lidelem4x25882">
									<item>
										<label>•</label>
										<para>Use preservative-free NS, add 5 ml/ 100-mg vial or 10 ml/500-mg vial; use immediately, discard unused product</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x25889">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x25897">
								<label>•</label>
								<sec_title>
									<route>Use cytotoxic handling precautions</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x25900">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x25904">
									<item>
										<label>•</label>
										<para>After diluting 100 mg/5 ml of sterile water for inj; given by direct IV over 1-3 min through free-flowing tubing (IV)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x25910">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x25914">
									<item>
										<label>•</label>
										<para>May be further diluted in 50-100 ml NS or D<emphasis style="inf">5</emphasis>W, given over 30 min to 24 hr, depending on dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x25923">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x25927">
									<item>
										<label>•</label>
										<para>May also be given by continuous infusion</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> Amino acids, D<emphasis style="inf">5</emphasis>/LR, D<emphasis style="inf">5</emphasis>/0.2% NaCl, D<emphasis style="inf">5</emphasis>/0.9% NaCl, D<emphasis style="inf">10</emphasis>/0.9% NaCl, D<emphasis style="inf">5</emphasis>W, invert sugar 10% in electrolyte #1, Ringer’s, LR, 0.9% NaCl, sodium lactate <emphasis style="sup">1</emphasis>/<emphasis style="inf">6</emphasis> mol/L, TPN #57</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, amsacrine, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyclophosphamide, cycloSPORINE, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, foscarnet, fosphenytoin, furosemide, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, pentamidine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propofol, propranolol, quinupristin-dalfopristin, ranitidine, rapacuronium, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x25962">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x25965">
					<section type="none" id="sidelem4x25966">
						<sec_title>CNS:</sec_title>
						<para> Neuritis, dizziness, headache, <emphasis style="bold">cerebellar syndrome,</emphasis> personality changes, ataxia, mechanical dysphasia, <emphasis style="bold">coma; chemical arachnoiditis (IT)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x25976">
						<sec_title>CV:</sec_title>
						<para> Chest pain, <emphasis style="bold">cardiopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x25983">
						<sec_title>CYTARABINE SYNDROME:</sec_title>
						<para> <emphasis style="bold">
								<emphasis style="italic">Fever,</emphasis> myalgia, bone pain, chest pain, <emphasis style="italic">rash,</emphasis> conjunctivitis, malaise (6-12 hr after administration)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x25995">
						<sec_title>EENT:</sec_title>
						<para> Sore throat, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x26000">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea, stomatitis,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> abdominal pain, hematemesis, <emphasis style="bold">GI hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x26012">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, <emphasis style="bold">renal failure, hyperuricemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x26020">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombophlebitis, bleeding, thrombocytopenia, leukopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x26027">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, fever,</emphasis> freckling, cellulitis</para>
					</section>
					<section type="none" id="sidelem4x26035">
						<sec_title>META:</sec_title>
						<para> Hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x26040">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pneumonia,</emphasis> dyspnea, <emphasis style="bold">pulmonary edema</emphasis> (high doses)</para>
					</section>
					<section type="none" id="sidelem4x26051">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, tumor lysis syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x26058">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x26061">
					<section type="none" id="sidelem4x26062">
						<sec_title>INTRATHECAL:</sec_title>
						<para> Half-life 100-236 hr; metabolized in liver; excreted in urine (primarily inactive metabolite); crosses blood-brain barrier, placenta</para>
					</section>
					<section type="none" id="sidelem4x26067">
						<sec_title>IV/SUBCUT:</sec_title>
						<para> Distribution half-life 10 min, elimination half-life 1-3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x26072">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x26080">
					<label>•</label>
					<sec_title>
						<route>Do not use with live virus vaccines</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x26086">
					<label>•</label>
					<sec_title>
						<route>Do not use within 24 hr of chemotherapy—sargramostim, GM-CSF, filgrastim, G-CSF</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—immunosuppressants, methotrexate, flucytosine, radiation, or other antineoplastics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, platelet inhibitors, salicylates, thrombolytics, NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of oral digoxin, gentamicin</para>
			</section>
			<section type="considerations" id="sidelem4x26101">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x26104">
					<section type="none" id="sidelem4x26105">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow suppression:</emphasis> CBC (RBC, Hct, Hgb), differential, platelet count weekly; withhold product if WBC is &lt;1000/mm3, platelet count is &lt;50,000/mm3, or RBC, Hct, Hgb low; notify prescriber of these results</bbw>
						</para>
						<para>
							<list id="lidelem4x26127">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before and during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26132">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26137">
								<item>
									<label>•</label>
									<para>Monitor temperature; fever may indicate beginning infection; no rectal temperatures</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x26145">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> hepatic studies before and during therapy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x26148">
								<item>
									<label>•</label>
									<para>Blood uric acid during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26154">
								<item>
									<para>
										<emphasis alert="nurse">For anaphylaxis: rash, pruritus, facial swelling, dyspnea; resuscitation equipment should be nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26160">
								<item>
									<para>
										<emphasis alert="nurse">Chemical arachnoiditis (IT): headache, nausea, vomiting, fever; neck rigidity pain, meningism, CSF pleocytosis; may be decreased by dexamethasone</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26165">
								<item>
									<label>•</label>
									<para>Cytarabine syndrome 6-12 hr after infusion: fever, myalgia, bone pain, chest pain, rash, conjunctivitis, malaise; corticosteroids may be ordered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26170">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, heme-positive stools, bruising or petechiae, mucosa or orifices q8hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26176">
								<item>
									<para>
										<emphasis alert="nurse">Dyspnea, crackles, unproductive cough, chest pain, tachypnea, fatigue, increased pulse, pallor, lethargy; personality changes, with high doses; pulmonary edema may be fatal (rare)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26181">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores or ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26186">
								<item>
									<label>•</label>
									<para>Local irritation, pain, burning, discoloration at inj site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26191">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping; antispasmodic may be used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26196">
								<item>
									<label>•</label>
									<para>Acidosis, signs of dehydration: rapid respirations, poor skin turgor, decreased urine output, dry skin, restlessness, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26201">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent urate deposits and calculi formation unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26206">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x26211">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x26215">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement of hematologic parameters</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x26221">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x26229">
							<label>•</label>
							<sec_title>
								<route>To report any coughing, chest pain, changes in breathing; may indicate beginning pneumonia, pulmonary edema</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x26232">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, spicy, or rough texture if stomatitis is present; use sponge brush and rinse with water after each meal; to report stomatitis: any bleeding, white spots, ulcerations in mouth; to examine mouth daily, report any symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x26242">
							<label>•</label>
							<sec_title>To report signs of infection<route> increased temperature, sore throat, flulike symptoms; to avoid crowds, persons with infections</route></sec_title>
						</section>
						<section type="none" id="sidelem4x26248">
							<label>•</label>
							<sec_title>anemia</sec_title>
							<para>
								<list id="lidelem4x26248">
									<item>
										<label>•</label>
										<para>To report signs of <emphasis style="bold">anemia:</emphasis> fatigue, headache, faintness, SOB, irritability</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x26256">
							<label>•</label>
							<sec_title>
								<route>To report bleeding; to avoid use of razors, commercial mouthwash, salicylates, NSAIDs, anticoagulants</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x26262">
							<label>•</label>
							<sec_title>
								<route>To use thrombocytopenia precautions</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x26268">
							<label>•</label>
							<sec_title>
								<route>To take fluids to 3 L/day to prevent renal damage</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x26274">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception during treatment and for 4 mo thereafter; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x26277">
								<item>
									<label>•</label>
									<para>To avoid receiving vaccines during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x26282">
								<item>
									<label>•</label>
									<para>That fever, headache, nausea, vomiting likely to occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>